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Summary. 
ZNF804A was (at the time this work started) one of only a few robustly implicated 
schizophrenia susceptibility genes, due to replicated genome-wide significant evidence 
for association between a polymorphism in the gene and schizophrenia. Determining the 
function of the ZNF804A protein, which is currently unknown, may provide a way of 
elucidating the pathophysiology of this relatively common, complex disorder. Based on 
the hypothesis that the ZNF804A protein regulates gene expression or splicing, the aim 
of this thesis was to identify genes that exhibit altered expression or splicing in brain 
tissue from mice in which the orthologue Zfp804a carries a nonsense mutation.  
 
No robust evidence was obtained that showed the effects of the mutation on differential 
expression in individual genes. Although this finding does not support the hypothesis 
that ZNF804A acts directly to regulate gene expression, the results may reflect the 
possibility that effects on gene expression may be too subtle to be detected using the 
methods applied. Evidence was obtained to show the mutation affected the alternative 
splicing of a number of individual genes, which could suggest a role for ZNF804A in 
the direct or indirect regulation of alternative splicing. 
 
Through RNA sequencing, I identified a novel transcript in Zfp804a with an alternative 
exon upstream of the Refseq exon 1. I also showed that a proportion of the significant 
splicing differences identified in mutants were artefacts of strain differences in gene 
sequences that are likely to affect the efficiency of hybridisation on the exon array.  
 
Genes identified as differentially spliced between mutants and wildtypes were enriched 
in axon guidance and cell adhesion pathways, both thought to be important during 
development. The findings of this thesis suggest the novel hypothesis that ZNF804A 
effects risk for schizophrenia via aberrant splicing in the above pathways that are 
critical to normal brain development. Further studies with increased power are required 
to understand the effects on gene expression.  
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Chapter 1: General Introduction. 
 
1.1 Schizophrenia  
Schizophrenia is a severe psychiatric disorder with psychosis being a prominent feature. 
Due to its chronic course, early onset and poor treatment response, it contributes 
substantially to human morbidity, and also has a major negative impact on the social 
and economic functioning of affected individuals, their families, and the wider society. 
At present little has been established about the specifics of schizophrenia aetiology. 
This lack of knowledge is a clear impediment for new approaches in the design of 
treatments with greater efficacy.  Schizophrenia is ranked within the top ten most 
disabling and costly disorders in society (Murray & Lopez, 1996; Freedman, 2003) and 
the estimated cost of schizophrenia to society in the UK in 2004-2005 was ~£6.7 billion 
(Mangalore & Knapp, 2007). There is a clear need to determine the underlying 
pathophysiology of this often devastating disorder to enable the improvement of 
treatment and outcome. 
  
1.1.1 History 
Schizophrenia was first described by Kraepelin (1899) whose classification of a 
dementia praecox described a degenerative disorder of cognitive disturbance distinct 
from manic depressive psychosis. The degenerative disorder Kraepelin described 
appeared inaccurate with many patients showing improvement in symptoms and so the  
disorder was re-termed in 1908 by Eugen Bleuler as schizophrenia from the Greek ‘split 
mind’ and refers to the disruption in thought and cognitive function that are 
characteristic of the disorder. 
 
1.1.2 Symptoms 
Schizophrenia is a heterogeneous disorder.  Symptoms are often classified as either 
positive or negative (Jablensky et al., 2006). Positive symptoms, those with features that 
are not present in normal individuals, include hallucinations, delusions and disorganised 
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thoughts. The negative symptoms, functions which are present in normal individuals but 
often absent in schizophrenia, include social withdrawal and emotional flattening. A 
cognitive deficit is also frequently observed affecting memory, attention and executive 
function (Dikeos et al., 2006). Diagnosis is based upon the assessment of behaviour as 
no biomarkers have been determined for the disorder. No disorder specific 
neuropathology has been identified preventing confirmation of a correct diagnosis in the 
post mortem brain. 
 
1.1.3 Prevalence 
Schizophrenia has a worldwide prevalence of 1%. (Gottesmann, 1991). Symptoms 
typically present in late adolescence to early twenties with a higher lifetime risk in 
males (McGrath et al., 2004).  
 
1.1.4 Neurobiology 
Whilst the pathophysiology underlying schizophrenia remains unclear the occurrence of 
hallucinations and delusions as well as cognitive deficits have implicated brain 
functions associated with perception and cognition in the underlying pathophysiology of 
schizophrenia (Ross et al. 2006). Early hypotheses of schizophrenia aetiology centered 
on a hyper-dopaminergic system based on the efficacy of D2 receptor antagonists at 
alleviating the positive symptoms (Snyder, 2006). Findings that dopamine activity is 
aberrant in sub-cortical regions during psychotic periods supports this view (Howes et 
al., 2009). The efficacy of drug treatments which in addition target serotonin 5HT2A 
receptors, points to a complex aetiology of the disorder and although these drugs are 
generally effective at treating positive symptoms, and in the case of clozapine, negative 
symptoms, the pharmacological studies of how they work have not advanced 
understanding of the complex pathophysiology underlying schizophrenia. The varying 
efficacy of such drugs in schizophrenia patients emphasize the heterogeneity of the 
disorder.  The occurrence of schizophrenia-like symptoms in healthy individuals 
following the use of phencyclidine (PCP) and ketamine which are both NMDA 
antagonists introduced the hypo-glutamatergic hypothesis (Coyle, 2006) and this has 
been given further credibility by some promising evidence for the treatment of 
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symptoms, including negative symptoms, by drugs which modulate NMDA-receptors 
(Coyle, 2006). A possible role for gabaergic, in addition to dopaminergic and 
glutamatergic input has also been supported in pharmacological studies (Javitt et al., 
2008).  
 
Gross abnormalities in the schizophrenia patient brain including enlargement of the 
lateral ventricles and an accompanying reduction in overall brain volume (Steen et al., 
2006) are present from birth and not progressive which has led to a neurodevelopmental 
hypothesis for schizophrenia (Weinberger, 1986). Regional structural differences such 
as reduced hippocampal and pre frontal cortex (PFC) volume as well as altered 
cytoarchitecture (Harrison, 2000) have also been observed, although these are less 
replicable than the changes in total brain and ventricular volume. In addition neural 
distribution and spine density appear abnormal in the hippocampus and prefrontal 
cortex in the brains of schizophrenic patients (Wong & Van Tol., 2003). Despite 
numerous hypotheses, the underlying aetiology and pathophysiology of schizophrenia 
remains elusive. 
 
1.1.5 Heritability 
Evidence from family, twin and adoption studies have shown there to be a large genetic 
component to schizophrenia risk, with heritability being ~80% (Cardno. & Gottesman, 
2000), yet evidence from monozygotic twins highlights the additional influence of 
environmental factors (Gottesman, 1991; McGrath & Murray 2003).   
 
1.1.6 Environmental Risk 
The immune response is thought to be involved in aetiology and infections such as 
influenza, poliovirus and Toxoplasma gondii (Brown & Susser, 2002) have been 
associated with schizophrenia.  Aberrant events occurring during pregnancy and birth 
have been suggested to increase risk of schizophrenia such as obstetric complications 
like preeclampsia (Dalman et al., 1999).  In addition urbanicity (Allardyce et al., 2001) 
and drug use (Arseneault et al., 2002) have all been suggested to contribute to risk, 
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although the mechanisms through which these environmental factors might act are 
unclear. 
 
1.1.7 Genetic Risk 
While its origins are enigmatic, it has been known for a long time that genes make a 
substantial contribution to population risk, the heritability of schizophrenia being ~80%, 
therefore genetics has been seen as an important tool in trying to understand the causes 
of the disorder. Despite this, finding the specific risk genes involved has, as in most 
complex diseases, been a major challenge and early linkage and association studies did 
not reliably identify any susceptibility genes operating in the wider case population at 
high levels of confidence. However, until recently, these studies have been subject to 
small sample sizes and in turn low power (Kirov et al., 2005; Owen et al., 2005; Ross et 
al., 2006).   
 
The common disease-rare variant hypothesis supports the idea that substantial 
knowledge of disease aetiology can be gained from understanding rare variants even if 
observed in very low frequency (only a limited number of people). Given relatively 
large effect sizes, they can inform a great deal on the underlying biology of a disease as 
has been exemplified in AD, PD and HD (Ross et al., 2006, Ross & Margolis, 2005).  A 
number of studies have found that specific rare copy number variants (CNVs) occur 
more frequently in schizophrenia (<1%) compared to controls (<0.1%) showing that 
rare alleles are involved in the disorder (ISC., 2008; Kirov et al., 2009; Stefansson et al., 
2008). Rare de novo CNVs occur significantly more frequently in cases (5%) than 
controls (2%) indicating the involvement of de novo CNVs in schizophrenia 
pathogenesis. De novo CNVs identified in schizophrenia patients were enriched for 
genes associated with the post-synaptic density particularly those involved in NMDA 
and ARC post-synaptic signalling suggesting the involvement of these pathways in 
schizophrenia pathophysiology (Kirov et al., 2012). A proportion of genetic risk for 
schizophrenia is therefore attributed to rare CNVs, however at present, it is in general 
unclear which of the (generally many) genes within specific CNVs are relevant to 
schizophrenia.  
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1.1.8. Genome-Wide Association Studies (GWAS)  
The advent of genome-wide association studies (GWAS), which like linkage but unlike 
candidate gene studies, requires no knowledge of disease pathophysiology, and like 
other association study designs can in principle detect small effect sizes, changed the 
way genetic studies could be carried out. In part this was because of the absence of an a 
priori requirement for selecting specific candidates based upon prevailing theories of 
disease origin, but another important factor was that the use of the very large sample 
sizes required for GWAS allowed robust evidence to emerge for a number of loci. Early 
GWAS of schizophrenia were small and did not strongly support any particular 
candidates (Lencz et al., 2007; Sullivan et al., 2008). The application of GWAS to very 
large discovery and replication samples, however resulted in the identification of strong 
evidence for association to a small number of loci. 
 
1.1.9 Polygenic Model of Schizophrenia 
The theory of a polygenic model for schizophrenia (Gottesman & Shields, 1967) 
remained unsubstantiated at the molecular genetic level for many years, but was 
recently confirmed empirically when a Genome Wide Association Study (GWAS) 
showed risk for schizophrenia to be conferred by very many, possibly thousands, of 
alleles conferring small increments to risk (OR<1.1) (ISC, 2009).  As schizophrenia is a 
polygenic disorder that is characterised by a heterogeneous set of symptoms it can be 
inferred that the underlying pathophysiology will also show heterogeneity. Despite the 
complex nature of the disorder and difficulties determining its aetiology, the 
identification of genes associated with the disorder, despite their small effect size, when 
considered together in the context of biological pathways and molecular mechanisms 
may inform networks and pathways aberrant in schizophrenia.  
 
1.2 ZNF804A 
1.2.1 Discovery as susceptibility gene 
Association of a polymorphism (rs1344706) within zinc finger protein 804A (ZNF804A) 
and schizophrenia was first highlighted by O’Donovan et al., in 2008 in a large 
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discovery and replication sample. The replication analysis provided strong evidence for 
association around ZNF804A (P = 1.61 x 10
-7
) and this association surpassed genome-
wide levels of significance when the affected phenotype included bipolar disorder (P = 
9.96 x 10
-9
) (O'Donovan et al., 2008). This indicated ZNF804A as a strongly supported 
candidate (O’Donovan et al., 2008) for both schizophrenia and bipolar disorder.  
 
1.2.2 Replication Studies 
The association of rs1344706 within the ZNF804A gene with schizophrenia has been 
replicated (ISC, 2009; Stefansson et al., 2009) several times, including in an Irish Case-
Control Study of Schizophrenia (ICCSS) sample (N=1021 cases, 626 controls) 
(P=0.0113). In this study 11 SNPs in linkage disequilibrium (LD) with rs1344706 were 
also investigated for association. Another SNP, rs7597593 (P=0.0013) showed the most 
significant association with schizophrenia (Riley et al., 2010). Another study replicated 
the association of rs1344706 and schizophrenia (odds ratio OR = 1.08, P = 0.0029) in 
5164 schizophrenia cases and 20,709 controls in addition to replicating the significant 
association when a bipolar disorder phenotype was added to the sample (OR = 1.09, P = 
0.00065) (Steinberg et al., 2011). A meta-analysis of almost 60,000 subjects provided 
convincing evidence that ZNF804A was a susceptibility gene for schizophrenia 
(P=4x10
-11
) and even more compellingly for a wider phenotype including bipolar 
disorder (p=2x10
-13
) (Williams et al., 2010).  In a meta-analysis undertaken by the 
schizophrenia Psychiatric GWAS Consortium (PGC) (PGC, 2011a) rs1344706 was not 
one of 7 genome-wide significant variants identified as being associated with 
schizophrenia. The odds ratio in this study was similar to that observed in the previous 
meta-analysis (OR 1.10) (Williams et al., 2010) despite the sample being almost half the 
size. Given that the odds ratio is similar in a sample half the size this is consistent for a 
true association between ZNF804A and schizophrenia. ZNF804A is therefore considered 
as one of the most robustly associated schizophrenia susceptibility genes. 
 
1.2.3 Psychosis and the overlap of Schizophrenia and Bipolar Disorder 
There is strong evidence for genetic overlap between schizophrenia and bipolar disorder 
(ISC, 2009). With regards to ZNF804A, joint analyses of schizophrenia and the bipolar 
disorder phenotype provide even stronger evidence for association (p = 2x10
-13
) than 
  
7 
schizophrenia alone. A stronger association between rs1344706 and bipolar disorder has 
been reported, but not yet confirmed, when considering a sub-group of bipolar disorder 
patients with psychosis (Lett et al., 2011) suggesting this gene operates as a more 
general risk factor for psychosis. Evidence for shared genetic risk has also been shown 
for other genome-wide significant susceptibility genes. CACNA1C originally associated 
with bipolar disorder is also significantly associated with schizophrenia (Green et al., 
2010, PGC, 2011a).  Neurogranin (NRGN) and the MHC region originally identified as 
schizophrenia susceptibility loci were shown to have nominally significant association 
(P < 0.05) with bipolar disorder while Polybromo-1 (PBRM1), originally associated 
with bipolar disorder is also significantly associated with schizophrenia (P = 0.00015) 
(Williams, et al., 2011). Based on this evidence it is now widely viewed that 
schizophrenia and bipolar disorder are not aetiologically discrete entities, and cross 
diagnostic approaches should be used with regards to research (Craddock & Owen, 
2010). 
 
1.2.4 Copy Number Variation in ZNF804A 
As well as common risk associated with ZNF804A, two CNVs that include ZNF804A 
(at least in part) in patients with psychosis were identified relative to none in controls 
(Steinberg et al., 2011). The same study also identified another CNV in ZNF804A in a 
patient with anxiety (Steinberg et al., 2011). Two independent studies of autism 
spectrum disorder (ASD) subjects respectively identified CNVs spanning ZNF804A 
(Griswold, 2012) and balanced chromosomal abnormalities in ZNF804A (Talkowski et 
al., 2012). No rare SNPs within ZNF804A itself have been associated with 
schizophrenia (Dwyer et al., 2010), but identification of CNVs which include ZNF804A 
provide evidence for the contribution of rare variation in ZNF804A to the risk of 
schizophrenia and again emphasises the overlap between schizophrenia and a wider 
psychosis phenotype as well as with neurodevelopmental disorders.  
 
 
1.2.5 ZNF804A mRNA Expression   
An RNA sequencing study of differential expression of inducible pluripotent stem cells 
(iPSCs) and differentiated neurons found large expression differences in genes involved 
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in neuropsychiatric disorders, including that of ZNF804A (Lin et al., 2011). Another 
study reported that in neurons derived from human iPSCs reprogrammed from 
fibroblasts derived from schizophrenia patients, altered expression of ZNF804A 
occurred in those derived from some but not all of the patients (Brennand et al., 2011). 
A novel exon within the intron 2 of ZFP804A (denoted Exon 2.2) was recently 
discovered in post mortem brain tissue from occipital lobe and LCL cultured cells 
(Okada et al., 2012), which the authors postulate could encode a novel immature 88 
amino acid protein. Compared to equal abundance of the protein coding transcript, the 
novel variant was found to be downregulated in schizophrenia patients relative to 
controls (Okada et al., 2012). Higher ZNF804A mRNA expression has been associated 
with the schizophrenia risk allele in post-mortem brain tissue from the prefrontal cortex 
(Riley et al. 2010; Williams et al., 2010) but the former is not thought to be attributable 
to the latter (Williams et al., 2010). Expression of ZNF804A in post mortem brain 
samples from healthy individuals has in one study been shown to be dependent on an 
interaction between genotype at another associated SNP in ZNF804A (rs7597593) and 
gender (Zhang et al., 2011a). Female carriers of the protective allele had significantly 
higher levels of ZNF804A mRNA relative to risk allele carriers and a trend for reduced 
levels was observed in males with the protective allele relative to risk allele carriers 
(Zhang et al., 2011a), but this is as yet unreplicated.  
 
 
1.3. Intermediate Phenotypes and ZNF804A risk Variant.  
Studying intermediate phenotypes can be beneficial in heterogenous disorders such as 
schizophrenia (Rose et al., 2012). Aberrant connectivity has been observed in the brains 
of healthy ZNF804A risk allele carriers relative to non risk allele carriers (Esslinger et 
al., 2009; Rassetti et al. 2011; Paulus et al., 2011). Although the neurophysiological 
basis for this is unknown, this abnormal connectivity between the dorso lateral 
prefrontal cortex (dlPFC) and hippocampus suggests a role for ZNF804A at the neural 
systems level.  
 
  
9 
Based on evidence of aberrant connectivity it was postulated that white matter volume 
or connectivity may be affected in rs1344706 risk carriers (Esslinger et al., 2009). 
Increased white matter volume has been observed in healthy subjects homozygous for 
the risk allele (Lencz et al., 2010; Wei et al., 2012; Wassink et al., 2012) which might 
relate to altered connectivity in the brains of those with the risk allele. In another study, 
no main effect of rs1344706 risk variant on total brain volume or regional brain 
volumes (Cousijn et al., 2012) was identified, but an interaction between genotype and 
disorder has been reported. In that study, reduced  grey matter thickness was found in 
healthy individuals homozygous for rs1344706 risk variant (Lencz et al., 2010; 
Voineskos et al., 2011), but this contrasted with increased gray matter volume in 
patients who were homozygous risk carriers relative to non-risk allele carriers (Donohoe 
et al., 2011).  
 
However, the increased gray matter in cases who carry the risk allele may relate to a 
finding that performance in working and episodic memory tasks is better in rs1344706 
risk allele carriers compared to non-risk allele carriers, but this is observed specifically 
in patients not in controls (Walters et al., 2010). The authors of the latter study proposed 
that ZNF804A was related to a type of schizophrenia with relative sparing of cognitive 
function rather than that ZNF804A was itself increasing cognitive performance.  This 
idea was also supported by evidence that association between rs1344706 and 
schizophrenia was stronger in patients with the highest IQ (Walters et al., 2010; Chen et 
al 2012).  The observation of preserved cognitive phenotype in ZNF804A risk variant 
carriers has been replicated in schizophrenia patients in a processing speed task (Van 
Den Bossche et al., 2012).  
 
However, a deletion syndrome known as "2q31.2q32.3 syndrome," which includes the 
deletion of ZNF804A as well as NEUROD1, PDE1A and ITGA4 has been reported in 3 
patients and is characterised by clinical features including mental retardation and 
developmental delay (Cocchella et al., 2010), although the causal gene(s) for this 
phenotype are unknown.  
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Theory of mind (ToM) is a concept which encompasses an individual’s ability to infer 
the thoughts, feelings and intentions of others and marked deficits in this cognitive 
process are observed in schizophrenia patients (Bora et al., 2009).  There is evidence of 
altered activity in brain areas associated with ToM (dorsomedial PFC and left tempero-
parietal cortex) in healthy carriers of the risk allele, possibly indicating a role for 
ZNF804A in the neural networks underlying ToM processes (Walter et al., 2010). 
Executive control has also been reported to be altered in rs1344706 risk allele carriers 
(Balog et al., 2011), suggesting a broader social cognitive function for ZNF804A.  
 
Although the evidence from endophenotype studies largely remain to be confirmed, and 
the statistical support for the associations is weaker than for association to the primary 
phenotype, imaging and cognitive studies on subjects with the rs1344706 variant have 
led to the hypothesis that a subtype of schizophrenia may exist defined by a preserved 
cognitive function and increased grey matter volume present only in risk allele carriers 
(Donohoe et al., 2011). This could reflect a relatively distinct pathophysiology in those 
with the ZNF804A risk variant which if confirmed could be used to inform drug 
targeting.  
 
1.4 ZNF804A and Drug Response.  
There is weak evidence to suggest association between the risk allele at ZNF804A and 
poor response to atypical antipsychotics. Patients with the risk allele had a poorer 
response to atypical antipsychotics measured using the Positive and Negative Syndrome 
Scale (PANSS) (Zhang et al., 2012; Mossner et al., 2012). Two additional SNPs in 
ZNF804A associated with schizophrenia, rs35676856 and rs61739288 were also 
correlated with a poor response to atypical antipsychotics as measured using the 
PANNS (Xiao et al., 2011). Again, this may point to a subtype of pathophysiology, but 
since spared cognitive function is usually considered a good prognostic factor, these 
results are not obviously compatible with those from the cognition studies.  
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1.5 ZNF804A Risk Variant.  
The ZNF804A gene found on chromosome 2q32.1 has 4 exons and spans 341 kb. 
Despite extensive searching, rs1344706 was found to be the variant with the strongest 
signal for association with schizophrenia (Williams et al., 2010). As there is no 
evidence that rs1344706 is in strong LD with any other variants, the association may not 
be attributable to rs1344706 being in LD with the casual variant. The rs1344706 SNP is 
within 30bp of conserved mammalian sequence (Donohoe et al., 2010) hypothesised to 
show this degree of conservation due to the presence of transcription binding sites 
(Riley et al., 2010). Given the location of the associated SNP (rs1344706) within intron 
2 of ZNF804A, the most likely predicted function is regulation of transcription or 
splicing leading to the hypothesis that risk is inferred via altered regulation of gene 
expression or RNA processing. The prediction that the rs1344706 risk allele (T) 
maintains binding sites for the brain expressed transcription factors MYT1l and 
POU3F1/OCT-655 (Riley et al., 2010), along with evidence to show that rs1344706 
does form sequence-specific DNA-protein complexes (Hill & Bray, 2011), provides 
evidence that rs1344706 is a functional variant, but the identity of the nuclear binding 
protein(s) remains unknown (Hill & Bray, 2011). Another variant (rs13423388) 
significantly associated with schizophrenia (Zhang et al., 2011b) is found in ZNF804A 
3kb downstream of rs1344706, this region is also highly conserved between mouse and 
human (Zhang et al., 2011b; using UCSC Browser, 2009) all of which supports the 
hypothesis that the allele may be involved in transcription factor binding or splicing. 
 
1.5.1 Putative Function of ZNF804A.  
As recently as 4 years ago there were no unequivocally implicated genes in 
schizophrenia (O’Donovan et al. 2009). The replication of association between 
ZNF804A and schizophrenia provides robust evidence that it is a schizophrenia 
susceptibility gene. At the time this study started, this was the most strongly implicated 
schizophrenia susceptibility gene from which insights into schizophrenia pathogenesis 
could be derived. However, deriving such insights was hampered by the fact that the 
function of the gene was unknown. The broad basis underpinning this thesis was that 
determining the function of the protein encoded by ZNF804A may provide a valuable 
way of elucidating the pathophysiology of this common, complex disorder. 
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1.5.2. ZNF804A Protein  
ZNF804A is predicted to be a zinc finger protein containing a single zinc finger domain. 
The single domain is a cysteine2histadine2 (C2H2)-type domain. This domain is 
commonly found in transcription factors, leading to the hypothesis that ZNF804A may 
also function as a transcription factor (Williams et al, 2010), although this proposition is 
tentative since zinc finger domains are found in other classes of protein such as those 
with housekeeping functions (Pieler and Bellefroid, 1994).  
 
Changes in gene expression have been observed in both the knockdown of ZNF804A in 
a neural cell line (Hill et al., 2012) and the over expression of ZNF804A in E11 rat 
forebrain progenitor cells (Girgenti et al., 2012) with chromatin immunoprecipitation 
assays suggesting this is a direct effect of ZNF804A on expression (Girgenti et al., 
2012).  These studies are discussed in much greater detail in chapter 3, section 1. 
 
 
1.6 Mouse Models in the Understanding of the Human Brain. 
There is a high degree of conservation between mouse and human with comparable 
biochemical pathways found in the two species.  Methods of genetic manipulation are 
well characterised in the mouse and generating a strain of mice is efficient due to their 
short gestation periods (Stevens et al., 2007).  In particular inbred strains of mice have 
been created by researchers to achieve genetic homogeneity between mice of the same 
strain offering valuable consistency across different mice and research carried out in 
different labs and in different countries when using the same strain. This valuable 
resource offers the chance to attribute any phenotype to the particular manipulations 
made by the researcher, rather than genetic heterogeneity. However, inbred strains of 
mice are not immune to genetic drift or to de novo mutations and so the stable strains of 
inbred mice may not be as homogenous as previously thought (Stevens et al. 2007).  
The advantages and disadvantages of mouse models with regards to the work in this 
thesis are outlined in more detail in chapter 3, section 1.  
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1.7 The Mouse Orthologue of ZNF804A. 
The mouse orthologue of ZNF804A is Zfp804a. It is a 206, 221bp gene which encodes a 
1200aa protein. A single Refseq mRNA (NCBI) has been identified. Zfp804a has been 
identified as a downstream target of the Hoxc8 protein both in vitro and in embryonic 
mice (Chung et al., 2010). A Hoxc8 binding site has been identified within intron one of 
Zfp804a and Hox binding sites were identified that were conserved across species.  In 
response to Hoxc8 binding, Zfp804a mRNA expression has been found to be 
unregulated in vitro, suggesting the possibility that the influence of Hoxc8 on Zfp804a 
may be relevant to the pathophysiology underlying schizophrenia and psychosis.  
 
In the adult mouse brain, interaction of Hoxc8 and Zfp804a has been demonstrated in 
the cortex and in the whole brain.  The HOX protein family has been previously 
implicated in development, including particularly brain patterning (Tischfield et al., 
2005). Members of the family have been described to have altered expression in 
epilepsy, mental retardation and subtypes of ASD (Zollino et al, 2011; Bosley et al., 
2007). As Hoxc8 appears to regulate the expression of Zfp804a this could implicate 
Zfp804a as being a mediator of the effects of HOX members in developmental 
processes relevant to schizophrenia.  
 
1.8 Aims and Objectives 
The broad objectives of this thesis are to identify mechanisms by which the zinc finger 
protein 804A gene encoding ZNF804A might influence risk of schizophrenia and a 
wider psychosis phenotype. To achieve this, based upon the hypothesis that ZNF804A 
is a regulatory protein, I studied the consequences of altered ZNF804A expression in 
the brains of mice carrying truncating mutations at ZNF804A (in mouse, known as 
Zfp804a). It was my hypothesis that genes identified as showing altered expression will 
contain downstream mediators of the effects of ZNF804A on disease risk, and that 
identifying these genes would inform both on the function of this gene and on pathways 
relevant to schizophrenia. Further, under a polygenic model of disease involving large 
numbers of risk alleles, I also postulated that the human orthologues of downstream 
targets, direct and indirect, of Zfp804a will contain variants that influence risk of 
psychosis. 
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Prior to the start of this thesis, an ENU mouse line with a Zfp804a nonsense mutation 
had been bred to isolate the Zfp804a mutation from the ENU parental strain genomic 
background in order to facilitate behaviour and expression studies.  My plan was to use 
a global transcriptomics driven approach to identify genes in which mRNA expression 
is altered in the brains of animals carrying the Zfp804a nonsense mutation, and 
functional pathways enriched for such genes. The specific approaches were initially 
based upon the Affymetrix GeneChip Mouse Exon 1.0 ST Array analysis followed by 
global transcriptomics approaches based upon Illumina next generation sequencing. 
Target genes identified as differentially expressed or otherwise regulated by Zfp804a 
were then tested for aetiological relevance in the large genome-wide association case-
control datasets from subjects with schizophrenia and bipolar disorder from the 
Psychiatric GWAS Consortium (PGC, 2011a; PGC, 2011b) using a multilocus genetic 
association approach. Overall, the aim was to elucidate genes and specific 
pathophysiological mechanisms relevant to the aetiology of schizophrenia and other 
psychoses. 
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Chapter 2: Materials and Methods. 
2.1 Samples 
2.1.1 Mouse Mutant 
Prior to the work described in this thesis, a premature termination codon (PTC) 
mutation in exon 2 of Zfp804a was identified (C59X) by another PhD student (T. 
AlJanabi) who had screened an ENU mouse library (ENU DNA Archive, MRC Mary 
Lyon Centre, Harwell) consisting of thousands of DNA samples from F1 ENU 
mutagenised mice (along side frozen sperm samples). The mutation resulted in a two 
base substitution from GT to AA replacing the wild type cysteine residue with a stop 
codon and is denoted from here on as C59X. The mutation is expected to either truncate 
the translated protein or initiate nonsense mediated decay (NMD), both of which are 
predicted to result in aberrant ZNF804A protein. Following this screen of the DNA 
archive a request to Harwell was made to recover the mutation into a mutant mouse.  
2.1.2 ENU Random mutagenesis and Speed Congenics. 
ENU random mutagenesis involves the use of a chemical mutagen, ENU (N-ethyl-N-
nitrosourea) to induce germline mutations. The mutations are thought to occur at 
random throughout the genome at a rate of approximately 1.5-6 mutations per locus per 
1000 mutagenised offspring but this may vary according to the mouse strain and dose of 
the ENU (Hitotsumachi et al., 1985; Quwailid et al., 2004). Once the ENU mutations in 
Zfp804a had been chosen the mutation was recovered into a mutant mouse using 
corresponding frozen sperm from the archive at Harwell via the in vitro fertilisation 
technique, as described in Coghill et al. (2002). The ENU strain was generated from 
ENU treated male Balb/c mice bred with C3H/HeJ females as part of the UK ENU 
mouse mutagenesis program. Mutations are then screened for in the F1 mutants (Nolan 
et al., 2000). A cohort was then bred from these mice in order to generate lines used in 
the present study. F1 heterozygote mutant males from Harwell with the C59X mutation 
were backcrossed onto a C57BL/6J background using a speed congenics approach 
(Markel et al., 1997; Visscher et al., 1999) by T. AlJanabi. Backcrossing is carried out 
onto a wildtype background to remove any potential confounding mutations, natural or 
ENU derived. Using backcrossing to achieve congenicity should ensure that any 
observations made are due to the mutation of interest rather than unwanted additional 
mutations. Mice were backcrossed onto the C57BL/6J background as this strain breed 
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well and are also genetically and phenotypically well characterised. Strain specific 
markers were used to identify mice heterozygous for the ENU mutation with the highest 
proportion of C57BL/6J background strain and these mice were backcrossed onto a 
C57BL/6 background.  Using this approach, by the F3 generation the mice were 
predicted to have ~96% of the C57BL/6 background.  F3 female and male, C59X 
heterozygotes were intercrossed to produce the F3i intercross generation.  The F3i 
generation were estimated to have 96.13% C57BL/6J background. Initial expression 
analysis was carried out on the F3i generation. Higher levels of purity are ideal but 
slower progress in deriving the lines made this necessary on pragmatic grounds. Whilst 
there is the possibility of additional ENU mutations it is unlikely the same mutation 
would be found in two mice.  At the start of the study, it was anticipated the impact of 
such mutations, if they were to arise, on expression results would be unlikely to cause 
group effects, although they might result in increased noise.  To generate the 
experimental cohorts, two heterozygotes (F3) were intercrossed so that F3i homozygote, 
heterozygote and WT littermates were generated (T. AlJanabi).  
 
Mice were housed in group cages of 2-5 mice in the Behavioural Neurosciences 
Laboratory in the School of Psychology, Cardiff University. Mice were kept under a 12 
hour light dark cycle with lights on at 07:00 and lights off at 19:00 and were given food 
and water ad libitum. For breeding of the F3i generation up to four females were 
introduced to the male’s homecage and left for one week. Females not pregnant after 
two weeks and infertile males were removed from the breeding programme.  
 
2.1.3 Brain Tissue Collection 
Mice were euthanized by cervical dislocation (schedule 1) following which the brain 
was extracted from the skull and immediately snap frozen in liquid nitrogen after which 
it was stored at -80°C until further processing.   
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2.2 DNA/RNA extraction 
2.2.1 DNA Extraction. 
Genomic DNA was extracted from mouse tail tips. Tail tips were immediately snap 
frozen in liquid nitrogen and stored at -80c until DNA extraction. Tails were lysed using 
a 400-500μl (dependent of tail size) mix of Protinase K and a tail lysis buffer and left 
overnight in a 55-60°c water bath. Samples were then spun for 10 minutes (13000rpm at 
4°C) and the supernatant was transferred to a new tube. An equal volume of isopropanol 
was added to the supernatant, mixed and then left for 20-30 minutes at 2-8°C. Each 
sample was then centrifuged for 10 minutes (13000rpm at 4°C) and the supernatant was 
discarded. Samples were left to air dry for 1 hour and the resultant DNA was 
resuspended in 100μl of nuclease-free water.   
2.2.2 RNA Extraction 
1ml of Trizol (Sigma,  St. Louis, MO) was added to brain tissue in a matrix tube (MP 
Biomedicals) and homogenised using a Bio-one homogenizer. Following centrifugation 
(12,000 x g for 5 minutes at 4°C) the supernatant was transferred to a new tube and 
allowed to stand at room temperature (RT) for 5 minutes. Chloroform (0.2ml/1ml of 
Trizol) was then added and the tube was shaken for 15 seconds before again being left 
to stand at RT this time for 10 minutes. Samples were centrifuged (12, 000 x g for 15 
minutes at 4°C) before removing the upper phase to a fresh tube. RT isopropanol was 
then added at 1/10
th
 the volume in the tube and samples were left to stand for 5mins at 
RT before centrifugation (12, 000 x g for 10 minutes at 4°C). 0.5ml of isopropanol was 
added to the supernatant in a new tube and left to stand at RT for 10 minutes then 
centrifuged (12, 000 x g for 10 minutes at 4°C). The supernatant was then discarded 
leaving the RNA pellet in the tube. Following a wash with 1ml of 75% EtOH (made 
with nuclease-free water) the samples were centrifuged (12, 000 x g for 5 minutes at 
4°C) and the supernatant was discarded. Pellets were air dried for ~ 10 minutes prior to 
resuspension in 50μl RNase-free water.  
2.2.2.1 RNA Clean Up – Column Purification. 
Following RNA extraction total RNA was purified to remove excess salts and 
contaminants using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions.  
  
18 
2.2.2.2 DNase Treatment 
Removal of contaminating DNA was facilitated by using the DNA-free kit (Ambion) 
which uses recombinant DNase1 for the digestion of any DNA present in the RNA 
sample. The procedure was carried out according to the manufacturer’s instructions.  
2.2.3 RNA quality assessment  
RNA quality was determined using two measures; the ratio of two ribosomal RNAs 
(28s/18s) and the RNA integrity number (RIN) both of which were analysed using the 
Agilent 2100 Bioanalyser.  
 
2.2.3.1 Agilent 2100 Bioanalyser. 
A chip containing the RNA samples, a size ladder and a fluorescence marker was 
inserted into a Bioanalyser, microfluidic station. The principle behind the instrument is 
much like electrophoresis. A voltage gradient is run across the chip via an electrode and 
due to the negatively charged nature of RNA it migrates through a polymer matrix.  
Smaller molecules pass through the matrix easier, thus the matrix separates the 
molecules according to size. The dye molecules intercalate and migrate with the RNA 
and fluorescence is recorded using laser activation.  An RNA 6000 ladder was run as a 
reference and contains 6 individual fragments which range in size from 0.2 – 6 Kb. 
Each sample was compared to the ladder fragments to determine its concentration and 
enable the identification of the rRNA peaks. Good quality, intact RNA is defined by the 
following features;  
 Two clear and distinct ribosomal RNA peaks (28s and 18s rRNA).  
 The baseline between the internal marker and the 18s peak is relatively flat. The 
absence of peaks in this region means there is no or very little smaller molecules 
in the sample which represent degraded rRNA or tRNAs. (rRNA is particularly 
sensitive to degradation if extracted from tissue using mechanical 
homogenisation or if the tissue has been frozen as both make shearing of the 
molecules more likely. The 28s rRNA is particularly sensitive to shearing as it is 
a larger molecule than the 18s rRNA). 
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2.2.3.2. 28s/18s rRNA Ratio. 
The rRNA ratio is determined by dividing the 28s peak by the 18s peak. As 28s is the 
larger molecule the ratio is expected to be 2:1 (2>) if no degradation of the RNA has 
occurred. Due to the mechanical nature of tissue homogenisation this is rarely the case 
and a ratio of 1 or above is acceptable for most analyses (Ambion).  
 
2.2.3.3 RNA Integrity Number (RIN). 
The RIN metric is produced after running the RNA sample on an Agilent bioanalyser. 
The entire electropherogram of each sample is considered, not just the two rRNA peaks 
and a score from 1-10 is generated with 1 representing the most degraded RNA and 10 
representing intact RNA.  
 
RIN is generally a reliable metric, but it does not always equate that a good RIN score 
will mean the experiment being undertaken will be successful. It is also important to 
note that rRNA integrity is used to infer mRNA integrity. Both are usually comparable, 
but differences can occur as rRNA is considered more stable.  For gene expression 
assays such as microarrays, the consensus is that a RIN of at least 7 is adequate, but 8 or 
above is preferable (Schroeder et al., 2006).  
 
2.3 Reverse Transcription.  
Using the Superscript II First-Strand synthesis system for RT-PCR (Invitrogen) and 
random primers (Invitrogen) 1μg of DNase treated total RNA was used as a template for 
cDNA synthesis according to the manufacturer’s instructions.  
 
2.4 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) allows the amplification of a specific DNA target. 
DNA is synthesised using the enzyme Taq Polymerase in addition to the 4 
deoxyribonucleotide triphosphates (dNTPs), adenine (A), cytosine (C), guanine (G) and 
thymine (T) and standard buffer. Oligonucleotide primers are designed which are 
complementary to the sequence flanking the region to be amplified. The complementary 
strand of DNA is then synthesised in a 5’-3’ direction with the two primers acting as the 
double stranded starting point, initiating DNA synthesis. A series of approximately 30-
  
20 
45 temperature cycles facilitates the 3 steps of PCR to be carried out. The first step 
involves the denaturing of the double stranded DNA leaving a single stranded DNA 
template. The primers then anneal to their complementary sequence on the single 
stranded DNA. The final elongation step allows the synthesis of the complementary 
DNA strand by taq polymerase.  
  
2.4.1 Primer design 
Primers were designed using primer3 (v 0.4.0, 
http://frodo.wi.mit.edu/primer3/input.htm) and BLAST Primer 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/), which uses a combination of the 
primer3 algorithm and BLAST to determine primer specificity against the mouse 
genome database (National Centre for Biotechnology Information). Specificity was also 
checked using BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat) (Kent, 2002a). Default 
settings were used where possible so that primer annealing temperature was ~60°C and 
GC content was between 30 and 80%. Primers were synthesised by Sigma. 
 
2.4.2 PCR Optimisation 
PCR reactions were performed using C1000 Thermocyclers (BioRad Laboratories, Inc). 
HotStar Taq (Qiagen) was used in all PCR reactions. The standard PCR cycling 
conditions are outlined below. When an assay failed using these conditions, PCR was 
carried out on control samples to find the optimum temperature for primer annealing 
(Tm) using a temperature gradient.  PCR was performed in 12µl reaction volumes using 
3µl genomic DNA (4ng/µl), 0.56µl of each primer (5pmol concentration), 0.96µl 
dNTPs (5mM each), 1.2µl of 10X buffer (Qiagen), and 0.06µl of HotStarTaq 
polymerase (10units/µl, Qiagen).   
For cDNA the 20μl product from the RT-PCR of 1μg RNA was diluted 1:5. Then 3μl 
added to the mastermix as described above.  
 
PCR cycling Conditions.  
1. 95°C for 15 minutes 
2. 94°C for 20 seconds 
  
21 
3. ~60°C for 30 seconds 
4. 72°C for 1 minute 
5. Repeats steps 2-4 for 44 cycles 
6. 72°C for 10 minutes 
7. 15°C hold 
 
2.4.3 Agarose Gel Electrophoresis  
PCR products were separated by size and visualised using agarose gel electrophoresis, 
which is facilitated by the negatively charged phosphate groups of DNA. The porous 
nature of the agarose gel allows the negatively charged DNA to move toward the anode 
when an electric current is applied. The rate at which the DNA fragment moves toward 
the anode is a property of fragment size, smaller fragments passing with less resistance 
than larger ones.  
Gels were 1-2% agarose, dependent upon the resolution required. A 1.5 % gel was 
comprised of 1.5g of agarose (AGTC Bioproducts) dissolved in 100ml of 0.5x TBE 
buffer (Ultra Pure electrophoresis grade, National Diagnostics).  The solution was 
heated to dissolve the agarose and then cooled slightly once clear. 1.5µl of Ethidium 
Bromide solution (10mg/ml) was then added. The solution was poured into a gel cast, 
into which gel combs had been placed to allow well formation and allowed to cool to a 
solid.  
Appropriate volumes of PCR product and a loading buffer were combined prior to 
loading into a well in the gel. 6x loading buffer was made up of 15% ficoll, 0.25% 
bromophenol blue, and 0.25% xylene cyanel in water. To determine the size of each 
fragment, 2µl of size standard (1kb plus DNA ladder, Invitrogen) was run alongside 
each row of samples. Gels were run in electrophoresis tanks at 100-120V for a time 
appropriate to separate a fragment of the expected size. DNA fragments were visualised 
using a UV transilluminator (UVP) and images were recorded using a Kodak 
Electrophoresis Gel analysis system.  
2.5 Genotyping 
Samples were initially genotyped by sequencing genomic DNA or mRNA using Sanger 
sequencing of exons 1-3 of Zfp804a (described in full in 2.6). Primers in Appendix 2.1.  
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An assay was then designed utilising high resolution melting analysis (HRMA) 
(described in full in section 2.7). 
 
2.6 Sequencing  
Sequencing was carried out using the Sanger Sequencing technique implemented using 
Big Dye termination chemistry (Applied Biosystems). Four fluorescently labelled 
dideoxy-nucleotide-triphosphates (ddATP, ddCTP, ddGTP and ddTTP) when 
incorporated, terminate DNA synthesis during primer extension. In doing so a series of 
nested fragments are produced each varying in length by a single base. By running the 
sample through a capillary on a 3100 capillary sequencer (Applied Biosystems, Foster 
City, CA) the fragments are sorted in size and a base specific fluorescent dye allows the 
identity of each terminal base to be identified using a fluorescence detector. 
 
2.6.1 PCR Clean up 
PCR products were purified using Ampure XP® (Agencourt). 12µl of the PCR product 
was mixed with 18µl of Ampure reagent using a Beckman-Coulter NX liquid handler. 
This enables the removal of contaminants such as salts, primers, DNA polymerases and 
unincorporated dNTPs. Ampure XP® consists of para-magnetic particles to which PCR 
amplicons bind. This facilitated the separation of PCR products from contaminants with 
the use of a magnet, to which the magnetic particles (bound with the DNA) adhered.  
Contaminants (not stuck to the magnetic beads) were then washed away using 85% 
Ethanol.  Purified product was eluted in 195µl of nuclease free water.  
 
2.6.2 Sequencing Reaction 
5µl of clean product was added to 5µl of sequencing reaction mix. Sequencing reaction 
mix was made up of 1.917µl 5X BigDye sequencing buffer, 0.116µl BigDye 
termination mix, 1µl of forward or reverse PCR primer (4pmol/µl) and 1.917µl nuclease 
free water. The BigDye termination mix includes the four dNTPs which are unlabelled 
along with the four fluorescently labelled dideoxyribonucleotide triphosphates 
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(ddNTPs) and the Sequenase enzyme. The sequencing reaction consisted of the 
following steps: 
1. 96°C for 2 minutes 
2. 96°C for 10 seconds 
3. 50°C for 5 seconds 
4. 60°C for 4 minutes 
5. Repeat steps 2-4 for 24 cycles 
6. 4°C for 4 minutes 
 2.6.3 Post Sequencing Clean up 
The clean up reaction was carried using the Beckman-Coulter NX liquid handler. 
Contaminants such as salts, primers, DNA polymerases and unincorporated ddNTPs 
were removed by mixing 10µl of PCR product with 7.5µl of CleanSeq® (Agencourt) 
reagent which contains magnetic beads to which the amplimeres bind. When the 
magnetic beads bind to a magnet, the unbound contaminants can be washed away with 
85% Ethanol.  Purified PCR products were then eluted in 90µl sterile water.  
2.6.4 Sequencing Analysis of C59X in Zfp804a  
Cleaned sequence products were passed to the School of Medicine Central Biological 
Services (CBS) for running on an ABI3100 36cm capillary sequencer (Applied 
Biosystems, Foster City, CA) with polyacrylamide POP6 (Applied Biosystems). The 
raw data generated were analysed using Sequence Analysis Software (Applied 
Biosystems) contained on the AB3100 PRISM genetic analyser. Each base was called 
according to its corresponding fluorescent signal. Genotype was then determined using 
a combination of NovoSNP (Weckx et al., 2005) and Sequencher (Gene Codes) 
software. In each instance the sequence traces of each sample were aligned to a 
reference sequence. The position of the C59X mutation was inspected in each sample to 
determine if the sample was a homozygous wildtype, C59X heterozygous or C59X 
homozygous mutant (Fig. 2.1).  
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Figure 2.1. Sequencing the C59X mutation.  Examples of sequencing traces from 
NovoSNP (Weckx et al., 2005). From top to bottom a homozygote wildtype mouse, a 
C59X heterozygote and a C59X homozygote mutant. Between the two vertical lines is 
the cysteine residue in the homozygote wildtype and the stop codon following a two 
base substitution from GT to AA in the C59X homozygote mutant. 
 
2.7 High Resolution Melting Analysis (HRMA). 
In order to quickly determine the genotype of each sample, an assay was designed 
which utilised the high resolution melting analysis technique.  This analysis is based on 
the principle that the melting temperature of a PCR amplimere is a product of its 
sequence composition (Ririe et al., 1997). Utilising fluorescent dyes which bind to 
double stranded DNA, the melt curve of the DNA during the extension phase of PCR 
can be monitored in real time using changes in fluorescence to indicate the release of 
the fluorescent dye from single stranded DNA. Melt profiles are compared to a 
reference sequence and differences from the reference are observed as a change in the 
melting temperature (Liew et al 2004; Palais et al., 2005). Changes in the shape of the 
melting curve are indicative of hetero and homoduplexes, which are formed during PCR 
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of heterozygous loci (Graham et al., 2005). Homozygous wildtypes and C59X mutants 
were distinguishable from C59X heterozygotes, which meant the requirement for 
further homozygotes was quickly determined, however the distinction between wildtype 
and C59X mutant homozygotes required the sample to be further processed using 
Sanger sequencing to confirm genotype and so the attempt to make the genotyping 
process more efficient was ultimately not achieved.  
2.7.1. HRMA PCR Conditions.  
A 12µl PCR reaction was made up of; 4µl genomic DNA (4ng/µl), 0.56µl of each 
primer (5pmol concentration), 0.96µl dNTPs (5mM each), 1.2µl of 10X LCgreen Plus 
(Idaho Technologies), 1.2µl of 10x LCgreen Plus 20mM MgCl PCR Buffer (Idaho 
Technologies) and 0.06µl of HotStarTaq polymerase (10units/µl, Qiagen). Primers were 
designed to span the mutation in exon 2 of Zfp804a (Appendix 2.2)and the PCR cycling 
conditions were as described in 2.4.2.  
HMRA was performed according to the manufacturer’s instructions using a 
LightScanner (Idaho Technologies). 12µl of each sample was denatured by increasing 
the temperature at a rate of 0.1°C/s to a maximum temperature of 98°C. Fluorescent 
datapoints were collected continuously at a rate of 14 points/°C. Using a semi-
automated analysis (Dwyer et al., 2009) the melting profiles were assessed. Once 
normalised, samples were analysed using the LightScanner software Call-IT
TM
 (Idaho 
Technologies) using the high sensitivity setting. The melt curve profile for each sample 
was plotted and then automatically called by the software by grouping samples 
according to similarity.   
 
2.8 Global Analysis of Gene Expression. 
2.8.1 Exon Arrays 
The Affymetrix GeneChip Mouse Exon 1.0 ST array (exon array) was chosen for 
expression analysis as it facilitates fairly comprehensive and accurate measurement of 
gene expression changes as well as the identification of both known and novel splice 
events. The chip contains over 5 million probes targeting all known and predicted 
mouse exons. The difference between the exon array and the more traditional 3’ in vitro 
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transcription (IVT) arrays is the removal of mismatch control probes for each of the 
probes on the chip, which frees considerable space for more probes to target exons 
throughout a transcript. Despite quite considerable differences in the design of exon 
chip relative to 3’ arrays, gene expression performance has been shown to be 
comparable in several studies (Bemmo et al., 2008; Okoniewski et al., 2007) with 
sensitivity levels for detecting gene expression in the same range as the 3’ IVT arrays 
(Abdueva et al. 2007). Each of the 5 million probes are 25 bases in length and have 
been synthesised on to the exon array which consists of a coated quartz surface. As 
described in detail below, fluorescently labelled RNA hybridised to the exon array and 
the fluorescent signal was used to infer and quantify expression levels.  
2.8.2 RNA Labelling, Hybridisation and Scanning of Exon Arrays 
All labelling, hybridisation and scanning steps were carried out by Central 
Biotechnology Services (CBS), Cardiff University.  
2.8.2.1 RNA Labelling  
Extracted total RNA was prepared for hybridisation to the exon chip using the Whole 
Transcriptome (WT) Expression Kit (Ambion) and the Affymetrix Genechip WT 
terminal labelling kit (Affymetrix, Santa Clara, CA, USA). RNA was reverse 
transcribed to first strand cDNA using specially engineered primers with a T7 promoter 
(Ambion). Primers were not complementary to ribosomal RNA (rRNA) sequences, 
removing the requirement to carry out an rRNA reduction step. Both poly-A and non 
poly-A mRNA (Ambion Protocol) was targeted.   
 
Second strand synthesis was carried out using DNA polymerase followed by RNA 
degradation using RNase H. Using an in vitro transcription step complementary 
(antisense) RNA (cRNA) was synthesised using T7 RNA polymerase from the second 
strand cDNA template (Van Gelder et al., 1990). Transcribed cRNA was then purified 
using nucleic acid binding beads and isopropanol to remove any unwanted salts or 
enzymes. A second cycle of cDNA synthesis was then completed by reverse 
transcribing 10μg of cRNA using random primers. Fragmentation of the cDNA was 
carried out as part of the Affymetrix Genechip WT terminal labelling kit. To ensure 
reproducible and uniform fragments the kit incorporated dUTP into the DNA as part of 
the first-strand cDNA synthesis reaction in the second cycle. Both UDG (uracil DNA 
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glycosylase) and APE 1 (apurinic/apyrimidinic endonuclease 1) were used to treat the 
DNA and recognise and cleave at the unnatural dUTP sites during the fragmentation 
step. Fragments were approximately 25-200 bases in length. RNase H was again used to 
degrade the RNA, followed by clean up of the remaining single stranded cDNA. Clean-
up was performed using nucleic acid binding beads and ethanol.   
 
Samples were labelled with terminal deoxynucleotidyl transferase (TdT) using an 
Affymetrix DNA labelling reagent covalently linked to biotin. This method, in contrast 
to the traditional 3’ IVT array, utilises random hexamer- linked T7 promoters to 
synthesise cDNA so that a DNA/DNA complex forms on hybridisation to the chip and 
amplification is not restricted to polyA RNA (Abdueva et al., 2007). 
 
2.8.2.2 Exogenous Spike-in Controls. 
Affymetrix kits include spike-in controls which are added to each sample prior to first 
strand synthesis and allow the user to assess the efficiency of the hybridisation process. 
These positive controls are a set of Escherichia coli genes; BioB, BioC, BioD and cre. 
The genes are not present in eukaryotic samples and so act as exogenous controls. Each 
is spiked-in at a known concentration and amplified simultaneously with the sample. 
The concentration of each control is such that a certain rank order of intensities is 
expected allowing the efficiency of the hybridisation process to be determined 
independent of sample quality (Affymetrix Protocol).  Oligo B2 is also used as it 
specifically hybridises to probes placed at the corners of each array and is used by the 
Affymetrix console software to align grids to the chip (Bolstad, 2008). 
 
2.8.2.3 Hybridisation and Scanning of the Exon Array 
A hybridisation cocktail made up of the labelled cDNA and the controls was inserted 
into the exon chips (Fig. 2.2). Following 16hr hybridisation, the hybridisation cocktail 
was removed and replaced with wash buffer. Chips were then washed and stained with a 
series of stain cocktails (Genechip Hybridisation, Wash and Stain Kit, Affymetrix) 
using a fluidics station 450 (Affymetrix). Streptavidin-phycoerythrin (SAPE) was used 
to stain the chips, binding to the biotin label (Bolstad, 2008). Each chip was inserted 
into the scanner (GeneChip Scanner 3000 7G, Affymetrix) and the Affymetrix 
GeneChip Command Console (AGCC) was used to control the scanning process. A raw 
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image or .dat file was initially generated.  Each exon array contains features or squares 
approximately 3μm in size. Raw data were aligned to the grid system using the Oligo 
B2 controls (2.8.2.2) allowing the intensity of each feature to be determined (Bolstad, 
2008).  Intensity of each feature was calculated by considering only pixels which 
resided within the feature, not those found on the border (Bolstad, 2008).  The intensity 
data for each feature or probe cell is then acquired by AGCC to generate the probe cell 
intensity file (CEL file) which is commonly the starting point for exon array analysis.  
The chip was then ejected from the scanner.  
 
      This image has been removed by the author for copyright reasons. 
 
Figure 2.2 The Affymetrix GeneChip Mouse Exon 1.0 ST Array. Hybridisation 
cocktail, including the labelled cDNA sample is inserted into the chip via the septa. 
(Diagram Courtesy of Affymetrix from the Affymetrix GeneChip® WT terminal 
labelling and hybridisation user manual).  
 
2.8.3 Expression Analysis  
2.8.3.1 Partek Genomics Suite. 
Partek Genomics Suite (version 6.5 and beta 6.6, St. Louis, MO) is a purpose built 
software suite designed to enable analysis of a number of high-throughput technologies.  
 
2.8.3.2 Data upload  
Initially samples were uploaded into Partek as CEL files. With each set of CEL files a 
corresponding sample sheet was prepared and uploaded. This contained information 
such as sample ID, age, gender and genotype and allowed the grouping of samples 
according to these attributes. The import process was customised to allow samples to be 
preprocessed with the criteria required for the specific experiment.  
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2.8.3.3 Preprocessing 
Once raw intensity values (CEL files) are generated several steps must take place in 
order to produce meaningful expression data. These steps collectively are termed 
preprocessing. The purpose of preprocessing is to standardise the data obtained across 
all of the chips in a study to produce results with minimal batch differences and to 
identify any potential outliers. Preprocessing consists of 3 discrete steps, which I carried 
out in the following order; background correction, normalisation and summarization.  
2.8.3.3.1. Robust Multichip Averaging (RMA).  
The method chosen to carry out preprocessing was the Robust Multichip Averaging 
(RMA) procedure (Irrizarry et al. 2003) which does not rely on mismatch (MM) probe 
values. Previous Affymetrix arrays contained a corresponding MM probe for each 
perfect match (PM) probe on the array. The MM probes differ from the PM probes at 
the 13
th
 base only and as such are used to measure non-specific binding.  As the exon 
array has no MM probes, RMA is therefore suitable for exon array analysis. RMA was 
carried out using both Partek Genomics Suite (Partek Incorporated, St Louis, USA) and 
Expression ConsoleTM V1.1.2 (Affymetrix). In each case only the core probes were 
included. During preprocessing using RMA, raw data (X) undergo background 
correction (B), normalisation (N) and then summarisation (S) to produce expression 
data (E) so that E = S(N(B(X))). 
2.8.3.3.2 Background Correction.  
RMA uses a convolution model for background correction. The idea is that the probe 
signal (S) will consist of both signal (x) and background (y), (S = x + y). The model 
uses a smoothed density plot to assume that x will be distributed exponentially (α) and 
that y is distributed normally (N(μ,σ2 )). Background correction uses the observed signal 
to predict the expected signal intensity for each probe, once non-specific signal has been 
removed (Bolstad, 2008). At this step each array is corrected independently using 
values found only on that array.   
To obtain the estimates a nonparametric test is used. PM probe intensities are plotted, 
and then a density estimator is fitted, which estimates the mode of the distribution. 
Anything above the mode is used to predict the exponential parameter. The normal 
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distribution is determined by fitting a half normal to anything below the model (Bolstad, 
2008; Irrizarry et al., 2003a) 
2.8.3.3.3 Normalisation.  
Normalisation is required to remove obscuring or technical variation, which is not a 
result of true biological differences between samples. Normalisation was carried out 
using the quantile normalisation method. Previous studies, reviewing several different 
methods showed quantile normalisation worked most effectively (Bolstad et al., 2003) 
and allowed more sensitive and specific detection of differential expression when using 
GeneChips, which have a 1 sample/array design (Irrizarry et al., 2003).  
The aim of quantile normalisation is to make the distribution of the probe intensities the 
same for each of the arrays in the experiment. Normalising the distribution of each array 
to the mean distribution should remove inter array variance. No reference array is used, 
instead each arrays’ probe level values are sorted (ranked).  Quantile normalisation is 
carried out at the probe level for every probe on each array (Bolstad et al., 2003). The 
non-parametric, quantile normalisation algorithm uses a matrix and essentially sorts and 
averages across rows and columns representing probes and arrays respectively. Initially 
the probe intensities are sorted from lowest to highest for each of the arrays. Then the 
average of each quantile is determined by averaging probe intensities across each row of 
the dataset.  The columns are then rearranged so that each probe intensity value goes 
back to its original ranked position (Bolstad et al., 2003).  
2.8.3.3.4 Probe Summarisation. 
A summary measure called median polish was carried out on background adjusted, 
normalised and log2 transformed PM values, to estimate log scale expression values 
(Irrizarry et al., 2003b). This was performed by fitting a robust linear model at the probe 
level, ensuring any probe-specific affinity differences would have a minimal effect. The 
RMA model uses the assumption that a probe’s expression level is determined by how 
much RNA there is available to bind to the probe (the chip effect, e) the affinity of the 
probe (a) and the error in measurement (ε) applied to the following formula: 
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PMij = ei + aj + εij 
 
Where i represents the array and j the probe. Based on the intensity value for a 
particular probeset (PMij) the algorithm determines the possible combinations of e and a 
that would result in the observed PM value (Irrizarry et al., 2003b). 
Each probe in an Affymetrix probeset interrogates a different segment of a gene 
(Gardina & Turpaz, 2008).  Summarisation acts to combine the signal intensity for 
probes within a probeset to obtain a single expression value for the probeset (Bemmo et 
al., 2008).    
2.8.3.4 Annotating the Dataset. 
Probes on the Affymetrix exon array are annotated as either core, extended or full. The 
labels denote the annotation confidence of the sequence targeted by each probe. Probes 
which target Refseqs or mRNAs from Genbank have the highest level of annotation 
confidence and are termed core probesets. Probesets with an extended annotation, target 
sequences defined using expressed sequence tags (ESTs). Probesets annotated as full 
have the lowest annotation confidence and target transcripts annotated using ab initio 
prediction software.  
All analyses reported in this thesis were restricted to the core metaprobe set, unless 
otherwise stated which target genes which have been sequenced, cloned and curated 
manually (Gardina & Turpaz, 2008). By removing more speculative content the 
likelihood of false positive calls was reduced (Gardina & Turpaz, 2008). All core 
probesets have been defined by Affymetrix as unique, meaning they should not cross-
hybridise. Restriction to the core probesets meant a total of ~15,000 genes, which were 
either RefSeq genes or full length mRNA from GenBank were included.  
There is no perfect congruence between a probeset and an exon. Each probeset covers 
what Affymetrix define as a probeset region (PSR). Each PSR represents a region of the 
genome which is considered to be independent unit (Robinson & Speed, 2009) and is 
generally represented by 4 probes.  Data were analysed using the Affymetrix annotation 
files, NetAffx, version na31. mm9. 
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2.8.3.5 Quality Control Measures. 
Standard QC measures were undertaken to identify potential dataset outliers that might 
indicate technical problems in the analysis of individual samples. A series of metrics 
were generated using Affymetrix Expression Console (Version 1.1.2) and Partek GS 
(v6.6). All metrics were generated following RMA at the gene level on core probes. 
Using only the core meta-probeset removes the potential of increased variability due to 
the higher rate of unexpressed genes found in the extended and full annotations.  
Both the mean absolute deviation (MAD) and relative log expression (RLE) metrics 
were chosen as they are robust against experimental conditions (Gardina & Turpaz, 
2008).  Present/absent calls were generated at the probeset level as detection p values. 
Whilst no standardised cutoffs currently exist, the QC measures were useful for 
identifying potential outliers, which if present were removed or closely monitored in 
downstream statistical analysis (Gardina & Turpaz, 2008). 
 
2.8.3.5.1 Affymetrix Expression Console (v1.1.2) 
Following download of the appropriate library file (MoEx-1_0-st-v1.) from Net affx 
(Affymetrix), CEL files were uploaded and summarised to produce a probe level 
summarisation file (CHP file). Exon arrays were analysed using the RMA-sketch 
workflow as this allows both gene and exon level analysis (Affymetrix).  
2.8.3.5.2 Principle Component Analysis (PCA). 
To visualise similarities and differences in the expression data PCA was carried out 
using Partek GS. PCA reduces the dimensionality of the data to a few components 
which between them explain most of the variance in the data.  
2.8.3.5.3 Exogenous Spike-in Controls. 
As described in 2.8.2.2, exogenous controls added at known concentrations were used 
to assess the efficiency of the hybridisation, wash and scanning procedures. Adequate 
efficiency was denoted by the correct rank order in the intensity of each control.   
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2.8.3.5.4 All Probeset (and Positive Control) RLE Mean. 
The ‘all probeset RLE mean’ measures the mean absolute relative log expression 
(RLE). To determine this statistic the signal of each probeset on an array is compared to 
the median signal value across all arrays in the study. The metric is the mean of these 
differences from all the probe sets. This is the measure of how different a sample is 
relative to the consensus, with very high values denoting an array with different signals 
from others in the experiment (Affymetrix, 2007).  
2.8.3.5.5 Perfect Match (PM) Mean.  
This metric is based on raw intensity data and represents the mean intensity for all 
perfect match (PM) probes on the array before pre-processing (e.g., RMA) (Affymetrix, 
2007).  
2.8.3.5.6 All Probeset (and Positive Control) Mean Absolute Deviation (Mad) 
Residual Mean.  
Different probes will give out different intensities even when a common target binds to 
them. RMA creates a model for these individual probe responses and arrays with 
multiple probes behaving differently to the model can then be identified.  Differences 
between predicted and actual values are defined as the residual. Each probe will have a 
residual value from the model. An individual probe residual value that varies from the 
median reflects a poor fit to the model. By determining the mean absolute deviation, the 
overall fit to the model of every probe on the array can be established.  If the residuals 
have a very large mean absolute deviation from the median value this is indicative of 
arrays with poor quality data (Affymetrix, 2007).  
2.8.3.5.7 Positive vs. Negative AUC. 
This metric measures the area under the curve (auc) of a receiver operating 
characteristic (ROC) plot. The ROC curve is a plot of the detection of positive controls 
against the false detection of negative controls (exon and intron probesets respectively, 
which target ~100 constitutively expressed genes). To generate the curve it must be 
determined if the probeset signals effectively separate positive control signals and 
negative control signals, which measure true and false positives respectively. It is a 
robust measurement for overall data quality often used as a first pass metric. Typical 
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values range between 0.8 and 0.9. In theory a value of 1 for this metric would indicate 
perfect separation, but a value of 0.5 or below indicates no separation and thus no 
difference between positive and negative controls (Affymetrix, 2007). Whilst values 
falling significantly below 0.8 may indicate an outlier, values above 0.8 do not 
necessarily indicate good quality data (Affymetrix, 2008).  
2.8.3.6 Statistical Analysis 
Statistical analysis was carried out using Partek Genomics Suite (v6.5 Partek Inc, St. 
Loius, MO, USA).  
2.8.3.6.1 Differential Expression Algorithm. 
Exons were first summarised to genes using the mean of probeset intensities. The core 
gene summary file was then used as the input file for the statistical analysis, performed 
to determine differentially expressed genes between wildtypes and C59X mutants. A 1-
way ANOVA model was used which implemented the Method of Moments (Eisenhart, 
1947). The model included: 
Yij = μ + Genotypei+ εij 
In this model Yij represents the j
th
 observation on the i
th
 Genotype.  μ is the common 
effect for the whole experiment.  εij represents the random error present in the j
th 
observation on the i
th
 Genotype.  Errors εij are assumed to be normally and 
independently distributed with mean 0 and standard deviation δ for all measurements. 
In addition to determining differentially expressed genes a linear contrast between 2 
specific groups within the context of an ANOVA was performed to determine fold 
changes between wildtype and C59X mutants. Fisher's Least Significant Difference 
(LSD) method was used to determine fold changes between wildtypes and C59X 
mutants (Tamhane and Dunlop, 2000). 
2.8.3.6.2 Filtering 
Whilst gene level analysis does not vary from the traditional 3’ IVT workflow, exon 
level analysis requires additional steps to control the false positive rate. These include 
filtering data prior to statistical analysis thus reducing the need for multiple test 
correction (MTC) and visual inspection of data (Affymetrix, 2006). The most common 
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filtering procedure is the removal of probesets based on low annotation confidence and 
as described previously only probesets with the highest annotation confidence (core 
probesets) were included. It is also common for probesets to be removed based on 
expression signal. This is particularly relevant to exon arrays as low expression can be 
misinterpreted as differential splicing. Probesets were filtered based on signal intensity 
values. Initially probesets with a maximum log2 signal < 3 were excluded from the 
statistical analysis. This threshold was then increased to 4, 5 and 6 and the group mean 
log2 intensity was also considered. Final analyses were based on criteria that excluded 
any probeset with a group mean, log2 intensity signal <6.  
 
2.8.3.6.3 Alternative Splicing Algorithm  
Alternative splice p values were generated using Partek Genomics Suite’s custom 
alternative splice ANOVA. A one-way ANOVA was used for the individual female and 
male experiments, but for the combined analysis a two-way ANOVA was used, which 
included gender as a factor in addition to genotype. In both cases the ANOVA 
implemented the Method of Moments (Eisenhart, 1947). In all instances genotype was 
used as the alternative splice factor, allowing splice differences between C59X mutants 
and wildtypes to be identified. Differential splicing in C59X mutants was identified 
using the following model: 
γ = µ + G + E + G*E + S(G) + ε 
Where γ is the expression of the transcript  
µ is the mean expression of the transcript,  
G is the gene expression differences between the two levels of genotype  
E is the differential exon expression, independent of genotype   
G*E is the interaction of splicing and genotype (differential exon expression between 
mutant and wildtype),  
S is the sample effect, denoted as both a random effect (this assumes animals used are 
representative of the population and these exact samples would not be represented 
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again) and nested in genotype (meaning no one sample belonged to both genotype 
groups) 
and ε is the error term  
The ANOVA uses an interaction term between the two groups and the probeset (G*E) 
to see if probeset expression varies at the two levels of group (C59X mutants and 
wildtypes) (Bemmo et al., 2008).  Both differential expression and alternative splice p 
values are generated from this model which is performed at the exon level. To 
determine fold change at the transcript and exon level a linear contrast was included in 
the model between C59X mutants and wildtypes using the Fisher's Least Significant 
Difference (LSD) method (Tamhane and Dunlop, 2000). 
2.8.3.6.4 Multiple Test Correction (MTC) and Non-independence of data. 
Carrying out multiple tests on the same dataset increases the chance of falsely rejecting 
the null hypothesis. This problem is particularly applicable to the exon array as 1.4 
million tests would need to be carried out to analyse all the data on the array. It has been 
estimated that this could result in as many as 70,000 false positives (5%) (Okoniewski 
& Miller, 2008). Conventionally this type of issue is corrected using a Bonferroni 
Correction (Holm, 1979) in which the desired p value threshold (e.g., p<0.05) is divided 
by the number of test being carried out. This type of correction conserves the family-
wise error rate (FWER) by reducing the probability that any given individual significant 
result represents a type I error. Using such a stringent correction does however have a 
direct consequence on the number of type-II errors generated (the rejection of true 
effects).  
Whilst the application of Bonferroni MTC to the array data is easy to implement to 
standard array results the exon array is more complex. Due to data being generated at 
the exon level, one of the key assumptions is violated as there is non-independence 
between the probesets of a gene.  
Currently, there is no consensus on how to deal with multiple testing in exome level 
data. Some recommend pre analysis filtering to reduce the number of tests by as much 
as possible to reduce the necessity for MTC (Della et al., 2008; Okoniewski and Miller 
2008; Whistler et al., 2010) but this offers no general solution.  
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In the absence of an accepted approach, I applied both Bonferroni correction and the 
false discovery rate (FDR) (Benjamini and Hochberg, 1995) methods to gene 
expression and alternative splice data. The FDR ascribes a threshold to the significant 
data so that it will contain a predefined number of false positives (Okoniewski and 
Miller 2008). It can also give an idea of how reliable the dataset is overall (Okoniewski 
and Miller 2008). An FDR threshold of 0.05 was set. The Bonferroni correction is the 
most conservative MTC method giving increased confidence that findings surviving this 
stringent correction are true findings.  
 
2.8.3.7 Visualisation of Alternative Splice Events. 
Predicted splice changes were visualised using the geneview produced as part of the 
alternative splice output. Probeset intensity was plotted for each group. To compare the 
results to known gene annotations, the data were also visualised using the UCSC 
genome browser (Kent et al., 2002b) (http://genome.ucsc.edu/). This was done by first 
identifying the sequence of the probeset using the probeset ID entered into NetAffx 
(http://www.affymetrix.com/analysis/index.affx). Then this sequence was BLATed in 
the UCSC genome browser (Kent et al., 2002a).  
 
2.8.4 Alternative Algorithms for Detecting Differential Splicing.  
The following software programmes and algorithms were used in addition to Partek GS 
and the Alternative Splice ANOVA to establish how robust the results generated were. 
2.8.4.1 easyExon  
easyExon (Chang et al., 2008) is a software tool developed for the assessment of CEL 
files to determine differentially expressed and spliced genes.  The software was used in 
addition to Partek GS as the different filtering criteria and statistical algorithms 
implemented allowed the opportunity to determine how robust events identified in 
Partek GS were by determining if they replicated with these different criteria.  easyExon 
was launched from the command line and CEL files were uploaded and preprocessed 
using Affymetrix Power Tools (APT), which generated the summary files required for 
statistical analysis. The RMA-sketch preprocessing algorithm was selected using the 
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mm9 mouse database and the core meta-probeset. Detection above background (DABG) 
p values were also generated and included in the summary files. This measure allows 
distinction between probesets expressed above and within the background signal. A 
significant p value (p≤0.05) represents a probeset with signal above background signal. 
Probesets were excluded if DABG p value was >0.05 in at least half of the samples 
(4/8) (default setting).  Any probesets not meeting the criteria were represented in grey 
in the graphical representation.  A log stabilisation factor of 16 was added to the 
summarised signal prior to log transformation. Transcript clusters were excluded if they 
contained less than 4 or more than 200 probesets as visual inspection is difficult when 
probesets exceed these limits. The statistical algorithm chosen was MiDAS (as 
described in 2.8.4.3). A MiDAS p value of ≤0.05 was considered significant.  
 
2.8.4.2 AltAnalyze (v.2.0.7) 
AltAnalyze is open access software for alternative splice analysis (Emig et al., 2010). 
After specifying the use of an Affymetrix platform, the species mus musculus and the 
Exon ST array, CEL files were processed. Prior to calculations of gene expression 
probesets with large cross-hybridisation scores were removed. The core meta-probeset 
was used to determine both gene expression and alternative splicing so as to be 
consistent with the Partek GS analyses. This is in accordance with the Affymetrix 
recommendation that core probes are used to determine constitutive gene expression. It 
is important to note at this stage, that the way in which AltAnalyze defines the core 
probeset differs slightly to that in Partek. Whilst the Affymetrix annotated core 
probesets form the core set of probesets, any probesets which uniquely align to a single 
Ensembl gene are included in addition.  This means the AltAnalyze defined core meta-
probeset contains a larger number of probesets therefore probesets may be included in 
the analysis which wouldn’t be present when carrying out core probeset analyses in 
Partek.  
Probesets were required to have detection above background (DABG) p values ≤0.05 
and an accompanying non-log expression value greater than 70 to be included in the 
analyses.  Gene expression was first calculated and the above expression criteria had to 
be met in at least one of the experimental groups for the probeset to be included. Gene 
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expression was calculated by averaging the expression of all core probesets aligning to a 
particular gene. Gene expression measures are also used to normalise probeset 
expression when determining differential splicing. In this case the probeset had to be 
expressed (as defined by the aforementioned criteria) in both groups. This excludes the 
possibility of a probeset being predicted as differentially spliced when in fact the gene is 
not expressed in one of the groups. Genes were excluded from differential splice 
analysis if none of the probesets within the gene met the criteria.  The FIRMA 
algorithm (Purdom et al., 2008) was chosen for the differential splice analysis again 
using the core probesets.  Mutants were defined as the experimental group and 
wildtypes as the baseline group.  By default genes with differential expression fold 
changes above 3 are excluded from the differential splice output as the differential 
splicing is likely to be a consequence of the differential gene expression.  
Differential expression is determined using a 1-way ANOVA and adjusted for multiple-
test correction using the Benjamini and Hochberg (1995) FDR.  Fold changes are 
calculated using a geometric subtraction of the experimental group from the wildtypes. 
Fold change is the non log2 transformed fold value.  
In AltAnlayse the FIRMA output differs slightly to the method initially proposed by 
Purdom et al. (2008) (described in 2.8.4.4) as only summary statistics are presented, 
which are generated by taking the average FIRMA score for the control group and 
subtracting it from the average FIRMA score of the experimental group. 
2.8.4.3 Microarray detection of Alternative Splicing (MiDAS). 
Microarray analysis of differential splicing (MADS or MiDAS) was developed to 
overcome the increased noise found on Affymetrix arrays due to having ~4 probes per 
exon (Xing et al., 2008). This increased noise was thought to impair the detection of 
true splice events. MiDAS is based on the ANOVA algorithm and determines 
differences in exon and gene level signals. The probe logarithmic intensity error 
(PLIER) algorithm is implemented to generate gene level signals from all probes within 
each exon of the gene (Affymetrix, 2005b). Background noise is removed by using the 
median intensity of GC matched antigenomic probes on the array then exon level 
expression is estimated using PLIER.  The method assumes that under the null 
hypothesis, if an exon is not differentially spliced the log expression at that exon will 
not differ from gene level signal for all samples (Affymetrix, 2005b). The ratio between 
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exon and gene signal is determined using the splicing index logged. Variance is 
stabilised by adding a constant prior to logging.  
2.8.4.4 FIRMA. 
Finding isoforms using Robust Multichip Analysis (FIRMA) is a robust RMA model, 
fitted at the probe level (Purdom et al., 2008). FIRMA determines how consistent 
expression is at a probeset relative to transcript expression within a particular sample. 
Initially each gene’s expression level is estimated using the RMA model (Irizarry et al., 
2003) then alternative splicing is determined using a score generated from the 
estimation step.  Each exon is given a score based on how much its probe’s signals 
deviate from the expected gene expression level (Purdom et al., 2008). FIRMA is a 
more general additive model than the RMA model (described in 2.8.3.3.1). First the 
RMA model is fitted then the residuals from this are produced. A score for each exon (j) 
and sample (i) is generated based on the median of the four residuals (one for each 
probe) of that exon (j) and sample (i). This score is used to determine how much the 
exon signal differs from the expected transcript expression.    
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Chapter 3: Expression analysis in Zfp804a ENU mutant mice 
3.1 Introduction.   
The availability of a mouse with disrupted Zfp804a offers the opportunity to investigate 
consequences of that disruption. In doing so, I aim to identify possible disease 
mechanisms.  Several approaches could be taken to achieve this, but I chose gene 
expression analysis, due to the availability of accurate and efficient global assays for the 
quantification of mRNA expression relative to global proteomics assays for mice, with 
the caveat that mRNA abundance would not necessarily equate to protein abundance 
due to post-transcriptional regulation processes. Measuring mRNA in the brains of mice 
with disrupted Zfp804a would allow consequential altered expression of downstream 
targets to be identified and if achieved this would provide evidence that Zfp804a does 
have a function in the regulation of the expression of other genes. Identifying the 
biological pathways, which subsets of these genes belong to may help identify 
molecular mechanisms relevant to the aetiology of schizophrenia and psychosis. By 
comparing gene expression in Zfp804a mutants and wildtype mice using a global exon 
microarray, expression or splicing changes between the mutants and wildtypes could 
highlight genes influenced by Zfp804a which could be implicated in schizophrenia and 
would imply a direct or indirect role for Zfp804a in the regulation of expression and or 
splicing. Determining a role for Zfp804a in splicing regulation irrespective of which 
genes are spliced would be informative. In addition to elucidating ZNF804A function 
other schizophrenia susceptibility genes, could be determined, which may allow a more 
comprehensive understanding of pathways affected in schizophrenia aetiology.  
 
To investigate the consequences of disrupted Zfp804a on gene expression and splicing, 
studies could be carried out using mouse models or cell lines. Whilst both have certain 
advantages and limitations, as discussed below, I chose to carryout global expression 
analyses using a mouse model, however complementary work using cell lines was also 
carried out by another PhD student.  The mouse as a model organism offers high system 
complexity and a high degree of conservation with humans.  The similar anatomy of the 
mouse and human brain is another advantage of using mice as model organisms as well 
as the availability of a broad range of validated behavioural tests, the results of which 
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can be used to complement genetic studies (Eriksen & Janus, 2007). In addition 
extensive research carried out using mouse models has facilitated the acquisition of a 
large amount of data and with the use of inbred strains of mice, assurance that mice will 
be genetically almost identical, with the exception of naturally occurring new mutations. 
The C57BL/6J strain used for backcrossing (described in chapter 2.1.2) was the first 
mouse strain to have its genome sequenced and as such is genetically well characterised 
(Mouse Genome Sequencing Consortium et al., 2002).  Mouse models are commonly 
used in expression studies to understand the function of human genes in diseases such 
as amyotrophic lateral sclerosis (ALS) (Chen et al., 2010) and Huntington’s disease 
(Morton et al., 2005). The short gestation of the mouse and ability to easily manipulate 
and monitor their external environment makes the mouse model extremely suitable for 
studies investigating gene expression.  Certain caveats need to be considered when 
translating findings from mouse models to human disorders. Results can be affected by 
genetic variation among mice, phenotypic differences can occur dependent on the strain 
of mouse used and biochemical differences can prevent the same mutation in the 
homologous gene creating the same phenotype in a mouse (Erickson, 1996). 
Differences in mouse and human life-spans are not always relative in terms of disease 
for example in Duchenne’s muscular (DM) dystrophy the mutation of the gene Mdx is 
not symptomatic in mice and may reflect that the disease is not normally diagnosed 
until the second year in humans which is the entire lifespan of a mouse (Erickson, 
1996). Generating mouse models can be very time consuming and costly in contrast to 
studies using cell lines which are relatively cost effective and cells can be readily 
manipulated, but the caveat with this work being that they do not necessarily provide an 
accurate model of the cell in vivo.    
 
A genome-wide significant and replicated association at the ZNF804A locus with 
schizophrenia (O’Donovan et al., 2008; Stefannson et al., 2009; ISC 2009, Riley et al., 
2010; Williams et al., 2010; Steinberg et al., 2011; Zhang et al 2011a 2011b) suggests 
that despite conferring a small effect ZNF804A is a schizophrenia susceptibility gene. It 
is important to consider that association studies point to a region not a gene, but there is 
no evidence for any other functional units in the region. At the time of the first 
published association, very little was known about the gene and its encoded protein and 
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four years later there is still very little published evidence pertaining to the function of 
ZNF804A and how it may influence disease risk.   
Given the location of the associated SNP (rs1344706) within intron 2 of ZNF804A, the 
most likely predicted function is regulation of transcription or splicing leading to the 
hypothesis that risk is inferred via altered regulation of gene expression or RNA 
processing. Fine mapping and resequencing have not uncovered a more strongly 
associated SNP, nor was rs1344706 found to be in strong linkage disequilibrium (LD) 
with any other variant. This led the authors to tentatively conclude the association is 
unlikely to be because rs1344706 is in LD with another variant that is causal (Williams 
et al., 2010). rs1344706 is located within a ~30bp region of conserved mammalian 
sequence (Donohoe, et al. 2010), hypothesised to show this degree of conservation due 
to the presence of transcription binding sites (Riley et al 2010). Higher ZNF804A RNA 
expression is associated with the risk allele in post-mortem brain tissue (Riley et al. 
2010; Williams et al., 2010).    
 
In the presence of the rs1344706 risk allele (T), the adjacent sequence was predicted, 
using bioinformatics, to be a binding site of the brain expressed transcription factors 
Myt1L and POU3F1/Oct655. Both are predicted to have functions in the development 
of the CNS and in particular oligodendrocyte development (Nielsen et al,. 2004; 
Collarini et al., 1992).  Sequence including the protective allele (G) was predicted to be 
a binding site for two other transcription factors, the ubiquitously expressed Homez and 
the CNS expressed Hmx2 (Riley et al., 2010). Evidence that rs1344706 does form 
sequence-specific DNA-protein complexes with nuclear binding proteins was found 
using electromobility shift assays (EMSA) and highlights rs1344706 as a functional 
variant (Hill & Bray, 2011). The prediction that the nuclear transcription factors Homez 
and Hmx2 bound to sequence containing the rs1344706 G allele (Riley et al., 2010) was 
not, however confirmed (Hill and Bray, 2011) and the identity of the nuclear binding 
protein(s) remains unknown.  The intensity of nuclear protein binding was increased 
when the protective allele (G) was present in the oligonucleotide sequence relative to 
the risk allele (T). Allele specific alterations in DNA-protein complex formation may 
explain the association of the risk allele with increased ZNF804A mRNA expression 
(Riley et al., 2010, Williams et al., 2010).  These findings do not rule out the presence 
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of other functional variants in ZNF804A, but they do provide a functional basis for a 
direct association involving rs1344706.  
Within ZNF804A, also within intron 2 approximately 3kb downstream of the associated 
SNP is another highly conserved region between mouse and human (Zhang et al., 
2011b; using UCSC Browser, 2009).  The conserved nature of this region may suggest 
its involvement in transcription factor binding or splicing. Interestingly, one variant 
within this conserved region, rs13423388 showed some evidence for association with 
schizophrenia (Zhang et al., 2011b) but no studies to date have determined if allelic 
differences at this SNP affect ZNF804A expression. 
The ZNF804A protein has been predicted to contain a single zinc finger domain. This 
domain, specifically a Cys2His2 (C2H2)-like fold group, is the best characterised of the 
many classes of zinc fingers. C2H2-type domains are known for their sequence specific 
DNA-binding properties, as well as protein-protein interactions and RNA binding 
(Gamsjaeger et al., 2007) and are commonly found in transcription factors. Thus a role 
for ZNF804A in the regulation of gene expression has been proposed. ZNF804A has 
two paralogues ZNF804B and GPATCH8. Like ZNF804A, little is known about these 
two genes affording little insight into the possible functions of ZNF804A. However, 
GPATCH8 is thought to encode a protein with a zinc finger domain and an RNA 
processing domain (Kaneko et al., 2011). 
 
To date, two independent studies have evaluated the effects of altered ZNF804A 
expression on downstream gene expression. Knockdown of ZNF804A in a neural cell 
line resulted in 154 consistent expression changes between mutant and wildtype in two 
siRNA experiments (Hill et al., 2012), more than would be expected by chance. 
Pathway analysis of the corresponding transcripts revealed enrichment for genes in 
biological adhesion pathways as well as the subsidiary cell adhesion pathway (Hill et 
al., 2012).  Overexpression of ZNF804A in E11 rat forebrain progenitor cells resulted in 
expression changes in 4 of 37 previously implicated schizophrenia genes (Girgenti et 
al., 2012). At the cellular level there is reason to believe from two studies that 
ZNF804A has a direct or indirect effect on gene expression. To evaluate if ZNF804A 
directly or indirectly regulates expression a Chromatin immunoprecipitation assay 
(ChIP) was utilised. Binding of ZNF804A was observed in the promoter regions of 2 of 
the 4 genes, PRSS16 and COMT. Both genes contained motifs predicted to interact with 
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zinc fingers consistent with the CHiP binding and a direct effect of ZNF804A on 
expression (Girgenti et al., 2012).  
Whilst there is a growing body of evidence pointing to a role for ZNF804A in 
transcription regulation, no study to date has considered the implications of altered 
ZNF804A on splicing. The proportion of splice events predicted to be conserved 
between human and mouse are small (Nurtdinov et al., 2003; Sorek et al., 2004). The 
splice events that are conserved may be indicative of isoforms with critical biological 
functions (Sorek et al., 2004).  
Alternative splicing is now thought of as the primary mechanism responsible for 
generating much of the diversity observed in the human proteome. Alternative splicing 
involves the processing of multiple mature mRNA transcripts from a single precursor 
mRNA and is thought to occur in as many as 50% of human genes (Johnson et al., 
2003) and ~95% of multi-exon genes (Wang et al. 2008; Pan et al. 2008). 
Approximately 15% of point mutations leading to Mendelian disease do so by affecting 
splicing (Johnson et al., 2003), with aberrant splicing being associated with a number of 
diseases including cancer (Venables, 2006) and cystic fibrosis (Faustino & Cooper, 
2003).  The omission or inclusion of functional domains via alternative splicing can 
alter the function of the encoded protein.  Alternative splicing can also affect protein 
function by altering the affinity of the protein to other proteins or ligands (Yeo et al., 
2005). Factors influencing alternative splicing include the secondary structure of the 
mRNA, the elongation rate of RNA polymerase II and perhaps most influential, RNA 
binding proteins, which bind to cis-elements found in both the exon and the intron of 
the pre-mRNA and either enhance or silence splicing. The length of the exon and intron 
as well as the strength of the splice site have also been implicated in splice regulation 
(Yeo et al., 2005) as have epigenetic mechanisms (Luco & Misteli, 2011).  Changes in 
chromatin conformation can alter the elongation rate of RNA polymerase II. A faster 
elongation rate increases the likelihood that multiple splice sites will become accessible 
to the splicing machinery essentially simultaneously. If one splice site is weaker than 
the other the machinery is likely to be recruited to the stronger splice site due to the 
competitive nature of the binding.  Studies have shown that dense nucleosome regions 
slow the elongation rate of RNA polymerase II (Hodges et al., 2009). This increases the 
time for spliceosome assembly at weaker splice sites promoting the inclusion of cassette 
exons. There is also thought to be an enrichment of histone marks at exons. The histone 
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marks are thought to recruit RNA binding proteins, which when bound to the pre-
mRNA can enhance or repress splicing (Luco & Misteli, 2011).   
Microarray analysis has, until recently been the primary technique used to study global 
gene expression. Its high throughput capabilities revolutionized the way in which the 
transcriptome was studied and with lowering costs, the use of arrays has enabled large 
amounts of expression data to be generated. However, the completion of the human 
genome project afforded a better understanding of the mechanisms important in 
generating proteome diversity namely alternative splicing, thus the shortcomings of 
traditional microarrays were highlighted. The placement of probes at the 3’ end of the 
transcript meant alternative isoforms in which the 3’ exon was spliced out were not 
assayed and that those with common 3’ ends could not be distinguished. From these 
arrays an incomplete picture of the transcriptome was generated as well as potentially 
incorrect measurements of total gene expression. The necessity to incorporate and 
measure expression of alternatively spliced isoforms is now widely recognised and 
investigators can now choose arrays in which probes are placed throughout the 
transcript allowing known and novel splice events to be interrogated in addition to the 
investigation of total gene expression changes (Okoniewski & Miller, 2008).  
GWAS of psychosis have identified several associations and pointed to a number of 
possible susceptibility genes, however understanding the function of these genes and the 
mechanisms responsible for disease pathophysiology requires additional experiments. In 
this thesis, to investigate potential effects of ZNF804A on gene expression and RNA 
processing, a mouse line in which the ZNF804A orthologue, Zfp804a had been 
identified as mutated in an ENU library at Harwell (ENU DNA Archive, MRC Mary 
Lyon Centre, Harwell) was utilised. The mutation generated a premature termination 
codon (PTC) in exon 2 of Zfp804a (chapter 2.1.2) which is likely to disrupt Zfp804a 
function either through an aberrant product or activation of the nonsense mediated 
decay mechanism.  
Nonsense mediated decay (NMD) is highly conserved across species and acts as both a 
surveillance mechanism, distinguishing premature and normal stop codons, as well as a 
regulator of gene expression (Stalder & Mühlemann, 2008). NMD inhibits translation 
and leads to the decay of the NMD substrate (Rebbapragada & Lykke-Anderen, 2009). 
Both transcription and splicing are necessary for NMD, exemplified by the insensitivity 
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of intronless genes harbouring PTCs to NMD (Stalder & Mühlemann, 2008). The NMD 
mechanism is only triggered if a premature termination codon (PTC) is more than 50-
54bp upstream of an exon-exon boundary (Nagy & Maquat, 1998).  NMD reduces the 
abundance of C-terminally truncated polypeptides which could have deleterious, 
dominant negative or gain of function effects (Frishmeyer & Dietz, 1999).   
Initiation of NMD is dependent upon the position of the PTC. If the PTC is less than 50-
54 nucleotides upstream of the last exon-exon junction it is possible that the transcript 
will escape NMD (Bashyam, 2009). Correct definition of exon-exon boundaries is 
critical to the NMD mechanism, exemplifying why splicing is critical to NMD, at least 
in the mammalian system. The regulation of this process is enhanced by exon junction 
complexes (EJC) which help to define exon-exon junctions.  EJCs are deposited during 
splicing 20-24bp upstream (5’) of each exon-exon junction, in a sequence non-specific 
manner. A termination codon upstream of one or more EJCs triggers NMD (Lykke-
Anderson, 2002).  Based on the above criteria it was anticipated that the PTC in exon 2 
of Zfp804a would trigger the NMD mechanism resulting in the reduced abundance of 
the Zfp804a mRNA transcript in the C59X mutants relative to the wildtypes.  
 
Work Described. 
The objective was to identify the unknown mechanisms by which the ZNF804A gene, 
encoding ZNF804A, influences risk of schizophrenia and bipolar disorder. The presence 
of a classic Cis(2)His(2) (C2H2) zinc finger domain commonly found in transcription 
factors, along with evidence of allelic differences in the binding intensity of nuclear 
binding proteins at rs1344706 (Hill & Bray, 2011; Riley et al., 2010) may predict a role 
for ZNF804A at the level of transcription regulation and RNA processing. To test these 
hypotheses, and with the aim of identifying mechanisms downstream of ZNF804A 
which may influence disease risk, the impact of  altered ZNF804A function on gene 
expression in the brains of mice which carry a truncating mutation in the mouse 
orthologue of ZNF804A, Zfp804a was determined.  
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3.2 Methods 
3.2.1 Sample  
A mouse line carrying an ENU induced premature termination codon (PTC) in exon 2 
of Zfp804a was rederived by in vitro fertilization at Harwell (ENU DNA Archive, MRC 
Mary Lyon Centre, Harwell). The mutation is denoted as C59X as it involves a two base 
substitution from GT to AA resulting in the replacement of a cysteine residue with a 
stop codon. Founder mice (F1) with the C59X mutation were then generated from a 
Balb/c x C3H/Hej cross (ENU treated male Balb/c mice bred with C3H/HeJ females) at 
Harwell, these F1 mice were then bred to form the experimental cohort by another PhD 
student at Cardiff University (T. AlJanabi). C59X mice were backcrossed onto the 
C57BL/6J mouse strain to obtain congenicity. This process was accelerated using the 
speed congenics method, in which mice were screened for strain specific markers. Mice 
carrying the ENU mutation which also had the highest proportion of C57BL/6J markers 
were used in the breeding experiments. F3 generation female C59X heterozygotes were 
intercrossed with F3 male C59X heterozygotes to produce the F3i intercross generation 
from which the brain tissue was derived for initial expression studies. The F3i 
generation were estimated to have 96.13% C57BL/6J background. This level of 
C57BL/6J background was not ideal (as discussed in 2.1.2), but provided a useful 
screen in which any observable expression differences could be validated in mice with 
>97% purity when these mice became available.  
3.2.1.1 The Zfp804a C59X Mice. 
All experiments were conducted on brain tissue extracted from mice with a nonsense 
mutation in exon 2 (C59X) of the Zfp804a gene (Fig. 1) or their wildtype littermates.  
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Figure 1. PTC Mutation in Zfp804a. The ENU mutation chosen to be re-derived into 
a line was a PTC in exon 2 of Zfp804a. The mutation is a dinucleotide polymorphism 
from GT to AA creating a premature stop codon (TAA) (C59X).   
 
Third generation (F3i) mice with estimated 96.13% pure C57BL/6J background (i.e., the 
non-ENU background) were available at the time of conducting the initial expression 
studies. While ideally, higher levels of non-ENU background are desirable (in case 
additional ENU induced mutations are present) the likelihood that any two mice would 
have the same undesired ENU mutation is small (probability calculations are discussed 
in Chapter 2.1.2).  
Genotype had no obvious effect on development or health of the mice (T. AlJanabi). 
Prior to expression analysis male Zfp804a mutant mice were observed on a range of 
behavioural tests carried out by another PhD student (T. AlJanabi) to characterise 
behavioural phenotypes that may result from the PTC. Behavioural tests included 
locomotor activity, PPI open field, elevated plus maze and rotarod and a subset of the 
mice spent 24hrs in a phenotyper. None of the mice received drug treatments nor did 
they undergo any food or water restriction programs. Further details are provided in 
Chapter 2.1.2.  
Two waves of expression studies were carried out on adult C59X brain tissue, the first 
in female mice and the second in males. As all the males of the F3i cohort were used for 
the initial battery of behavioural experiments there was a restricted number of C59X 
mutants available for expression studies as the availability of brain tissue from the mice 
was dependent upon their completion of behavioural tests. A greater availability of 
female C59X homozygotes dictated that the first wave of expression analyses was 
carried out on 3.5 month old female C59X mutant and wildtype mice. A sufficient 
number of male C59X mutants of the same generation (F3i) became available once all 
Zfp804a 
PTC NTC 
 PTC = Premature Termination Codon 
NTC = Natural Termination Codon 
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behavioural tasks had been completed, by which time these mice were 6 months old. 
Both time points represent sexually mature adult mice. 
 
3.2.2 Female C59X Expression Study. 
8 mice were included in the first expression experiment, 4 wild type at the ZNF804A 
locus and 4 homozygotes (for the PTC mutation in exon 2). All were 3.5 months old. 
Following brain dissection (Chapter 2.1.3) RNA was extracted from the left hemisphere 
as described (Chapter 2.1.3). The integrity of the RNA was determined using the 
Agilent 2100 Bioanalyser (Chapter 2.2.3.1). 
 
 
3.2.3 Male C59X Expression Study. 
The second wave of expression experiments consisted of 8 male mice, 5 wild type at the 
ZNF804A locus and 3 homozygotes (for the PTC mutation in exon 2). RNA was 
extracted from the whole brain as previously described. Male mice were 6 months old. 
Evaluation in male mice allowed the exclusion of expression changes occurring due to 
variation in stage of the female oestrous cycle.  
Whilst half brains were used in the first wave, whole brains were considered in the 
second wave to rule out hemispheric effects on expression.  
 
3.2.4 Combined Analyses. 
To increase the power of the study all 16 samples were analysed in a combined analysis 
consisting of 9 wildtype and 7 C59X mutant samples. Differences in gender, age and 
scan date were accounted for in the study as described later.   
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3.2.5 Zfp804a mRNA Levels. 
The nonsense mutation within exon 2 of Zfp804a was predicted to initiate the nonsense 
mediated decay surveillance mechanism. Activation of such a mechanism would be 
expected to result in the reduced abundance of the mRNA transcript. To determine if 
such a mechanism was occurring in the C59X mice qualitative analysis of the Zfp804a 
mRNA transcript was performed using RT-PCR. 
 
3.2.6 Sequencing the Mutation. 
Amplified cDNA was sequenced from the mice to ensure the mutants were expressing 
the mutation in the mature message. Sequencing was carried out using the primers 
specified in appendix 2.1. Sequencing is described in full in Chapter 2.6. 
 
 
3.2.7 Sample preparation and quality. 
Brains were removed and immediately snap frozen in Liquid Nitrogen. Brains were 
taken from storage at -80°C and RNA was isolated by myself from either the left 
hemisphere or whole brain (minus olfactory bulbs) and stored at -80°C. RNA was 
isolated and processed as described in Chapter 2.2 & 2.3. 
 
3.2.8 The Affymetrix Genechip Mouse Exon 1.0 ST Array 
The initial acquisition of brain tissue, RNA preparation and all statistical analyses were 
carried out by me. The labelling, hybridisation and scanning steps were carried out at 
Cardiff University by M. Musson within the Central Biotechnology Services (CBS) 
facility as described in section 2.8.  
Labelling, hybridisation and scanning procedures are described in full in Chapter 2, 
Section 2.8.2.  
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3.2.9 Statistical Analysis 
3.2.9.1 Partek Genomics Suite (Version 6.5) 
Partek Genomics Suite (version 6.5 and beta 6.6, St. Louis, MO) is a purpose built 
software suite designed to enable analysis of a number of high-throughput technologies.  
3.2.9.2 Data upload 
CEL files were uploaded into Partek GS and sample files were produced using Excel 
(2007) allowing the identification of experimental groups to be recognised by the 
software (See 2.8.3.2).  
 
3.2.9.3 Probe Filtering  
Only the core meta-probeset was included in the analysis, unless stated otherwise. 
 
3.2.9.4 Preprocessing  
Once raw intensity values (CEL files) were generated several steps were taken in order 
to produce meaningful expression data. These steps collectively are termed 
preprocessing (Chapter 2, Section 2.8.3.3). Samples were preprocessed using robust 
multichip averaging (RMA) (Irrizarry et al. 2003). The algorithm consists of three 
discrete steps background correction, normalisation using quantile normalisation and 
summarisation using the median polish technique. Intensity values were Log 
transformed (base 2).  Full details are given in Chapter 2, section 2.8.3.3. 
 
3.2.9.4.1 Background Correction 
Background correction removed non-biological variation. This was carried out on each 
chip independently (Chapter 2, section 2.8.3.3.2).   
 
3.2.9.4.2 Quantile Normalisation 
Following background correction the data were normalised to remove array bias or 
variation which is not a result of true biological differences between samples. The 
technique used for normalisation was quantile normalisation which was carried out 
across all chips on background corrected data (Chapter 2.8.3.3.3).   
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3.2.9.4.3 Probe Summarisation 
Summarisation of probe level data to a combined probeset intensity value was achieved 
using the median polish algorithm. This was the final of the three RMA steps and was 
performed on background corrected, normalised and log transformed intensity values 
(Chapter 2.8.3.3.4). 
3.2.9.5 Annotating the Dataset 
Data were analysed using the Affymetrix annotation files, NetAffx, version na31. mm9. 
Using only the core meta-probeset meant targeted sequences had been sequenced, 
cloned and curated manually and therefore had high annotation confidence 
(Affymetrix).  Only probes annotated by Affymetrix as unique were included in my 
analysis to account for the problem of probe cross-hybridisation. 
 
3.2.9.6 Quality Control (QC) 
Following preprocessing, I reviewed a number of recommended quality control metrics 
in order to check the quality of the data. QC is particularly important with exon array 
data which is prone to greater numbers of false positives as excess noise can be 
misinterpreted as differential splicing (Gardina & Turpaz, 2008).  I generated standard 
QC measures, described in chapter 2.8.3.5 using Expression Console (Affymetrix, 
Version 1.1.2) and Partek GS (v6.6). QC was run at the Gene level on all CEL files 
using RMA sketch on core probes and using a log2 scale.  
There are no standardized cut offs. For this reason, as recommended by Affymetrix the 
distribution of several metrics was assessed to ensure the microarray experiment has 
passed a minimum level of quality control. Within each metric, any sample with values 
two standard deviations away from the mean was flagged. Samples outside of this range 
across 3 or more metrics were either excluded or monitored in all downstream analyses, 
dependent on the severity of the case (Gardina & Turpaz, 2008). Removal of an outlier 
in only two or three metrics may be more detrimental than beneficial depending on 
sample size, as power may be considerably reduced. As there was no standard 
procedure outliers were removed in extreme cases (outlying in more than 3 metrics). 
Samples with values outlying in 3 or less metrics were instead monitored after statistical 
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analysis to ensure they were not behaving differently to other samples within the 
experimental group. Samples were considered as one single group and also within their 
experimental group (wildtype or C59X mutant). Samples were assessed within their 
experimental groups as they would be expected to behave more similarly and so outliers 
may be more apparent. 
3.2.9.7 Filtering 
Probesets were filtered prior to statistical analysis based on annotation confidence and 
intensity, to optimise the likelihood of identifying true expression differences.  
Probesets were initially excluded if they had a maximum log2 intensity value <3, but 
this was increased for more stringent analysis. 
 
 
3.2.9.8. Statistical Algorithm. 
Details of the algorithms used to calculate differential expression and splicing p values 
are given in Chapter 2, section 8.3.6.1 & 3. Briefly I determined differential expression 
and splicing using the custom alternative splice ANOVA in Partek Genomics Suite. A 
one-way ANOVA was performed for individual female and male experiments with a 
two-way ANOVA used in the combined male/female analyses in order to covary for 
gender differences. In all instances genotype was added to the model and was specified 
as the alternative splice factor, meaning differential splicing was determined based on 
differential probeset expression across the 2 levels of genotype (wildtype and C59X 
mutant). A total of 15,808 and 15,813 transcript clusters were included in the female 
and male analyses respectively which equates to ~194,000 probesets. Gender was added 
to the model for all combined analyses to account for gender differences. This was also 
perfectly correlated with age, scan date, and hemisphere versus whole brain differences 
between samples. Thus all variance attributable to these factors are embraced by a 
single factor. For combined analyses 15,833 probesets were tested following probeset 
filtering. Both differential expression and differential splicing p values were generated 
from this model. Genes showing significant differential expression and splicing were 
then filtered and prioritised based on statistical significance.  To determine fold change 
at the transcript level a linear contrast was included in the model between C59X 
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mutants and wildtypes using the Fisher's Least Significant Difference (LSD) method 
(Tamhane and Dunlop, 2000).  
3.2.9.9 Multiple Test Correction (MTC) 
Data were corrected for multiple testing using both the step up False Discovery Rate 
(FDR) (Benjamini & Hochberg, 1995) and the more stringent Bonferroni correction 
(Holm, 1979). An FDR threshold of 0.05 was set, meaning 5% of the results were 
expected to be false positives. The Bonferroni correction is the most conservative MTC 
method as p values are corrected by the number of tests carried out.  
 
3.2.10 Visualisation of Alternative Splice Events. 
Visual inspection was carried out for differentially expressed and spliced genes using 
the geneview produced as part of the alternative splice output. The geneview plots the 
expression at each probeset across the transcript for each experimental group and allows 
the position of the probeset to be visualised relative to the exons of the transcript using a 
RefSeq track from the UCSC genome browser (Kent et al., 2002b) 
(http://genome.ucsc.edu/).  
 
3.2.11 Degree of Overlap. 
To determine how robust the differential expression and splice results were, the degree 
of overlap or replication between female and male experiments was assessed. Simply 
considering whether compared with a null distribution, there is an excess of transcripts 
significant in the female experiment that are also significant in the male experiment 
does not account for the possibility of non-null distributions in the two datasets (i.e. if in 
a replication dataset, 50% of all genes show nominally significant effects, then by 
chance, not 5% but 50% of genes significant in a discovery sample should show effects 
that replicate at the P=0.05 level). To account for this a 2x2 contingency table (Table 1) 
was constructed and statistical analysis performed using the chi-square test (χ2) to 
determine whether the proportion of genes that replicate differ contingent on whether 
they were or were not significant in the other dataset. The Pearson’s chi-square test was 
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performed using SPSS (v16), except for instances in which the expected cell frequency 
was less than 5, in which case the Fisher’s exact test was used.   
 
 
 Male Experiment -
Significant Genes 
Male Experiment – Non-
Significant Genes 
Female 
Experiment -
Significant Genes 
n =  number of genes 
significant in both 
female and male 
analyses 
n = number of genes significant 
in the female experiment that are 
not significant in the male 
experiment 
Female 
Experiment -  Non-
Significant Genes 
 n = number of genes 
not significant in 
Female experiment 
that are significant in 
the male experiment 
n = number of genes that are not 
significant in either analysis 
Table 1. 2x2 Contingency table used for Chi-square test. 
 
3.2.12 Alternative Algorithms for Detecting Splicing. 
Multiple statistical algorithms are available for the analysis of differential splicing from 
exon array data. The underlying structure of each model has the same fundamental 
assumptions in that probeset expression is predicted by the model and compared to the 
null hypothesis that the expression of the probeset is proportional to other probesets 
within a gene across all samples considered (Affymetrix, 2005b). Each algorithm 
determines how much the probeset expression diverges from the model and a p value is 
generated based on this. Affymetrix recommended considering several different tests on 
the data for robust identification of alternative splice events. Within this thesis I used 
the ANOVA (Chapter 2.8.3.6.3) FIRMA (Chapter 2.8.4.4) and MiDAS (Chapter 
2.8.4.3) statistical algorithms each described in full in Chapter 2.  
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3.3 Results. 
3.3.1. Abundance of Zfp804a Transcript. 
To establish if the NMD mechanism was operating in the C59X homozygote mice, 
levels of Zfp804a mRNA were qualitatively assessed using RT-PCR. Zfp804a mRNA 
was expressed in homozygote C59X mice as well as in WT mice (Figure 3.3.1). This 
result provides evidence to strongly argue against the NMD mechanism and could 
indicate that a compensation mechanism is being utilised (Chapter 4, section 4.3.3).   
 
Figure 3.3.1 Abundance of Zfp804a in WT and ENU Mutants. The abundance of the 
Zfp804a transcript in F3i mice was determined using an RT-PCR assay. PCR products 
were run out on a gel. An amplimer of 209bp corresponds to Zfp804a. NTC No 
template control WT Wildtype Hom Homozygote C59X mutant RT- Reverse 
Transcriptase negative control. 
 
 
3.3.2 Sequencing the C59X mutation. 
To ensure the mutation was present in the mRNA transcript of the mutant mice, 
sequencing of the mRNA transcript was carried out by myself. Sequence traces from 
both homozygote mutants and WT controls can be seen in Figure 3.3.2. I confirmed 
genotype from the sequencing traces to ensure mRNA matched previous genotype 
assignment using gDNA from tail tips (carried out by T. AlJanabi). 
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Figure 3.3.2. Zfp804a Exon 1-3 Sequence Results. Sequencing from exon 1-3 of 
Zfp804a viewed in NovoSNP (version 3.0.1) enabled the site of the ENU mutation to be 
observed in each of the four female mice used in the expression study (right hand side, 
red box) rather than the wildtype cysteine residue (left hand side, red box). 19c, 7c, 19a 
and 7b = 4 wildtype mice. 31b, 18a, 22a and 22b = 4 mutant mice.  
 
3.3.3 RNA Quality.  
Prior to establishing mRNA expression or splice differences which may be present 
between mutant and wt, RNA samples were analysed for quality. One of the most 
important determinants of the quality of an expression study is the quality of the RNA. 
Standard thresholds for quality RNA include a 28s/18s ratio above 1.0, ideally close to 
2 (Ch 2.2.3.2) and an RIN of 7 or above, ideally 8 (Ch 2.2.3.3) (Shroeder et al., 2006). 
An example of one of the Agilent Bioanalyser (Ch 2.2.3.1) traces is presented in figure 
3.3.3. All 16 samples (male & female) had a RIN above 8 and 28s/18s ratios at 1 or 
above.  
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Figure 3.3.3. Determination of RNA quality. Each sample was run on an Agilent 
2100 Bioanalyser to determine RNA quality using the RIN and rRNA ratio. The above 
example displays the results from sample 22b, a female mutant. The bioanalyser uses 
electrophoretic separation of RNA and both an electropherogram (left) and a gel image 
(right) is produced for each sample. Fluorescence (Fu) is plotted on the Y axis and time 
in seconds (s) on the X axis. The above example had a RIN of 9.1 and a 28s/18s ratio of 
1.7. This high quality RNA is observable from the graph by the two clearly defined 18s 
and 28s peaks (2 clear bands on the gel) (a) as well as low levels of smaller RNA 
molecules which are the products of degraded 18s and 28s rRNA and tRNAs (b).  
 
3.3.4 Affymetrix Genechip Exon 1.0 ST Array.  
To determine the expression profiles of C59X mutants relative to wildtypes I used the 
Affymetrix exon array. Exon arrays not only facilitate more accurate determination of 
gene expression levels, but also allow processes such as alternative splicing to be 
interrogated.  As the study was performed in two stages the results are presented 
accordingly. The initial analysis performed in female mice and the second analysis in 
male mice. The degree of overlap in the results across the two studies was then 
identified.  
3.3.4.1 Quality Control. 
The experiment can be assessed for quality using a number of variables. Each 
experiment was assessed first using a hybridisation efficiency metric, then by 
qualitative assessment using principle component analysis (PCA), signal distribution 
and relative log expression signal. Following this 6 quality metrics that I generated 
using expression console (Affymetrix Version 1.1.2) and Partek GS were used to 
determine if any sample met outlier criteria as outlined by Affymetrix as lying more 
 
a 
b 
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than 2 standard deviations from the mean. This was done both as a whole group and 
within biological replicates (experimental groups). 
3.3.4.1.1 Hybridisation Efficiency. 
The efficiency of sample hybridisation to the chip was assessed using 4 E.coli internal 
controls. Each is hybridised to the chip at a known concentration and based on this 
predefined concentration the signal intensities of each should follow an order from 
lowest expression in BioB hybridised at the lowest concentration up to Cre, hybridised 
at the highest concentration. From the graph (Fig 3.3.4) it is clear that each of the 4 
controls has a Log 2 expression in each of the 8 female samples in the expected rank 
order and from this it can be inferred that the hybridisation of each of the samples to the 
exon chip was efficient and should have no detrimental effects on expression.  
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Figure 3.3.4 Quality Control. Hybridisation Efficiency of Affymetrix GeneChip 
Mouse Exon 1.0 ST Arrays.  Hybridisation Efficiency is determined by the ranked 
signal intensities of four E.Coli controls (BioB, BioC, BioD and Cre). The expression 
signal of the hybridisation for each of the 4 controls (y-axis) is plotted for each of the 8 
female samples (x-axis). Efficient hybridisation is denoted by a rank order of 
BioB<BioC<BioD<Cre and is observed in all 8 female samples.  
 
3.3.4.1.2 Examining the Global Expression Pattern with Principle Components 
Analysis (PCA). 
To determine the global expression profile in C59X mutants I performed PCA on the 
normalised intensity of all core probesets. Visual inspection of the PCA plot (Fig 3.3.5) 
showed no obvious clustering of samples suggesting the gene expression profiles of 
each samples was different. The spread of the samples suggests there is a considerable 
degree of variation in the expression profiles of the female mice and this variation 
occurs across all samples not between Wt and C59X mutants. Whilst this makes 
observing outliers difficult there were no egregious outliers observed by looking at the 
plot, although more thorough quantitative QC analyses would be needed to determine if 
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this is correct. There is a very slight degree of separation of mutants and wildtypes 
along the second principle component although there is no clustering of biological 
replicates.  
 
 
Figure 3.3.5. Principal Components Analysis (PCA) of Female  C59X mutant and 
wildtype samples. The first and second principal components are displayed in the plot. 
Samples do not appear to cluster by genotype and a considerable amount of variation 
between biological replicates is observed.  Hom Mutant C59X (red); WT wildtype 
(blue). 
 
Each sample will have an expression profile which can be plotted as the range in signal 
intensities and the frequency of each of these signal intensities. From this plot the 
distribution of the signal intensity for each sample can be observed (Fig 3.3.6). The plot 
shows that all samples followed a normal distribution. There was little variation 
observed in this distribution for all 8 samples therefore data appeared to be of good 
quality. A number of other QC metrics were assessed using data I generated from 
expression console (Affymetrix) and Partek GS.  
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Figure 3.3.6. Histogram of Signal Intensity. The range of signal intensities were 
plotted on the x-axis with the frequency of each of these intensities for each of the 8 
samples plotted on the y axis to create the distribution of signal intensities. Each of the 8 
samples follows a normal pattern of distribution with the distribution of all 8 samples 
tightly clustered.   
 
 
Box plots were also generated to assess the degree of variation in signal distribution in 
the 8 samples prior to and after preprocessing steps (Fig. 3.3.7). The mean, interquartile 
range and spread of the data were comparable across all samples even prior to 
normalisation and summarisation (Ch2.8.3.3.3 & 2.8.3.3.4). Any observable differences 
were corrected for by the preprocessing procedures. The relative log expression signal 
boxplot was also plotted which was used to determine, overall how differently one 
sample behaves relative to all other samples.  This metric was also quantitatively 
assessed in tables 1 and 2.  
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Figure 3.3.7. Quality Control. Boxplots of Expression Signals. The left box plot 
shows the log probe cell intensity for each sample prior to any normalisation or 
summarisation, with the central box plot showing the log expression signals of probsets 
following normalisation and summarisation. The small amount of variation prior to 
preprossecing is corrected by the normalisation and summarisation procedures. The 
right boxplot is generated by taking the expression signal at a particular probeset on a 
particular chip and comparing it to the median signal across all the chips, this is done 
for every probeset on the chip and so gives an indication if one sample is behaving very 
differently to the other samples, this was not apparent for the 8 female samples.   
 
The quality of the data generated for each sample were also quantitatively assessed by 
generating values for 6 quality metrics in both Partek GS and Expression Console 
(Affymetrix). A detailed description of each of these metrics can be found in 
(Ch2.8.3.5.4 - 2.8.3.5.7) but briefly the overall brightness of the chip was assessed (PM 
mean), comparison of residuals to the median (Mad residual mean using all probesets 
and just the positive controls), the overall performance of each chip relative to the other 
chips (RLE mean, using all probesets and just the positive controls) and finally how 
well the probesets signals separated positive and negative signals (pos vs. neg auc). The 
samples were considered both within experimental group (C59X mutant or wildtype) 
(Table 1) and as a whole group (Table 2). This is because it may be expected that 
mutants and wildtype would behave differently from each other, but within the wildtype 
or mutant group the samples would be expected to behave similarly. Calculating the 
values which were 2 standard deviations either side of the mean (Bold values in each 
table) allowed thresholds to be established to determine if any sample was defined as an 
outlier (2> standard deviations from the mean). The results presented, were metrics I 
generated using Partek GS. Whilst differences in the absolute numbers were found 
between Partek and Expression Console the same outcome was observed in both QC 
analyses.  No outliers were identified in any of the metrics generated when using either 
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software, even when considering the samples within their experimental groups. All 8 
samples were considered good quality and were taken forward for statistical analysis.  
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C59 Mutants       
Sample ID 
 
PM 
Mean 
 
All probeset mad 
residual mean 
 
Pos control mad residual 
mean 
 
All probeset rle mean 
 
Pos control rle mean 
 
Pos vs neg 
auc 
 
18A C.CEL 375.32 0.15 0.1 0.16 0.13 0.87 
22A C.CEL 422.82 0.13 0.09 0.15 0.11 0.88 
22B C.CEL 512.25 0.15 0.11 0.21 0.18 0.87 
31B C.CEL 409.68 0.16 0.11 0.21 0.18 0.87 
Mean -2*SD 313.29 0.12 0.08 0.12 0.08 0.86 
Mean +2*SD 546.75 0.17 0.12 0.25 0.22 0.88 
Within Threshold YES YES YES YES YES YES 
       
Wildtypes       
Sample ID 
 
PM 
Mean 
 
All probeset mad 
residual mean 
 
Pos control mad residual 
mean 
 
All probeset rle mean 
 
Pos control rle mean 
 
Pos vs neg 
auc 
 
7B C.CEL 297.56 0.17 0.13 0.19 0.15 0.87 
7C C.CEL 372.48 0.16 0.11 0.18 0.14 0.87 
19C C.CEL 379.77 0.16 0.11 0.18 0.14 0.87 
19A.CEL 388.97 0.14 0.09 0.14 0.1 0.87 
Mean -2*SD 275.75 0.13 0.08 0.13 0.08 0.87 
Mean +2*SD 443.64 0.18 0.14 0.21 0.18 0.88 
Within Threshold YES YES YES YES YES YES 
Table 1 Quality Control Metrics. Six quality control metrics were generated following sample pre-processing. Each metric is described in full in 
chapter 2 and can be used to determine the quality of the data for each sample. The mean and standard deviation are given for both experimental 
groups (Wt and C59X Mutants). Affymetrix recommend that any sample more than 2 standard deviations from the mean be flagged as an outlier and 
potentially excluded from further analyses. The thresholds for values more than 2 standard deviations from the mean, in either direction are reported in 
bold. The final row states whether or not each of the biological replicates had a value within this threshold, with YES denoting that all samples are fine 
and NO denoting that an outlier(s) has been flagged up.  N.B: Figures are displayed to 2 decimal places. To determine if the value was within threshold 
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the figures were considered to more decimal places therefore each instance where the value displayed for a sample matches a threshold, the value is 
within threshold when considering to more decimal places. 
 
Sample ID pm_mean 
All probeset mad residual 
mean Positive control mad residual mean All probeset rle mean Positive control rle mean Pos vs neg auc 
7B C.CEL 297.56 0.17 0.13 0.19 0.15 0.87 
7C C.CEL 372.48 0.16 0.11 0.18 0.14 0.87 
18A C.CEL 375.32 0.15 0.10 0.16 0.13 0.87 
19C C.CEL 379.77 0.16 0.11 0.18 0.14 0.87 
22A C.CEL 422.82 0.13 0.09 0.15 0.11 0.88 
22B C.CEL 512.25 0.15 0.11 0.21 0.18 0.87 
31B C.CEL 409.68 0.16 0.11 0.21 0.18 0.87 
19A.CEL 388.97 0.14 0.09 0.14 0.10 0.87 
Mean -2xSD 274.39 0.12 0.08 0.12 0.08 0.86 
Mean +2xSD 515.32 0.18 0.13 0.23 0.20 0.88 
Within Threshold Yes Yes Yes Yes Yes Yes 
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Table 2. Quality Control Assessment of all 8 female Samples Combined. When considering the 8 female samples as one group there is no 
indication that any sample is an outlier and behaving differently to any of the other samples.  
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3.3.4.2 Identification of Differentially Expressed Genes between Female Wildtype 
and C59X Mutant Mice.  
Following QC, gene expression analysis was conducted using an alternative splicing 
ANOVA (Partek GS) to identify genes differentially expressed between C59X mutant 
and wildtypes. Due to the increased numbers of probes and their placement throughout 
the transcript the exon array should facilitate more accurate measurement of gene 
expression. As described in the methods, gene expression p values can be generated 
using the differential expression and the alternative splice algorithms (Ch2.8.3.6.1&3). 
Whilst both the workflows were used to determine gene expression differences for 
clarity only the alternative splice algorithm data will be presented in the next section. I 
set the algorithm so that genotype was the splicing factor as described in Ch2.8.3.6.3 to 
determine changes in gene expression between wildtype and C59X mutants. Only 
probesets annotated by Affymetrix as unique (and not known to cross-hybridise) were 
included. Cross-hybridising probesets have been previously described to greatly 
increase the numbers of false positives (Xing et al., 2008).  Any probeset with a mean 
log2 intensity <3 was excluded leaving a total of 15,808 transcripts (equating to 194,293 
probesets). The output of the experiment was a list of genes with both differential 
expression and alternative splice p values. I then determined the number of genes 
significantly differentially expressed and spliced using a number of p value stringencies 
and following multiple test corrections using the false discovery rate (FDR) and the 
Bonferroni correction (Ch2.8.3.6.4).    
3.3.4.3 Identification of Differentially Spliced Genes between Female C59X Mutant 
and wildtype Mice.  
The identification of both known and novel splice events is facilitated with the exon 
array due to probeset placement within the exons and not across exon boundaries.  It is 
important to note that when using chips such as the exon array the idea is to determine 
differential splicing rather than identify known or novel alternative splice events per se. 
Either type of alternative splice event can be detected by the platform but only if the 
expression of each isoform differs between the groups in the experiment, thus it is a 
relative measure. It is only when the expression of an isoform/exon in one group 
diverges from that seen in the other group that differential splicing is called and 
significant p values are observed (Robinson and Speed, 2009).  
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The numbers of significant differentially expressed and spliced genes at different 
significance thresholds are displayed in table 3. The hypothesis that ZNF804A may 
function as a transcription factor was addressed by looking to see if there were any 
genes significantly differently expressed between the WT controls and the Zfp804a 
mutant mice.  6% of genes were significantly differentially expressed (p≤ 0.05). Given 
that 15808 transcripts were included in the analysis the family-wise error rate needed to 
be controlled to limit the number of false positives. The false discovery rate (Benjamini 
& Hochberg, 1995) was set at 0.05 at which threshold it is expected that 5% of the 
significant changes are false positives. The more stringent Bonferroni correction was 
used to set a threshold adjusted for number of tests such that this P value is expected to 
be attained by chance by any transcript only once in 20 complete experiments (Holm, 
1979). Using an FDR threshold of 0.05 and a Bonferroni correction for 15,808 tests, in 
no genes were the expression levels significantly different between the groups. The 
results provide no evidence for a direct link between the mutation in Zfp804a and 
regulation of gene expression.  
 
As the evidence for a role in the regulation of transcription was not apparent, 
differential splicing was assessed between C59X mutants and Wildtypes to determine if 
the mutation in Zfp804a was affecting RNA processing.  The alternative splicing 
algorithm predicts splicing based on expression at a particular probeset (or exon) 
relative to the pattern of expression observed throughout the whole transcript. 
Significant differential splicing is called when probeset expression diverges from the 
transcript expression pattern (Ch2.8.3.6.3). Results showed that a similar proportion 
(~6%) of the total number of transcripts were differentially spliced between wildtype 
and C59X mutants as those predicted to be differentially expressed at the nominal p 
value p≤0.05 (Table 4). The splicing results were however more robust than in the 
differential expression as evidenced by the number of transcripts remaining significant 
at more stringent p values and following multiple test correction. A total of 79 and 21 
genes remained statistically significant following multiple test correction with an FDR 
threshold of 0.05 and the Bonferroni correction for 15808 tests, respectively.   
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P Value Threshold  No. of Significant Genes  % of Genes 
Unadjusted p≤0.05  968 6.12 
p≤0.01  226 1.43 
p≤0.001  23 0.15 
p≤0.0001  2 0.01 
Following Multiple Test Correction 
With FDR 0.05   0 0 
With Bonferroni Correction 
(15808 tests) 0 0 
Table 3. The number of genes differentially Expressed between Female Wildtype 
and Mutant C59X mice. Whilst a considerable number of genes are found to be 
differentially expressed at a nominal p value following adjustments for multiple testing 
the number of significant genes reduces to 0, suggesting no individual genes show 
strong expression differences between the wildtypes and the mutants.  
 
From the initial exploration of the data, there is more evidence for the hypothesis that 
aberrant Zfp804a effects RNA processing than that proposing an effect on differential 
expression.  
 
Following the acquisition of male C59X brain tissue the experiment was repeated, using 
the same methodological and analytical procedures (Ch2). Replication in male mice was 
carried out to ascertain if the results observed in the female mice could be recapitulated 
and to remove any possibility that the results were attributable to variation in the stage 
of the oestrous cycle among the female mice.  
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Alternative Splicing   No. of Significant Genes  % of Genes 
Unadjusted p<0.05  1010 6.39 
p<0.01  400 2.53 
p<0.001  136 0.86 
p<0.0001  54 0.34 
Following Multiple Test Correction 
With FDR 0.05   79 0.50 
With Bonferroni Correction 
(15808 tests) 21 0.13 
Table 4. The number of differentially spliced genes between wildtype and C59X 
mutant female mice. Whilst a similar proportion of genes are shown to be 
differentially spliced to those differentially expressed at a nominal p value of p<0.05, 
when considering the more stringent p values and in particular the number of genes 
significant following multiple test correction there is a greater proportion of spliced 
genes.  
 
3.3.4.4. Replication study in Male C59X mice. 
The experiment was repeated when there were sufficient numbers of male homozygote 
C59X mice available for expression analysis. The same QC measures were generated 
and the same criteria used for outlier analysis. The hybridisation efficiency of all 9 male 
(4 C59X mutants, 5 wildtypes) samples was sufficient, as denoted by the correct rank 
order in expression values of 4 internal controls (Fig 3.3.8). Whilst observing the 
expression patterns of these 4 E. Coli controls it was noted that sample 6, a C59X 
mutant, had a divergent log2 expression pattern of the four controls relative to the other 
8 samples.  Following the generation of a PCA plot (Fig 3.3.9) the overall pattern of 
gene expression for each of the samples was assessed. There was no indication of 
samples clustering by genotype. A single cluster is observed in the top right of the plot 
where the majority of samples lie. Two samples were not found within this cluster one 
of which is separated from the other samples along the first principle component 
(Indicated with arrow A). This sample corresponds to sample that appeared divergent in 
the hybridisation efficiency assessment. The other sample, a wildtype (17c) is separated 
from the other samples along principle component 2 (Indicated with arrow B). A normal 
distribution of signal intensity was observed for all male mice (Fig. 3.3.10) however 
both 17b and 17c, highlighted in the PCA, were at the extremities of the distribution 
toward the mean frequency range of the plot. I then generated boxplots of the log 
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expression signal to establish if the degree of variation in 17b and 17c was consistent in 
these plots and if so whether the 2 samples should be excluded (Fig. 3.3.11).  
 
 
Figure 3.3.8. Quality Control. Hybridisation Efficiency of Affymetrix GeneChip 
Mouse Exon 1.0 ST Arrays. Efficient hybridisation is denoted by a rank order of 
BioB<BioC<BioD<Cre, four E.Coli internal controls that are hybridised to the chip at 
known, staggered concentrations. This rank order is observed in all of the Male 
wildtype and C59X samples (n = 9). In assessing the quality of the hybridisation process 
it was also noted that the log 2 expression in sample 6 (a C59X mutant) was quite 
different to the other samples. 
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Figure 3.3.9. Quality Control. Principal Component Analysis of Male samples. The 
samples do not appear to cluster by genotype along the first and second principle 
components. Instead a cluster of samples is observed in the top right of the plot with 
two samples (labelled with arrows) separated from this cluster suggesting a different 
overall pattern of gene expression in these two samples. 
 
A 
B                      
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Figure 3.3.10. Quality Control. Histogram of Signal Intensity. The distribution of 
signal intensities.  Intensity is plotted along the x-axis and frequency of intensity plotted 
on the y-axis. Distribution is normal across all male wildtype and C59X mice. At the 
peak of the curve the differences in the distribution of the samples becomes slightly 
evident with both the mutant, 17b and the wildtype, 17c furthest from the cluster of the 
other samples. 
 
Boxplots generated to examine the log expression signals of each male sample are 
shown in Figure 3.3.11. Whilst the normalisation and summarisation of the data 
appeared to correct the variance in expression, the relative log expression signal boxplot 
(right plot) clearly shows that sample 17b (6), the same C59X mutant as observed 
previously, is behaving differently relative to the other 8 samples. The inter-quartile 
range (IQR) of this sample is much larger than that observed in the other samples and 
this characteristic is often present in samples of poor quality.  Sample 17c (7), also 
separate from the PCA cluster, had a slightly larger IQR but was not as distinguishable 
as sample 17b. In the four qualitative and subjective measures analysed so far, the male 
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C59X mutant (17b) appeared to be a consistent outlier, whilst the male wildtype (17c), 
demonstrated outlier characteristics in several of the metrics but not all. To more 
quantitatively establish if either of these samples should be excluded I generated the 
same 6 metrics as described previously (Ch2.8.3.5.4-7) to determine as accurately as 
possible if 17b and 17c were outliers, defined as metric values consistently greater than 
2 standard deviations away from the mean.  First considering all male samples together 
(Table 5), the mutant 17b (sample 6) that appeared to be an outlier in the qualitative 
metrics, had values greater than 2 standard deviations from the mean in 5 of the 6 
metrics generated. Again the results presented are those I generated in Partek GS, but 
analysing the QC results in Expression Console also resulted in sample 17B being an 
outlier in 5 of the 6 metrics. In both instances the metric in which sample 17b was 
within 2 standard deviations of the mean was the positive versus negative auc metric. 
17b has a value (0.88) above which Affymetrix guidelines suggest may be an outlier, 
Affymetrix stipulate that values above 0.8 do not guarantee good quality data (Chapter 
2.8.3.5.7)  Samples were then considered by experimental group, as a better indication 
of an outlier may be how samples behave relative to their biological replicates 
(Affymetrix, 2008) (Table 6). Within experimental group comparisons showed no 
evidence of outlier behaviour again this was consistent between analyses performed in 
Partek GS and Expression Console. As the wildtype sample, 17c satisfied criteria both 
within and across groups it was deemed of adequate quality for gene expression 
analyses. Due to the ambiguous outlier nature of sample 6, I plotted several MA plots to 
establish the extent to which the intensity of this sample varied when directly compared 
with each of the other samples and to enable the decision of whether the sample should 
be excluded (Fig. 3.3.12).   
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Figure 3.3.11. Quality Control. Boxplots of Expression Signals.  The variation observed in the probe cell intenisty before normalisation and 
summarisation (left) is corrected following normalisation and summarisation (centre). The relative log expression signal boxplot (right), which is used 
to give an indication of samples behaving differently to the consensus, demonstrates sample 6 has a much wider IQR. Samples with a larger IQR may 
represent a low quality array.  
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Sample ID  PM Mean 
All Probeset Mad Residual 
Mean 
Pos Control Mad Residual 
Mean 
All Probeset RLE 
Mean Pos Control RLE Mean 
Pos vs. Neg  
AUC 
Z2C.CEL 414.85 0.12 0.09 0.13 0.10 0.86 
Z2D.CEL 396.00 0.13 0.10 0.15 0.13 0.87 
Z2E.CEL 430.13 0.12 0.09 0.13 0.10 0.86 
Z4A.CEL 356.77 0.14 0.09 0.14 0.11 0.86 
Z6A.CEL 435.08 0.12 0.09 0.12 0.09 0.86 
Z17B.CEL 276.81 0.23 0.16 0.48 0.49 0.88 
Z17C.CEL 381.87 0.15 0.10 0.19 0.14 0.86 
Z21B.CEL 437.45 0.12 0.09 0.14 0.11 0.87 
Z21C.CEL 484.40 0.13 0.10 0.15 0.13 0.86 
Mean -2xSD  282.63 0.07 0.05 -0.04 -0.10 0.86 
Mean +2xSD  520.34 0.21 0.15 0.41 0.41 0.88 
Within Threshold No No No No No No 
Table 5. Quality Control. 6 Quality Control Metrics Generated for Male wildtype and C59X mutants.  In 5 of the 6 metrics the values generated for 
sample Z17B were outside of the thresholds recommended by Affymetrix (red).
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C59X Mutants       
Sample ID PM Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD Residual 
Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean Pos vs. Neg AUC 
Z2D.CEL 396.00 0.13 0.10 0.15 0.13 0.87 
Z2E.CEL 430.13 0.12 0.09 0.13 0.10 0.86 
Z4A.CEL 356.77 0.14 0.09 0.14 0.11 0.86 
Z17B.CEL 276.81 0.23 0.16 0.48 0.49 0.88 
Mean -2*SD 233.03 0.05 0.04 -0.11 -0.18 0.86 
Mean +2*SD 496.83 0.26 0.18 0.56 0.59 0.88 
Within Threshold Yes Yes Yes Yes Yes Yes 
       
Wildtypes       
Sample ID PM Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD Residual 
Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean Pos vs. Neg AUC 
Z2C.CEL 414.85 0.12 0.09 0.13 0.10 0.86 
Z6A.CEL 435.08 0.12 0.09 0.12 0.09 0.86 
Z17C.CEL 381.87 0.15 0.10 0.19 0.14 0.86 
Z21B.CEL 437.45 0.12 0.09 0.14 0.11 0.87 
Z21C.CEL 484.40 0.13 0.10 0.15 0.13 0.86 
Mean -2*SD 356.01 0.11 0.08 0.10 0.08 0.86 
Mean +2*SD 505.45 0.15 0.10 0.20 0.15 0.88 
Within Threshold Yes Yes Yes Yes Yes Yes 
Table 6. Quality Control. Considering the 6 quality control metrics by experimental groups. When considering the samples as biological 
replicates within their experimental groups none of the samples had values which surpassed the threshold in any of the 6 metrics (When considering 
more than 2 decimal places). 
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To evaluate the exclusion of sample 17b, MA plots (3.3.12) were generated.  The MA 
plot is used to compare the intensity of two samples. Each point in the plot represents a 
probe intensity value. The average for each probe intensity value is plotted on the x-axis 
with the difference between the two samples plotted on the y-axis. I first generated plots 
comparing sample 17b to all other samples (Fig. 3.3.12A & B) and then by exploring all 
sample combinations with the exception of those including 17b (Fig. 3.3.12C & D). To 
further evaluate the decision to retain sample 17c this was also plotted against sample 
21b. The variation in intensity was much greater in sample 17b and so it was decided 
that this samples would be excluded and omitted from all downstream analyses. MA 
plots of sample 17c were consistent with the other samples and so confirmed the 
decision to retain the sample in the statistical analysis. QC following the removal of 17b 
(Table 3.7& 3.8) did not indicate any outliers and therefore following the exclusion of 
sample 17b the remaining 8 male samples (3 homozygote C59X mutants and 5 
wildtypes) were pre-processed (Ch2.8.3.3). The Partek GS and Expression console QC 
analyses varied only in that sample 17c was outside the 2 standard deviation rule for one 
metric in Partek but two in expression console. This still does not qualify 17c as an 
outlier, but highlights the slight variation in metrics generated by the two programmes. 
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Figure 3.3.12. MA plots of signal Intensity.  Signal intensities at all probesets on the 
array were directly compared between two samples at a time and the difference in 
intensity at each probeset plotted. A Comparison of potential outlier 17b and another 
male mutant sample (4a). This plot was representative of all plots generated when 
comparing each male sample in turn with 17b as exemplified in B where 17b was 
compared to 21B, a male wildtype. There was considerable variation between the two 
samples, in each case, particularly when considering probesets with higher average 
intensity values as indicated by the wider spread of the data at the right of the plot (A 
&B).  When the same two samples (4a and 21b) were compared to each other C and 
when 21b was compared to 17c D the plots all had a reduced variation toward the right 
of the graph representing probesets with higher average intensity values. Both plots 
were representative of those generated when comparing any 2 male samples with the 
exception of 17b.  
A 
D C 
B 
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Sample ID PM Mean 
All Probeset Mad 
Residual Mean 
Pos Control MAD Residual 
Mean All Probeset RLE Mean 
Pos Control RLE 
Mean 
Pos vs Neg 
AUC 
Z2C.CEL 414.85 0.12 0.09 0.13 0.11 0.86 
Z2D.CEL 396.00 0.13 0.10 0.16 0.13 0.87 
Z2E.CEL 430.13 0.12 0.09 0.13 0.10 0.86 
Z4A.CEL 356.77 0.14 0.09 0.15 0.11 0.86 
Z6A.CEL 435.08 0.12 0.09 0.12 0.09 0.86 
Z17C.CEL 381.87 0.15 0.10 0.19 0.13 0.86 
Z21B.CEL 437.45 0.12 0.09 0.14 0.11 0.87 
Z21C.CEL 484.40 0.13 0.10 0.15 0.13 0.86 
Mean -2xSD 338.63 0.11 0.08 0.11 0.09 0.86 
Mean 
+2xSD 495.51 0.15 0.10 0.19 0.14 0.87 
Within 
Threshold Yes Yes Yes No Yes No 
Table 3.7. QC measure following the removal of 17b showed the data to be consistant and no samples were determined to be outliers.  
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C59X Mutants              
Sample ID PM Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean All Probeset RLE Mean Pos Control RLE Mean Pos vs Neg AUC 
Z2D.CEL 396.00 0.13 0.10 0.16 0.13 0.87 
Z2E.CEL 430.13 0.12 0.09 0.13 0.10 0.86 
Z4A.CEL 356.77 0.14 0.09 0.15 0.11 0.86 
Mean -2xSD 320.88 0.12 0.09 0.12 0.09 0.86 
Mean +2xSD 467.73 0.14 0.10 0.17 0.14 0.87 
Within Threshold Yes Yes Yes Yes Yes Yes 
       
Wildtypes             
Sample ID PM Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean All Probeset RLE Mean Pos Control RLE Mean Pos vs. Neg AUC 
Z2C.CEL 414.85 0.12 0.09 0.13 0.11 0.86 
Z6A.CEL 435.08 0.12 0.09 0.12 0.09 0.86 
Z17C.CEL 381.87 0.15 0.10 0.19 0.13 0.86 
Z21B.CEL 437.45 0.12 0.09 0.14 0.11 0.87 
Z21C.CEL 484.40 0.13 0.10 0.15 0.13 0.86 
Mean -2xSD 356.01 0.11 0.08 0.10 0.08 0.86 
Mean +2xSD 505.45 0.15 0.10 0.20 0.15 0.88 
Within Threshold Yes Yes Yes Yes Yes Yes 
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Table 3.8 Male C59X mice Quality Control Metrics. Following the removal of sample 17b normalisation and summarisation were again carried 
out in Partek Genomics Suite and the same metrics were generated to analyse the quality of each array in order to identify any outliers. Samples were 
separated by genotype prior to determining if any individual arrays were outside of a pre-defined threshold of 2 standard deviations from the mean for 
each of the metrics generated.  
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The 8 samples were preprocessed simultaneously using quantile normalisation and 
median polish summarisation (Ch2.8.3.3).  As with the female samples, I next 
determined the number of transcripts predicted to be differentially expressed and 
spliced. The same criteria as used in the female analysis enabled comparisons to be 
made across the two experiments and the degree of overlap to be established.   
Differential Expression   No. of Significant Genes % of Genes 
Unadjusted p≤0.05   744 4.7 
p≤0.01   152 0.96 
p≤0.001   25 0.16 
p≤0.0001   6 0.04 
Following Multiple Test Correction 
FDR 0.05   0 0 
Bonferroni Correction 
(15813 tests) 0 0 
Table 3.9. Total number of transcripts included in the analysis was 15,813.  
 
 
Approximately 5% of the total number of transcripts were significantly differentially 
expressed at a nominal p value (p≤0.05) (Table 3.9). Following correction for multiple 
testing no genes were significant using an FDR threshold of 0.05 and Bonferroni 
correction for 15,813 tests respectively. A slightly larger proportion of the total number 
of transcripts (15,813) was predicted to be differentially spliced.  As seen in the female 
mice the numbers remaining significant were greater for differentially spliced genes 
than differentially expressed genes, with a small proportion of genes remaining 
statistically significant following multiple test correction (Table 3.10).  
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Alternative Splicing   No. of Significant Genes % of Genes 
Unadjusted p≤0.05   1240 7.84 
p≤0.01   462 2.92 
p≤0.001   143 0.9 
p≤0.0001   68 0.43 
Following Multiple Test Correction 
FDR 0.05   99 0.63 
Bonferroni  Correction (15813 
tests) 34 0.22 
Table 3.10. Differentially Spliced Genes in Male C59X Mutant Mice. ~7% of the 
total number of transcripts were found to be differentially spliced in the C59X mutants 
(p≤0.05) with ~0.6% still significant following correction for multiple testing using the 
FDR at a threshold of 0.05.   
 
3.3.4.5 Multiple Test Correction. 
Pre-analytical filtration steps, including probeset filtering by intensity, were applied to 
the data to reduce the impact of multiple testing (Della et al., 2008). To further reduce 
the number of potential false positives in the data the Bonferroni correction and the 
Benjamini and Hochberg FDR correction were applied to the data. Whether or not MTC 
should be applied to data at the exon level is still a matter of contention. In alternative 
splice analysis the data are considered at the level of the probeset (exon) relative to the 
expression across a transcript. Thus far more data points are included in the analysis and 
the exons belonging to a given transcript are dependent (correlated) and thus violate the 
assumption of independence of data points in many multiple test correction approaches, 
including the Benjamini and Hochberg FDR. Whilst the application of the correction 
may not be statistically accurate, the exemption of such a correction would most likely 
result in a high proportion of false positives in the dataset.  
One way to establish the contribution of false positives to the number of significant 
genes would be to permute the data and observe if the number of significant genes 
varies considerably to those originally observed. A similar proportion of significant 
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genes in the permuted data set would be suggestive of a high degree of false positives. 
This option could not be applied to the data as random permutations and subsequent p 
values could not be generated on such a small data set. As a compromise and in the 
absence of adult heterozygote samples, cases were compared with other cases and 
controls with other controls in order to understand the contribution of false positives to 
the results. The total of 16 male and female samples were split by genotype comprising 
of 7 mutants and 9 wildtypes and then within in each genotype group samples were split 
balancing litter and gender as best as possible. First the wildtype controls were divided 
into either group 1 or 2, with 4 and 5 samples in each respectively. The preprocessing 
was carried out in the same way as described previously the only difference in the 
analysis was that differential expression and alternative splicing were determined 
between the two arbitrary groups (1 and 2) as only wildtype samples were included. 
This enabled an estimate to be determined of the number of genes predicted to be 
differentially expressed and spliced by chance alone. The same was repeated for the 
mutant samples comparing group 1 (3 mutants) to group 2 (4 mutants) again balanced 
by gender and litter. Gender was covaried in each instance, as the PCA in both sets of 
data showed clustering of samples by gender. A max intensity filter of Log2 3 was used 
with probesets included if they were below this threshold but showed significant results 
p≤0.05.  A considerable number of genes are significant (Table 3.11) even when 
comparing samples of the same genotype split into arbitrary groups, but the numbers are 
less than those observed in the actual analysis comparing mutants to wildtypes in each 
instance. This suggests there are true positives in the data.  
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Differential Expression p≤0.05 FDR 0.05 
Bonferroni 
Correction 
    
Wildtype vs. Wildtype 559 0 0 
Mutants vs. Mutants 712 0 0 
Females Wildtype vs. Mutant 968 0 0 
Males Wildtype vs. Mutant 744 0 0 
    
Differential Splicing 
    
Wildtype vs. Wildtype 352 7 5 
Mutants vs. Mutants 580 22 9 
Females Wildtype vs. Mutant 1010 79 21 
Males Wildtype vs. Mutant 1240 99 34 
Table 3.11. False Positives Rate. The number of significant differentially expressed or 
spliced genes are represented in the table either at an unadjusted p value of p≤0.05 or 
following multiple test correction with an FDR threshold of 0.05 or with the Bonferroni 
correction for the number of tests performed. The data generated by comparing within 
genotype groups is shown in the table with the original data, generated by comparing 
C59X mutants and wildtypes below (blue).  The number of significant differentially 
expressed genes was slightly greater in the original comparison relative to the within 
genotype dataset suggesting the results are more than would be expected by chance 
artefacts.  The number of predicted differentially spliced genes observed between C59X 
mutants and wildtypes was approximately double that observed in the within genotype 
data. This suggests that the predictions of differential splicing are not just chance 
findings produced by artefacts of the statistical algorithm.  
 
3.3.4.6 Analysis to Determine the Degree of Replication.  
Significant results are usually prioritised for validation based on significance, fold 
change and functional relevance to the disease being studied. An advantage of having 
both female and male datasets was that it enabled the degree of overlap across the two 
studies to be assessed. Genes found to overlap, despite the differences in gender, brain 
preparation and age would therefore be considered more robust and make good 
candidates for validation by quantitative PCR (qPCR).  Overlap was measured by 
comparing the observed number of overlapping genes between males and females to the 
number that would be expected to overlap by chance.  If the number of significant 
changes that overlap were greater than the number expected by chance the data would 
be considered more robust.  To precisely calculate the overlap, 2x2 contingency tables 
were produced and the significance of the overlap was tested using the Chi squared test 
(Methods 3.2.11). A summary of the results is shown in Table 3.12. A significant 
overlap was found for differentially spliced transcripts at all stringency thresholds 
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investigated. Overlap for differentially expressed transcripts was less convincing with a 
significant overlap observed only for transcripts found to be significantly differentially 
expressed in the females at p≤0.01.  This suggests the splicing data were more robust 
than the differential expression data. 
3.3.4.7 Manual inspection of Results to Determine Direction of Effect. 
Due to the significant overlap of differentially spliced transcripts across the two 
experiments a manual inspection was undertaken to establish if the replicating 
transcripts were predicted to show splice events in the same exon and have the same 
direction of effect.  Starting with the most stringent set of overlapping transcripts (those 
significant in the females at p<0.0001 and significant in the males at p<0.05) the 
geneviews (Fig. 3.3.13), which I generated in Partek GS, were manually inspected to 
establish the exon(s) generating the significant splice signal in the female dataset and 
whether the same event was evident in the males. If the same exon(s) was differentially 
spliced in the males I then determined if the direction of effect was concordant.  
N.B: The geneview displays the probeset expression of all probesets within a transcript 
cluster. Varying levels of intensity are evident for each probeset, however this does not 
represent true intensity differences across the transcript and is often attributable to 
sequence specific probe effects. Therefore when assessing the geneview for a real splice 
event, the differences in intensity between probesets should be ignored and the parallel 
nature of the lines joining the probesets should be considered. If parallel lines are 
apparent across the length of the transcript this suggests that the transcript is 
differentially expressed between the two groups. Where there is a divergence from the 
parallel nature of the lines this is indicative of differential splicing of an exon between 
the two groups. 
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Differential Expression      
Significance 
Threshold Observed Expected Exact sig 2-sided Exact sig 1-sided  Replication 
P≤0.05 54 45.4 0.18 0.11 Not significantly more than expected by chance 
P≤0.01 17 10.6 0.06 0.04 Significantly more than expected by chance (p<0.05) 
P≤0.001 2 1.1 0.30 0.30 
Not significantly more than expected by chance (Fisher's Exact 
test) 
P≤0.0001 1 0.1 0.09 0.09 
Not significantly more than expected by chance (Fisher's Exact 
test) 
 
Alternative Splicing      
Significance 
Threshold Observed Expected Exact sig 2-sided Exact sig 1-sided  Replication 
P≤0.05 111 79.2 0.00 0.00 Significantly more than expected by chance  
P≤0.01 61 31.4 0.00 0.00 Significantly more than expected by chance  
P≤0.001 34 10.7 0.00 0.00 Significantly more than expected by chance alone  
P≤0.0001 23 4.2 0.00 0.00 Significantly more than expected by chance (Fisher's Exact test) 
Table 3.12. Replication Analysis using Chi Square Test.  Significant replication in the male study was determined by establishing whether the 
number of genes that overlapped was greater than the number expected by chance using Pearson’s Chi Square test. Results were determined for both 
one and two-tailed hypotheses, however as the null hypothesis was that results would not replicate in the male study the one-tailed significance value 
was used to determine replication.  Only when considering the 226 genes significant at p≤0.01 in the females is an overlap observed in the males which 
is significantly more than would be expected by chance (χ2 (1) = 4.061, p<0.05) for differentially expressed genes. In contrast at every significance 
threshold the genes significantly differentially spliced in the females overlap with numbers significantly more than would be expected by chance. Due 
to an expected count less than 5 the Fisher’s Exact test significance value is reported for differential expression p≤0.001, p≤0.0001 and alternative 
splicing p≤0.0001.
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Figure 3.3.13 Replication of Potential Splice Events. After I generated geneviews in 
Partek GS, I manually inspected plots of all genes showing significant overlap to 
determine if the position and direction of the splice events was consistent. At the top of 
each geneview the known Refseq transcript(s) is plotted, with the log2 expression values 
for each of the probesets (within the defined transcript cluster) plotted underneath. 
Probeset expression is plotted for the C59X mutants and wildtypes in red and blue 
respectively. In this figure, the geneviews of four genes are displayed with the female 
and male plots on the left and right hand side respectively.  The splice event thought to 
be generating the significant splice p value is highlighted within the shaded box. The 
top 3 plots show genes in which the same splice event is observed in both males and 
females. The bottom plot shows potential differential isoform expression between 
mutants and wildtypes in the females, however only a subset of the probesets are also 
differentially expressed in the males and in one probeset the effect is in the opposite 
direction.  
 
 
Geneviews were inspected (Fig. 3.3.14) to establish how many of the 17 significantly, 
overlapping differential expression results were consistently regulated in the same 
direction in both males and females (Table 3.13). 14 genes (82%) were consistently up 
or downregulated in the females and males. Differential spliced transcripts were 
inspected to ensure the position of the predicted spliced exon(s) and the direction of 
effect was consistent in both experiments (Table 3.13).  A significant overlap between 
males and females was observed at each of the p value stringencies tested. Each set of 
genes was inspected starting with the most stringent group (p≤0.0001). Of the 111 genes 
found to overlap between male and female experiments, 70% replicated in at least one 
of the exons predicted to be differentially spliced and in the same direction. With 
increased p value stringency the percentage of splice events found to be consistent 
across the two experiments increased, with 91% of genes overlapping at p≤0.0001 
showing concordant changes. The observed degree of overlap not only increased the 
confidence in the data, but suggests that the predicted splice events are not resultant of 
technical artefacts such as probe bias.  
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Differential Expression     
Significance threshold in Females No. Genes Significant 
Overlap in Males 
(p≤0.05) No. of Genes with Same direction of Effect % 
p≤0.001 226 17 14 82 
     
Alternative Splicing     
Significance threshold in Females No. Genes Significant 
Overlap in Males 
(p≤0.05) 
No. of Genes in which the Differentially spliced 
Exon and Direction of Effect is Consistent % 
p≤0.0001 54 23 21 91 
p≤0.001 136 34 29 85 
p≤0.01 400 61 48 79 
p≤0.05 1009 111 78 70 
Table 3.13 Determining the consistency in the overlap in Male and Female Results. Manual inspection of both females and male geneviews 
allowed the percentage of overlapping genes in which the differential expression (top) or splice (bottom) event was consistent to be determined. 
Differentially expressed genes had to have altered expression in the same direction in both females and males to be counted. Consistent overlap in a 
differentially spliced transcript required that the splice event, thought to be contributing to the splice signal in females, was replicated in the males and 
that the change was in the same direction.    
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Figure 3.3.14 Inspection of Alternative Splicing Results. The geneviews displayed 
represent 3 genes (1 in each row) with the expression results for both females (left 
column) and males (right column). A. The geneview for Slc39a13 is an example of a 
result in which the splice event was easy to identify, demonstrated by a similar 
expression pattern in wildtypes and mutants across all probesets in the transcript except 
one, where a clear divergence in the expression between mutants and wildtypes was 
observed. B. An example of a transcript which only partially replicates across the male 
and female experiments. 3 differentially expressed probesets (circled) were identified in 
females, but only two of these are differentially expressed in the same direction in the 
males.  C. The geneview is representative of transcripts in which the large number of 
probesets made it difficult to determine where the alternative splice signal was coming 
from, which made determining if there was an overlap between males and females 
difficult.  
 
  
  
  
  Female  Male  
  
 
 
  
A 
C 
B 
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3.3.4.8 Combined Analysis. 
Due to the observed overlap in the two individual experiments I felt it was appropriate 
to combine the samples to increase the power and then repeat the analysis. This meant 
the expression and splicing was compared between 9 wildtypes (4 female, 5 male) and 7 
C59X mutants (4 female, 3 male) using a two-way ANOVA model, which included 
gender as a covariate. A total of 15,833 transcripts were tested and the proportion of 
these predicted to be significantly differentially expressed or spliced is shown in Table 
3.14. The number of transcripts significantly differentially expressed at a nominal p 
value (p≤0.05) was 7% of the total number of transcripts, more than observed in the 
individual female and male experiments (6% and 4% respectively). There were also a 
small number of genes in the combined experiment which survived correction for 
multiple testing even after using the very stringent Bonferroni correction. The impact of 
combining the samples did not increase the number of differentially spliced as expected. 
With the increase in power a decreased number of predicted splice events was observed. 
From the 7% and 6% observed previously the proportion of spliced transcripts 
decreased to 4%, almost half the number of differentially expressed transcripts.    
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Differential 
Expression 
No. of Significant 
Genes % Of Genes Expected  
Unadjusted p≤0.05 1043 7 792 
p≤0.01 242 2 158 
p≤0.001 30 0.19 16 
p≤0.0001 11 0.07 2 
FDR 0.05 9 0.06   
Bonferroni Correction 
( 15,833 tests) 3 0.02   
 
Alternative Splicing 
No. of Significant 
Genes % Of Genes Expected  
Unadjusted p<0.05 617 4 792 
p≤0.01 226 1 158 
p≤0.001 92 1 16 
p≤0.0001 54 0.34 2 
FDR 0.05 65 0.41   
Bonferroni Correction 
(15,833 tests) 29 0.18   
Table 3.14. Combined Analysis Results. The top table shows the proportion of genes 
differentially expressed between C59X mutants and wildtypes. A small number of 
genes remained significant following multiple test correction (FDR 0.05 and 
Bonferroni), something which was not observed when considering the female and male 
experiments separately.   
 
 
The combined analysis showed 3 genes to be significant following a Bonferroni 
correction of 15,833 tests and 9 using the less stringent FDR correction at a threshold of 
0.05. Whilst this number is small it is still important to consider these genes, as one or 
more of them may have downstream effects on the expression or splicing of other 
genes. For this reason these 9 genes were viewed to determine how likely the expression 
change was (Appendix 3.1). Of the 9 only 2 looked like differential gene expression 
(Mettl5 and Nfe212) with two others possibly being differential expression of known 
alternative transcripts. The remaining 5 showed differential expression in only a subset 
of the probesets within the transcripts, which could suggest differential expression of 
novel isoforms. Of the 3 Bonferroni significant transcripts only Mettl5 displays 
attributes of a differentially expressed gene, with all probesets showing differential 
expression in the geneview. None of the 9 transcripts had differential expression fold 
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changes greater than or equal to 1.5 which is a standardised cut off for differential 
expression, reducing the reliability of the results.    
The top 6 results from the combined analysis for differential splicing are shown in Fig 
3.3.15. In each case the predicted splice event was inspected to determine the likelihood 
of such an event. Of the six events 2 were potential false positives as only one of 
multiple probesets in the exon showed differential expression. From this Frzb, 
Slc39a13, Fam171b and Ssfa2 remain potential differential splice candidates.  
 
 
Figure 3.3.15. Geneviews of Significantly Differentially Spliced Genes (Combined 
Analysis). The majority of cases appear to be called due to alternative exon usage. This 
type of splice event is the most common and also the easiest to detect in this type of 
analysis. The event in Tcp11l1 is suggestive of a false positive as not all probesets 
within the exon follow the same expression pattern, as is this case in Prdm4.  Frzb’s 
  
  
  
Prdm4 Slc39a13 
Ssfa2 Tcp11l1 
Fam171b Frzb 
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geneview is suggestive of an unknown alternative isoform, or 3’ and 5’ edge effects 
masking a differentially expressed rather than spliced transcript.  
 
3.3.4.9 Alternative Algorithms.  
Assessment of differential expression and splicing were carried out using alternative 
algorithms in different software packages to establish the robustness of the data.  Both 
easyExon and AltAnalyze are open source, freely available applications. In easyExon 
the MiDAS algorithm was used to determine differential splicing and the FIRMA 
algorithm was applied in AltAnalyze, the methods for each are described in full in 
Chapter 2.8.4. Identification of the same differentially expressed and spliced genes 
when using different algorithms and filtering criteria would add validity to the data.  
3.3.4.9.1 easyExon.  
The false positive rate was controlled by first removing probesets which did not have a 
DABG p value ≤0.05 in at least 50% of the samples. With a significance threshold of 
p≤0.05 and a fold change cut off of greater than or equal to 1.5, 34 genes were predicted 
to be differentially expressed in the female experiment of which 10 had RefSeq IDs. 16 
genes were significant in Partek when applying the same thresholds. Of the 10 
easyExon results with Refseq IDs, 8 genes were found to overlap between Partek GS 
and easyExon (Table 3.15). Using EasyExon to assess the male experiment, 26 genes 
met the criteria for differential expression, but only 1 had a gene symbol; Frizzled 
related protein (Frzb).  Applying the same significance and fold change cutoffs in 
Partek GS resulted in three differentially expressed genes, one of which was Frzb.  
 
741 and 764 genes were significantly differentially spliced in female and male C59X 
mice respectively. This corresponds to the 1010 and 1240 genes identified when using 
Partek GS.  Genelists were cross referenced with significant differentially spliced genes 
in Partek GS using the Affymetrix transcript cluster ID annotation. 146 and 197 genes 
overlapped in the female and male datasets respectively. Whilst the nominally 
significant numbers vary quite considerably this probably reflects the different 
algorithms and stringency cut offs used. The number of genes which do overlap are 
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similar to the number significant in Partek GS at p≤0.001 and perhaps represents more 
reliable calls of alternative splicing by both algorithms.  
 
 
Gene 
Symbol RefSeq ID Gene Description 
Snca NM_001042451 Synuclein, alpha  
Egr2 NM_010118 early growth response 2  
Arc NM_018790 activity regulated cytoskeletal-associated protein  
Scg5 NM_009162 secretogranin V  
Mela D10049 melanoma antigen 
Npas4 NM_153553 Neuronal PAS domain protein 4  
Dusp1 NM_013642 dual specificity phosphatase 1  
Nr4a1 NM_010444 nuclear receptor subfamily 4, group A, member 1  
Table 3.15 Significantly Differentially Expressed Genes.  Using a p value cut off of 
p≤0.05 (nominal) and a fold change threshold of greater than or equal to 1.5, 8 genes 
were significant using both Partek GS and EasyExon software tools on the female 
dataset.  
 
3.3.4.9.2. AltAnalyze (Version 2.0.7).  
AltAnalyze is an integrated software workflow (Emig et al., 2010) used to preprocess 
samples and carry out statistical analysis. This software has previously been shown 
(AltAnalyze manual) to predict splicing with high specificity and reasonable sensitivity 
in a previously published dataset (Xing et al., 2008). Both the adult female and male 
datasets were analysed using AltAnalyze to detect differential gene expression and 
splicing as described in Chapter 2.8.4.2.  
The results of the analyses are shown in table 3.16. Following software specific 
filtering, as described in chapter 2 which included the core meta-probeset and excluded 
probesets with a DABG p value ≥0.05 and a non log expression value ≤70, the number 
of genes predicted to show differential expression and splicing were calculated (Table 
3.16). Overlap with Partek was then determined using the transcript cluster ID. First 
considering the female data the differential expression overlap showed that of the 1464 
genes significant in AltAnalyze and the 968 in Partek, 373 overlapped when using the 
transcript cluster ID. It is important to note that due to the different filtering methods 
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and different annotation criteria (chapter 2.8.4.2) that the probesets included in the two 
statistical analyses will have varied. 860 transcripts were predicted to show differential 
splicing in AltAnalyze compared to the 1010 predicted by Partek GS.  The overlap 
between Partek and AltAnalyze for differential splicing in female C59X mutants and 
wildtype was 167 transcripts. Next considering the male experiment, 1272 genes were 
significantly differentially expressed in AltAnalyze and 744 in Partek, of which 234 
overlapped between the two analyses. 966 genes were predicted to be differentially 
spliced in AltAnalyze and 1240 in Partek, of which 212 transcripts were significant in 
both. 
There is a degree of overlap observed considering the differences in the initial 
annotation of genes and the differences in the algorithms used. To determine if any of 
the predicted expression or splice differences between the C59X mutants and wildtypes 
were common to all 3 of the software programmes the overlap was established again 
using the Transcript cluster ID as the common identifier.  
 
Differential Expression AltAnalyze  
Female  1464   
Male 1272   
Differential Splicing    
Female  860   
Male 966   
    
Differential Expression AltAnalyze Partek Overlap  
Female  1464 968 373 
Male 1272 744 234 
    
Differential Splicing AltAnalyze Partek Overlap  
Female  860 1010 167 
Male 966 1240 212 
Table 3.16. AltAnalyze Results and Overlap with Partek GS. The number of 
differentially expressed and spliced genes predicted when using the algorithms in 
AltAnalyze.   
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3.3.4.10 Significant Results Overlap between easyExon, AltAnalyze and Partek GS. 
When using easyExon, by default significance and fold change criteria are applied so 
that only genes with a significance p value ≤0.05 and an accompanying fold change of 
greater than or equal to 1.5 are considered differentially expressed between C59X 
mutants and wildtypes. Due to the additional fold change threshold the number of genes 
in the easyExon output predicted to be differentially expressed is considerably lower 
than that predicted using Partek and AltAnalyze. For consistency the same fold change 
cut offs (greater than or equal to 1.5) were applied to the Partek and AltAnalyze results 
prior to determining any overlap.  
Caveats to determining the overlap lie in the different ways in which the data were 
annotated, filtered and the statistical approach as well as the different ways in which 
cross-hybridising probesets are dealt with. First considering genes predicted to be 
differentially expressed between female C59X mutants and wildtype only 6 genes were 
found to be common to all 3 different methods (Fig. 3.3.16). These genes were Arc, 
Dusp1, Egr2, Npas4, Nr4a1 and Snca. When considering that only 16 genes in Partek 
GS meet both the significance (p≤0.05) and fold change (greater than or equal to 1.5) 
criteria then over a third of these are significant in the other two analyses. None of the 6 
overlap with the 9 FDR (0.05) significant genes from the combined analysis but this 
may reflect the small fold changes (less than or equal to 1.5) observed in the 9 genes 
and reduced the likelihood of them being true expression changes. In contrast to the 9 
genes from the combined analysis, all 6 of these overlapping expression candidates 
looked like true expression changes from the manual inspection of the geneview. Due to 
the robust nature of these 6 candidates, in terms of significance from multiple 
algorithms and fold changes above a suggested 1.5 cut-off each one is a candidate for 
validation using an independent assay.   
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Figure 3.3.16. Genes Overlap. Genes predicted to be significantly differentially 
expressed (top) between Partek GS, AltAnalyze and easyExon. Only 6 genes were 
found to be common to all 3 significant gene lists, these genes were Arc, Dusp1, Egr2, 
Npas4, Nr4a1 and Snca.  81 genes were predicted to be differentially spliced when 
using Partek GS, AltAnalyze and easyExon for analyses. 
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Figure 3.3.17.  Male Differential Expression and Splicing Overlap. No genes were 
predicted to be significantly differentially expressed between male C59X mutants and 
wildtypes (top) when combining the results from the 3 statistical algorithms. 111 genes 
were predicted to be differentially spliced and common to the 3 statistical algorithms 
applied using Partek GS, AltAnalyze and easyExon. 
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For differential splicing 81 genes were found to be common to all 3 analyses. For male 
results no significantly differentially expressed genes were common to all 3 analyses 
(Fig. 3.3.17). The splicing results showed 111 genes to be significant in all 3. An 
overlap of the 81 and 111 genes revealed a splice overlap of 13 genes common to all 
statistical algorithms and programs and male and females (Table 3.17).  
Of these 13, 9 were found to have at least one predicted differentially spliced probeset 
common to female and male experiments, whether analysed in Partek GS, easyExon or 
AltAnalyze.  9 were significant following multiple test correction with an FDR 
threshold of 0.05 and 5 were significant following a Bonferroni correction for the 
15,800 tests in both experiments using Partek GS.  Examples of these splice events are 
displayed in Figure 3.3.18. Adding to this the results from the combined analysis 
Fam171b, Slc39a13, and Ssfa2 are strong differential splice candidates.  
From the data generated in easyExon and AltAnalyze and the overlap with Partek GS, a 
manageable list of potential expression and splice candidates for validation could be 
generated. Prior to any validation using RT-PCR the results of the planned RNAseq 
data were awaited to further confirm the results and add to their validity. 
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Transcript 
ID Gene Symbol 
6890648 2010106G01Rik* 
6919195 Centb5/Acap3* 
6858773 Colec12 
6878657 D4300389N05Rik/Fam171b** 
6918763 Dffa 
6888151 Frzb* 
6878031 Itga6 
6878655 Itgav* 
6879054 Lrp4 
6878038 Rapgef4** 
6825657 Rhobtb2/Prdm4** 
6888744 Slc39a13** 
6878469 Ssfa2** 
Table 3.17. Predicted Differentially Spliced Probesets. Manual inspection of the 
geneview (Partek GS) and indicated probesets in AltAnalyze and easyExon allowed the 
probesets predicted to be differentially spliced to be identified in the 13 genes 
significant in all analyses. In 9 (grey) of the 13 genes, at least one of the differentially 
spliced probesets was common to both female and male experiments using each of the 
statistical algorithms. * Significant following FDR threshold of 0.05 in Partek GS. ** 
Significant following Bonferroni correction of 15,808 and 15,813 tests in female and 
male analyses respectively.   
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Females 
Slc39a13 
Rapgef4 
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Males 
D430039NO5Rik/Fam171b D430039NO5Rik/Fam171b 
Rhobtb2/Prdm4 
Rhobtb2/Prdm4 
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Figure 3.3.18. Differentially Spliced Transcripts Common to AltAnalyze, easyExon 
and Partek GS. Predicted splice events in Slc39a13(top) and Rapgef4 (bottom) 
(Females) and Fam171b (top) and Prdm4/Rhobtb2 (bottom) in males. The geneviews 
from easyExon (left) and Partek GS (right) are displayed. The probeset predicted to be 
differentially spliced between C59X mutants and wildtypes is highlighted by a grey 
box. In each instance the predicted probeset was identical in Partek and easyExon with 
the same probeset being identified as significantly differentially spliced by AltAnalyze 
(no geneview is produced in the output) for both female and male experiments. The 
easyExon trace shows the mean normalised, log transformed and variance-stabilised 
intensities for each probeset.   The fold change values are plotted below the intensity 
plot and a significant MiDAS p value is indicated by (*) next to the corresponding 
probeset ID, all of which helped identify the splice event.  The splice index diverges 
from 0 when the intensity signal ratio at a probeset is different from the average 
intensity signal ratio across the transcript, which in each of the examples above was 
consistent with the significant splice p value.  
N.B: Prdm4/Rhobtb2 is found on the antisense strand and so is displayed from right to 
left in easyExon. In Partek GS the Refseq is displayed in a 3’ to 5’ direction but from 
left to right, which is why the geneviews appear different at first inspection.  
 
3.3.4.11 C59X Mutant and Wildtype expression of Zfp804a. 
All results presented were carried out using the core meta-probeset, due to the increased 
annotation confidence in this set. One of the disadvantages of using only the core meta-
probeset, specific to this study, was that Zfp804a was not targeted by any core probes. 
Instead the two Zfp804a transcripts (one protein coding, the other a processed 
transcript) were targeted by 11 extended probesets and 17 full probesets. As the primary 
objective of this study was to determine the effects of altered Zfp804a on gene 
expression and splicing, and as a qualitative difference in Zfp804a between C59X 
mutants and wildtype was not obvious from the RT-PCR (3.3.1), an analysis using the 
extended meta-probeset (which includes all core probes in addition to extended probes) 
was carried out to determine if any differences in Zfp804a expression could be observed 
between C59X mutants and wildtypes (Figure 3.3.19).  
No significant differential expression was observed, as predicted from the RT-PCR 
(3.3.1), but a trend for upregulation in the mutants was observed in all 3 analyses. Using 
the FIRMA algorithm in AltAnalyze resulted in significant differential expression of 
Zfp804a in male and female C59X mutants (unadjusted FIRMA p value = 0.02) with 
upregulation of Zfp804a in the mutants. The results did not remain after applying the 
1.5 fold change cut-off, as fold change was 1.26 and 1.24 in female and male 
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respectively. Following a t-test in easyExon to determine differential expression at 
Zfp804a the results showed that no significant difference was present between C59X 
mutants and wildtypes when using a fold change cut-off of 1.5. Without this cut-off 
significant differential expression was observed in female C59X mutants (p = 0.008) 
and males (p = 0.01) with upregualtion of Zfp804a observed in mutants as seen in 
Partek GS and AltAnalyze.  
Significant differential splicing was observed in Zfp804a between C59X mutants and 
wildtypes (Females p = 5.16x10
-9
; Males p = 3.07x10
-8
; combined p = 3.31x10
-16
). 
From manual inspection of each geneview it appeared that the splicing signal was being 
generated from the central of three probesets targeting intron 1 of the protein coding 
transcript (Refseq), which corresponds to the alternative exon 1 in the Ensemble 
processed transcript (Figure 3.3.19). The processed transcript is predicted to have an 
alternative promoter and so the first exon overlaps with intron 1 of the RefSeq 
transcript.  
Three of the probesets are unique to the processed transcript, the central one of which is 
predicted to show differential expression between the wildtypes and C59X mutants. The 
possibility of differential expression of the two Zfp804a transcripts between C59X 
mutants and wildtypes is unlikely due to the absence of differential expression in the 
two flanking probesets. The predicted differentially spliced probeset and the adjacent 
downstream probeset are separated by only 3bp, the differences in expression at only 
one of these probesets is suggestive of a false positive prediction.  
The observed pattern of expression could be explained by a novel variant, but this 
would be a small fragment of less than 82bp or a technical artefact such as probe cross-
hybridisation to another part of the genome. The probeset sequence was checked for any 
potential cross-hybridisation using both BLAST and BLAT and was found to be a 
perfect match to Zfp804a only. The probeset does contain a dbSNP (rs28042740), if 
however this SNP was present in the mice, then it would be expected to affect 
hybridisation in both groups equally and so should not cause the differential expression 
observed. Next the sequence surrounding the probeset was checked for the presence of 
potential splice sites.  The consensus 5’and 3’splice sites are GT and AG respectively. 
Within the 3 bases separating the spliced probeset and adjacent 3’ probeset the 5’ 
consensus splice site of GT is present in the sequence, upstream of the spliced probeset 
  
110 
also contains the conserved AG 3’ splice site (Fig. 3.3.20). If an alternative cassette 
exon were present and incorporated more frequently in wildtypes, then it would be 
expected that a separate band with an additional ~80bp would be present when carrying 
out RT-PCR between exon one and three and this is not present in any of the 16 samples 
analysed. The splice event could also be indicative of an independent transcript, albeit a 
short transcript based on the lack of differential expression in the two flanking 
probesets. Primers specific to such a transcript could not be designed due to the very 
small distance between this probeset and the downstream probeset.  
The extended analysis in easyExon gave a significant result for differential splicing in 
Zfp804a in both the female and male analyses (MiDAS p value = 0.04 in both) (Figure 
3.3.21). The probeset predicted to be differentially spliced, however was different. In 
female C59X mutants the probeset predicted to be differentially spliced was in 
agreement with the Partek GS results. In the male analysis the probeset targeting the 
third exon of Zfp804a (4929502) was predicted to be differentially spliced in male 
C59X mutants.  
In AltAnalyze (as explained in Chapter 2.8.4.2) Zfp804a was actually included in the 
core analysis. No differential splicing was found in female C59X mice, but two 
probesets were predicted to be differentially spliced in male C59X mutants. One of 
these probesets (4929502) replicates the finding from the easyExon analysis, again 
found specifically in male C59X mutants. The other differentially expressed probeset 
(5424882) is upstream of exon 1 and is predicted to be due to alternative promoter 
usage. As no splicing event is found consistently across the different statistical 
algorithms and as there appears to be inconsistencies between female and male C59X 
mutants this suggests the finding may be a false positive.  
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 Female Male Combined  
Differential 
Expression p value                                    0.19 0.75 0.99 
Differential Splice 
p value    5.16x10-9 3.07x10-8   3.31x10-16  
Fold Change                                                       1.05 -1.04 1.02 
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Figure 3.3.19 Zfp804a Expression and Splicing.  No differential expression was 
observed in Zfp804a. Significant differential splicing was present in female, male and 
combined experiments and appeared to be due to the differential splicing observed in a 
single probeset targeting the first intron of the processed transcript. Both the Refseq, 
protein coding transcript and the Ensembl, processed transcript are displayed at the 
bottom of the figure. 
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agctgtagtgccatctctctctctctctctctctctctctctctctcatctctttagatgaagaacttaaataatttgcagaaaagtaacttag
ggtgcaaaaattcaatttttaaaatttaataaaatttatcatggaatcaattacaatgacaaaataaatgaagtttaaattaacaatata
tttatgtaaatatttatgaaaagaatgaaaatatccatttgcatatataattggcagtacatatctcttcttaaaggccacatttcagatgt
tcaccaaagaggattttatagtagctaagaattagctgtttacagcagaaccaaactacttttggaagctgtattttaatgttggcaaag
attggatctatgttcacttaatgcctctttctatatgatttactgtctttcttgtacttctgctgttttcttttttttcatttatattggcttaatctg
tgaattctttgctttttttgactcatgttttcaaacttgttttgctgatttttttatttgtcttttgttctttttctagttctaattgttatattaaagt
tgacaacagttgggtcaaagtaaactcaagggagtgctcattgtatgtttcccttgaaattttatgtttcag 
Figure 3.3.20. The sequence represents the alternative exon 1 from the Zfp804a 
processed transcript. 3 Affymetrix extended probesets are found in this sequence 
(shaded) with the middle one predicted to show differential expression between C59X 
mutants and wildtypes (bold). No differential expression is observed in the two flanking 
probesets suggestive of an alternative exon, specifically within this region. The 
consensus 5’ splice site (GT) is observed downstream of the probeset in the 3 
nucleotides residing between this probeset and the downstream probeset. A potential 3’ 
splice site is also present (AG) upstream of the differentially expressed probeset. 
Variable and less conserved sequences surrounding the consensus 5’ and 3’ splice sites 
have been proposed, which are thought to be important for accurate recognition of 
splice sites by the spliceosome. The above sequence does resemble these sequences in 
part.  These sequences are known to be particularly variable in alternative exons.  
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Figure 3.3.21. easyExon Extended Analysis C59X Mutants and Wildtypes. Whilst significant differential splicing between C59X mutants and 
wildtypes is observed in both females (Left, p = 0.04) and males (right, p = 0.04) the probeset predicted to be differentially spliced is different. In 
females the probeset is the same as that observed when carrying out the analysis in Partek GS. Differential splicing in male C59X mutants is observed 
at the 7
th
 probeset, 4929502 which targets exon 3 of Zfp804a.   
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3.4 Discussion.  
Sequencing confirmed the presence of a nonsense or PTC mutation in exon 2 of the 
Zfp804a transcript carried by the mutant mouse line. Qualitative assessment by RT-
PCR and quantitative assessment using the exon array (Affymetrix) revealed no 
significant differential expression of Zfp804a between the C59X mutant and wildtype 
mice. This finding was unexpected based on the prediction that the PTC would initiate 
the nonsense mediated decay surveillance mechanism and thus reduce the abundance of 
the Zfp804a mRNA specifically in the mutants.  
The C59X mutant transcript with the PTC is not a substrate for NMD, however this 
does not mean that protein levels are unaffected. The only way to determine the effects 
of the PTC on Zfp804a protein is to measure the protein itself using a suitable antibody, 
unfortunately such an antibody is not currently available.  There are examples in which 
transcripts with PTCs in the first exon escape NMD, for example β-globin (Neu-Yilik et 
al, 2011). PTCs in exon 1 of β-globin are bypassed with re-initiation of translation 
occurring at an upstream, in-frame start codon (Neu-Yilik et al, 2011), although the N-
terminally truncated protein is not functional (Neu-Yilik et al., 2011). I have not found 
any known examples where a PTC in exon 2 of a gene escapes NMD.   
Read through can occur when a PTC is actually read as a normal codon by the tRNA, 
due to the fidelity of the 3
rd
 base of the codon. The transcript escapes NMD and 
translation continues in the normal reading frame which generally results in full length 
protein being translated but at reduced levels.  
tRNA has been described to temporarily detach from the mRNA being translated, 
particularly at stop codons, where the ribosome is thought to pause. This can result in 
tRNA reattachment at an in frame nucleotide to the +1 frame, a process known as 
frameshifting (Farabaugh et al., 1993). When the distance between detaching and re-
attachment of the ribosome is greater and reattachment occurs at an out of frame codon 
this is called bypassing (Weiss et al., 1987). Bypassing and frameshifting are examples 
of ways in which a PTC containing mRNA transcript can escape the NMD mechanism 
but may result in an aberrant protein (Herr et al 2000; Neu-Yilik et al., 2011). If a shift 
in the reading frame occurs, this could result in a protein which is mis-folded which 
could result in the removal of the protein via the endoplasmic reticulem-associated 
protein degradation (ERAD) system (Sommer & Wolf, 1997). The system is responsible 
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for the detection of the incorrectly or incompletely folded proteins and their subsequent 
degradation (Hamptom, 2002).   
Literature on the stop codon as a tetranucleotide suggests the 4
th
 base is important to the 
fidelity of a stop codon with UAAG and UAAA being much more efficient at causing 
termination than UAAC and UAAU (McCaughan et al., 1995). The 4
th
 base in C59X 
mutants is a G, therefore the ability of the stop codon to terminate translation would be 
expected to be high. In the absence of nonsense mediated decay, a truncated Zfp804a 
protein may be translated.   
 
The absence of reduced Zfp804a mRNA abundance in the C59X mutants was 
unexpected, however I postulate that it is likely that the resulting translated protein will 
be truncated with a loss of function in homozygotes potentially accompanied by a gain 
of function if there is a truncated protein. In the absence of an antibody, I am unable to 
test these hypotheses.  
 
A detailed look at the expression across the Zfp804a transcript in both C59X mutants 
and wildtype revealed if anything a trend for upregulation of the protein coding 
transcript in mutants. Significant differential splicing of Zfp804a mRNA between C59X 
mutants and wildtypes was also observed which replicated across the female and male 
experiments, and the significance of which increased when combining all samples into 
one group. Differential splicing between C59X mutants and wildtypes appeared to be 
occurring in the processed transcript (Ensembl) rather than the Refseq protein coding 
transcript at a single probeset, suggestive of differential cassette exon usage. The idea 
that a novel smaller transcript may be present was explored but validation was impeded 
due to the proximity of the predicted spliced probeset from the adjacent probeset which 
showed no differential expression between C59X mutants and wildtypes. When 
considering splicing of Zfp804a in other software packages this splice event failed to 
replicate across algorithms and experiments. This event may therefore reflect a technical 
artefact.  
The number of genes differentially expressed between the C59X mutants and wildtypes 
were small. In the female and male experiments no genes were significantly 
differentially expressed following multiple test corrections. Whilst the role of Zfp804a 
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in transcription regulation can not be dismissed, these data do not support the 
hypothesis that Zfp804a regulates gene expression. When combining male and female 
data together to increase power, several genes were significantly differentially 
expressed following multiple test correction, but when inspecting the geneviews the 
transcripts did not show differential expression across the entire transcript.   
When the data were processed using alternative filtering and statistical methods, 
differential expression was seen for only 6 genes across all methods. These 6 genes are 
relatively robust candidates for altered expression as they were identified in the female 
experiment in each of the three statistical packages. The geneviews for all 6 generated 
in Partek GS are also indicative of true expression differences across the whole of the 
gene. Each gene displayed expression differences between C59X mutant and wildtypes 
of more than or equal to 1.5 fold. Despite the robust nature of these findings, identifying 
only 6 genes from ~15,000 does not provide conclusive evidence that Zfp804a regulates 
gene expression. Although these 6 changes are less likely to be technical errors, the 
statistical support is not strong enough to exclude these being chance positives. It is 
important not to dismiss these genes though or rule out a role for Zfp804a in gene 
expression regulation, particularly in light of the results of previous studies in which 
evidence for such regulation has been found in cellular models (Hill et al., 2012; 
Gigenti et al., 2012).   
The results of the alternative splicing analysis are somewhat more robust with ~7% of  
transcripts tested showing differential splicing between C59X mutants and wildtypes, 
many remaining significant following multiple test correction. When assessing the 
replication across the female and male experiments, significantly more genes than 
expected by chance replicated. Detailed inspection of the specific splice events, which is 
important as splicing results are known to be subject to more false positives (Bemmo et 
al., 2008), showed that in a high proportion of the transcripts the differentially spliced 
probeset(s) was the same in female and male experiments. Altered splicing between the 
C59X mutants and wildtype also occurred in the same direction across experiments.  
Combining the male and female data in addition to carrying out the independent 
analyses with alternative filtering criteria and algorithms produced a list of 9 strong 
differential splice candidates.  The lists used for the overlap had not been corrected for 
multiple testing and so differences in the lists may reflect the different false positive 
calls arising from the different annotation, filtering and statistical procedures used. To 
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allow for the fact that transcripts are included/excluded in each method according to 
different criteria, I included only transcripts that were included under each approach. 
The genes remaining are less likely to result from artefacts of a particular type of 
analysis. The overlap also produced a more manageable list size from which manual 
inspection of the data was carried out.  
Whilst the use of female brain tissue and F3i generation mice was not ideal this was all 
that was initially available. A major limitation of using mice from this generation is the 
potential for mice to harbour a number of additional ENU mutations, although at the 
outset, it was thought unlikely that the same additional ENU mutation would be found 
in enough mice to impact upon the experiment. Nevertheless, clearly it was important to 
carry out the study on mice from a later generation in which the likelihood of such 
additional mutations is reduced further (This analysis is presented in Chapter 5).  
Despite gender differences, there is a robust overlap of splicing changes replicated 
across the male and female mouse studies. In addition when combining the samples in a 
larger analysis and covarying for gender, splice differences are still apparent between 
C59X mutants and wildtypes. These are apparent despite the use of half and whole brain 
in female and male mice respectively, and the fact that the male animals were twice the 
age of the female mice, adding to the robustness of the data. In mice of different genders 
and age groups common expression and splice variation is found between C59X 
mutants and wildtypes.  
Of the differential splice candidates, Rap guanine nucleotide exchange factor (RapGef4) 
is highly enriched in the brain. Rare non-synonymous variants in this gene have been 
associated with autism (Bacchelli et al., 2003).  Two further interesting genes are the 
integrins Itga6 and Itgav which form part of a family of cell adhesion proteins.  Itga6 is 
expressed in neuronal tissue and there is evidence of its role in development processes 
(De Arcangelis et al., 1999).  Itgav is expressed in the striatum and all cortical layers 
(Pinkstaff et al., 1999) and is thought to have a role in neuronal migration during 
cortical development (Anton et al., 1999).  
 
To determine if these genes, and the others identified as altered in the exon array, could 
be validated in an independent assay, exploratory expression and splicing analysis was 
carried out using next generation RNA sequencing (RNAseq).   
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Chapter 4. RNA-Sequencing  
4.1 Introduction. 
Having looked at expression and splice changes in the C59X mouse strain using the 
exon array (Affymetrix) I found that the F3i generation mice homozygous for the 
mutation exhibited altered expression and splicing relative to wildtype controls. 
Replication across 2 independent experiments and 3 different software programs 
highlighted a number of consistent changes. To support the exon array work I 
proceeded by monitoring expression and splicing in the same mice using next 
generation RNA sequencing (RNAseq).  
The implementation of next-generation sequencing has enabled global RNA sequencing 
in a relatively unbiased and quantitative way. I sought to apply this technology to 
confirm the expression and splicing changes I had observed in the array data. Unlike 
microarray analysis in which gene expression is determined indirectly from the degree 
of hybridisation to probes, in RNAseq a direct measurement can be taken based on the 
number of sequence reads at specific transcripts. This is therefore an unbiased approach, 
with no restriction to the transcripts represented on the chip one happens to be using. 
Given the unbiased nature of RNAseq, novel transcripts can be identified, and the 
application of RNAseq has led to the realisation that the transcriptome is far from 
complete, novel transcripts being discovered in each successive study (Trapnell et al 
2012).  
Given the expense of RNAseq, the initial plan was to carry out a pilot study on a subset 
of the samples from F3i mice used in the exon array analysis, and, if technically 
successful, followed up with a larger independent, later generation sample. The 
intention was that the initial pilot would allow the validity of the exon array findings to 
be determined whilst acting as a technical validation of the exon array procedure and 
analysis. The larger follow-up study would then allow a biological validation of any 
consistent expression or splice changes in the C59X mutants. 
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4.2 Methods.  
4.2.1 Sample. 
Brain RNA samples from 4 of the males used in the previous chapter were chosen for 
the pilot based on quality and volume of RNA.  2 C59X mutants (ZBDEZ2e & 
ZBDEZ4a) and 2 wildtypes (ZBDEZ6a & ZBDEZ21c) were chosen. All samples had 
an RNA integrity number (RIN) above 8.  
4.2.2. Sample Preparation. 
RNA was prepared using the low-throughput (LT) protocol with the Illumina TruSeq® 
RNA sample prep kit (Illumina, San Diego, CA, USA). Samples were initially re-
quantified using 1μl of sample on the Nanodrop 1000 spectrophotometer and then 
prepared as per the manufacturer’s instructions by myself and K. Matripriganda (Lab 
manager responsible for setting up new technologies in the host lab) with assistance 
from laboratory technicians. In addition to the 4 samples a Universal Human reference 
RNA (Stratagene) sample was used as a positive control and a no template sample as a 
negative control. 4μg RNA in 50μl H2O was purified using oligo dT magnetic beads to 
capture poly-A RNA which was then fragmented. Based on the published protocol, to 
ensure optimal coverage of the transcriptome in conjunction with efficient library 
production, fragments were expected to range from 120-200bp with an average size of 
150bp. Double stranded cDNA synthesis was achieved using reverse transcriptase and 
random hexamer primers. Blunt ends were formed by removing overhangs with a 
proprietary mix either of exonuclease (degrade 3’ overhangs) or polymerase (to fill in 5’ 
overhangs). Prior to ligating indexing adapters to the fragments, a single A nucleotide 
was added to the 3’ blunt end of the fragment which is complementary to the T 
nucleotide at the 3’ end of the adapter and so aids the ligation of fragment and adapter. 
This is done using an A-tailing mix.  PCR was used to amplify the DNA library and 
only fragments with adapters at both ends were amplified. Each step was carried out in 
accordance with the manufacturer’s instructions.  
 
4.2.3. cDNA Library Quality Control. 
To determine the fragment sizes within, and quality of each cDNA library, 1μl of 
sample was loaded into a DNA chip and run on the Agilent 2100 Bioanalyser (Agilent 
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Technologies, Palo Alto, CA). Distribution must be within the expected range for 
enrichment to be successful. Fragment size and purity were assessed with a product size 
of 200-300bp expected for paired-end libraries, according to the manufacturer’s 
instructions. 
 
4.2.4 Sequencing. 
Samples were sent to the core sequencing facility at Bristol University. Paired end 
(~100bp) reads were generated on an Illumina Genome Analyzer IIx.  Raw sequence in 
the form of fastq files were acquired from the Bristol facility for analysis.   
 
4.2.5 RNAseq Quality Control.  
Raw files (FASTQ) files were imported into the FastQC program (v.0.10.1) (Babraham 
Bioinformatics) (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to 
determine the quality of the sequencing. Basic statistics as well as 10 QC statistics are 
generated. For each metric FastQC will mark the sample as either acceptable in quality, 
warn that sample may be verging on poor quality or state that the sequence has an error 
or has failed the metric. If a sample fails a certain metric this simply means the results 
differ from that expected in FastQC and should not be taken that the sample is poor 
quality and should be discarded. FastQC is used to determine areas in the data which 
may have quality issues and allows you to determine if the source is one that was 
expected given the type of experiment or if a genuine quality issue has arisen. Errors 
made during cluster generation and sequencing are easier to detect than errors made 
during library preparation. This is because the errors made in the former two affect the 
detected signal and therefore the quality score. Basic statistics such as the total number 
of sequences processed, sequence length and the number of sequences filtered are 
produced for each input sequence. An explanation of the 10 QC metrics is described in 
detail alongside the presentation of the results (4.3.2.1-4.3.2.10) (Further information 
can be found at: 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/Help/3%20Analysis%20Mod
ules/).  
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4.2.6 Alignment, Assembly and Differential Expression Analysis.  
To align reads to the genome, assemble transcripts and quantify expression changes the 
Tuxedo protocol was followed (Trapnell et al., 2009; Trapnell et al., 2010). This 
protocol is in wide use (Lin et al., 2011, Trapnell et al., 2012). It is particularly 
compatible with sequencing carried out using the Illumina sequencing platform and 
works best with sequencing generated on model organisms for which a reference 
sequence is available. The following procedure was carried out using Unix.  
 
4.2.6.1. Sequence Alignment and Identification of Splice Junctions 
Raw sample files were aligned to the genome (mus musculus NCBI build 37.1) and 
splice sites identified using TopHat (v.1.3.2) (Trapnell et al., 2009) 
(http://tophat.cbcb.umd.edu/), which is part of the software suite collectively known as 
the tuxedo protocol/suite. TopHat runs on the Linux operating system and was 
developed specifically for reads generated using the Illumina genome analyser. Reads 
that are 75bp or greater are optimal for analyses.  TopHat utilises Bowtie (http://bowtie-
bio.sourceforge.net/index.shtml) (Langmead et al., 2009) for initial sequence alignment 
to the genome. Bowtie alone is not sufficient as the software cannot align reads to 
reference sequences which differ as the result of large mismatches such as might occur 
if the read spans an intron. TopHat takes initially unaligned reads and separates them 
into shorter reads called segments which are then re-aligned to the reference genome.  
Tophat then infers that segments within a read that map more than 100bp apart most 
likely span a splice junction and in this way a list of splice sites is generated. As no 
reference splice site annotations are used in this process, novel splice sites can be 
identified (Trapnell et al., 2012). Fastq files were used as the input for TopHat. The 
script used for alignment, alongside a description of the components can be found in 
Appendix 4.1  
The output from TopHat is a BAM file (binary version of sequence alignment map 
(SAM)).  Alignments were viewed by indexing the BAM file for each sample using 
SAMtools (http://samtools.sourceforge.net/) (For script see Appendix 4.2) and then 
uploading them into the Integrative Genomics Viewer (IGV) 
(http://www.broadinstitute.org/igv/) (Robinson et al 2011; Thorvaldsdottir et al., 2012)  
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4.2.6.2. Transcript Assembly. 
Cufflinks (v.1.2.1) (Trapnell et al., 2010) (http://cufflinks.cbcb.umd.edu/) was then used 
to assemble transcripts from splice site information from TopHat. Cufflinks also forms 
part of the tuxedo protocol.  The aligned BAM file is used as input into Cufflinks.  Due 
to many genes having multiple isoforms, the assignment of reads to a particular isoform 
rather than another is not straightforward. Cufflinks assembles the data in the most 
parsimonious way possible to explain the data, assembling the minimum number of 
transcript fragments which can explain the splice sites identified. Removal of pre-
mRNA transcripts and artefact transcripts is also carried out at this point. Each sample 
is aligned individually. When sequencing is of insufficient depth (less than 10 million 
reads) the amount of partial transcript fragments is greater which can increase the risk of 
false isoform calls. To overcome this, identified novel isoforms and transcripts of high 
interest should be validated using an alternative method such as RT-PCR, or Rapid 
Amplification of cDNA Ends (RACE) can also be used to ensure transcripts ends are 
more accurately defined as recommended by Trapnell et al. (2012) (Scripts used for 
transcript assembly can be viewed in Appendix 4.3). 
A normalisation procedure is required in RNAseq, as longer transcripts produce more 
fragments compared to shorter transcripts.  If two transcripts had equal abundance but 
one was twice as long as the other, the longer transcript would appear to have twice the 
(reads) abundance of the shorter transcript. Therefore the length of a transcript must be 
taken into account in abundance calculations. In Cufflinks this is done by considering 
the number of reads per transcript and then normalising this value by the length of the 
transcript. In addition the reads need to be normalised to the total number of sequenced 
fragments from the sequencing machine to account for run to run variability (Trapnell et 
al., 2012).    
The normalisation method used in Cufflinks for paired-end reads is FPKM (fragments 
per kilobase of transcripts per million mapped fragments) (Mortazavi et al., 2008). 
FPKM is comparable to the RPKM (reads per kilobase of transcripts per million 
mapped reads) used for single-end sequences. The FPKM is proportional to the 
abundance of a transcript (Trapnell et al 2010).  
When the data contain a small proportion of genes that are highly expressed, FPKM is 
subject to a known bias that can skew the differential expression analysis and results.  
This is dealt with by using the –N option (described in Appendix 4.3) which normalises 
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to the upper quartile of expressed genes rather than the total number of mapped 
fragments as the former is more robust when there are less abundant genes or transcripts 
(http://cufflinks.cbcb.umd.edu/).  
The assemblies of each sample were then merged together using CuffMerge (part of the 
Cufflinks software package). This helps to compensate for relatively poor sequencing 
depth. Correct reconstruction of a gene in a single sample is difficult when there is 
insufficient sequencing depth. By merging all samples together the gene is more likely 
to be reconstructed accurately. The reference (NCBI build 37.1) was also merged with 
the samples forming a comprehensive annotation (Trapnell et al., 2012).  To merge the 
assemblies I used gedit (a text editor) to create a file called ‘assemblies.txt’ within 
which the assembly files for each sample were listed and then CuffMerge (Appendix 
4.4).  
 4.2.6.3. Differential Expression Analysis. 
To compare the relative amounts of assembled transcripts represented in each sample 
and determine if the difference was statistically significant Cuffdiff 
(http://cufflinks.cbcb.umd.edu/) was used (Appendix 4.5). Samples were compared 
according to experimental group, therefore samples 1 and 2 representing the 2 C59X 
mutants were compared to samples 3 and 4 representing the 2 wildtypes.  The 
expression of a transcript is calculated based on the number of reads as described above.  
To increase the accuracy of expression measurements, Cuffdiff models the technical 
variation in the data, which can arise due to artefacts in the library preparation or 
sequencing procedure and this is then adjusted for. Cuffdiff tries to estimate this 
variation using a likelihood based approach (Roberts et al., 2011) and uses this 
information when determining expression differences between experimental groups 
(Trapnell et al., 2012). The relative abundances of each transcript are compared using 
the Cuffdiff command. If a transcript or gene has several isoforms it can be problematic 
to determine which isoform a read is from. A linear model is used in Cuffdiff to work 
out, using maximum likelihood, which way of assigning abundance to each transcript 
best explains the reads generated (Trapnell et al., 2012). Total gene expression equals 
the combined expression of the relevant isoforms. Following this a results file is 
produced containing results of differential expression and differential splicing analyses. 
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4.3 Results. 
4.3.1 cDNA Library Quality Control. 
To ensure the cDNA library preparation was comprised of uniform sized fragments each 
sample was run on the Agilent Bioanalyser (Fig. 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. cDNA library Quality Assessment. 1μl of each of the 4 samples was 
loaded into a chip and run on the Agilent 2100 Bioanalyser. In each sample the majority 
of fragments were around ~270bp, which is within the expected size range. The second 
peak at ~1500bp is likely to represent concatenated adapter sequences. As this 
represents only a small proportion of the sample this is considered adequate quality 
(Illumina) and I was able to proceed to the cluster generation step with these samples.  
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4.3.2 Sequence Quality Control.  
From the bioanalyser trace the fragments in each sample appeared to have a similar 
distribution.  Therefore the cDNA library preparation stage passed this quality control 
measure. The sequencing data were assessed for quality using FastQC software. Initially 
basic statistics were generated which showed all samples to contain mate-paired end 
reads of 110bp sequences.  The total number of sequences was 41M, 61M, 61M and 
54M for samples 1-4 respectively.  
4.3.2.1 Assessing ‘Per base sequence quality’  
The distribution of quality scores at each position in the read is plotted. Each base in a 
read is assigned a quality score using a Phred-Like algorithm where Qphred = -10log10(p), 
where p represents the estimated probability that a base call is incorrect (Ewing et al., 
1998; Ewing & Green, 1998). For example a quality score of 30 would represent a 1 in 
1000 chance that the base had been called incorrectly (Ewing & Green, 1998). At each 
position a box and whisker plot is drawn (Fig. 4.2). A higher quality score represents a 
more accurate base call. A warning is issued if the lower quartile of any base is less than 
10 or if the median is less than 25 at any base position. Sequencing is deemed to have 
failed quality control if the lower quartile of any base is less than 5 or if the median is 
less than 20 at any base position 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The plot in Figure 4.2 was 
generated from the sequencing of sample 1 (a C59X mutant) which had the lowest per 
base quality score. The median quality in each sample went below a median quality 
score of 20 in at least one base toward the end of the read. The low quality scores in this 
metric for each of the 4 samples indicate poor quality sequencing. The very low quality 
scores at the end of the sequences most likely reflect the decrease in quality calls on 
most sequencing platforms further into the sequencing process. 
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Figure 4.2. Per Base Sequence Quality. The position of the base within the read is 
plotted on the x-axis with quality (phred) score on the y-axis. A higher quality score 
represents a more accurate base call. Three zones are present on the y axis, depicted by 
a green, orange and red background colour, which depict good, reasonable and poor 
quality base calls respectively (as defined in section 4.3.2.1).  The yellow boxes 
represent the inter quartile range (IQR), with the upper and lower whiskers representing 
the 10 and 90% points. The red line represents the median and the blue line the mean 
quality. The above is an example showing sample 1, a C59X mutant. All the samples 
failed this metric due to the median quality being less than 20 at, at least one base 
position.   
 
 
4.3.2.2 Per sequence quality Scores. This metric is generated to determine if a subset 
of sequences from each sample have universally low quality scores. Low quality scores 
can arise due to poor imaging based on position on the flow cell. Sequences with low 
quality scores should only represent a small percentage of the total number of 
sequences. FastQC denote sequences with modal mean quality scores below 27 (0.2% 
error rate) as quality of that sample is poor 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Samples 2 (Fig. 4.3) and 4 
had modal mean quality scores of greater than 27 (Fig. 4.3), with the quality score being 
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38 in both. The modal mean quality score in samples 1 and 3 was only 2, in one of the 
pair-end reads. Both samples were considered to have poor quality based on this quality 
score. As more than a small proportion of the data had low mean low quality score this 
could reflect a systematic error where perhaps one end of the flow cell was incorrectly 
read, however this is merely speculative.  
 
Figure 4.3. Per sequence quality Scores. Along the x-axis the mean phred quality 
score was plotted with frequency on the y-axis. In this example of sample 2 (C59X 
mutant) the modal mean quality score is 38 which is above the FastQC cut-off of 27 and 
represents good sequence quality scores. The majority of sequences have good quality 
scores and only a small subset have low quality scores, which most likely reflects their 
position on the edge of the field of view when imaging the sequences.  
 
 
4.3.2.3 Per base sequence content. 
This metric determines the proportion of G, T, A and C bases as a function of the 
position along the read throughout the sequence run for a given sample (Fig. 4.4). 
Across the read you would expect the line representing %G, T, A and C to be constant. 
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This demonstrates the relative amount of each base and should reflect the overall 
amount of each base in the transcriptome. If the cDNA library generated was random 
then the lines would be expected to run parallel as an equal proportion of each base 
would be expected.  A bias in one particular base is indicated by a divergence form the 
parallel lines. If this divergence occurs in different bases according to the position 
within the read this may reflect a contaminating overrepresented sequence. If a 
divergence from parallel lines (and therefore unequal representation of each of the four 
bases) is seen across all positions of the read it indicates that the library was biased for 
particular sequences or a systematic error may have occurred during sequencing, such 
as difficulty in sequencing AT rich repetitive sequences (Harismendy et al., 2009).  A 
difference of more than 10% between A and T or C and G at any position in the read 
would indicate questionable quality, likewise a difference of more than 20% between A 
and T or C and G in any position is representative of an unequal proportion of each of 
the 4 bases throughout a read which is indicative of low quality sequencing 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). This however was not the 
case in any of the 4 samples. Each had a difference between A and T or C and G that 
was >20% at one or more position in the sequence. In each case this occurred in the first 
~10bp of the read. As this bias is not present across the whole sequence it is unlikely 
due to a systematic error. That fact it occurs in the first ~10 bases is most likely 
accounted for by the random primers used in the cDNA library preparation, which bias 
the nucleotide composition of a sequence specifically at the start of a read (Hansen et 
al., 2010).  
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Figure 4.4 Per base Sequence Content. The proportion of G, T, A and C bases as a 
function of the position along the read throughout the sequence run is plotted above for 
sample 3 (this plot is representative of the plot observed for all 4 samples). The 
difference between A and T or C and G that was greater than 20% at one or more 
positions in the read occurred in all 4 samples which may indicate poor quality 
sequencing as defined in (4.3.2.3), however this was only observed in the first ~10bp of 
the read in all 4 of the samples.  
 
 
4.3.2.4 Per base GC content.  
This metric determines the GC content as a function of the position along the read 
throughout the sequence run for a given sample (Fig. 4. 5). Variable GC content across 
the positions in a read may indicate a strongly overrepresented sequence that is 
contaminating the library. A greater than 10% fluctuation from the mean GC content at 
any base position indicates that the sequencing is of poor quality 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The GC content at one or 
more base positions varied from the mean by more than 10% in each sample which 
therefore failed this metric. This always occurred in the first 15 bases of the read and 
again most likely reflects the random primers used in library preparation (Hansen et al., 
2010) 
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Figure 4.5 Per base GC content The GC content as a function of the position along the 
read, throughout the sequence run for sample 4 was plotted. A horizontal line is 
expected as the GC content should not vary when using a random primed RNAseq 
library. The GC content at one or more positions in the read varied from the mean by 
more than 10%.  This was the case in samples 1, 2 and 3 as well.  The variation in GC 
content from the mean was observed only at positions 1-15 of the read.  
 
 
4.3.2.5. Per sequence GC content  
The distribution of GC content across all sequences for a given sample was compared to 
a reference distribution predicted from the modal GC content in the actual data. A 
normal distribution is expected. The central peak should reflect the GC content of the 
underlying transcriptome. Contamination, e.g., from an adapter sequence, can cause an 
unusual distribution. If more than 15% of the reads deviate from the normal distribution 
this could be indicative of poor quality sequencing and should be looked into further. 
Distribution of GC content did not deviate from a normal distribution in samples 1 and 
3. GC content deviated by more than 15% in samples 2 and 4 (Fig. 4.6) and may 
indicate contamination from an overrepresented sequence such as an adapter. FastQC 
recommends looking into fluctuations occurring in more that 15% of reads, but that 
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fluctuations in over 30% of reads is a real cause for concern and neither sample 2 or 4 
passed this threshold (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
Figure 4.6 The distribution of GC content across all sequences for sample 4 was 
plotted. More than 15% of the reads deviated from the normal distribution which could 
be indicative of poor quality sequencing and should be looked into further. The central 
peak should reflect the GC content of the underlying transcriptome. 
 
 
4.3.2.6 Per base N content.  
When there is not enough confidence to make a base call, a base is designated ‘N’ rather 
than one of ACTG. The ‘per base N content’ metric is used to determine the percentage 
of base calls that were called as N’s over each position of a read. A small proportion of 
N calls are expected, particularly toward the ends of reads but if greater than 5% of base 
calls were ‘N’, this indicates that there was insufficient evidence to make a sequencing 
call at that position most likely due to poor quality sequencing and this is even more 
likely if more that 20% of the calls at a particular position are given as 
‘N’(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The results are 
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displayed for sample 1 (Fig. 4.7) and reflect that at no position along the read did the % 
N call exceed 5%. This was true of the results for samples 2, 3, and 4 as well.  
 
Figure 4.7. The percentage of ‘N’ base calls over each position of a read for 
sequences from Sample 1. The position in the read was plotted along the x-axis and the 
% of N’s on the y-axis, to determine the percentage of N base calls at each position of a 
read.  In this and the other 3 samples the % of N base calls at any of the positions of the 
reads did not exceed 5% which reflects adequate quality.  
 
 
4.3.2.7 Sequence length distribution.  Some sequencing machines will remove poor 
quality bases from the ends of each fragment resulting in sequences of varying length 
despite the library containing uniform sized fragments. If more than one sized sequence 
is observed in your sample or if any sequences have a length of zero then FastQC will 
highlight that sample as having potential quality issues. Sequence size distribution was 
plotted to ensure sequence length did not vary due to the removal of poor quality bases 
from the ends of fragments by sequencers. The graph should display a peak at a single 
size and this was the case for all 4 samples (Fig 4. 8) 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  
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Figure 4.8 The distribution of Sequence lengths for all sequences in Sample 1. All 
sequences in Sample one were a uniform length of 110 bases. Exactly the same plot was 
generated for Samples 2, 3 and 4 with all sequences having a length of 110bp.  
 
 
4.3.2.8 Sequence Duplication Level.  Most sequences will be represented once (except 
in the final output). Low levels of sequence duplication are expected and indicate a high 
level of coverage of the target. High duplication levels may indicate an enrichment bias 
possibly during PCR amplification. How many times a sequence is duplicated is 
determined. Each sequence is then put in 1 of 10 categories based on how many times it 
is duplicated ranging from 1 (it is unique) to 10+ which indicates the sequence is 
present in the output 10 or more times.  The proportion of duplicate to singleton (unique 
sequences represented only once) sequences in each of these 10 groups is then plotted 
(Fig. 4.9). A slight increase in the proportion of duplicates to singletons is expected in 
the 10+ category due to it including all sequences duplicated 10 or more times not just 
10.   FastQC truncates each sequence to 50bp because an exact sequence match is 
required to define a duplicate.  FastQC only considers the first 200,000 sequences in a 
file to reduce processing time, and proposes that this is an adequate number to gauge the 
% of duplicate sequences in the whole sample 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).   
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Figure 4.9. The Percentage of Duplicates in the Total Sample. A large increase in the 
10+ category indicates that ~35% of samples appear in the final dataset 10 or more 
times. More than 50% of the total number of sequences in sample 2 (above) were 
estimated to be duplicates which is indicative of poor quality sequencing The 
percentage of duplicates relative to singleton sequences was plotted for each level of 
duplication from unique (1) to 10+ (duplicated 10 or more times in the sequencing 
output). 
 
In Samples 1 and 3 more than 20% of the total sequences were duplicates. In samples 2 
and 4, 54% and 52% of the total sequences were duplicates respectively.  In FastQC if 
more than 50% of the total number of sequences were duplicates then this is indicative 
of low quality sequencing (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
The large number of duplicates is comprised mainly of samples represented 10 or more 
times in the output.  The plot shown in figure 4.9 was representative of each sample and 
although FastQC guidelines suggest that a plot like this represents poor quality 
sequencing it is commonly observed in RNA-sequencing.  The reason for this is that 
with RNAseq a certain proportion of sequences will occur very frequently (e.g., 
housekeeping genes) whilst others will be very rare. In order to sequence the rare 
transcripts the common transcripts are over-sequenced, resulting in a high level of 
duplicates present in the data. Therefore some duplication is unavoidable for RNAseq 
data.   
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4.3.2.9 Overrepresented sequences. No single sequence is expected to contribute a 
significant proportion of the total sequences. If this does occur, it might reflect 
contamination, maybe of adapter sequences, or it could be true biological variation. Any 
sequence contributing more than 0.1% of the total is identified in FastQC.  Again only 
the first 200,000 sequences are analysed so there is the possibility of missing an 
overrepresented sequence that occurs later in the file. The flagged overrepresented 
sequences are then compared to a list of common contaminants from a database 
accessed by FastQC and if a match is found, which is at least 20bp long and has a 
maximum of one mismatch, the identity is displayed. This is not robust but should be a 
good indicator of the type of contaminant. Often adapters are the cause and as they have 
similar sequences the precise adapter may not be flagged up, but another adapter will.  
Again reads are trimmed to 50bp. A sequence which makes up more than 0.1% of the 
total is considered overrepresented in FastQC and depending on the source may require 
further processing of the data to remove it 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
No overrepresented sequences were identified in the 4 forward reactions. In the reverse 
a single sequence was identified in all 4 samples and contributed to 0.23-0.28% of the 
total number of sequences and so was identified as overrepresented by FastQC. The 
sequence was not identified as a common contaminant, rather it was a string of N’s. 
Given that a sequence consisting of N’s is overrepresented in the sample it is surprising 
that the ‘per base N content’ was not a cause for concern. Although greater than 0.1% 
this is not a great enough proportion of the total number of sequences to have an impact 
upon the other QC results, as the problems appear to arise in the first 1 to 10 bases and 
the overrepresented sequence would effect more bases than this if it were contributing 
to low quality scores. No adapter contamination was observed in the sequences.  
 
4.3.2.10 Overrepresented K-mers.  
Smaller overrepresented sequences (less than 20bp) will be overlooked in the 
‘overrepresented sequence’ metric (4.3.2.9) due to the applied stringency (the match 
must be at least 20bp with only 1 mismatch). Overrepresented 5-mers are analysed to 
compensate for this. The expected proportion of a k-mer is estimated using the whole 
library base content and then the observed proportion of the k-mer is determined from 
the actual count. An observed-expected ratio is then calculated. The top 6 
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overrepresented k-mers were plotted in a graph to demonstrate their relative enrichment 
across the read length. This plot can be used to determine if the enrichment in each k-
mer occurs at the same position within the read each time or if it is random. To be 
reported as overrepresented the k-mer must show a 3-fold enrichment in the observed 
proportion relative to the expected proportion or there must be more than 5-fold 
enrichment in observed relative to expected proportion at a particular base.  Greater than 
10-fold enrichment of a specific k-mer indicates potential poor quality sequencing. 20% 
of the library is actually tested 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  
k-mers with relative 3-fold enrichment were identified in all 4 samples. A list of the 
overrepresented k-mers was generated and the top 6 were plotted in a graph to 
demonstrate the enrichment across the read length. The most overrepresented k-mer was 
either TTTTT or GGGGG occurring from position 2 or 105 within the read 
respectively. With the exception of the GGGGG at position 105 all overrepresented k-
mers were in the first 10bp of the read. Each sample had ~30 overrepresented k-mers. 
As the majority of overrepresented k-mers occur from the start of the read this is most 
likely attributable to the use of random primers in the generation of the cDNA library.  
4.3.2.11 RNAseq Quality  
The metrics I generated using FastQC were not designed to be used to dismiss samples 
based on the passing or failing of a metric, but instead used to identify areas in the 
sequencing where there could be a problem 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Whilst the sequencing in 
this experiment does diverge from this expected range in some metrics this is due to the 
expected high proportion of duplicates in an RNAseq experiment and the variation at 
base position 1-10 in a read due to the use of random hexamers in the library 
preparation. These are well documented and are not a cause for concern with regards to 
the quality of the data. The low ‘per base sequence content’ quality scores were 
however a cause for concern as this metric generated particularly low quality scores.  
The RNAseq data were analysed to determine genes differentially expressed and spliced 
in the C59X mutants, but with the caveat the any results obtained could be artefacts of 
the low quality sequencing and would therefore require validation with a 
complementary technique.  
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4.3.3 Zfp804a C59X mutation. 
Each BAM file was visualised in the Integrative Genomics Viewer (IGV) to confirm the 
presence of the C59X mutation in the mutants (Fig. 4.10). The mutation was present in 
both mutants and the constitutive GT present in both wildtypes. 
When viewing the coverage of Zfp804a I also identified two additional reads 5’ of the 
constitutive exon 1 in one of C59X mutants that mapped across to constitutive exon 2.  
These two reads could indicate an alternative isoform with an alternative exon 1 that 
skips the constitutive exon 1 in its entirety and maps to the start of exon 2 (Fig. 4.11).  
 
Figure 4.10. Zfp804a C59X mutation. Output from the integrative genomics viewer 
(IGV) shows the sequencing data of four samples following alignment. The viewer is 
zoomed onto exon 2 of the Zfp804a Refseq. Each of the grey bars represents a read. The 
C59X mutation can clearly be seen in the two mutants. The two base substitution 
GT>AA results in a STOP rather than the constitutive cysteine residue.  
 
 
In order to confirm the predicted alternative isoform I designed primers (Appendix 4.6) 
to amplify between the alternative exon 1 and exon 2 which spanned the C59X mutation 
Wt 
Wt 
Mutant 
Mutant 
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in exon 2. The read representing the alternative exon is 150bp long, 94bp different to 
constitutive exon 1 and lies ~1300bp upstream of exon 1 with no obvious sequence 
similarities.  These were used to amplify cDNA for the same samples used in the 
RNAseq experiment (Fig. 4.12). In all samples, a PCR product was detected of the size 
expected if the predicted novel isoform exists.   
 
Figure 4.11. Predicted Alternative Zfp804a Isoform. The BAM alignment files 
(displayed using the Integrative Genomics Viewer (IGV)) are shown for all 4 samples 
with reads from the RNA derived from two C59X mutants (top) and two wildtypes 
(below). Specifically the region between Chr2 81,891638-81,895808 is shown. At the 
bottom is the RefSeq track. Zfp804a constitutive exon 1 is in blue. In the second track 
the black circle highlights 2 reads from which a novel exon upstream of Zfp804a 
constitutive exon 1 was identified. From the plot the reads can be seen to skip the 
constitutive exon 1 and map to exon 2 (out of view). This was present in only one 
sample, a C59X mutant. 
 
 
 
The PCR product was next sequenced, confirming that the alternative exon links to the 
start of constitutive exon 2 (Fig 4.13). Sequencing also showed that the C59X mutation 
was present in this isoform in both the mutants. This is a novel isoform not yet 
documented in any of the genome browsers. 
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Figure 4.12. RT-PCR of Zfp804a Alternative Exon1 – Exon 2. The 4 samples run in 
the RNAseq experiment were assessed to determine if an isoform containing an 
alternative exon 1 was expressed in the mRNA. Not only was this isoform expressed 
(band at 173bp) in the C59X mutant from which the presence of this exon was inferred 
from the RNAseq output, it was expressed in all of the samples. Mut C59X mutant 1 
and 2. Wt C59X Wildtype 1 and 2. RT+ Reverse transcriptase positive RT- Reverse 
transcriptase negative control NTC no template control. 
 
 
 
Following visualisation of the alignment files I used Cufflinks and Cuffdiff to determine 
if there were differences in expression or splicing at Zfp804a between C59X mutants 
and wildtypes as suggested by the exon array data. Based upon Cuffdiff metrics, both 
alignment and the depth of sequencing was adequate to test differential expression. 
Zfp804a mRNA was significantly upregulated in mutants (fold change = 1.56 
upregualtion in C59X mutants relative to wildtypes, p = 2.26x10-7) and this remained 
significant following Benjamini and Hochberg (1995) FDR correction for multiple 
testing, replicating the findings from the exon array analysis. However, there were not 
enough alignments for splice analysis. Despite the apparent poor quality of the RNAseq 
data the validation of the predicted novel Zfp804a exon suggested some insights could 
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be gained and therefore I evaluated the most robust differential expression and splicing 
events predicted from the array in the sequencing data.  
 
Figure 4.13 Sequencing of Zfp804a Alternative Isoform. Sequencing of the RT-PCR 
product showed that the constitutive exon 1 was skipped in this isoform and the 
alternative exon 1 sequence runs straight into constitutive exon 2 sequence (indicated by 
the arrow). As the C59X mutation position was spanned by the primers the traces could 
be analysed to see if the C59X mutation was present in this isoform. As the traces show 
the mutation was present in both mutants and the cysteine residue in both wildtypes 
(Shown in the sequence within red rectangle). Grey shaded areas indicate where 
sequence quality decreased toward the end of the amplicon near the reverse primer.   
 
 
 
4.3.4 Differential Expression in C59X Mutants. 
The differential expression analysis was run on 31,974 transcripts of which 30,199 had 
suitable quality sequencing for the tests. Of the 30,199, 2571 were significantly 
differentially expressed between C59X mutant and wildtype with 489 genes remaining 
significant following Benjamini and Hochberg FDR correction. Of the 6 genes found to 
be differentially expressed in females in all 3 exon array software analyses, 5 were 
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highly significantly differentially expressed in the RNAseq data, with the remaining 
gene unable to be identified in the output from cuffdiff (Table 1).  
 
Gene 
Symbol 
Status Fold 
Change  Direction of Change 
P value FDR Sig 
Arc OK 
2.76 Mutant up vs Wildtype 
0 yes 
Dusp1 OK 
2.41 Mutant up vs Wildtype 
1.53x10
-13
 yes 
Npas4 OK 
1.92 Mutant up vs Wildtype 
4.77x10
-09
 yes 
Nr4a1 OK 
2.42 Mutant up vs Wildtype 
0 yes 
Snca OK 
>154.77 Mutant up vs Wildtype 
4.13x10
-30
 yes 
Egr2  No Data 
Table 1. Replication of Top candidates from Exon Array in RNAseq Data. Of the 6 
most robust differential expression findings from the exon array, 5 replicated in the 
RNAseq data. Egr2 was not identified in the output from Cuffdiff.   
 
4.3.5 Alpha Synuclein (Snca) 
One of the most significant differentially expressed genes was the alpha synuclein gene 
(Snca). The fold change in Snca was greater than 154.77 upregulated in C59X mutants 
relative to wildtypes due to the normalised expression value in the wildtype groups 
being 0, i.e., no expression of Snca in either of the 2 wildtype samples. To determine if 
any sequence reads were present in the wildtypes, I viewed the alignment files in IGV 
(Fig. 4.14). This confirmed the absence of any Snca reads in the two wildtypes. Reads 
for both Snca transcripts were present in both the C59X mutants. 
Given this surprising result, I undertook a literature review of the Snca gene in mice. 
This revealed a paper describing a C57BL/6J substrain that have a deletion spanning the 
Snca locus (Specht & Schoepfer, 2001). This deletion was originally identified by 
chance in a similar gene expression study using a transgenic mouse model that had been 
backcrossed onto the C57BL/6JOlaHsd substrain from Harlan (Bicester, UK).  Since 
C57BL/6J mice were used in the backcross breeding experiments in this study, it 
seemed possible the substrain with this deletion had been used.  By determining the 
source of the C57BL/6J mice used for backcrossing I confirmed that the substrain used 
for backcrossing the C59X ENU mutants was indeed the C57BL/6JOlaHsd substrain 
from Harlan (Bicester, UK). To determine how widespread this effect was the average 
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Snca expression, based on the expression values from the array, was determined for all 
16 mice used in the exon array (Fig. 4.15).  
 
Figure 4.14. Alpha Synuclein (Snca) Expression. Viewing the alignment files of all 4 
samples in IGV confirmed no reads of Snca transcripts (Displayed in the Refseq genes 
track) in the two wildtypes (bottom) where as reads were present in both C59X mutants.   
 
 
 
All but one of the 7 C59X mutants expressed both Snca transcripts. Of the 9 wildtypes, 
one expressed both transcripts and two others expressed only one of the transcripts. 
These results therefore confirmed that the expression of the Snca gene by chance 
correlated with the C59X mutation in Zfp804a. Given that Snca expression correlates 
with Zfp804a genotype, differences in expression between C59X mutants and wildtypes 
could be attributable to deletion of the Snca gene.  
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Figure 4.15. Alpha Synuclein Expression. Plotting the average expression of alpha 
synuclein (y-axis) for each sample (x-axis) showed that 6 of the 7 C59X mutants still 
expressed Snca and 2 of the 9 wildtypes expressed Snca. Therefore Snca expression 
appears to correlate with Zfp804a genotype.  
 
4.3.6 RNAseq Predictions of Differential Splicing. 
Next taking the splicing data, only 2957 transcripts passed read depth and quality for 
statistical testing. 1211 transcripts showed significant differential spicing between the 2 
C59X mutants and the 2 wildtypes and 1044 remained significant following FDR 
multiple test correction (Benjamini and Hochberg, 1995). The numbers of nominally 
significant differentially spliced genes were similar to the numbers in the individual 
male and female analyses in the exon array study which is a surprisingly high number of 
genes in the RNAseq data considering only 2957 transcripts were statistically tested and 
may represent a large number of false positives. From the exon array 13 genes were 
consistently significantly differentially spliced based on 3 different software packages 
and in both male and female analyses of which only 5 have sufficient data to generate a 
test statistic in the RNAseq data. Of these, two were significantly differentially spliced, 
Itga6 (p = 0.0068) and Dffa (p = 0.01) both of which remained significant following 
FDR correction. The three genes that were not significant were some of the most robust 
findings from the exon array with Bonferroni corrected significance values. This was 
surprising considering the exon array data showed them to replicate across gender, 
experiment, different age, different filtering criteria and different statistical algorithms. 
The issue of power must be considered given only two samples were in each group.  To 
determine if there was an alternative reason the sequences targeted by probesets 
identified to be differentially spliced in the exon array were searched in the alignment 
files in IGV (Fig. 4.16).  
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Rapgef4 
Ssfa2 
Slc39a13 
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Figure 4.16. C59X Mutant Specific Single Nucleotide Polymorphisms in Probe 
Target Regions. Consistently significant differential splicing at 3 genes (Rapgef4, 
Slc39a13 and Ssfa2) observed in the exon array experiment failed to replicate in the 
RNAseq analysis. Visualisation of the sequences targeted by the probesets in IGV 
highlighted the presence of C59X mutant specific SNPs which might have had an 
impact upon hybridisation efficiency on the Exon array. In each of the three examples 
the 2 C59X mutant sequencing reads are displayed as the first two tracks of the IGV 
display and the 2 wildtypes the second two. The SNPs lie between the tram tracks and is 
presented as the letter which represents the base change. In all 3 the probeset sequence 
matches the wildtype sequence. The corresponding exons were downregulated in the 
C59X mutants relative to the wildtypes. In Ssfa2 and Slc39a13 the SNPs were dbSNPs 
(dbSNP build 128) in Rapgef4 the SNP was novel. 
 
 
 
 
In each instance the alignment files for the corresponding probeset region contained a 
SNP which was present in the majority of all reads of the 2 C59X mutants and not 
present at all in both wildtypes. Each of these SNPs corresponded to the location of a 
probe and so the identified mutant specific SNP may have affected the hybridisation 
efficiency of the probe binding to the target. Revisiting the geneviews of these same 
three genes from the exon array data showed that in each instance it was the C59X 
mutants which showed down regulation relative to the wildtypes and this would fit with 
a reduced hybridisation efficiency effect since the probe sequence corresponds to that of 
the wildtype and not the C59X background (Fig. 4.17).  Each of these genes lies on 
Chromosome 2 and the SNPs may potentially represent mutations linked to the C59X 
mutation.  
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Figure 4.17. Direction of Effect in Probesets with Predicted Differential Splicing. 
The exon array results predicted differential splicing in the circled probesets in each of 
the 3 genes Rapgef 4 (top), Slc39a13 (middle) and Ssfa2 (bottom). The C59X mutants 
differ from the wildtype at a base, and that base does not match the sequence of the 
probe which is perfectly complimentary to that of the WT. This may cause reduced 
hybridisation efficiency specifically in the mutants resulting in a false call of 
downregulation in the relevant probeset. The probesets are downregulated in C59X 
mutants (Hom) in all 3 genes for females (left) and males (right).  
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4.4 Discussion. 
Next generation RNA sequencing was carried out on a pilot sample of 2 male C59X 
mutants and 2 male wildtypes. Initial RNA and library preparation quality control 
showed good quality RNA and fragments respectively, yet QC on the sequencing data 
highlighted numerous poor quality attributes of the data. Most notably the reliability of 
base calling based on phred quality scores was poor particularly towards the end of each 
read. It was evident that there was variable GC content and disproportionate 
representation of each of the four bases both of which occurred within the first 10 bases 
of the read. Based on common causes for such results I hypothesised that the most 
likely explanation was that a sequence such as an adapter was contaminating the 
sample, however no adapter or any other contaminating sequence was identified 
frequently enough in the total number of sequences to confirm this. Duplicate levels 
were high but this is often observed in RNAseq data when highly expressed sequences 
are over-sequenced in order to sequence the rare transcripts. Despite a high number of 
duplicate sequences present in the data no reads were excluded as this is actually more 
detrimental to the results due to the considerable loss in data and the ambiguity of the 
source of such duplicates. Whilst PCR amplified duplicates can result in false positive 
results, duplicates from highly expressed genes represent true positive findings 
(Bainbridge et al., 2010).  
Following the Tuxedo Protocol alignment files were initially assessed in the Integrative 
Genomics Viewer (IGV) (Robinson et al., 2011; Thorvaldsdόttir et al., 2012) with the 
intention of determining the presence of the C59X mutation in the mutants specifically. 
This was confirmed and led to the identification of a novel exon in Zfp804a upstream to 
the Refseq exon 1 in 1 C59X mutant. The alternative exon 1 appeared to skip the 
constitutive exon 1 and splice to exon 2 of Zfp804a. RT-PCR followed by sequencing 
validated this transcript which was found in all 4 samples, and confirmed the C59X 
mutation was also retained in exon 2 of both C59X mutants. Determining the open 
reading frame as well as the start and end positions of the alternative exon and transcript 
is necessary to fully understand Zfp804a expression in the C59X mice, but was not able 
to be carried out within the timeframe of this PhD.  
Although the RNAseq was generally of poor quality, I undertook an assessment where 
possible of the most robust results from the exon array experiment. It is important to 
consider when comparing the exon array and RNAseq data that each protocol used 
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slightly varying amplification methods. The RNAseq protocol targeted polyA RNA 
whereas the exon array samples were random primed. Despite this, concordance 
between the two platforms has been demonstrated (Raghavachari et al., 2012).  5 of the 
6 most robust differential expression results replicated in the RNAseq data with 
significance surviving multiple test correction using the FDR correction (Benjamini and 
Hochberg, 1995).  This therefore provides strong evidence that these are true expression 
changes. I discovered that both wildtype samples had no reads in Snca. This was found 
to be the result of a deletion which spans the Snca locus present in the C57BL/6JHsdOla 
substrain which was used for backcrossing the C59X mutation. Expression results from 
the array of all 16 F3i mice found the issue to be widespread and most worryingly to 
correlate with genotype.  
Silent mutations are a common problem in inbred strains of mice and have been 
documented on numerous occasions. Examples include the discovery that the 
129S6/SvEv inbred substrain has a 25bp deletion in the Disc1 gene resulting in a 
frameshift and a premature termination codon (Koike et al., 2006). Silent mutations, 
which have no observable phenotype, are particularly problematic as the mice are 
continually used for breeding and the de novo silent mutation becomes fixed in the 
strain.  Stable silent mutations in an inbred strain can confound studies when attempting 
to determine the effects of a particular mutation, when in fact two mutations are present. 
In the C57BL/6JHsdOla strain the deletion occurred following transfer of the strain to a 
breeding centre in Harlan. Due to the lack of an observable phenotype the mice are 
continually used in breeding and the deletion became stable in the substrain. It was only 
when expression studies began that used the C57BL/6JHsdOla strain for backcrossing 
that the deletion which spans the Snca locus was discovered (Specht & Schoepfer, 
2001).   
Specifically the deletion affects 365kb of chromosome 6, which includes Snca and one 
other gene; Multimerin (Specht & Schoepfer, 2004), but this gene is not thought to be 
brain expressed (Leimeister et al., 2002). Neither compensatory up regulation of β or γ 
synuclein has been observed in the strain nor changes in the expression of other genes in 
an array study in these mice (Specht and Shoepfer., 2001). These observations suggest 
that mice with the Snca deletion would not have altered expression in other genes as a 
result of this mutation alone and therefore differential expression observed between 
C59X mutants and wildtypes is most likely the result of disrupted Zfp804a, however 
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this is not definite and there is always the caveat the Snca deletion could confound the 
results.   
De novo mutations which arise and have no apparent phenotype become problematic  
when the mutation is in such close physical proximity that it tends to be co-inherited 
with  the mutation that is the target of the study, so distinguishing the effects of each is 
difficult (Gajovic et al., 2006).  This cannot have occurred in the C59X mice as Zfp804a 
lies on Chromosome 2 and Snca on Chromosome 6.  The problem lies with the use of 
the F3i generation in expression studies as the mice only had ~96% C57BL/6JOlaHsd 
purity and you would expect ~7 additional mutations from the ENU derived founder 
strain. 
The evidence for a deletion at the Snca locus puts into question the validity of the exon 
array and RNAseq experiments using tissue derived from the F3i generation.  
Unfortunately, delays in the availability of mice meant the F3i generation had to be used 
for the initial experiments, although the intention was to repeat the experiments in later 
(F7) generations which are expected to have at least 98% of the C57BL/6JHsdOla 
genome.  
Poor sequence quality meant 8 out of the 13 differential splice candidates from the exon 
array were not able to be tested in the RNAseq data. Of those that had adequate read 
quality, replication of significant differential splicing was observed in only two of the 5. 
Considering only 2957 genes were statistically tested and 1211 were significant this is 
no greater than would be expected by chance.  The lack of replication is possibly 
attributable to false positives in the array data or not enough power in the study given 
only an n of 2 in each group. The variants observed in the C59X mutant sequence may 
have influenced the efficiency of probe hybridisation on the exon array, and 
consequently a false positive splice prediction due to misinterpreted downregulation of 
the exon in the mutants is observed. A large source of errors in array results are 
generated by SNPs in sequences targeted by probes. Humans are outbred and 
genetically heterogeneous and there is an abundance of literature on the best way to deal 
with probes that target SNPs on assays designed for humans (Duan et al., 2008; 
Gamazon et al., 2010). Isogenic samples should not produce such false positives.  The 
mice in this experiment are heterogeneous and differences correlate with the Zfp804a 
genotype. The most likely explanation for C59X mutant specific polymorphisms is that 
at F3i, polymorphisms that distinguish the C57BL/6JHsdOla and Balb/c or C3H/HeJ 
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strains are still present, as indicated with the Snca finding. There is also the possibility 
that the C59X mutant specific SNPs found on chromosome 2 are linked to the C59X 
mutation and being inherited together. A major strength of the RNA sequencing data 
was the ability to assess the region surrounding the C59X mutation in both C59X 
mutant and wildtypes at single base resolution. Whilst only two mice from each 
experimental group were sequenced, there was an unambiguous finding of sequence 
variants in the C59X mutants specifically. It is possible that these strain specific 
sequence variants will not be separated from the C59X mutation by recombination by 
the F7 generation and therefore the same genes would be predicted to be differentially 
spliced.    
Whilst the data were not of the most robust quality, the RNAseq experiment enabled me 
to make several critical findings. The identification of a novel Zfp804a isoform when 
fully characterised is likely to be informative. Without the RNAseq data the 
identification of a deletion at the Snca locus and several polymorphisms in the C59X 
mutants would not have been possible. These findings are critical to the interpretation of 
the data generated with F3i generation mice. The occurrence of these strain specific 
sequence variants was investigated in the F7 generation to enable the correct 
interpretation of the results (Chapter 6). 
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Chapter 5. Expression Analysis in Embryonic C59X Mice. 
5.1 Introduction. 
One of the leading hypotheses of schizophrenia is that it has its early origins in 
disruption of brain development in utero, but that the major symptoms remain latent 
until adolescence or adulthood (Weinberger, 1986). Although the evidence is not 
definitive, a number of lines of evidence are broadly in favour of this hypothesis (Owen 
et al., 2011).  
Follow up of births occurring during or just after the 1957 influenza epidemic showed 
those exposed to the epidemic in utero had an increased rate of schizophrenia diagnosis 
in adulthood compared to those not exposed to the epidemic (Mednick et al., 1988; 
O’Callaghan et al., 1991a; Cooper, 1992) leading to the hypothesis that the influenza 
virus might be an in utero insult increasing risk of schizophrenia, but these conclusions 
have been widely challenged (Kendall and Kemp, 1989; Bowler & Torrey, 1990; Crow 
et al., 1991, Crow et al., 1994). Increased rates of influenza in pregnant women with 
young children have been observed (Hennessy et al., 1964), an observation considered 
by some to support a contribution to schizophrenia from in utero infection since an 
increased rate of schizophrenia has been suggested in younger siblings (Farina et al., 
1963). An enrichment of winter and spring births in those with schizophrenia has being 
widely reported (O’Callaghan et al., 1991b) and may be more common in patients who 
have no family history of the disorder, again possibly implicating environmental factors 
such as viral infection which are more prevalent at that time of year (Sham et al., 1992). 
Malnutrition during the first trimester (Susser et al., 96), toxoplasmosis (Brown et al., 
2005), respiratory infection (Brown et al., 2000) and bacterial infections (Sorenson et 
al., 2009) have also been suggested to cause damage in utero resulting in aberrant 
development as well as neonatal adversity, including obstetric complications (Murray et 
al., 1985) and CNS infection (Rantakallio et al., 1997). While the nature of the insult is 
disputed there appears to be a body of evidence that pre and perinatal insults may 
contribute to schizophrenia. Early studies indicated the second trimester of pregnancy as 
the temporal window when increased susceptibility occurred (Mednick et al., 1988) 
more recently studies have suggested insults occurring as early as the first trimester and 
as late as the neonatal period increased risk, with the Prenatal Determinants of 
Schizophrenia (PSD) study reporting risk is incurred during either conception or the 
first few weeks of pregnancy (Meyer et al., 2007).   
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How the putative insults lead to pathophysiology which predisposes schizophrenia is 
less clear. The immune response, which is common to the different types of infections, 
may play a role. Increased levels of IL-8 in mothers of schizophrenia spectrum disorder 
patients have been reported (Brown et al., 2004). IL-8 is thought to have an important 
role in brain development and thus increased levels may cause aberrant development 
(Gilmore, 1997), but IL-8 protein levels may themselves be mediated by genetic risk. 
Insults during development of the CNS may disrupt important processes such as cell 
proliferation and migration leading to aberrant axonal connectivity (Murray and Lewis, 
1987).  
Structural differences in the schizophrenic brain such as enlarged ventricles and reduced 
cortical volume appear to be present at the onset of disease (Roberts, 1991) and are 
often described as non-progressive, again suggesting important brain changes have 
already occurred prior to the onset of clinical symptoms. Other features which favour a 
neurodevelopmental hypothesis of schizophrenia include observations of motor, 
behavioural and cognitive impairment in children suggestive of a ‘pre-schizophrenic’ 
brain. These observations are not apparent in every schizophrenia patient and it maybe 
that factors occurring during development are responsible for increased risk in a subset 
of schizophrenia cases (Sham et al., 1992). The neurodevelopmental hypothesis of 
schizophrenia is also strengthened by the finding that copy number variants (CNVs) 
have been identified that are common to schizophrenia and neurodevelopmental 
disorders such as ADHD, autism and mental retardation (Mefford et al 2008; Wassink 
et al., 2001). 
Infectious agents administered to pregnant rats have consequences on 
neurodevelopment and the timing of the insult affects the extent of damage, with earlier 
insults associated with more widespread damage (Meyer et al., 2007). Administration of 
infectious agents in rats at E18 caused brain atrophy and whiter matter thinning as well 
as gene expression changes in the PFC and hippocampus at P35 (equating to 
adolescence) (Fatemi et al., 2008). Lesions in the rat hippocampus at P7 have been 
reported to impair the pre-pulse inhibition (PPI) startle response (a putative 
schizophrenia endophenotype or biomarker) following puberty (P35) relative to rats 
with sham lesions. This fits with a neurodevelopmental model of schizophrenia where 
by an insult occurs during development but a phenotype is not observed until early 
adulthood (Lipska et al., 1995).  Prenatal exposure of rats to viruses (Piontkewitz et al. 
2012), bacteria or cytokines (Samualsson et al., 2006) have elicited behaviours in 
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offspring akin to certain cognitive and behavioural symptoms observed in schizophrenia 
and perhaps more convincingly some of these studies have shown amelioration of these 
symptoms following administration of atypical antipsychotics (Borrell et al., 2002). 
Whilst a number of studies report findings in favour of a neurodevelopmetal hypothesis 
it is best to view the animal literature with caution particularly when inferring 
similarities between animal models and infection in humans (Samuelsson et al., 2006). 
A developmental hypothesis implies a latent period prior to the onset of clinical 
symptoms, but understanding what is happening during this latent period has proven 
difficult. Extensive maturation processes occurring during adolescence may initiate the 
requirement for systems in the brain that up until that point were not utilised 
(Weinberger, 1986).  Synaptic development and pruning could be affected by genetics 
or the hormonal imbalances and stress common during adolescence (Benes et al 1994; 
Walker, 1994).  
There are a number of studies showing genes which switch from foetal to adult 
expression patterns in the first few postnatal weeks. This switch is observable during 
this period in NRXN1 and NRXN3 (Lijima et al., 2011). The SNAP25 gene is thought to 
switch between isoforms a and b between postnatal day 25 and 35 which is thought to 
alter the efficacy of synaptic transmission to allow the stabilisation of the developed 
neuronal circuit (Bark et al., 2004). Similar postnatal switches in isoform expression are 
seen in NUMB (Bani-Yaghoub et al., 2007) CELF and MBNL (Kalsotra et al., 2008). 
The latter two regulate a number of alternative splice events themselves and 
misregulation of their targets has been implicated in Myotonic Dystrophy (DM) 
(Charlet et al., 2002).  DM is characterised by muscle wasting and myotonia and is 
caused by the misregulation of splicing. Several of the genes involved fail to switch 
from foetal to adult isoforms resulting in the isoforms being expressed at inappropriate 
times (Charlet et al., 2002).    
A number of splice regulatory factors are themselves developmentally regulated for 
example PTB (Boutz et al., 2007), which has implications for the splicing of 
downstream targets. In this way it is thought that a splicing network exists initiated from 
regulation of splice factors which in turn regulate their downstream targets resulting in 
extensive developmental regulation of alternative spliced isoforms (Revil et al., 2010).  
If Zfp804a does have a role in regulation of transcription and or splicing the genes it 
regulates may be developmentally regulated. In support of this hypothesis an RNA 
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sequencing study looking at differential expression during neurogenesis of human 
neurons from iPS cells showed one of the genes with large expression changes to be 
ZNF804A (Lin et al., 2011). Based on a neurodevelopmental hypothesis of 
schizophrenia, splicing differences observed between C59X mutants and wildtypes that 
occur during development may point to genes fundamental to aberrant development 
relevant to the aetiology of schizophrenia. To determine if developmentally regulated 
splice or expression changes occurred as a result of the C59X mutation, I undertook an 
exon array experiment using brain tissue from embryonic day 18.5 mice as this time 
point has been likened to the second trimester of pregnancy in humans (Fatemi et al., 
2008), which although controversial, is the period when the embryo may be most 
susceptible to environmental factors which could predispose schizophrenia risk in later 
life.  
 
 
 
5.2 Materials and Methods 
5.2.1 Sample  
To study embryonic expression in later generation mice (~98.5% C57BL/6HsdOla 
background), I set up heterozygote intercrosses using mice with ~98.5% C57BL/6 
HsdOla genome from either the 7
th
 or 8
th
 generation (Appendix 5.1). Mice used for 
breeding were caged individually. Female mice were placed in the male home cage in 
the evening and the observation of a vaginal plug the following morning was recorded 
as embryonic day 0.5 (E0.5). Female mice were then returned to their home cage. 18 
days later whole brain and tail tip samples were collected from each embryo on 
embryonic day 18.5 (E18.5). The pregnant female was killed by cervical dislocation and 
then placed ventral side up and 70% ethanol was applied to the body. An incision was 
made and then a cut down the midline using scissors to expose the uterus from which 
the embryos were carefully removed. The embryo was decapitated and the tip of the tail 
collected. The head was then placed in ice cold 1x PBS solution if necessary and the 
brain extracted from the skull. Brain and tail samples were immediately snap frozen in 
liquid nitrogen then stored at -80°c until RNA extraction. 
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5.2.2 Genotyping 
DNA was extracted from tail tips (Chapter 2.2.1) and quantified using the Nanodrop 
1000 spectrophotometer (Thermo Scientific) before being amplified in a PCR reaction 
(Chapter 2.4) using primers spanning the C59X mutation (Appendix 2.1). Sequencing 
was carried out as previously described (Chapter 2.6) and genotype assessed in 
NovoSNP version 3.0.1 (Weckx et al., 2005).  
 
5.2.2.1 Gender PCR. 
The gender of the embryonic samples was assessed using a multiplex PCR with gDNA 
extracted from tail tips. Two primer sets were used, one for the Y-linked gene, Ssty and 
one for an autosomal control gene, Om1a (Myogenin) (Appendix 5.2). Running the 
product on a 1.5% gel enabled males, with a band representing both Ssty and Om1a, to 
be distinguished from females with the single band corresponding to the Om1a product.  
 
 
PCR Reaction.  
The PCR reaction was performed using C1000 Thermocyclers (BioRad Laboratories, 
Inc). The PCR cycling conditions are outlined below. PCR was performed in a 25µl 
reaction volume using 1µl genomic DNA, 15.75μl Sterile water, 2.5μl 10X buffer, 2.0μl 
25mM MgCl2, 1.0μl 5mM dNTPs, 1.0μl Ssty (forward) 10μM and 1.0μl Ssty (reverse) 
10μM, 0.25μl Om1a (forward) 500ng/μl and 0.25μl Om1a (reverse) 500ng/μl and 
0.25μl HotStar Taq (Qiagen).  
 
The PCR cycling conditions. 
1. 94°C for 4 minutes  
2. 94°C for 45 seconds 
3. 61
o
C for 45 seconds 
4. 72
o
C for 45 seconds   
5. Repeat steps 2-4 for 35 cycles  
6. 72
o
C for 5 minutes 
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5.2.3 RNA Processing  
RNA was extracted from whole brain and purified using an RNeasy column (Qiagen) as 
described in Chapter 2.2.2. Samples were then quantified and assessed for quality using 
the NanoDrop 1000 spectrophotometer (Thermo Scientific) and the Agilent 2100 
Bioanalyser respectively (Chapter 2.2.3.1). 
 
5.2.4 Affymetrix Exon Array 
Total RNA was labelled and prepared for hybridisation to the Affymetrix Genechip® 
Mouse Exon 1.0 ST array as described in full in Chapter 2.8. Sample preparation and 
chip scanning protocols did not differ to those used on adult mice (Chapter 2.8). 
 
5.2.4.1 Quality Control. 
This was assessed as described in Chapter 2.8.3.5.  
 
 
5.2.4.2 Determining Snca Expression 
To establish how many of the embryonic mice had the C57BL/6JHsdOla specific 
deletion, which spanned the Snca locus I calculated the average raw expression values 
across all Snca probesets for each sample.  
 
 
5.2.4.3 Partek Genomics Suite 
The same filtering criteria and statistical algorithms were applied to the embryonic 
dataset as described for the adult data in chapter 3. As before, an initial analysis focused 
on C59X mutant and wildtype samples homozygotes but an additional analysis that 
included the heterozygote samples was also performed.  
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5.2.4.4 EasyExon. 
I analysed the embryonic data in easyExon as described in chapter 2. Briefly CEL files 
were uploaded for the 12 mutant and wildtype samples. For a probeset to be included 
the DABG p value had to be ≤0.05 in 6 of the 12 samples. For differential expression 
analysis genes required a fold change of greater than 1.5 and a MiDAS p value ≤0.05 to 
be significant. Significant differential splicing was defined by a MiDAS p value ≤0.05. 
As only two groups can be included in the analysis only the C59X mutant and wildtype 
samples were compared.  
 
5.2.4.5 AltAnalyze. 
I uploaded the 12 CEL files into AltAnalyze and compared expression and splicing in 
C59X mutants and wildtypes using the MiDAS and FIRMA algorithms respectively as 
described in chapter 2.  
 
5.2.4.6 Overlap Analysis 
Using the method outlined in Chapter 3, section 2 the overlap between differentially 
expressed and spliced genes in embryonic samples at different p value thresholds 
(p≤0.05, p≤0.01, p≤0.001 and p≤0.0001) was determined in the adult dataset at a 
nominal p≤0.05. The adult data set used was that of all 16 samples (male and female) 
combined with gender covaried.  
The degree of overlap for the embryonic results in each of the 3 software packages 
(Partek GS, easyExon and AltAnalyze) was then assessed. Differentially spliced genes 
from this overlap found to be significant following an FDR correction (threshold 0.05) 
in Partek GS were assessed to determine how many overlapped in the adult dataset at 
p≤0.05. Genes that were significantly differentially spliced following Bonferroni 
correction in adult and embryonic samples were also assessed to determine the genes 
common to both analyses at this stringent p value threshold.  
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5.3 Results  
5.3.1 Embryonic Sample.  
5 successful heterozygote intercrosses were set up between mice with 98.5% 
C57BL/6JHsdOla background (Appendix 5.2). Brain and tail tips were collected from 
the embryos on E18.5. DNA was extracted from the tail tips and processed using PCR 
(Fig. 5.1) and sequencing (Fig. 5.2) to determine gender and genotype of each 
embryonic sample (Table 5.1). The results of each revealed there to be a total of 7 C59X 
homozygote mutants and 6 wildtypes. 12 C59X heterozygotes were also selected for 
inclusion on the exon array. Of the 25 samples 12 were female and 13 male.  
 
 
 
 
 
 
 
 
Figure 5.1 Determining Gender in E18.5 Mice. A multiplex PCR was used to 
determine the gender of each embryonic sample by using a Y-linked gene (Ssty) and an 
autosomal control gene (Om1a). Ssty had a product of 434bp and Om1a 245bp. Samples 
with both bands represented males and samples with only the smaller band (Om1a) 
represented female samples.   
 
 
 
Ssty 434bp 
Om1a 245bp 
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Figure 5.2 Sequencing of the C59X mutation in Embryonic Samples. PCR was 
carried out on gDNA using primers which spanned the C59X mutation in Zfp804a. The 
PCR product was then sequenced to determine the genotype of each embryo. The 
example above shows sequencing traces from 4 of the embryonic samples. The red 
rectangle highlights the position of the normal cysteine codon (TGT) in exon 2 of 
Zfp804a. The top trace represents a homozygous wildtype. The second trace is from a 
C59X homozygote mutant in which both alleles have the ENU C59X mutation. The 
bottom 2 traces are C59X heterozygotes each with one C59X mutant allele.  
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Sample ID Genotype Gender Age 
    
B8A2P1 Het Male E18.5 
B8A2P4 Het Female E18.5 
B8A2P5 Het Female E18.5 
B8E1P1 Het Male E18.5 
B8E1P7 Het Male E18.5 
B8E1P8 Het Male E18.5 
E27AD2P3 Het Male E18.5 
E27AD2P4 Het Female E18.5 
E27AD2P5 Het Female E18.5 
E27AM2P2 Het Male E18.5 
E27AO4P3 Het Female E18.5 
E27AO4P4 Het Male E18.5 
    
B8A2P2 Mut Male E18.5 
B8E1P2 Mut Female E18.5 
E27AD2P6 Mut Male E18.5 
E27AD2P2 Mut Male E18.5 
E27AM2P3 Mut  Female E18.5 
B8E1P3 Mut  Female  E18.5 
B8E1P4 Mut  Male E18.5 
    
B8A2P3 Wt Female E18.5 
B8E1P5 Wt Female E18.5 
E27AD2P7 Wt Female E18.5 
B8E1P6 Wt Male E18.5 
E27AO4P2 Wt Female E18.5 
E27AM2P1 Wt Male E18.5 
 
Table 5.1. The C59X Embryonic Sample. Tail tip gDNA was extracted and used for 
assessment of genotype and gender in the embryonic mice. The sample was comprised 
of 12 C59X heterozygotes (Het), 7 C59X mutants (Mut) and 6 wildtypes (Wt), with 12 
females and 13 males.  
 
5.3.2 RNA quality. 
The whole brains from these 25 samples were then processed to extract RNA and the 
quality was determined (Table 5.2). With the exception of E27AM2P3, RNA was of 
good quality with RIN above 8 and 28s/18s ratios above 1. RNA was hybridised to the 
exon array chips and then assessed on a number of quality metrics using Partek GS and 
Expression Console (Affymetrix) as described previously (Chapter 2.8.3.5). 
 163 
 
Sample ID Genotype Gender 
rRNA Ratio 
[28s/18s] RIN 
B8A2P1 Het Male 1.8 10 
B8A2P2 Hom Male 1.8 10 
B8A2P3 Wt Female  1.8 10 
B8A2P4 Het Female  1.8 10 
B8A2P5 Het Female 1.9 10 
B8E1P1 Het  Male 1.7 10 
B8E1P2 Hom Female 1.7 9.8 
B8E1P3 Hom Female 1.6 9.8 
B8E1P4 Hom Male 1.8 9.7 
B8E1P5 Wt Female 2 10 
B8E1P6 Wt Male 1.7 9.8 
B8E1P7 Het Male 1.8 10 
B8E1P8 Het Male 1.9 10 
E27AD2P1 Hom Male 1.5 9.9 
E27AD2P3 Het Male 1.9 10 
E27AD2P4 Het Female 1.9 10 
E27AD2P5 Het Female 2 10 
E27AD2P6 Hom Male 1.8 9.8 
E27AD2P7 Wt Female  1.8 10 
E27AM2P1 Wt Male 1.6 9.5 
E27AM2P2 Het Male 1.8 10 
E27AM2P3 Hom  Female  0.1 6.7 
E27AO4P2 Wt Female 1.8 10 
E27AO4P3 Het Female 1.8 10 
E27AO4P4 Het Male 1.7 10 
Table 5.2. RNA quality Scores. RNA samples were run on the 2100 Bioanalyser 
(Agilent). The resulting 28s/18s ratio and RIN scores are presented in the table.  Sample 
E27AM2P3 (highlighted in red) has values less that the accepted (chapter 2.2.3) 
thresholds of 1 and 7 for the 28s/18s ratio and RIN scores respectively.  
 
 
Despite its low RNA quality scores, given the difficulty obtaining samples, I decided to 
process E27AM2P3 along with the other 24 samples to determine if the resultant quality 
of the array data was sufficient for inclusion.  
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5.3.3 Quality Control. 
I generated the same quality control metrics described in Chapter 2.8.3.5 in both Partek 
GS and Expression Console for all 25 samples. Initially a PCA plot was generated 
including all samples (Fig. 5.3). Visualisation of the PCA plot shows one sample to 
have very different patterns of gene expression relative to the other samples. This 
sample is E27AM2P3, the C59X mutant which had low RNA quality scores. The other 
samples do not appear to separate along the first principle component but there is 
indication there is some separation along the second principle component, although 
importantly, they do not cluster by C59X genotype.  
 
Figure 5.3. PCA of 25 Embryonic Samples. The gene expression patterns of the 25 
samples is divided along the first principle component with 1 sample, found at the top 
left of the plot (Female, mutant), having very different expression patterns to the other 
24 samples. The other samples appear to have similar patterns of global gene expression 
with the majority clustering in the top right of the plot.   
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The expression profile of each sample was plotted next (Fig. 5.4). Again, E27AM2P3 
did not cluster with the other samples. To determine if the difference in expression 
pattern and distribution of signal intensity in E27AM2P3 may have arisen due to a 
reduced hybridisation efficiency, this metric was assessed next (Fig. 5.5). The expected 
rank order of signal intensities of 4 exogenous control genes was observed in all 
samples, but the expression pattern in sample E27AM2P3 is clearly different to that of 
the other samples. I then generated box plots of the log expression signal distribution 
(Fig. 5.6) to determine if preprocessing procedures corrected any of the variation 
observed in E27AM2P3. The mean and interquartile range of E27AM2P3 was lower 
relative to the other samples and the difference was not corrected by normalisation and 
summarisation procedures. A good way to determine if the general behaviour of a 
sample is different to the other samples is to plot the relative log expression signal 
(Chapter 2.8.3.5.4). From this plot it was apparent that the data arising from sample 
E27AM2P3 are different from those of all other samples.  
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Figure 5.4. Distribution of Signal Intensity. The expression profile of all 25 samples 
was plotted in Partek GS (top) and Expression Console (below). The range of signal 
intensities are plotted along the x-axis with the frequency of each signal intensity 
plotted on the y-axis. One sample can be clearly distinguished from the others due to the 
difference in the distribution of signal intensities observable in both plots, this sample is 
E27AM2P3 (indicated by the arrow).  
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Figure 5.5 Hybridisation Efficiency in Embryonic C59X mice.  4 exogenous 
Escherichia coli genes included on the exon array were used to assess hybridisation 
efficiency. As each of the 4 genes are added at known concentrations, adequate 
hybridisation efficiency is observed from the following rank order of signal intensities 
from lowest to highest; BioB, BioC, BioD and cre. Whilst this rank order is observed in 
all samples, the log2 expression pattern of each of the 4 control genes is very different 
in one sample relative to the others and this sample (17) corresponds to sample 
E27AM2P3.   
 
To formally assess if the sample should be removed, quantitative quality assessment 
was next performed using the 6 metrics described in Chapter 2.8.3.5. Samples were first 
considered all together (Table 5.3) and then after in groups separated by genotype 
(Table 5.4). Values greater than 2 standard deviations from the mean in any metric are 
considered outlying values, while samples with values greater than 2 standard 
deviations from the mean in 3 or more metrics are considered outlier samples. 
E27AM2P3 had values greater than 2 standard deviations from the mean in each of the 
6 metrics and therefore was an egregious outlier. Based on these results there is a clear 
argument in favour of removing this sample from the study.  Considering the samples 
stratified by genotype, two other samples were identified with quality values greater 
than 2 standard deviations from the mean; B8A2P4 and B8A2P5. B8A2P5 was only 
highlighted in a single metric so was not defined as an outlier. B8A2P4 had more than 3 
metrics with values outside of the defined threshold and was therefore regarded as an 
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outlier.  The same metrics were also generated in Affymetrix Expression Console (data 
not shown) which gave the same pattern of results.  
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Figure 5.6 Distribution of Log Expression Signals. Sample E27AM2P3 has a reduced log probe cell intensity relative to the other samples (left) as 
indicated by the lower mean and inter quartile range (arrow) and this is not corrected by normalisation and summarisation procedures (central). This is 
indicative of a dim array, which would correlate with the lower RNA quality observed for this sample. From the relative log expression plot (right) it is 
clear that E27AM2P3 is behaving very differently to the other 24 samples. 
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Sample ID Genotype PM Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean 
Pos vs. Neg 
AUC 
1. B8A2P1.CEL Het 453.28 0.13 0.10 0.13 0.10 0.87 
2. B8A2P2.CEL Mutant 424.61 0.14 0.10 0.15 0.11 0.87 
3. B8A2P3.CEL Wt 490.42 0.13 0.09 0.13 0.10 0.87 
4. B8A2P4.CEL Het 407.82 0.19 0.16 0.26 0.22 0.86 
5. B8A2P5.CEL Het 504.31 0.14 0.11 0.15 0.12 0.87 
6. B8E1P1.CEL Het 382.91 0.16 0.12 0.18 0.17 0.86 
7. B8E1P5.CEL Wt 333.17 0.18 0.13 0.19 0.16 0.87 
8. B8E1P7.CEL Het 392.05 0.17 0.12 0.18 0.13 0.87 
9. B8E1P8.CEL Het 368.41 0.16 0.12 0.18 0.15 0.87 
10. E27AD2P3.CEL Het 425.85 0.15 0.11 0.19 0.15 0.86 
11. E27AD2P4.CEL Het 457.78 0.14 0.10 0.15 0.12 0.86 
12. E27AD2P5.CEL Het 387.87 0.16 0.11 0.16 0.12 0.87 
13. E27AD2P7.CEL Wt 432.60 0.14 0.10 0.15 0.12 0.86 
14. E27AM2P2.CEL Het 454.74 0.14 0.11 0.16 0.12 0.87 
15. E27AO4P3.CEL Het 401.01 0.14 0.11 0.14 0.11 0.87 
16. E27AO4P4.CEL Het 366.23 0.14 0.10 0.14 0.10 0.87 
17. E27AM2P3.CEL Mutant 214.34 0.43 0.36 0.99 0.98 0.79 
18. B8E1P2.CEL Mutant 433.18 0.16 0.12 0.20 0.17 0.87 
19. B8E1P3.CEL Mutant 352.13 0.17 0.12 0.19 0.16 0.87 
20. B8E1P4.CEL Mutant 409.25 0.16 0.12 0.23 0.18 0.87 
21. B8E1P6.CEL Wt 401.05 0.15 0.11 0.20 0.17 0.87 
22. E27AD2P1.CEL Mutant 395.13 0.16 0.12 0.19 0.17 0.87 
23. E27AD2P6.CEL Mutant 329.21 0.20 0.15 0.25 0.21 0.87 
24. E27AO4P2.CEL Wt 383.60 0.18 0.14 0.26 0.24 0.85 
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25. E27AM2P1.CEL Wt 343.60 0.18 0.15 0.28 0.30 0.85 
Mean -SD*2   279.43 0.05 0.02 -0.11 -0.16 0.83 
Mean +SD*2   516.13 0.28 0.23 0.55 0.53 0.90 
Table 5.3. Quantitative Outlier Analysis in all E18.5 Samples combined. I generated values for 6 quality metrics in Partek GS which together 
assess the general performance of each of the chips.  Following Affymetrix recommended guidelines, samples with values more than 2 standard 
deviations from the mean in any metric were highlighted (yellow). If any one sample was consistently highlighted in more than 3 metrics it was 
considered to be an outlier. From the above table it is clear that sample E27AM2P3 is an outlier as it exceeds the threshold in all 6 of the metrics 
analysed.  
 
 
 
 
 
 
 
 
 
 172 
 
Sample ID Genotype PM Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean 
Pos vs. 
Neg AUC 
17. E27AM2P3.CEL Mutant 214.34 0.43 0.36 0.99 0.98 0.79 
18. B8E1P2.CEL Mutant 433.18 0.16 0.12 0.20 0.17 0.87 
19. B8E1P3.CEL Mutant 352.13 0.17 0.12 0.19 0.16 0.87 
2. B8A2P2.CEL Mutant 424.61 0.14 0.10 0.15 0.11 0.87 
20. B8E1P4.CEL Mutant 409.25 0.16 0.12 0.23 0.18 0.87 
22. E27AD2P1.CEL Mutant 395.13 0.16 0.12 0.19 0.17 0.87 
23. E27AD2P6.CEL Mutant 329.21 0.20 0.15 0.25 0.21 0.87 
Mean -SD*2   212.19 0.00 -0.03 -0.28 -0.33 0.80 
Mean +SD*2   518.62 0.40 0.33 0.91 0.90 0.92 
         
 
Sample ID Genotype PM Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean 
Pos vs. 
Neg AUC 
13. E27AD2P7.CEL Wt 432.60 0.14 0.10 0.15 0.12 0.86 
21. B8E1P6.CEL Wt 401.05 0.15 0.11 0.20 0.17 0.87 
24. E27AO4P2.CEL Wt 383.60 0.18 0.14 0.26 0.24 0.85 
25. E27AM2P1.CEL Wt 343.60 0.18 0.15 0.28 0.30 0.85 
3. B8A2P3.CEL Wt 490.42 0.13 0.09 0.13 0.10 0.87 
7. B8E1P5.CEL Wt 333.17 0.18 0.13 0.19 0.16 0.87 
Mean -SD*2   280.39 0.11 0.08 0.09 0.03 0.84 
Mean +SD*2   514.42 0.21 0.16 0.32 0.34 0.88 
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Sample ID Genotype PM Mean 
All Probeset MAD Residual 
Mean 
Pos Control MAD 
Residual Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean 
Pos vs. 
Neg AUC 
1. B8A2P1.CEL Het 453.28 0.13 0.10 0.13 0.10 0.87 
10. E27AD2P3.CEL Het 425.85 0.15 0.11 0.19 0.15 0.86 
11. E27AD2P4.CEL Het 457.78 0.14 0.10 0.15 0.12 0.86 
12. E27AD2P5.CEL Het 387.87 0.16 0.11 0.16 0.12 0.87 
14. E27AM2P2.CEL Het 454.74 0.14 0.11 0.16 0.12 0.87 
15. E27AO4P3.CEL Het 401.01 0.14 0.11 0.14 0.11 0.87 
16. E27AO4P4.CEL Het 366.23 0.14 0.10 0.14 0.10 0.87 
4. B8A2P4.CEL Het 407.82 0.19 0.16 0.26 0.22 0.86 
5. B8A2P5.CEL Het 504.31 0.14 0.11 0.15 0.12 0.87 
6. B8E1P1.CEL Het 382.91 0.16 0.12 0.18 0.17 0.86 
8. B8E1P7.CEL Het 392.05 0.17 0.12 0.18 0.13 0.87 
9. B8E1P8.CEL Het 368.41 0.16 0.12 0.18 0.15 0.87 
Mean -SD*2   331.54 0.12 0.08 0.10 0.06 0.86 
Mean +SD*2   502.17 0.18 0.15 0.24 0.20 0.87 
Table 5.4. Quantitative Outlier Analysis of groups stratified by Genotype. When considering the same 25 samples by C59X genotype group (in 
Partek GS) E27AM2P3 was still an outlier. All wildtype samples had quality values within the specified thresholds. 2 heterozygote samples were 
highlighted as having at least one measure greater than two standard deviations from the mean, B8A2P4 and B8A2P5 (marked in yellow).   
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Regardless of the type of analysis, E27AM2P3 was a clear outlier a finding consistent 
with its relatively poor RNA quality. B8A2P4 was acceptable in the whole group 
analysis but had 4 outlier values in the stratified by genotype analysis. As it was not 
such an obvious outlier, and as the main analysis is focussed on comparing 
homozygotes, this sample was retained but was monitored in the downstream output as 
described later.  
 
5.3.4 Deletion at the Snca Locus 
That the mice used for backcrossing (C57BL/6JOlaHsd, Harlan) had a deletion at the 
Snca locus was established in Chapter 4. Whilst this may have had a confounding effect 
on the results generated on the F3i adult mouse data it was hypothesised that by F7 the 
mice would have 98.5% C57BL/6JOlaHsd background and so the deletion was likely to 
present in all embryonic samples. The exon array data were used to determine the 
expression of Snca in the embryonic mice. The raw expression at each probeset 
targeting the Snca gene was averaged across the genes and plotted for each of the 25 
samples (Fig. 5.7).  This revealed that two of the 25 mice did not have the deletion at 
the Snca locus. Both were excluded from further analysis to avoid confounding by Snca 
genotype. In addition to the outlier E27AM2P3, the exclusion of these two sample left 
22 embryonic samples, 6 C59X homozygous mutants, 5 wildtypes and 11 C59X 
heterozygotes. The QC was repeated following the removal of the 3 samples. The 
Partek GS analysis is reported in Table 5.6.  All samples considered together showed no 
outliers. Within C59X experimental group only B8A2P4 behaved slightly differently to 
other C59X heterozygote in 4 metrics. This sample was flagged previously and was 
retained and monitored for the same reasons described in 5.3.3. 
 
 175 
 
Figure 5.7 Snca Expression in E18.5 C59X Samples. Average raw expression values 
from the exon array across all probesets targeting Snca were plotted on the y-axis. The 
two peaks clearly indicate expression of the Snca gene in two of the samples, 
E27AO4P2 (female, wildtype) and E27AO4P4 (male, C59X heterozygote).
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Sample ID Genotype 
PM 
Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean 
Pos vs. 
Neg AUC 
B8A2P1.CEL Het 453.28 0.13 0.10 0.13 0.10 0.87 
B8A2P2.CEL Mutant 424.61 0.14 0.10 0.15 0.11 0.87 
B8A2P3.CEL Wt 490.42 0.13 0.09 0.13 0.10 0.87 
B8A2P4.CEL Het 407.82 0.19 0.16 0.26 0.22 0.86 
B8A2P5.CEL Het 504.31 0.14 0.11 0.15 0.12 0.87 
B8E1P1.CEL Het 382.91 0.16 0.12 0.18 0.17 0.86 
B8E1P5.CEL Wt 333.17 0.18 0.13 0.19 0.16 0.87 
B8E1P7.CEL Het 392.05 0.17 0.12 0.18 0.13 0.87 
B8E1P8.CEL Het 368.41 0.16 0.12 0.18 0.15 0.87 
E27AD2P3.CEL Het 425.85 0.15 0.11 0.19 0.15 0.86 
E27AD2P4.CEL Het 457.78 0.14 0.10 0.15 0.12 0.86 
E27AD2P5.CEL Het 387.87 0.16 0.11 0.16 0.12 0.87 
E27AD2P7.CEL Wt 432.60 0.14 0.10 0.15 0.12 0.86 
E27AM2P2.CEL Het 454.74 0.14 0.11 0.16 0.12 0.87 
E27AO4P3.CEL Het 401.01 0.14 0.11 0.14 0.11 0.87 
B8E1P2.CEL Mutant 433.18 0.16 0.12 0.20 0.17 0.87 
B8E1P3.CEL Mutant 352.13 0.17 0.12 0.19 0.16 0.87 
B8E1P4.CEL Mutant 409.25 0.16 0.12 0.23 0.18 0.87 
B8E1P6.CEL Wt 401.05 0.15 0.11 0.20 0.17 0.87 
E27AD2P1.CEL Mutant 395.13 0.16 0.12 0.19 0.17 0.87 
E27AD2P6.CEL Mutant 329.21 0.20 0.15 0.25 0.21 0.87 
E27AM2P1.CEL Wt 343.60 0.18 0.15 0.28 0.30 0.85 
Mean-SD*2   313.77 0.12 0.08 0.10 0.06 0.86 
Mean+SD*2   502.62 0.19 0.15 0.27 0.25 0.88 
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Sample ID Genotype 
PM 
Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean 
Pos vs. 
Neg AUC 
B8A2P1.CEL Het 453.28 0.13 0.10 0.13 0.10 0.87 
B8A2P4.CEL Het 407.82 0.19 0.16 0.26 0.22 0.86 
B8A2P5.CEL Het 504.31 0.14 0.11 0.15 0.12 0.87 
B8E1P1.CEL Het 382.91 0.16 0.12 0.18 0.17 0.86 
B8E1P7.CEL Het 392.05 0.17 0.12 0.18 0.13 0.87 
B8E1P8.CEL Het 368.41 0.16 0.12 0.18 0.15 0.87 
E27AD2P3.CEL Het 425.85 0.15 0.11 0.19 0.15 0.86 
E27AD2P4.CEL Het 457.78 0.14 0.10 0.15 0.12 0.86 
E27AD2P5.CEL Het 387.87 0.16 0.11 0.16 0.12 0.87 
E27AM2P2.CEL Het 454.74 0.14 0.11 0.16 0.12 0.87 
E27AO4P3.CEL Het 401.01 0.14 0.11 0.14 0.11 0.87 
Mean-SD*2   338.46 0.12 0.08 0.10 0.07 0.86 
Mean+SD*2   504.45 0.19 0.15 0.24 0.21 0.87 
 
Sample ID Genotype 
PM 
Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean 
Pos vs. 
Neg AUC 
B8E1P6.CEL Wt 401.05 0.15 0.11 0.20 0.17 0.87 
E27AM2P1.CEL Wt 343.60 0.18 0.15 0.28 0.30 0.85 
E27AD2P7.CEL Wt 432.60 0.14 0.10 0.15 0.12 0.86 
B8E1P5.CEL Wt 333.17 0.18 0.13 0.19 0.16 0.87 
B8A2P3.CEL Wt 490.42 0.13 0.09 0.13 0.10 0.87 
Mean-SD*2   270.22 0.11 0.07 0.08 0.01 0.85 
Mean+SD*2   530.12 0.20 0.16 0.31 0.33 0.88 
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Sample ID Genotype 
PM 
Mean 
All Probeset MAD 
Residual Mean 
Pos Control MAD 
Residual Mean 
All Probeset RLE 
Mean 
Pos Control RLE 
Mean 
Pos vs. 
Neg AUC 
B8A2P2.CEL Mutant 424.61 0.14 0.10 0.15 0.11 0.87 
B8E1P2.CEL Mutant 433.18 0.16 0.12 0.20 0.17 0.87 
B8E1P3.CEL Mutant 352.13 0.17 0.12 0.19 0.16 0.87 
B8E1P4.CEL Mutant 409.25 0.16 0.12 0.23 0.18 0.87 
E27AD2P1.CEL Mutant 395.13 0.16 0.12 0.19 0.17 0.87 
E27AD2P6.CEL Mutant 329.21 0.20 0.15 0.25 0.21 0.87 
Mean-SD*2   307.70 0.13 0.09 0.13 0.10 0.86 
Mean+SD*2   473.46 0.20 0.15 0.27 0.23 0.88 
Table 5.6. QC following the removal of an outlier and Snca expressing Samples. When considering all 22 samples no outliers were observed. 
When considering the samples by C59X genotype only B8A2P4 had more than 3 metrics with values more than 2 standard deviations from the mean. 
This sample had been flagged previously for this reason.
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5.3.6 Embryonic C59X Mutant vs Wildtype Analysis. 
After exclusions, samples from 6 C59X homozygous mutants and from 5 wildtypes 
were analysed for differential expression and splicing.  
5.3.6.1 Differential Gene expression.  
I evaluated gene expression in the 6 embryonic C59X mutants relative to the 5 
wildtypes using a 3-way ANOVA in Partek GS. Genotype, gender and scan date were 
all included as ANOVA factors. A total of 15,830 transcripts passed the filtering 
thresholds and were included in the analysis. The number of genes found to be 
significantly differentially (P≤0.05) expressed in the C59X mutants was 1346 (9%), 
almost double that expected by chance alone (Table 5.7) but none survived correction 
for multiple testing (as was observed in the adult data). Of the 6 robust differentially 
expressed genes between C59X mutants and wildtype in the adult data only Npas4 was 
nominally significantly differentially expressed (p = 0.046) between embryonic C59X 
mutants and wildtype.   
Unadjusted p value 
Significant 
Genes % of Genes  
Expected by 
Chance   
0.05 1346 8.50 792 
0.01 225 1.42 158 
0.001 15 0.09 16 
0.0001 0 0 2 
FDR 0.05 threshold 0 0   
Bonferroni Correction for 15830 
tests 0 0   
Table 5.7 Genes differentially expressed in C59X embryonic mutants. Prior to 
correction for multiple testing, 1346 genes were significantly differentially expressed at 
p≤0.05 in the C59X mutants, however following either FDR or Bonferroni correction no 
genes were significant.  
 
 
5.3.6.2 Differential Splicing.  
I evaluated differential splicing using the alternative splice ANOVA in Partek GS. 
Genotype was added as the alternative splice factor (as in the adult C59X dataset) with 
both gender and scan date added as covariates. As before, probesets with a maximum 
log2 intensity <3 were excluded. The default option to retain probesets if significant 
differential splicing between the two groups at a p value ≤0.05 was observed, despite an 
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intensity below 3, was included. As observed previously in the adult data the number of 
significant differentially spliced genes at a nominal p value ≤0.05 was greater than the 
number differentially expressed (Table 5.8) with 11% (1808) of genes predicted to be 
differentially spliced in the C59X mutants. Using the FDR step up (Benjamini & 
Hochberg, 1995) set at 0.05, 172 genes were found to be significantly differentially 
spliced, of which 5% (~9 genes) would be predicted to be false positives. Using the very 
conservative Bonferroni correction, 30 genes (0.2%) were predicted to be differentially 
spliced in the C59X embryonic mutants. This appears to replicate the general pattern of 
the data observed in the adult C59X mutants, in that the number of differential splice 
predictions is greater and more robust than the differential expression predictions. When 
considering the splicing data the numbers of predicted differential splice events are 
greater than expected by chance alone at the more stringent statistical thresholds.  
 
Unadjusted p value 
Significant 
Genes % of Genes  
Expected by 
chance 
P≤0.05 1808 11.42 792 
P≤0.01 721 4.55 158 
P≤0.001 214 1.35 16 
P≤0.0001 104 0.66 2 
FDR (0.05 threshold)  172 1.09   
Bonferroni Correction for 15830 
tests 30 0.19   
Table 5.8. Differentially Spliced Genes. A total of 1808 genes were significantly 
differentially spliced in the embryonic C59X mutants at p≤0.05. 172 of these genes 
were still significant following an FDR correction using the 0.05 threshold. With a 
stringent Bonferroni correction for the 15,830 tests, 30 genes were significantly 
differentially spliced.  
 
 
5.3.7 Overlap between the findings from the Embryonic and Adult studies.  
The validity of the adult data came into question following the discovery that the 
C57BL/6JHsdOla strain harboured a mutation at the Snca locus which at F3i correlated 
with C59X genotype, Snca being expressed in all but one C59X mutant and deleted in 
the majority of the wildtypes. Prior to the discovery of the Snca deletion, my intention 
had been to investigate if there was developmental specificity between mutant and wild 
type animals with respect to differences in expression and splicing. However, due to the 
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confounding Snca deletion, differences between the results observed in the adult and 
embryonic might simply reflect the confounding effect of Snca. The primary use 
therefore of the comparison between adult and embryonic data was therefore to test the 
validity of the adult data by determining if any of the embryonic expression or splice 
changes replicated in the adult results. This is clearly not an ideal replication experiment 
given splice events are known to be developmentally regulated, and therefore true 
differences might be expected between the results obtained in the embryonic and adult 
studies. Nevertheless, results consistent across the studies would suggest the adult data 
may contain true positives unrelated to the Scna confound.  I did consider whether in 
the adult data, the Snca deletion could be statistically adjusted for but due to the high 
degree of correlation between Snca deletion and the C59X genotype, covarying for Snca 
would essentially remove any differences between the strains.  
To assess the degree of overlap between the embryonic and adult data, I compared if the 
observed number of genes attaining significance thresholds for each of the expression 
and splicing analyses in both datasets was greater than the number expected by chance 
(Table 5.9 & 5.10). The adult data set used was that of all 16 samples (male and female) 
combined with gender covaried.  
In the embryonic data, significant genes were defined as those attaining a range of p 
value thresholds (p≤0.05, p≤0.01, p≤0.001 and p≤0.0001). Based on the number of 
genes surpassing each threshold in the embryonic data, the number of genes expected by 
chance to attain significance at p≤0.05 in the adult brain analysis were estimated using 2 
x 2 contingency tables and the χ2 test (method described in Chapter 3.2).  The results for 
differential expression and splicing are summarised in tables 5.9 and 5.10 respectively.  
For both differential expression and splice changes, among genes attaining each of the 
thresholds in the embryonic experiment, more also showed significant differences 
between mutant and wildtype in the analysis of the samples from adult brain than 
expected by chance. This data suggests that at least some of the differential expression 
and splice predictions in the adult data are neither due to chance nor to differences in 
Snca expression in the C59X mutant and wildtype groups.   
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Significance Threshold OR Significance of Overlap  
P≤0.05 1.25 p=0.021 
p≤0.01 1.79 p=0.007 
p≤0.001 7.13 p=0.002 
p≤0.0001 No genes significant 
Table 5.9 Differential Expression changes common to Embryonic and Adult C59X 
Mutants. OR is the odds ratio that genes nominally (≤0.05) significantly differentially 
expressed in the embryonic mutants will be nominally significant in the adult mutants 
conditional on the gene being significantly differentially expressed at the indicated P 
value threshold in the embryonic expression data. 
 
 
 
 
 
 
 
Significance 
Threshold OR  Significance of Overlap 
p≤0.05 1.51 p<0.01 
p≤0.01 2.00 p<0.01 
p≤0.001 4.00 p<0.01 
p≤0.0001 5.28 p<0.01 
Table 5.10 Differential Splicing changes common to Embryonic and Adult C59X 
Mutants.  OR is the odds ratio that genes nominally (≤0.05) significantly differentially 
spliced in the embryonic mutants will be nominally significant in the adult mutants 
conditional on the gene being significantly differentially spliced at the indicated P value 
threshold in the embryonic splicing data.  
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5.3.8 Alternative Algorithms. 
To determine how robust the embryonic data were the data were analysed using 
alternative software packages which offer different filtering and statistical methods. 
5.3.8.1 easyExon. 
Using the easyExon, which unlike the other approaches, requires an accompanying fold 
change of greater than or equal to 1.5 fold only 18 genes were nominally significantly 
differentially expressed (MiDAS p≤0.05) and 345 genes nominally differentially spliced 
(MiDAS p≤0.05).   
5.3.8.2 AltAnalyze. 
Using the MiDAS algorithm in AltAnalyze, 1407 genes were differentially expressed 
(unadjusted p<0.05) which is similar to that in Partek GS (1346). Including a fold 
change filter of greater than or equal to 1.5 to make the analysis analogous to easyExon 
reduced this number to 38 genes. Thus many of the significant expression changes have 
small fold changes, and this explains the major numerical differences between easyExon 
and Partek GS. Using the FIRMA algorithm, 489 genes were predicted to be 
differentially spliced in AltAnalyze, similar to that observed in easyExon (345), but 
considerably less than the number observed in Partek GS (1808 genes). This may reflect 
the more stringent intensity filters used in easyExon and AltAnalyze to remove signals 
close to the background. Both use the DABG algorithm. The DABG p value represents 
the likelihood that the intensity value of a particular probe set is part of the background 
(null) distribution (Della et al., 2008). Probesets with an average DABG p value less 
than or equal to 0.05 in a biological group were excluded in AltAnalyze and probesets 
with a DABG p value less than or equal to 0.05 in half the samples were excluded in 
easyExon. In Partek GS probesets with a log2 intensity <3 were excluded. The larger 
number of results in Partek GS may therefore reflect false positives due to low 
expressing probesets close to the background signal being included in splicing 
calculations or that the smaller number of results in AltAnalyze and easyExon reflect a 
larger number of false negatives.  
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5.3.8.3. Differential Expression and Splicing Results Common to Partek GS, 
AltAnalyze and easyExon.  
To determine how robust the expression and splicing data were the overlap between 
Partek GS, AltAnalyze and easyExon was established. 
 
5.3.8.3.1. Expression:  
To be included as significant in each of the methods, genes were required to have 
significant differential expression in C59X mutants at an unadjusted p value ≤0.05 and 
with an accompanying fold change of greater than or equal to 1.5. (Fig 5.8) as used in 
the adult analyses.  
With these criteria in place a single gene showed consistent expression changes in 
AltAnalyze, easyExon and Partek GS (Fig. 5.8). That gene was Osteoglycin (Ogn), 
(Partek p = 0.0025; AltAnalyze p = 0.0032; easyExon p = 0.0032).  Ogn was not 
significant in the adult data (Fig. 5.9). Ogn is a leucine-rich proteoglycan (Iozzo., 1999; 
Kukita et al., 1990) forming part of the brain exctracellular matrix. The observation of 
only a single gene showing consistent expression changes is not suggestive of a role for 
Zfp804a in the direct regulation of gene expression.  The fact that only a single gene 
surpasses a threshold of p ≤ 0.05 and a fold change greater than or equal to 1.5 suggests 
this requirement is excessively stringent. Under a null model 1 in 20 genes would be 
expected to be differentially expressed by chance (~800 genes) and under this same 
model finding only 1 that overlaps suggests the approach is very insensitive. When 
considering the results of Partek and AltAnalyze using just a p value threshold of less 
than or equal to 0.05 (p≤0.05) then 281 genes overlap, one of which is Npas4 which was 
a robust differential expression candidate in the adult dataset. When reducing the 
stringency of the overlap threshold the proportion of genes is greater than the proportion 
you would expect by chance.    
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Figure 5.8 The number of Differential Expression results that replicate across 
Partek GS, easyExon and AltAnalyze. Only one gene (Ogn) is predicted to be 
differentially expressed in C59X mutants in all 3 programmes. 
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Figure 5.9 Differential Expression of Osteoglycin in Embryonic C59X Mutants. Osteoglycin was upregulated in embryonic C59X mutants (left). 
This expression change was not apparent in adult C59X mutants (combined sample) (p = 0.64) (right) and may reflect the developmental regulation of 
this gene. N.B. C59X homozygotes are represented in the above plots by a red line and wildtypes by a blue line.  
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5.3.8.3.2. Splicing:  
Considering the alternative splicing results, 62 genes were predicted to be significantly 
differentially spliced across all three algorithms (Fig. 5.10). Of the genes significantly 
differentially spliced in C59X mutants relative to wildtypes in easyExon and 
AltAnalyze a large proportion were also significant in at least one other software 
package (185/350 for easyExon and 216/467 in AltAnalyze). Of these 62 genes, 20 had 
been significant after using a FDR threshold of 0.05 in Partek GS (Table 5.11).   
 
 
Figure 5.10 The number of Differential Splice results that replicate across Partek 
GS, easyExon and AltAnalyze. 62 genes are predicted to be differentially spliced by 
all 3 algorithms.  
 
 
Of these 20 genes, 6 showed significant differences (at P ≤0.05) in the analysis of adult 
samples of which no less than 4 were among the 13 most robust differential splice 
predictions in the adult data (defined as being significant in male and female datasets 
separately and being significant with all three software algorithms, see chapter 3 section 
3) However, as shown in chapter 4, section 3.6, the apparent differential splicing at two 
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of these genes, Slc39a13 and Ssfa2 arises from probesets which span sequences at 
which the two strains, C3H/HeJ or Balb/c (the ENU strain), and C57BL/6JHsdOla (the 
strain used for backcrossing) differ by a single base with the potential to impact on 
probe binding and generate a false prediction of differential splicing. Also of note, of 
these top 20 genes, 7 mapped to chromosome 2, the same chromosome as Zfp804a, of 
which 4 mapped within 15 Mb of Zfp804a (Table 5.11).   
 
This led me to the hypothesis that like Slc39a13 and Ssfa2, the other robust splicing 
differences at genes on chromosome 2 might also reflect background strain specific 
sequence variants affecting probe binding which due to genetic linkage to the Zfp804a 
locus, still had not been randomly segregated with respect to the C59X mutation among 
offspring. To test this hypothesis the sequences targeted by the other 2 probesets 
predicted to be differentially spliced (Fam171b and Prdm4) out of the 4 genes that had 
shown robust effects in both adult and embryonic analyses were checked for dbSNPs.  
The sequence corresponding to the probeset predicted to be differentially spliced in 
Fam171b had relatively lower expression in the C59X mutants and had sequence 
variants that were present in adult mutant sequences specifically. The sequence 
corresponding to the probeset predicted to be differentially spliced in Prdm4 was highly 
expressed in the mutant relative to the wildtype and there was no evidence of 
polymorphism in the sequence. Interestingly Slc39a13, Ssfa2 and Fam171b are all on 
chromosome 2 where as Prdm4 is on chromosome 10. 
In the data I generated using Partek GS, 29 genes had differential splicing effects that 
were Bonferroni significant in the adult (combined male female) analysis and 30 genes 
in the embryonic dataset. Although the proportion of genes with these effects was 
similar in each, only 6 genes were common to both analyses (Table 5.12).  Three of the 
six (Fam171b, Slc29a13 and Ssfa2) were suspected to be attributable to C59X mutant 
strain specific variants and are found on chromosome 2. Tcp11l1 and Zc3h15 are also 
on chromosome 2 and so there was the possibility that a strain specific variant in the 
target sequence was causing a false positive result and it was these false positives which 
were responsible for the common results between embryonic and adult C59X mutants. I 
found both Zc3h15 and Tcp11l1 to contain dbSNPs in the sequence targeted by the 
probeset that was predicted to be differentially spliced. The exon targeted by the 
probeset was downregulated in the C59X mutants in both cases. A bias for genes 
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predicted to be highly significantly differentially spliced in both embryonic and adult 
C59X mutants was found on chromosome 2. This could indicate a region of 
chromosome 2 that was being inherited with the C59X mutation which resulted in 
additional C59X mutant strain specific variants (This is assessed in detail in chapter 6 
section 3.1). 
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Gene 
Symbol Chromosome 
Start 
Position  Stop Position 
Differential Splice P value 
(Nominal p<0.05) 
FDR (0.05 
threshold) Adult Splice p value  
Inpp4a 1 37356703 37476203 8.13x10-5 0.01 0.89 
Cds2 2 132088919 132137786 7.23x10-6 0.003 0.13 
ext2 2 93535349 93662754 5.79x10-5 0.01 0.66 
Fam171b 2 83652803 83723677 1.34x10-14 1.06x10-10 5.16x10-18* 
Itih2 2 10016224 10089270 1.10x10-6 8.74x10-4 1.00 
Pla2g4e 2 119992148 120071314 3.33x10-6 0.002 4.23x10-4 
Slc39a13 2 90901953 90928948 1.95x10-10 4.40x10-7 3.74x10-17* 
Ssfa2 2 79475519 79513499 2.03x10-6 1.27x10-3 2.54x10-27* 
Nomo1 7 53289086 53344037 7.79x10-9 1.23x10-5 0.72 
Xab2 8 3608421 3621314 2.36x10-4 0.03 0.06 
Baz2a 10 127528233 127567216 5.97x10-5 0.01 0.99 
Myh10 11 68505007 68630180 8.21x10-7 6.84x10-4 0.90 
Trim37 11 86940579 87064356 2.24x10-5 0.006 0.90 
Dync1h1 12 111839631 111905126 6.57x10-9 1.16x10-5 0.04 
Atp8a2 14 60266382 60816016 1.03x10-4 0.02 0.99 
Prdm4 14 70162232 70237257 2.83x10-6 1.55x10-3 8.67x10-20* 
Arf3 15 98565314 98593635 4.12x10-6 0.00186 0.86 
Serpind1 16 17331484 17343665 5.91x10-5 0.01 0.51 
Fbn2 18 58168277 58392191 5.84x10-5 0.01 0.98 
Huwe1 X  148235370 148369956 6.46x10-6 0.002 1.00 
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Table 5.11 Overlapping Genes Significant After Multiple Test Correction. Of the 62 genes predicted by AltAnalyze, easyExon and Partek GS to 
be differentially spliced in the embryonic C59X mutants 20 were significant in Partek GS following an FDR correction set at 0.05. 6 Genes were 
significant in the embryonic data in Partek GS, easyExon and AltAnalyze and were also significant in the adult data at a nominal p value of <0.05. *4 
genes were among the 13 most robust differential splice predictions in the adult data (defined as being significant in male and female datasets 
separately and being significant with all three software algorithms) and were also significant in all 3 programmes in the embryonic dataset. 
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Gene 
Symbol Cytoband 
Adult Splice p value 
(p<0.05) 
Bonferroni Correction 
for 15833 Tests 
E18.5 Splice p value 
(p<0.05) Bonferroni Correction for 15830 Tests 
Ssfa2 2qC3 2.53x10-27 4.01x10-23 2.03x10-6 0.03 
Prdm4 14qD2 8.67x10-20 1.37x10-15 2.83x10-6 0.04 
Tcp11l1 2qE2 1.80x10-19 2.85x10-15 1.48x10-10 2.34x10-6 
Fam171b 2qD 5.16x10-18 8.18x10-14 1.34x10-14 2.13x10-10 
Slc39a13 2qE1 3.75x10-17 5.93x10-13 1.94x10-10 3.08x10-6 
Zc3h15 2qD 1.28x10-14 2.03x10 1.40x10-8 2.22x10-4 
Table 5.12 Genes with Bonferroni Significant Differential Splicing in embryonic and Adult C59X mutants. The 6 genes in the table above were 
all predicted to be differentially spliced in embryonic and adult C59X mutants following a Bonferroni correction. 5 of the 6 genes are found on 
chromosome 2.  
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5.4 Discussion.   
I determined the effects of the C59X mutation on expression and splicing in embryonic 
mice from the F7 generation which were expected to have at least 98.5% of the 
C57BL/6HsdOla genome. Whole transcriptome expression and splicing were 
investigated in brain tissue derived from E18.5 embryos. Embryonic tissue was chosen 
due to evidence for a neurodevelopmental origin of schizophrenia as well as the 
growing evidence in support for substantial alternative splicing prevalent during 
development. The aim was to identify expression and splice changes that occur during 
this developmental period which in mouse, is thought to be roughly comparable to the 
second trimester of human pregnancy when it is thought impaired or altered 
development influences predisposition to schizophrenia.  
Expression of Snca in the ENU background strain was still observed in 2 of the 25 
embryonic samples. Although deletion of Snca did not strongly correlate with C59X 
genotype, I excluded these 2 samples to rule out confounding effects expression of this 
gene might have on the results. The Snca deletion has been reported to have some 
phenotypic effects (Oksman et al., 2006) and may alter the expression of other genes, 
though evidence of this is as yet lacking (Specht & Shoepfer, 2001).  
Expression and splice differences between mutant and wild type mice followed the 
same general pattern as observed in adult results. The proportion of differentially 
expressed genes was for adult and embryonic samples respectively 7% and 8%. Only 
one gene, Ogn was found to be differentially expressed in the embryonic C59X mutants 
using 3 different software tools. Leucine-rich proteoglycans such as Ogn are thought to 
have roles in neurite outgrowth, ECM assembly and cell adhesion (Ruoslahti, 1996). 
Extracellular matrix proteins such as Ogn (Jung et al., 2012), whilst having structurally 
supportive functions in the brain, are also thought to be important to the architecture of 
the brain and contribute to plasticity (Bonneh-Barkay & Wiley, 2009). The expression 
of Ogn is reduced in the amygdala of chronic immobilisation stress (CIS)-induced 
depressed mice (Jung et al., 2012). The authors suggest this may affect plasticity in the 
amygdala and neural circuits involved in stress which could have implications in 
psychiatric disorders (Jung et al., 2012). As the expression difference between C59X 
mutant and wildtype is not found in the equivalent analysis of the adult samples it may 
represent a developmentally specific expression difference between embryonic and 
adult C59X mutants, which could reflect the importance of this gene in development. 
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Interestingly, known functions of Ogn include the assembly of the extracellular matrix 
and cell adhesion. Extracellular matrix and cell adhesion pathways are enriched for 
developmentally regulated differentially spliced genes in embryonic mice (Revil et al., 
2010). The absence of robust expression differences between C59X mutants and 
wildtypes does not appear to support a role for Zfp804a in the direct regulation of gene 
expression. The identification of Ogn is however interesting with regards to the 
developmental hypothesis of schizophrenia. Ogn was identified in all software at a 
nominally significant p value (p=0.003). Despite it not being one of the most significant 
expression differences the geneview shows consistent upregulation across the transcript 
in the C59X mutants with a fold change of greater than or equal to 1.5. This indicates 
that the observed differential expression of the Ogn gene between C59X mutants and 
wildtypes is a real difference in the sample not attributable to the software. 
The percentage of genes predicted to be significantly differential spliced was slightly 
higher in the analysis of embryonic samples than adult (11% compared to ~6% in the 
adult data) but when applying a Bonferroni correction ~30 genes remained significant in 
both datasets. However, when considering the specific overlap of genes in this 
Bonferroni significant set and also from the overlap between Partek GS, easyExon and 
AltAnalyze it would appear that the consensus between the adult and embryonic results 
may, at least in part, be due to the effects of C59X mutant strain specific variants which 
are in genetic linkage with the C59X mutation.  As this observation has been made in 
both adult and embryonic datasets, it is difficult to establish the proportion of true splice 
events which may be functionally interesting until the linked region has been 
determined and the false positives excluded. Further investigation of the alternative 
splicing results on chromosome 2, and indeed other chromosomes is therefore necessary 
to establish the extent of this issue. This analysis is presented in detail in the next 
chapter. As the observation of mutant specific variants was in genes on chromosome 2 it 
is likely these variants were being inherited along with the C59X mutation and therefore 
sequence variants specific to the mutants would not be expected in genes on other 
chromosomes.   
When considering the splicing results in embryonic C59X mutants the number of 
significant results was much greater in Partek GS compared to easyExon and 
AltAnalyze and this may reflect the intensity filter being used in Partek GS. The default 
intensity filter in Partek GS may result in background signal being used to calculate 
differential splicing; resulting in a large number of false positives or alternatively the 
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number of false negatives in the easyExon and AltAnalyze may be greater due to very 
stringent filters being used. To ensure the distinction between true expression and 
background signal in Partek GS it may be necessary to undertake the analysis with more 
stringent intensity filters.  
 
More in depth analysis of differential splicing taking into account inherited SNPs and 
intensity thresholds is necessary to ensure more accurate determination of differential 
splicing results which when taken forward to pathway and other downstream analyses 
will provide insight into sets of genes and their functions which are relevant to the 
pathophysiology of schizophrenia. Downstream analysis carried out on these results 
prior to assessing the apparent enrichment of significant splice results on chromosome 2 
and the intensity cut offs would result in the identification of pathways that would not 
truly represent the effects of the C59X mutation and the function of Zfp804a.  Therefore 
before conducting any further functional analyses the technical issues arising from using 
the C59X mouse model were further explored. 
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Chapter 6. Technical Artefacts 
6.1 Introduction 
Microarrays have been in wide use for many years in expression studies. Certain issues 
which have arisen from this study appear to be common pitfalls of such technology 
particularly when using mouse models in which backcrossing of a specific mutation is 
carried out on a different strain (Gajovic et al., 2006). In an attempt to address some of 
these issues in this chapter, I explore the technical artefacts in such experiments which 
can lead to false positives and where possible, address these with further analyses.   
Sequence variants affecting cDNA-probe binding: The RNAseq experiment (chapter 4) 
identified the potential issue of linked mutations in sequences targeted by probesets 
predicted to be differentially spliced between C59X mutants and wildtypes.  This 
problem is not well documented in mouse literature. The microarray technique is based 
on cDNA hybridising to a probe on the array with its complementary sequence. A 
polymorphism in the cDNA sequence that influences complementarity may reduce the 
hybridisation efficiency, resulting in an altered expression measure at the probeset. This 
is a problem if the polymorphism affecting hybridisation is specific to one of the 
experimental groups being studied as this could lead to false positive splicing results.  
The failure of some of the most significant splice changes from the adult exon array to 
replicate in the RNA sequencing data brought up the possibility of a technical artefact 
leading to false positive splice calls in the array experiment.  After the F3i experiment, I 
assumed this to be attributable to the mice having ~96% congenicity to the 
C57BL/6JHsdOla background strain, leaving the possibility that additional ENU 
induced mutations might still be present. However since the same genes showed highly 
significant changes in the embryonic data as well, this raised the issue that these 
mutations were in genetic linkage (i.e. these mutations had not been separated from the 
C59X mutation by a recombination event) with the C59X mutation since they were 
retained despite the now 98.5% congenicity to the C57BL/6JHsdOla strain. Based on 
preliminary analyses, significant differentially spliced genes around the Zfp804a locus 
and on chromosome 2 were investigated to determine if differential splicing correlated 
with the presence of dbSNPs in the associated probesets.  
Impact of intensity filter: The use of relatively stringent intensity filters removes 
probesets corresponding to sequences with low expression. Low intensity signals in 
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probesets when normalised to total gene expression have the potential to be 
misinterpreted as differential splicing, so aggressive filtering for intensity can be 
expected to reduce the false positive rate. The optimal choice of intensity filters is 
dependent upon the aim of the experiment (Whistler et al., 2010). If the aim is to 
minimize false negative findings, or identify novel splicing events, the filter needs to be 
less stringent but the trade off for higher sensitivity is lower specificity, that is a higher 
false positive rate.  The first intensity filter used was the Partek GS default which is a 
maximum log2 intensity <3 (except when that probeset has significant differential 
expression p≤0.05). This threshold is recommended in the Partek Manual to prevent the 
exclusion of true positives and is used elsewhere (Tian et al., 2010). This threshold 
corresponds to fairly low expression, and as a result, probesets corresponding to 
sequences that are not expressed won’t be included.  Others report that a more stringent 
log2 intensity > 6 represents reliable expression (Zhang et al., 2008), so I investigated 
the effects of increasing stringency up to this level.  
The use of a log2 intensity filter of 3 in Partek GS resulted in the prediction of many 
more differential splicing events than easyExon and AltAnalyze which both filter 
probesets using the DABG p value. The detection above p value represents the 
likelihood that the intensity value of a particular probe set is part of the background 
(null) distribution (Della et al., 2008). In a paper by Whistler et al., (2010) they 
observed a similar finding where the percentage of probesets removed from the analysis 
was double when using the DABG (p≤0.05) over a log2 intensity of 3. With the number 
of genes predicted to be differentially spliced almost 3 times as many when using the 
log2 intensity <3 filter (Whistler et al., 2010).   
Impact of gene size: Alternative splicing is thought to affect ~ 70% (Johnson et al., 
2003) of mammalian genes, but this is known to increase to ~97% in multi-exon genes, 
with a linear increase in the number of alternative splicing events per gene as the 
number of exons increases (Pan et al., 2008). When considering the results of exon 
arrays, increased splicing in large, multi-exon genes may reflect a genuine biological 
finding, but the number of spurious apparent differential splice events could also 
increase in genes with a larger number of exons as more probes implies a greater 
potential for an impact of chance fluctuations. Both true biological and chance effects 
would imply a relationship between the probability of finding a significant differential 
splicing effect and gene size. To determine if this relationship was found in the C59X 
mice the embryonic splicing data were assessed.  
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After the above potential artefacts were assessed, I reappraised all the previously 
presented data from Chapters 3 and 5.   
 
6.2 Methods 
6.2.1. Linked Sequence variants affecting cDNA-probe binding. 
To investigate potential effects of strain specific alleles in genetic linkage with the 
C59X mutation, I concentrated on the splicing data. Due to the way in which total 
expression and splicing changes are calculated, alleles affecting hybridization are 
expected to have a greater impact on splicing data. This is because splicing is 
determined by comparing expression at a single probeset relative to expression across 
the transcript whereas expression changes are based on average expression across all 
probesets in a transcript and are therefore less likely to be effected by a SNP in a single 
probe.  
The hypothesis investigated is that C3H/HeJ or Balb/c strain alleles within sequences 
representing probesets that generate apparent differential splicing effects remain 
associated with the C59X mutation on chromosome 2 because of genetic linkage. To 
test this hypothesis, using the embryonic data, I determined the 50 most significant 
splicing events to identify if there was an enrichment of results around the Zfp804a 
locus on chromosome 2. I then took the 17 most significantly differentially spliced 
genes on chromosome 2 and the 50 most significantly differentially spliced genes 
elsewhere in the genome (17 on chromosome 2 as these had an equivalent p value level 
(2x10
-5
) to the 50 non chromosome 2 genes) and in each identified the probeset 
indicative of differential splicing (Fig. 6.1). The probeset sequences were then identified 
using NetAffx (an Affymetrix tool for finding annotation and design information for 
GeneChip® arrays. http://www.affymetrix.com/analysis/index.affx) and the presence of 
a dbSNP (dbSNP 128) using UCSC. If a dbSNP was found within the sequence targeted 
by a probeset, the corresponding region was viewed in the adult mice RNAseq data 
(Chapter 4) using the Integrative Genomics Viewer (IGV) to confirm it distinguished 
C59X mutants from wildtypes.   
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Figure 6.1 To establish the number of genes that contained dbSNPs linked to the C59X 
mutation the sequences corresponding to the probeset (red circle) indicative of 
differential splicing was checked in UCSC to determine known dbSNPs (dbSNP 128) 
within the targeted sequence.   
 
6.2.2. Exclusion of Chromosome 2. 
The core meta-probeset file consisted of 194,293 probesets, following the removal of 
the 15,713 probesets found on chromosome 2, 178,580 remained.  A custom probeset 
file was made (Excel, 2007) with these 178,580 probeset IDs and the analysis was re-
run with all other criteria as described in chapter 2.8.3.1 
6.2.3 Impact of Intensity Threshold. 
To determine the effects of altering the stringency of intensity filter, the alternative 
splice ANOVA (Partek GS) was run with both the embryonic and adult data (excluding 
probesets targeting chromosome 2). The original analyses, which excluded probesets 
with a maximum (in a sample) log2 intensity <3 unless there was differential expression 
of the probeset (p≤0.05) were compared with those using filters at log2 intensity <4, <5 
and <6, retaining as before probesets that significantly differed (p≤0.05) between 
mutant and wildtype. I also investigated using a filter of mean log2 intensity <3, <4, <5 
and <6, both retaining (as before) and excluding differentially expressed (p≤0.05) 
probesets.     
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6.2.4 Impact of Gene size. 
To determine if there was a bias of significant splicing events in genes with more exons, 
I tested for correlation between probeset number (used as a proxy for exon number, as 
on average each exon is represented by one probeset) and –log alternative splice p value 
using the embryonic data. Both probeset number and alternative splice p value were not 
normally distributed and therefore a bivariate correlation using the non parametric 
Kendall’s tau b statistic was calculated using SPSS (v16.0).  
 
6.2.5 Re-analysing the data with more stringent thresholds and exclusion of 
Chromosome 2. 
To obtain a more conservative analysis, I reanalyzed the embryonic data without 
probesets targeting chromosome 2 and with the more stringent intensity filters indicated 
by the above evaluation.  
 
6.2.6 Embryonic and Adult Dataset Replication Following Stringent Analyses.  
To obtain a more conservative analysis of the extent of overlap between adult and 
embryonic datasets, I re-examined both datasets after exclusion of chromosome 2 
probesets and with a mean log2 intensity filter of 6. The embryonic data had gender and 
scan date covaried and the adult data were the combined data set of 16 samples with 
gender covaried. Overlap was determined as described in chapter 3.2.11. 
 
6.2.7 Expression and Splicing of Zfp804a.  
To establish if more stringent intensity cut-offs affected the previously generated 
expression and splicing results for Zfp804a, the more conservative analysis was run for 
both adult and embryonic datasets as described in chapter 2.8.3.6 but using the extended 
meta-probeset file and a mean log2 intensity = 6 filter. 
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6.3 Results  
6.3.1 Linkage with the C59X Mutation. 
6 genes (Fam171b, Prdm4, Slc39a13, Ssfa2, Tcp11l1 and Zc3h15) were predicted to 
have differential splicing in embryonic and adult C59X mutants following a Bonferroni 
correction for multiple testing, 5 of which (all but Prdm4) had reduced expression in the 
exon targeted by the probeset in the C59X mutants. All 5 were identified as having 
C59X mutant specific alleles in the sequence targeted by the probeset predicted to be 
differentially spliced. These observations had led to the hypothesis that reduced 
hybridisation efficiency caused by the C59X specific alleles was resulting in false 
differential splicing predictions. All 5 were on chromosome 2 and all were in dbSNP, 
thus unlikely to be ENU generated, suggesting that a region of chromosome 2 with 
ENU strain dbSNPs was co-segregating with the C59X mutation. When assessing the 
distribution of the 50 most significant differential splice results from the embryonic 
data, there was an obvious enrichment of significant events on chromosome 2 (Fig. 6.2).   
 
 
Figure 6.2 Genomic Distribution of the most Significant Differential Splice Events. 
Plotting the frequency of the 50 most significant differentially spliced genes from the 
embryonic analysis across the genome showed enrichment on chromosome 2.  
 
In the embryonic data, the top 17 significant differentially spliced genes on 
chromosome 2 (Table 6.1) and the top 50 elsewhere in the genome (Table 6.2) were 
investigated to determine how frequently the predicted spliced probeset targeted a 
sequence with a dbSNP that when investigated in the RNAseq data was found to 
distinguish C59X mutants and wildtypes. Whilst none of the top 50 results found 
elsewhere in the genome had dbSNPs in the predicted spliced probeset that could be 
identified in the RNAseq to distinguish C59X mutants from wildtypes, 7 of the 17 on 
chromosome 2 did.  
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For each of the 7 dbSNPs in sequences targeted by probesets on chromosome 2, the 
RNAseq revealed the allele in the wildtype C57BL6J/HsdOla background was a perfect 
match for that of the probeset, the C3H/Hej or Balb/c ENU strain having a base that was 
non complementary to the probe. This is expected since the probesets were designed by 
Affymetrix based upon the NCBI build 37/mm9 sequence which itself is derived from 
the C57BL/6J strain. The 7 genes affected were also in proximity to Zfp804a. 
Consistent with an adverse effect of the non-reference allele on hybridisation, 6 of the 7 
probesets indicated downregulation in the mutants. The exception is the gene Calcrl. 
This might point to a genuine upregulation of splicing of the gene, or simply a chance 
finding.  This suggests that the mice are inheriting a region (under linkage) rather than 
just the C59X mutation which is not being broken up by recombination. 
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Gene Symbol Start Position  Alt Splice P value dbSNP Strain carrying non-probe allele Direction of Change 
Itih2 10016220 1.10E-06 None   Mutant up 
Mllt10 17986021 2.37E-05 None   Mutant up 
Traf2 25373502 2.73E-05 3 dbSNPs Variants not observed in Mutant or Wt Mutant down 
Bat2l 32079483 2.53E-06 None   Mutant down 
Ssfa2 79475509 2.03E-06 rs13471129  Mutant Mutant down 
Zc3h15 83484592 1.40E-08 rs33018080  Mutant Mutant down 
Fam171b 83652793 1.34E-14 rs28032403  Mutant Mutant down 
Calcrl 84170783 1.26E-05 rs28028711  Mutant Mutant up 
Slc39a13 90901948 1.95E-10 rs13463033  Mutant Mutant down 
Caprin1 103603098 5.65E-06 rs33587735  Mutant Mutant down 
Tcp11l1 104497445 1.48E-10 rs27414619  Mutant Mutant down 
Eif2ak4 118214354 4.29E-06 2 dbSNPs rs27424057 in both  Mutant down 
Pla2g4e 119992148 3.33E-06 None   Mutant up 
Zfp106 120332556 6.26E-09 None   Mutant down 
Ubr1 120686005 9.62E-14 rs27438911  Both  Mutant down 
Ccndbp1 120834139 2.77E-05 2 dbSNPs Both  Mutant down 
Cds2 132088884 7.23E-06 None   Mutant up 
 
Table 6.1 Frequency of dbSNPs in Sequences of Differentially Spliced Genes on Chromosome 2. The top 17 significant differentially spliced 
genes found on chromosome 2 are ordered from top to bottom by genomic location. Those highlighted in yellow were genes in which the differentially 
spliced probeset contained a dbSNP specifically found in the mutant samples. This occurred in 7 of the genes and in 6 of the 7 the probeset was 
downregulated in the C59X mutants. Zfp804a is located between Ssfa2 and Zc3h15.  
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Gene Symbol Chromosome Start 
Coordinate 
Alternative Splice p value dbSNP Strain carrying non-probe allele Direction of 
Change 
Cul3 1 80261498 4.66E-06 None   Mutant up 
Kif1a 1 94912033 6.03E-06 None   Mutant down 
R3hdm1 1 129999883 9.10E-06 None   Mutant up 
Cp 3 19857054 7.08E-06 None   Mutant up 
Tnfsf15 4 63388118 8.52E-06 None   Mutant down 
Elavl2 4 90917397 2.17E-05 None   Mutant up 
Ift74 4 94281182 3.31E-06 None   Mutant up 
Agrn 4 155539407 1.10E-05 None   Mutant down 
Akap9 5 3928054 7.91E-06 None   Mutant up 
0610007C21Rik 5 31350685 1.87E-06 None   Mutant up 
Vps33a 5 123978773 3.44E-06 None   Mutant up 
Eefsec 6 88173756 1.07E-05 rs37659956  Variants not observed in Mutant or 
Wt 
Mutant down 
Plxna1 6 89265692 2.27E-05 None   Mutant down 
Emp1 6 135312949 3.15E-06 None   Mutant down 
Saps1 7 4,583,196 7.64E-06 None   Mutant down 
Supt5h 7 29099917 1.30E-06 rs36348871  Variants not observed in Mutant or 
Wt* 
Mutant down 
   Table 6.2  
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Gene 
Symbol 
Chromosome Start 
Coordinate 
Alternative Splice p value dbSNP Strain carrying non-probe 
allele 
Direction of 
Change 
Nomo1 7 53289066 7.79E-09 2 nonsynonymous; 3 
synonymous 
Variants not observed in 
Mutant or Wt 
Mutant Down 
Alg8 7 104520116 2.41E-05 None   Mutant up 
Eif4g2 7 118214082 1.04E-05 None   Mutant down 
Spon1 7 120909512 2.21E-11 None   Mutant up 
Odz3 8 49285946 1.95E-05 None   Mutant up 
Robo3 9 37223264 1.13E-05 None   Mutant down 
Anxa2 9 69301447 1.18E-05 None   Mutant up 
Clstn2 9 97344814 1.85E-05 None   Mutant down 
Gpr126 10 14122391 4.75E-06 None   Mutant up 
Prdm4 10 85354711 2.83E-06 rs30113788  Variants not observed in 
Mutant or Wt 
Mutant up 
Zdhhc17 10 110381449 1.79E-05 None   Mutant up 
Lrp1 10 126975217 3.41E-06 None   Mutant down 
Myh10 11 68505061 8.21E-07 None   Mutant up 
Trim37 11 86940579 2.24E-05 None   Mutant up 
Med24 11 98565905 2.02E-06 rs27041085 (C/T) Variants not observed in 
Mutant or Wt* 
Mutant up 
Nol11 11 107027977 3.97E-07 None   Mutant up 
   Table 6.2 
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Gene 
Symbol 
Chromosome Start 
Coordinate 
Alternative Splice p value dbSNP Strain carrying non-probe allele Direction of 
Change 
Abca9 11 109962063 2.09E-06 rs27036976 (C/T) Variants not observed in Mutant or Wt* Mutant up 
Dync1h1 12 111839662 6.57E-09 None    Mutant up 
Bap1 14 32064675 1.21E-06 None   Mutant up 
Pcca 14 122933546 8.53E-08 None   Mutant up 
Zfr 15 12047586 2.53E-06 None   Mutant up 
Cdh6 15 12963955 1.04E-10 None   Mutant up 
Arf3 15 98568052 4.12E-06 None   Mutant up 
Ktelc1 16 38,525,264 3.12E-15 None   Mutant up 
Grik1 16 87896441 1.70E-07 None   Mutant up 
Dopey2 16 93712152 2.35E-05 None   Mutant down 
Gtpbp2 17 46297981 8.69E-09 None   Mutant up 
Ptprs 17 56551854 1.76E-08 None   Mutant down 
Dpysl3 18 43480633 4.69E-06 None   Mutant up 
Mus81 19 5482355 1.50E-05 None   Mutant up 
Cybasc3 19 10652213 7.43E-08 None   Mutant down 
Hcfc1 X 71188131 2.00E-07 None   Mutant down 
Eda X 97170945 7.91E-06 None   Mutant up 
Huwe1 X 148235350 6.46E-06 None   Mutant up 
Table 6.2 Frequency of dbSNPs in Sequences of Differentially Spliced Genes not on Chromosome 2. The top 50 significant differentially spliced 
genes found in the rest of the genome were investigated to determine if a dbSNP was present in the sequence targeted by differentially spliced 
probesets and if so whether that variant was specifically in the C59X mutants (identified using the RNAseq alignment files). None of the dbSNPs 
identified were found in the RNAseq data although the coverage was poor in the RNAseq data for 3 of the genes (*). Gene listed from top to bottom by 
genomic location. 
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Strain information could only be obtained for 3 of the 7 dbSNPs (using the SNP query 
form from MGI based on dbSNP build 128, 
http://www.informatics.jax.org/javawi2/servlet/WIFetch?page=snpQF) (Table 6.3). All 
3 of the sequence variants were specific to one or both of the strains used to generate the 
ENU mouse line and suggests that each of these mutations was being inherited from the 
ENU strain along with the C59X mutation.  
 
 
 
Gene Symbol Strain Info 
Ssfa2 Specific to C3Hej and Balb/cByJ 
Zc3h15 Not there 
Fam171b Specific to C3Hej and Balb/cByJ 
Calcrl Not there 
Slc39a13 Not there 
Caprin1 Not there 
Tcp11l1 Specific to C3Hej and Balb/cByJ 
 Table 6.3. Inbred Mouse Strain Specificity of C59X Mutant Specific dbSNPs. Of 
the 7 dbSNPs identified, strain information could only be found for 3. All 3 were 
specific to one or both of the mouse strains used to generate the ENU mouse line.  
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The data above strongly support the hypothesis that a proportion of the splice events on 
chromosome 2 are artefacts of ENU strain specific alleles co-segregating with the C59X 
mutation.  
 
6.3.2 Exclusion of Chromosome 2.  
Given the impact of linkage between polymorphisms on chromosome 2 and the C59X 
mutation on the analyses, I repeated the analysis after excluding all probesets that 
targeted chromosome 2. The general pattern of the data was broadly similar to that 
observed previously (chapter 5) in that more significant results were observed for 
splicing following multiple test correction, although there were fewer differentially 
expressed (Table 6.4) and spliced genes (Table 6.5).  
Expression 
(embryonic) 
Including Chr. 2 
Total Transcript 
Number: 15830 
Excluding Chr. 2 
Total Transcript  
Number: 14512 
p≤0.05 1346 1228 
p≤0.01 225 204 
p≤0.001 15 11 
p≤0.0001 0 0 
FDR 0.05 0 0 
 
Expression (adult) 
Including Chr. 2 
Total Transcript 
Number: 15833 
Excluding Chr. 2 
Total Transcript  
Number: 14515 
p≤0.05 1043 902 
p≤0.01 242 194 
p≤0.001 30 13 
p≤0.0001 11 3 
FDR 0.05 9 2 
Bonferroni 3 1 
Table 6.4 Differentially Expressed Genes following the removal of Chromosome 2 
Probesets. After the ~15,700 probesets on chromosome 2 had been removed the 
number of differentially expressed genes in the C59X mutants was slightly lower at 
each p value threshold for both embryonic (top table) and adult (bottom table) results. 
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The number of apparently differentially spliced genes also decreased following the 
removal of chromosome 2 probesets from the analysis, with the adult analysis 
proportionately affected more than the embryonic.  Following the removal of 
chromosome 2 probesets, only Prdm4 (see chapter 5) remained significant in both 
datasets after a Bonferroni correction. 
 
 
Splicing 
(Embyonic) 
Including Chr. 2 
Total Transcript Number: 
15830 
Excluding Chr. 2 
Total Transcript Number: 
14512 
p≤0.05 1808 1627 
p≤0.01 721 629 
p≤0.001 214 170 
p≤0.0001 104 80 
FDR 0.05 172 125 
Bonferroni 30 23 
 
Splicing 
(adult) 
Including Chr. 2 
Total Transcript Number: 
15833 
Excluding Chr. 2 
Total Transcript Number: 
14515 
p≤0.05 617 514 
p≤0.01 226 162 
p≤0.001 92 51 
p≤0.0001 54 22 
FDR 0.05 65 22 
Bonferroni 29 9 
Table 6.5 Differential splicing in C59X embryonic (top) and adult (bottom) 
mutants following the exclusion of all probesets on chromosome 2.  
 
 
 
Due to the decreased numbers of significant differentially expressed and spliced genes it 
does suggest an unusual proportion of the significant results were genes found on 
chromosome 2 and favours the removal of these probesets as it is probable the majority 
are artefacts and in the absence of the ability to distinguish between true and false 
positives it is best to remove them all.  
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6.3.3 Assessment of Intensity Cut-offs. 
All analyses presented thus far used the default intensity filter in Partek GS which 
excludes any probeset with a maximum log2 intensity less than 3 unless it is 
significantly differentially expressed (p≤0.05). Given the substantially higher numbers 
of significant differentially spliced genes with Partek GS relative to others based on the 
DABG algorithm (chapter 3 and 5) more stringent thresholds were tested. Analyses 
excluded chromosome 2.  As expected, all increases in stringency (increasing the 
intensity threshold, using the mean threshold rather than requiring at least one sample to 
attain that threshold) reduced the total number of transcripts in the analyses (Table 6.6). 
However, when probesets are excluded based on intensity alone irrespective of 
differential expression p value (column called no exception), as the intensity threshold 
is increased, the numbers of differentially expressed and spliced genes decreases. The 
reverse is true when those probesets below the threshold are retained if they show 
significant differences between groups (columns called Max and Mean). The reduction 
in the former is easily explained by the exclusion of probesets with significant 
differential expression (p≤0.05) that have low intensity. However, it is less obvious why 
there should be an increase in the number of significant observations when the more 
stringent thresholds are applied in the latter two analyses. It maybe that a probeset with 
low expression is not differentially expressed between the two groups, however the 
probesets across the remainder of the transcript are differentially expressed. When the 
filters are less stringent the low expressing probeset is included so no significant 
differential expression is observed. When the more stringent filters are applied the low 
expressing probeset is excluded and the differential expression observed throughout the 
remained of the transcript becomes significant.   
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Adult Dataset Log2 Intensity   Embryonic Dataset Log2 Intensity 
  Max<3 Mean<3  Mean<3 Without 
Exceptions 
  Max<3 Mean<3  Mean<3 Without 
Exceptions 
Total Transcripts  14515 14440 14422 Total Transcripts  14512 14459 14444 
Expression (P≤0.05) 902 911 902 Expression (P≤0.05) 1228 1229 1227 
Splicing (P≤0.05) 514 517 510 Splicing (P≤0.05) 1627 1631 1628 
  Log2 Intensity   Log2 Intensity 
  Max<4 Mean<4 Mean<4 Without 
Exceptions 
  Max<4 Mean<4 Mean<4 Without 
Exceptions 
Total Transcripts  14426 14302 14258 Total Transcripts  14410 14304 14261 
Expression (P≤0.05) 911 918 896 Expression (P≤0.05) 1223 1239 1219 
Splicing (P≤0.05) 516 537 502 Splicing (P≤0.05) 1639 1637 1607 
  Log2 Intensity   Log2 Intensity 
  Max<5 Mean<5 Mean<5 Without 
Exceptions 
  Max<5 Mean<5 Mean<5 Without 
Exceptions 
Total Transcripts  14288 14102 14006 Total Transcripts  14253 14080 14002 
Expression (P≤0.05) 913 935 876 Expression (P≤0.05) 1239 1253 1208 
Splicing (P≤0.05) 539 562 462 Splicing (P≤0.05) 1625 1631 1534 
  Log2 Intensity   Log2 Intensity 
  Max<6 Mean<6 Mean<6 Without 
Exceptions 
  Max<6 Mean<6 Mean<6 Without 
Exceptions 
Total Transcripts  13998 13712 13498 Total Transcripts  13982 13693 13535 
Expression (P≤0.05) 936 967 849 Expression (P≤0.05) 1250 1280 1184 
Splicing (P≤0.05) 584 639 425 Splicing (P≤0.05) 1650 1682 1440 
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Table 6.6 The Effect of Intensity Filters on Determining Differentially Expressed and Spliced genes in Embryonic and Adult analyses of 
mutants versus wildtype. ‘Without Exceptions’ refers to the analyses which excluded probesets based on intensity alone and does not retain 
differentially expressed probesets (p≤0.05). 
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The analysis at the most stringent threshold which also excluded differentially 
expressed probesets with intensity values below the designated cut-off is the most 
conservative, and one would assume is the most robust. Previous analyses were aimed 
at capturing as many expression and splice differences as possible and therefore lower 
intensity stringencies were used to reduce the number of false negatives. When carrying 
out pathway analyses (presented in chapter 7) I chose what I felt to be the more robust 
intensity filter, where probesets are removed based on intensity, irrespective of 
significance. As when a probeset has low expression (log2 intensity <6) it is far more 
likely that the differential expression prediction is a false positive due to the probeset 
being expressed at an intensity which is not distinguishable from the background 
distribution.  The caveat being real data could also be excluded. When taking this 
analysis into consideration and the exclusion of chromosome 2 reduction in the total 
number of transcripts is observed, but this time an accompanying reduction in the 
number of significant differentially expressed and spliced genes is also observed.  
 
6.3.4 Determining the Effect of Gene Size on Differential Splicing Results.  
Larger genes have a greater number of exons, and as a result a larger number of 
probesets and a greater degree of multiple testing may introduce a bias towards such 
genes appearing to be significant in the differential splicing assay.  Larger genes may 
also have a true biological increase in alternative splicing.  Significant differential 
splicing results would therefore contain a disproportionate number of larger genes.  
When carrying out pathway analysis on such data the analysis would be bias in 
identifying pathways that happen to be comprised of larger genes irrespective of the 
cause. To determine if there is a relationship between the probability of observing a 
significant splicing event in a gene and the number of probesets in the gene, I sought 
correlation between the number of probesets targeting a gene and the –log alternative 
splice p value in the embryonic data. 
I hypothesised that as probeset number increased, the likelihood of a significant 
alternative splice event would also increase. As variables were not normally distributed, 
I undertook bivariate correlation with the Kendall’s tau b statistic. A two-tailed test was 
carried out. The number of markers in a gene and the –log of the differential splice p 
value were weakly (r = 0.061) but significantly (P<0.01) correlated (Fig. 6.3). This 
supports the hypothesis that the more probesets that target a gene, the more likely that 
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gene is to have a significant differential splice p value. Again it is important to note this 
increased differential splicing may be a result of a real biological effect or the impact of 
multiple testing. Whilst a significant correlation is observed, less than 1% of the 
variance in differential splice p value is explained by the number of probesets in a 
transcript, which is very small.  
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Figure 6.3 Correlation between the Number of probesets Targeting a Gene and the 
Signficance of Differential Splicing (-log P value).  
 
 
6.3.5 Re-analysis With More Stringent Intensity Filters and Exclusion of 
Chromosome 2. 
Having determined that the conservative analysis would be to exclude probesets that 
target chromosome 2 or that are expressed at a mean log2 intensity <6, the embryonic 
dataset was re-analysed using these filters. 
6.3.5.1 Differential Expression between C59X Mutants and Wildtypes.   
The number of genes differentially expressed between the C59X mutants and wildtypes  
at a p value ≤0.05 when probesets that target chromosome 2 are excluded was 1184 
(Table 6.7) approximately 200 fewer than when using the original filters (Chapter 5, 
Table 5.7). As before, no genes remained significant after multiple test correction (FDR 
threshold 0.05).  
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Unadjusted p value Significant Genes % of Genes  
Expected by 
Chance   
p≤0.05 1184 9 677 
p≤0.01 199 1 135 
p≤0.001 12 0 14 
p≤0.0001 1 0 1 
FDR 0.05 threshold 0     
Bonferroni Correction for 15830 
tests 0     
Table 6.7. Differentially Expressed Genes between Embryonic C59X Mutants and 
Wildtypes.  
 
 
 
The AltAnalyze software predicts 1246 (p≤0.05) differentially expressed genes when 
chromosome 2 is removed of which 260 genes are also among those nominally 
significant in the Partek analysis. Of 1019 genes significantly differentially expressed in 
easyExon, 263 of them are among those nominally significant in the Partek analysis. 
When considering the results of all 3 analyses, 157 genes are predicted to be 
differentially expressed in all 3. The fold change of the expression difference was not 
considered with this data. This is because, using what I consider to be a more robust 
analysis in Partek GS with the more stringent intensity threshold, the addition of a fold 
change filter in addition to a significance filter seemed excessively stringent (as 
observed in Chapter 5.3.8.3.1). The degree by which significant differential expression 
results from the embryonic data replicated in the adult dataset was evaluated using 
Partek GS (Table 6.8). This analysis took the data generated using the more stringent 
approach. Significant genes were defined at a series of p value thresholds beginning at 
p≤0.05 in the embryonic data with a progressively more stringent threshold applied 
(p≤0.01, p≤0.001 and p≤0.0001). There was no obvious concordant significantly 
differentially expressed genes in the adult and embryonic datasets. 
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Differential Expression 
O.R 
χ2 
p≤0.05 
1.11 
p = 0.216 
p≤0.01 
1.22 
p = 0.273 
p≤0.001 
2.98 
p = 0.172 
p≤0.0001 
0 
p = 0.937 
Table 6.8 Replication of Differential Expression Results in C59X Embryonic and Adult Following the Removal of Low Expressing and 
Chromosome 2 Targeting Probesets. When more stringent filters were applied to the data no overlap was observed between embryonic and adult 
studies. O.R. is the odds ratio that a finding is significant in the adult data conditional on it being significant in the embryonic data. An O.R. <1 means 
findings that are significant in the embryonic data are not more likely to be significant in the adult data compared with those that are not significant in 
the embryonic data.  
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6.3.5.2 Differential Splicing Between Embryonic C59X Mutants and Wildtypes. 
The number of differentially spliced genes between embryonic C59X mutants and 
wildtypes following the removal of low intensity and chromosome 2 probesets 
decreased by ~400 genes at an unadjusted p value of ≤0.05 (Table 6.9). Although fewer 
than before, there were still an appreciable number of genes (Chapter 5, table 5.8) 
significant following multiple test correction.  
 
Unadjusted p value 
Significant 
Genes % of Genes  
Expected by 
Chance   
p≤0.05 1440 11 677 
p≤0.01 544 4 135 
p≤0.001 140 1 14 
p≤0.0001 58 0 1 
FDR 0.05 threshold 88     
Bonferroni Correction for 
15830 tests 16     
Table 6.9. Number of Differentially Spliced Genes between Embryonic C59X 
Mutants and Wildtypes.  
 
In AltAnalyze 412 genes are predicted to be differentially spliced (p≤0.05 FIRMA) of 
which 130 overlap with genes predicted by Partek GS. The easyExon analysis using the 
MiDAS algorithm (p≤0.05) predicts 316 significant differential splice events of which 
114 overlap with those significant in Partek GS. 55 significant differentially spliced 
genes were common to all 3 analyses.  
Revisiting the overlap of differential splicing results between C59X mutants and 
wildtypes in embryonic and adult data using the more robust filtering criteria, there 
were no more replications between embryonic and adult data than expected by chance at 
any p value stringency (Table 6.10). This suggests the highly significant overlap before 
was likely driven by false positive results due to a combination of low intensity 
probesets and polymorphisms linked to the C59X mutation on chromosome 2. The 
apparent lack of overlap in the more stringent analyses can be interpreted in four ways. 
First, the results of the adult experiment could be confounded by the Snca deletion, and 
a high proportion of changes seen between C59X mutants and wildtypes could be 
attributable to the Snca deletion. Second, changes observed in the adult mutants could 
be different from those seen in embryonic mutants due to the developmental regulation 
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of the expression or splice changes. Third, the results from both adult and embryonic 
studies were chance findings (although the number of FDR and Bonferroni significant 
genes would argue against this (Chapter 3, Table 3.10).  Fourth, there could be an as yet 
unaccounted for technical confounder in the embryonic data.      
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Differential Splicing  O.R  χ2 
p≤0.05 0.97 p = 0.472 
p≤0.01 0.87 p = 0.360 
p≤0.001 1.38 p = 0.279 
p≤0.0001 2.29 p = 0.109 
Table 6.10 Replication of Differential Splicing events observed in embryonic and adult studies following the removal of low expressing and 
chromosome 2 targeting probesets. When more stringent filters were applied to the data no overlap was observed between embryonic and adult 
studies. O.R. is the odds ratio that a finding is significant in the adult data conditional on it being significant in the embryonic data. An O.R. <1 means 
findings that are significant in the embryonic data are not more likely to be significant in the adult data compared with those that are not significant in 
the embryonic data.  
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6.3.6 Expression and Splicing in Zfp804a Following increased Intensity Filtering.  
6.3.6.1 Differential Expression of Zfp804a.  
Using the original less stringent intensity filters in the adult data no significant 
differential expression was observed in either the female or the male analyses using 
Partek GS (Table 6.11), although a trend was observed for upregulation in the mutants. 
In AltAnalyse there is the option to make intensity filters less stringent. The default is to 
exclude probesets with a non log expression below 70. I reduced this to exclude only 
probesets with a nonlog expression below 1. A similar non significant result was 
observed in AltAnalyze when using this less stringent intensity cut-off. In easyExon 
(without the default fold change filter), significant upregulation of Zfp804a was 
observed in the C59X female and male mutants (p = 0.008 and p= 0.01 respectively). I 
repeated the analysis in Partek GS using the extended metaprobeset file (as no core 
probesets target Zfp804a) with the mean intensity <6 exclusion criterion, and in 
AltAnalyze excluding probesets with a non log (absolute) expression below 70. 
Significant differential expression was observed in both AltAnalyze (female p< 0.02; 
male p<0.02) and Partek GS (females p < 0.01 and males p <0.0007) concordant with 
the easyExon results. In the embryonic data, no differential expression is observed 
between mutants and wildtype irrespective of intensity filter.  
In the RNAseq data Zfp804a was significantly upregulated in mutants (fold change = 
1.56), p = 2.26x10
-7
) and this remained significant following Benjamini and Hochberg 
(1995) FDR correction for multiple testing.  Thus, significant upregulation of Zfp804a 
was consistently observed in Partek GS, easyExon, AltAnlayze and the RNAseq data 
for adult C59X mutants, but no differential expression was observed in the embryonic 
C59X mutants.   
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  Differential Expression of Zfp804a P value 
Differential Expression Adult Female C59X  Adult Male C59X  Embryonic C59X  
Partek GS (Log2 Intensity >3) 0.18 0.75 0.84 
AltAnalyze (No nonLog expression Filter) 0.17 0.83 Not Significant 
easyExon 0.008 0.01 Not Significant 
 
 
With More Stringent Intensity Filters  Differential Expression of Zfp804a P value 
Differential Expression Adult Female C59X  Adult Male C59X  Embryonic C59X  
Partek GS (Log2 Intensity >6) 0.01 0.007 0.58 
AltAnalyze (Non log expression >70) 0.02 0.02 Not Significant 
 
Table 6.11 Expression of Zfp804a in Embryonic and Adult C59X mutants. When using the most stringent intensity cut offs significant 
upregulation of Zfp804a is observed in female and male adult C59X mutants in all 3 software tools. Differential expression is not observed in 
embryonic C59X mutants.  
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6.3.6.2 Differential Splicing of Zfp804a. 
In the adult data with the default intensity filter (Max log2 intensity <3), significant 
differential splicing was observed at Zfp804a using Partek GS in both female and male 
datasets (Females p = 5.16x10
-9
; Males p = 3.07x10
-8
) (Table 6.12). Using all three 
packages (Partek GS, AltAnalyze and easyExon) significant differential splicing at 
probeset 5023975 was observed in the analysis of female mice, and the same probeset 
showed the same effect using Partek GS in male mice. Significant differential splicing 
was also observed in males in AltAnalyze and easyExon, but at different probesets 
(4929502 and 4710659 in AltAnalyze and 4929502 in easyExon). There were an 
inadequate number of alignments in the RNAseq data for differential splicing to be 
calculated. 
When more stringent filters are applied in both Partek GS and AltAnalyze the 
significant differential splicing in female adult mice is nominal (p=0.05) and in 
embryonic C59X mice it disappears.  Significant differential splicing in Male C59X 
mutants is observed in all 3 software programmes and appears to be robust to more 
stringent intensity filters. In the adult males, probeset 5424882 (p<0.007) was 
significantly differentially spliced between C59X mutants and wildtypes in AltAnalyze 
and Partek GS while probeset 4929502 was significant in AltAnalyze and easyExon.  
 
Zfp804a appeared to be upregulated in the adult C59X mutants (male and female), but 
differential splicing robust to software and threshold changes was observed only in the 
adult male analyses (Fig. 6.5). As the spliced probeset varied depending on the software 
programme, the splice differences may reflect technical artefacts. Overall, no significant 
differential expression and splicing changes in Zfp804a were observed in the embryonic 
study using the most conservative criteria (Fig. 6.6). As upregualtion of Zfp804a in 
C59X mutants relative to wildtypes in observed only in adult mice, the difference may 
be the result of an unknown technical confounder. 
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  Differential Expression of Zfp804a Pvalue 
Differential Splicing Adult Female C59X  Adult Male C59X  Embryonic C59X  
Partek GS (Log2 Intensity >3) 5.16x10
-9
 3.07x10
-8
 0.002 
AltAnalyze (No nonLog expression Filter) 0.009 0.04 Not Significant 
easyExon 0.04 0.04 Not Significant 
 
 
With More Stringent Intensity Filters  Differential Expression of Zfp804a Pvalue 
Differential Splicing Adult Female C59X  Adult Male C59X  Embryonic C59X  
Partek GS (Log2 Intensity >6) 0.05 1.28x10-8 0.07 
AltAnalyze (Non log expression >70) Not Significant 0.02 Not Significant 
 
Table 6.11 Splicing of Zfp804a in Embryonic and Adult C59X Mutants. When more stringent filters are applied in both Partek GS and AltAnalyze 
the significant differential splicing in female and embryonic C59X mutants disappears.  Significant differential splicing in Male C59X mutants is 
observed in all 3 software programmes and appears to be robust to more stringent intensity filters.  
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Figure 6.5 Differential Expression and Splicing of Zfp804a in Partek GS in female 
adult mice (top) and male adult mice (bottom). When probesets with expression 
values below a mean log2 intensity of 6 are excluded from the analysis (drawn 
transparent and circled in red) significant upregulation of Zfp804a in female and male 
C59X mutants is observed. The significant differential splicing from the central of the 3 
circled probesets is removed. Differential splicing is observed for the 5’ probeset 
(circled black) in male C59X mutants relative to increased mutant expression in all 
other probesets. Mutants Red Wildtype Blue. 
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Figure 6.6 Differential Expression and Splicing of Zfp804a in Partek GS. Using a 
log2 intensity threshold <6 the 3 circled probesets are excluded and so no significant 
differential expression or splicing was observed between embryonic C59X mutants and 
wildtypes. Expression for each of the probesets targeting Zfp804a are displayed in a 5’ 
to 3’ direction with expression plotted on the y axis using a log2 scale. The blue line 
represents Wildtypes and the red line represents C59X Mutants. 
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The probeset predicted to be differentially spliced in Partek GS using lower stringencies 
targeted sequence containing a dbSNP (rs28042740) and was downregulated in C59X 
mutants. Based on earlier findings of linked variants causing reduced hybridisation 
efficiency, in the mutants I hypothesised that the differential splicing in Partek GS could 
have be generated due to this sequence variant. Only perfect match alleles to the 
probeset were present in the RNAseq data suggesting reduced hybridisation efficiency 
at the probeset did not explain the differential splicing. This rules out the effects of a 
C59X mutants specific SNP generating a false positive. The possibility of the probeset 
cross-hybridising was ruled out by ensuring that the probeset sequence specifically 
targeted Zfp804a (Chapter 3.3.4.11). This suggests the differential splicing at this 
probeset could be an artefact of the low expression of the probeset. When using more 
stringent filters this probeset is excluded.  
To determine if any strain specific alleles lay within the Zfp804a all exons of the gene 
were inspected in the RNAseq data. In addition to the C59X mutation, the mutant line 
differs from wildtype at two points. Both are known dbSNPs, both in exon 4, and are 
targeted by probeset 5147435. One is non-synonymous (H782R) the other synonymous 
(V340V).  
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6.4 Discussion. 
The removal of probes with known SNPs is an important part of the analysis workflow 
when using human samples (Kwan et al., 2007 & 2008) and options to do so are 
provided within the Partek GS software. This option is omitted from the mouse array 
workflow and the issue of probes targeting mouse sequences with SNPs is largely 
absent from the literature and Affymetrix support. This is most likely due to the 
presumption that inbred mouse strains will be genetically identical, but as I have shown, 
this is an important consideration when mouse lines are derived by backcrossing when 
genetic linkage can generate correlations between experimental groups and genotype. 
Gene level analyses will take into account intensities at a larger number of probes than 
exon level data and therefore false positives due to polymorphisms are much more 
likely to be prevalent in splicing data.  Polymorphisms found at the centre of a probe 
sequence can generate a 2 fold decrease in expression measure relative to a near 0 fold 
change when the polymorphism is found at either end of the probe sequence (Benovoy 
et al., 2008) and thus are more likely to cause erroneous results. Several methods have 
been developed to overcome this problem when using human data. Most methods deal 
with the issue by masking probes that target sequence containing SNPs then carrying 
out expression analysis (Duan et al., 2008). Only one method has been developed which 
considers mouse array data and uses a post analysis statistical method to remove false 
positives caused by differential hybridisation efficiency as a result of polymorphisms in 
probe sequences (Alberts et al., 2007).  
All probesets targeting chromosome 2 were excluded from the present analysis.  Whilst 
this is not an approach that has been reported in the literature, the excess of significant 
results on the same chromosome as the mutation of interest in probesets spanning 
dbSNPs was suggestive of a technical artefact and, in my opinion, justified a 
conservative approach to data analysis. Without the removal of these false positives on 
chromosome 2 the results would impact on multi-locus pathway analysis, and 
conclusions about biological functions would have been made based on these inaccurate 
results.  
 
A number of C59X mutant specific dbSNP were identified, including a nonsynonymous 
SNP found in exon 4 of Zfp804a. Nonsynonymous genetically linked mutations could 
have an impact on the relevant protein’s function in the C59X mutants specifically 
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independent of the effects of the C59X mutation, and therefore influence the expression 
and splicing results of the present study. Unfortunately, the presence of such variants 
could not be adjusted for in the present study, leaving the caveat that any expression or 
splicing changes observed may not be attributable to Zfp804a.  
Probesets that cause many of the technical artefacts are difficult to filter out using the 
currently available filtering methods and as exon arrays are relatively new there is no 
general consensus yet as to which probesets are problematic. As more results are 
generated this will allow this information to become available which should aid 
appropriate analyses (Whistler et al., 2010). Due to the number of different pre- and 
post-analytical filtering and the different software and algorithms available to analyse 
exon arrays, it is difficult to determine the best approach. A more systematic approach 
would increase the identification of robust splicing events and lessen the requirement 
for time consuming visual inspection of the data (Whistler et al., 2010).  
 
I discovered that a linear relationship between the size of a gene and significant 
alternative splicing existed and this is in accordance with an mRNA sequencing study 
(Pan et al., 2008). Increased alternative splicing in larger genes may be attributable to a 
real biological increase of splicing in genes with more exons or as a result of the 
increased multiple testing in larger genes. Due to the weak relationship observed it is 
most likely not attributable to multiple testing.  
Covarying for Snca expression was not possible in the adult data therefore the overlap 
analysis offered an alternative way of determining how confident to be in the data. 
When using the most conservative filtering (excluding probesets targeting chromosome 
2 and with a mean log2 intensity <6) no overlap was observed between the embryonic 
and adult data that was more than would be expected by chance. This makes it difficult 
to interpret the results. The different gene expression and splicing profiles could reflect 
developmental regulation by Zfp804a, but could also represent changes that are a direct 
or indirect effect of the deletion in Snca. The findings in both experiments could be 
attributable to chance and this would account for the differences, although the overlap 
of multiple test corrected data and the control of type I error analysis (Chapter 3, pp.88.) 
would discount this. Finally it can not be disregarded that an as yet unaccounted for 
technical confounder in the embryonic data is responsible for the different findings 
between embryonic and adult C59X mutants. As it was difficult to determine which of 
these hypotheses was correct, the confidence in the data was not enough to extrapolate 
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meaningful conclusions about Zfp804a gene’s function nor the potential ways in which 
mutations in this gene influence the pathophysiology of schizophrenia. The lack of any 
overlap does not negate the embryonic data which I regarded as the most reliable due to 
the consistent deletion of the Snca locus in all mice. These were therefore used in 
further downstream analyses described in the next section. Based upon the work of the 
present chapter, the downstream analyses are informed by a better understanding of the 
technical limitations of the data and analytic methods.  
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Chapter 7. Relevance of altered Zfp804a function for 
Schizophrenia.  
7.1 Introduction. 
The use of microarray experiments to study gene expression is now common place, but 
the output of these experiments at the level of single transcripts is generally inadequate 
for making functional inferences. The data need to be placed in the context of biological 
processes to infer knowledge about the changes in function related to the experimental 
conditions. One method commonly used to acquire functional relevance to microarray 
results is pathway analysis. Whilst the benefits of pathway analysis have been 
exemplified in some studies (Mootha et al., 2003) the potential for bias and ambiguity 
must be considered. 
Ascertaining biological insights from a microarray study is a time consuming and 
demanding task if each gene were to be considered individually. Investigating the data 
at the level of biological pathways enables information to be gained about the entire 
dataset simultaneously without highly specific a priori functional hypotheses, which is 
one of the main advantages of pathway analysis (Drăghici et al., 2003). 
Small sample sizes can limit the power of a gene expression study. Difficulty in 
distinguishing between true signal and noise is also often amplified by high variability 
between samples and the large number of genes that are tested (Mootha et al., 2003). 
Pathway analysis can offer a way of gaining more insight into the data from small 
samples because the data are viewed at the level of biological pathways rather than 
individual genes, the latter often being known to act as sets of coregulated gene sets. 
Power can then be increased by considering changes in multiple sets of functionally 
related genes. In essence, a large expression change observed in a single gene may 
provide less information than multiple smaller changes in a group of genes all belonging 
to the same biological pathway (Subramanian et al. 2005). 
 
The basic hypothesis is that if changed function in a pathway results from the presence 
of the mutation at Zfp804a, genes found within that pathway would be enriched for 
those with significant differential expression or splicing. One major caveat of pathway 
analysis is the fact that functionally related genes are often co-regulated which means 
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observations cannot be strictly considered as providing fully independent evidence for a 
given set of genes.  If a particular pathway shows significant changes in the expression 
or splicing of multiple members, this could simply be attributable to a chance 
fluctuation affecting an entire group of genes due to their correlated expression (Mootha 
et al., 2003). This is important to consider in pathway analysis where often 
independence of genes is assumed, and where doing so can increase the false positive 
rate (Emmert-streib & Glazko, 2011).  
Often the approach taken to pathway analysis is to restrict pathways to those thought 
relevant to what is already understood about the condition. This user definition of how 
the gene lists and pathways are chosen can bias the results toward biological processes 
already known to be relevant to the pathophysiology of the disorder being studied. In 
other words, significant findings have high plausibility simply because they are defined 
in advance to have such plausibility. In addition the statistics can prioritise gene sets 
with more genes ascribed to them than gene sets that include genes demonstrating the 
greatest expression changes, which may be counter intuitive (Damian & Gorfine, 2004).   
 
The numerous pathway analysis tools available can hinder the interpretation of 
expression results. The use of a variety of algorithms, databases and thresholds makes it 
difficult for a standardised approach to be followed and no consensus or gold standard 
currently exists which further impairs the comparison of results across studies.  
 
One important aspect of pathway analysis is the use of an appropriate comparator 
reference set of genes (hereafter called a background list) (Huang et al., 2009a) against 
which the changes in specific target pathways can be assessed. The significance of 
overrepresentation in the target versus background sets can be determined using a 
number of tests, for example Fisher’s exact test, the Chi squared test or the 
hypergeometric distribution (Huang et al., 2009a). As with pathways analysis in general 
there is no gold standard for background or the statistical approach. Generally the larger 
(i.e., the more comprehensive) the list the more accurate the estimate of enrichment 
(Huang et al., 2009a). Often several pathway analyses tools are used to gauge the 
robustness of results (Huang et al 2009b). 
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In order to understand the consequences of the Zfp804a mutation, I used complete lists 
of significant results for the pathway analysis.  Enrichment analysis (EA) was 
performed using Metacore (GeneGO) (Inc., St Joseph, MI) and DAVID (Database for 
Annotation, Visualisation and Integration Discovery (Dennis et al., 2003; Huang et al., 
2009a; Huang et al., 2009b). There are many different pathway tools available each 
using different annotation databases, but one common annotation database widely used 
is the Gene Ontology (GO) database (The Gene Ontology Consortium, 2000). The GO 
database consists of a hierarchy of 5 levels with level 1 representing the most general 
terms and 5 the most specific. Since level 1 incorporates all level terms, and genes may 
be members of multiple categories, the pathways are overlapping in membership and 
are not independent. This is generally not compensated for in available pathway tools 
(Jantzen et al., 2011). The occurrence of similar terms in functionally related pathways 
can obviously result in multiple similar pathways being simultaneously identified as 
significant, which might be misinterpreted as increased evidence for the relevance of the 
broad biological function to the question being studied (Jantzen et al., 2011). Both 
Metacore GeneGO and DAVID use the GO ontology as well as other annotation 
databases to allow a more thorough evaluation of functional enrichment in the gene list. 
The current level of annotation does however bias results in favour of systems for which 
more information is known.   
 
As well as assessing the consequences of the C59X mutation through pathway analysis 
of the array data, the expression results were also considered within the context of 
human genetic data. It was my hypothesis that genes identified as showing altered 
expression or splicing would contain downstream mediators of the effects of ZNF804A 
on disease risk. The polygenic model of schizophrenia suggests the involvement of 
thousands of genetic variants (ISC, 2009) and therefore I postulated that a number of the 
downstream targets of ZNF804A might contain genetic variants that influence disease 
risk. Genes identified in the exon array as showing altered expression and splicing were 
therefore tested for genetic association using large genome-wide schizophrenia case-
control association resources available from the Psychiatric GWAS Consortium 
(https://pgc.unc.edu/). To identify genes influenced by ZNF804A that might mediate 
disease risk, I used two gene-wide analyses, one which had been previously 
implemented and validated by the host department (Moskvina et al., 2009), the other 
based on the Simes’ tests, the applicability of which for extracting valid gene-wide 
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genetic association values allowing for multiple testing has been demonstrated (Li et al., 
2011).  
Aim  
The overall aim of this section is to assess the gene expression data in the context of 
biological pathways, and to determine if any of the genes showing altered expression or 
splicing are relevant to disease risk by assessing association with disease in a large case-
control genetic dataset.  
 
7.2 Methods 
7.2.1 Pathway Analysis. 
Pathway analysis was carried out using Metacore GeneGO and DAVID seeking 
biological pathways enriched for genes differentially expressed and spliced in 
embryonic C59X mutants compared to wildtype mouse brain.  
 
7.2.1.1 Gene and Background lists  
When referring to the ‘gene list’ I refer to all genes significantly differentially expressed 
or spliced at the relevant statistical threshold.  In order to evaluate enrichment a 
background list must be provided for a comparator as discussed above. Default 
background lists are provided in both DAVID and Metacore GeneGO, but these lists 
represent either the complete mouse transcriptome or all genes included on specific 
array platforms. Both are inappropriate as a comparator group as these sets include 
genes that are not included in the analysis (e.g. genes not expressed in brain). The use of 
default sets would therefore inflate the significance of almost all pathways relevant to 
brain expression as only brain expressed genes have any chance of showing significant 
effects in the present study.  There is no consensus as to the most appropriate 
background list to use, but in principle, the most appropriate set would include only 
those genes that were evaluated for significant changes in expression or splicing. 
 Both Metacore and DAVID offer the option to upload a customised background list. To 
construct the most relevant background list, I compiled a list consisting of all genes 
which had been entered into the expression or splicing analyses. This meant I included 
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only genes that met with the most stringent criteria (excluding probesets on 
chromosome 2 and with a mean Log2 Intensity <6). This same background list was used 
for both expression and splicing pathway analyses.  
Of 13,535 genes included in the background list, 28 had no gene symbol or other useful 
identifier and were removed. Different transcripts of the same gene can be significantly 
differentially spliced meaning the same gene identifier will be represented in the list 
more than once, biasing the results related to this gene and its associated pathways. 
Duplicate genes symbols were removed to allow only one representation, of which there 
were 163 leaving 13,344 unique gene symbols. Using MGI Biomart 
(http://biomart.informatics.jax.org/biomart/martview/06197243657fc4ec9d186dc2cb2df
738) gene symbols were converted to Entrez IDs, of which 12,943 unique identifiers 
were found and these comprised the background list for all analyses.   
1184 genes were significantly differentially expressed at p<0.05 of which 1 had no gene 
symbol and the remaining 1183 were unique. 199 unique genes were significantly 
differentially expressed at p<0.01. These arbitrary thresholds were used to obtain gene 
lists of adequate size for pathway analysis. The gene symbols were converted to 1141 
and 191 unique Entrez IDs respectively. The alternatively spliced gene lists were made 
up of either the genes significant at p<0.01 (544) or the genes significant at p<0.001 
(140) of which all had gene symbols and no duplicate gene symbols were present. 530 
and 135 unique Entrez IDs were identified in MGI Biomart for each list respectively. 
Pathway analysis was conducted in both Metacore and DAVID with the species 
selected as Mus musculus. 
 
7.2.1.2 Metacore GeneGO 
Metacore (GeneGo, Inc., St Joseph, MI, http://www.genego.com/metacore.php) is based 
on a collection of protein-protein, protein-DNA, protein-RNA, protein-compound and 
compound-compound interactions. The GeneGO database has been manually curated, 
with the content based on literature published from 2002-present.  
Gene lists of Entrez IDs were uploaded into Metacore and the number of IDs recognised 
by Metacore was determined. Options to filter data based on fold change and 
significance are available but the lists entered had already been filtered for significance, 
and I did not apply fold change thresholds. P value thresholds for gene selection for 
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pathway analyses are generally not as conservative as those applied for inference from 
single locus analyses since the idea is to obtain information from multiple changes that 
are not themselves necessarily highly significant. Enrichment Analysis was carried out 
using the GO ontologies of ‘Biological processes’, ‘Molecular Functions’ and 
‘Localisations’ in addition to the proprietary GeneGO datasets of ‘Pathway Maps’ and 
‘Cellular Process Networks’. The GeneGo Pathway Maps are made up of about 650 
signalling and metabolic pathways. The GeneGo Process Network ontology is made up 
of 110 cellular and molecular processes each comprised of a set network of protein 
interactions which contain information about empirically validated interactions between 
the products of the genes.  Annotations were curated by Metacore using an oracle 
database consisting of information from full text articles. Only empirically validated 
data are included in the database and the database is updated daily.  I chose to include 
the Metacore GeneGO ontologies in addition to the GO ontologies as the GeneGO 
ontologies are more frequently updated and are, according to Metacore, more 
comprehensive. I also included GO ontologies. Following upload of the gene and 
background lists the Entrez gene IDs were mapped onto gene IDs from the GO 
ontologies or Metacore’s own GeneGO database. 
In Metacore all statistics are calculated according to the gene ID and whether or not the 
genes were associated with a particular pathway relative to the background list. A 
number of the GO processes have no actual gene content and for this reason, these 
“empty terms” are excluded.  After each analysis was performed the results were 
presented in a histogram ordered according to the negative log p value for enrichment of 
the pathway for transcripts showing significant changes in expression or splicing that 
meet the significance thresholds described above. Enrichment analysis statistics were 
calculated using the hypergeometric p value. This evaluates the significance of the 
number of genes surpassing the chosen threshold in the test gene set given the 
distribution of results in the background comparator set (Tavazoie et al., 1999). Multiple 
testing was controlled using the FDR set at a threshold of 0.05. In Metacore the FDR is 
determined using the q-value (Storey, 2002), where a q value of 0.05 corresponds to a 
FDR of 0.05.  
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7.2.1.3 DAVID 
DAVID (v6.7) (Database for Annotation, Visualisation and Integration Discovery) was 
also used for pathway analysis (Dennis et al., 2003; Huang et al., 2009a; Huang et al., 
2009b). The gene list and background list were uploaded into DAVID and the Entrez 
IDs were then mapped to DAVID gene IDs. Each DAVID gene ID is unique to account 
for redundancy in the input gene list, although all lists I compiled had already had 
duplicates removed.  I then used the functional annotation chart option to carry out 
enrichment or overrepresentation analysis. Statistics in DAVID are based on an 
adaptation of the Fisher’s exact test called the EASE score, which is a one tail Fisher’s 
exact probability value (Fig. 7.1). The EASE score is more conservative than the 
Fisher’s exact test. In DAVID for a pathway to be considered significant, that pathway 
must contain at least 2 genes from the test set. This is because a finding derived from a 
single gene in a pathway is neither likely to be robust nor can in implicate convergence 
in a pathway as convergence implies multiple lines of evidence. As the intention is to 
discover overrepresented pathways the EASE score in DAVID is always a one tailed p 
value (Huang et al., 2009b).   
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Figure 7.1. The Ease Score Method. In the above example a gene list of 332 
‘significant’ genes is compared to a background list of 14959 genes. 19 genes from the 
significant gene list hit the pathway being tested and 214 genes from the background list 
are also found in this pathway. To determine if this pathway is overrepresented in the 
gene list 2x2 contingency tables are compiled. In DAVID a modified version of the 
Fisher’s Exact Test is used to determine if the gene list is overrepresented in a particular 
pathway. The modification is that the positive count (i.e., number of genes in the 
pathway that are found in the gene list) is penalised by subtracting 1. In the above 
example 19 genes from the pathway are found in the ‘significant’ gene list which is 
entered as 18 (19-1). To determine the significance of this a one tail Fishers Exact Test 
is then used (Huang et al., 2009b). Example taken from http://david.abcc.ncifcrf.gov/  
 
 
To prevent redundancy among pathways, only one type of database is usually included 
in pathway tools but this can limit the depth of information obtained. In contrast, 
DAVID allows multiple databases to be examined and explored simultaneously. In 
order to avoid the issue of redundancy, a specific DAVID ID is used representing all 
possible identifiers of one gene. This enables that gene to be cross referenced across all 
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the different databases irrespective of what identifier is used by each database (Huang et 
al., 2009b).  
 
To avoid repetition of GO ontologies from different levels of the hierarchy, and to 
reduce multiple testing, I used the GO FAT database (Dennis et al., 2003). The GO FAT 
database was developed by DAVID to filter out broad terms with numerous child terms, 
thereby including specific terms with less repetition at lower levels in the hierarchy 
(Huang et al., 2009b).  
 
7.2.3 Genetic Analysis using the PGC database 
7.2.3.1 Investigating PGC Schizophrenia top hits for Differential Expression and 
Splicing in C59X mutants. 
The mouse orthologues at loci showing genome wide significance in the Psychiatric 
GWAS consortium (PGC) (PGC, 2011a) schizophrenia GWAS were specifically 
investigated for differential expression and splicing in the embryonic exon array data. 
MIR137 was not targeted by any core probesets and so could not be investigated. 
PCGEM1 is found on chromosome 2 and so was also omitted from the analysis. The 
MHC region was also excluded in this analysis given the imprecision of mapping the 
association signal due to long range LD in this region (PGC, 2011a).  
 
7.2.3.2 Investigating the C59X Differentially Expressed and Spliced Genes for 
Association with Psychosis. 
In order to investigate a relationship between the expression and splicing data from my 
mouse experiments, and the human genetic data the significant genes were investigated 
in the Psychiatric GWAS Consortium (PGC) schizophrenia and bipolar disorder 
datasets (PGC, 2011a; PGC, 2011b). The schizophrenia PGC carried out meta-analyses 
of GWAS data from 17 studies consisting of ~9000 cases and ~12,000 controls of 
European Ancestry. The most significant 81 SNPs identified were followed up in an 
independent sample of ~8,000 cases and ~21,000 controls (PGC, 2011a). The PGC 
Bipolar Disorder Working Group carried out combined GWAS on 7481 patients with 
bipolar disorder and 9250 controls. In this study the top 34 SNPs were tested in an 
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independent sample of 4,496 bipolar disorder and 42,422 controls. Both schizophrenia 
and bipolar disorder PGC studies used data collected from subjects of white European 
ancestry. These datasets are the largest GWAS datasets available. To investigate 
differentially spliced and expressed genes in these GWAS datasets, I used gene-wide 
estimates of significance (discussed below).  
7.2.3.2.1 Approximation Method using Brown’s p value 
Across a gene, genotypes at many SNPs may be correlated with each other due to 
linkage disequilibrium. If this non independence is not allowed for when combining the 
SNP p values, highly inaccurate gene-wide p values can result. Traditionally, this is 
dealt with though permutation testing requiring the availability of individual genotypes 
but Moskvina and colleagues (Moskvina et al., 2011) reported a method that allows 
gene-wide p values to be derived from summary association statistics in the absence of 
individual genotype data. The derived P values, based upon theoretical approximation 
of the Fisher’s Statistic (Brown, 1975), I refer to as Browns P values.  All Browns P 
values were derived from the PGC data by Dr Moskvina.  
7.2.3.2.2 Simes’ P value 
An alternative approach to establishing gene-wide significance value is based on the 
Simes’ method, the validity of which has been demonstrated for GWAS data (Li et al., 
2011). Using this approach the p values of each SNP are ranked from most significant 
to least. The p value ranked 1 is then multiplied by the number of markers divided by its 
rank (n/1). This process is repeated for the SNP ranked 2 (and so on) until all SNPs had 
been adjusted. The smallest p value is the Simes’ corrected p value. The Simes’ 
corrected p values for the PGC SZ and BP datasets were based on the data published by 
the PGC (2011). I personally calculated the Simes’ values for the genes of highest 
interest, but otherwise accessed a database available in the host department.  
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7.3 Results  
7.3.1 Pathway Analysis based on embryonic expression data. 
Pathway analysis was carried out on the embryonic expression data. Chromosome 2 
probesets were excluded as were probesets with mean log2 intensity <6. Both Metacore 
and DAVID were used for the analysis.  
 
7.3.1.1 Pathways Enriched for Differentially Expressed Genes.  
Gene sets comprising those differentially expressed at two thresholds, p<0.05 and 
p<0.01 were chosen for the analysis. When converted to unique Entrez IDs this resulted 
in lists of 1411 and 191 genes respectively. Both lists along with the background list of 
12,943 Entrez IDs were uploaded into Metacore GeneGO and DAVID to enable 
enrichment of the gene lists in pathways to be quantified relative to the background list. 
1137 of the 1141 Entrez IDs at p<0.05 mapped to DAVID IDs. Of the smaller list (n= 
191) based upon the more stringent threshold for differential expression (p<0.01), 190 
of them mapped to DAVID IDs.  The ‘functional annotation chart’ option was chosen to 
test pathways for enrichment for genes in the differential expression dataset. The GO 
ontologies ‘biological processes’ (BP), ‘molecular functions’ (MF) and ‘cellular 
component’ (CC) were investigated as were KEGG and PANTHER databases. For each 
GO ontology, the FAT database was chosen. In Metacore, all 1141 Entrez identifiers 
were recognised. For each gene list the analysis was run in DAVID and then in 
Metacore first using the GO ontologies (as in DAVID), then using Metacore’s own 
proprietaty GeneGO databases which have been curated differently to the GO 
ontologies.  
P≤0.05  
In DAVID 21 pathways were significantly enriched for genes with altered expression 
between C59X mutants and wildtype following a Bonferroni correction for the 
pathways tested. The top 10 most significant pathways are presented in Table 7.1. 7 of 
the 10 pathways related to the mitochondria or energy metabolism.  
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Differentially Expressed Genes between C59X mutants and Wildtypes (p≤0.05) 
DAVID GO, KEGG, PANTHER  pValue Bonferroni 
GO:0005739~mitochondrion 5.42E-14 2.32E-11 
GO:0044429~mitochondrial part 7.49E-13 3.21E-10 
GO:0005743~mitochondrial inner membrane 1.35E-10 5.80E-08 
GO:0031966~mitochondrial membrane 1.95E-10 8.36E-08 
GO:0006091~generation of precursor metabolites and energy 2.24E-10 5.43E-07 
GO:0006412~translation 3.62E-10 8.78E-07 
GO:0005740~mitochondrial envelope 6.27E-10 2.69E-07 
GO:0019866~organelle inner membrane 1.16E-09 4.98E-07 
GO:0006413~translational initiation 1.35E-07 3.27E-04 
mmu05016:Huntington's disease 4.33E-07 7.41E-05 
Table 7.1 DAVID annotation categories significantly enriched for genes which 
show differential expression in the embryonic expression data. The pathways 
displayed above are the top 10 most significant pathways enriched for genes with 
significant (p≤0.05) differential expression between C59X mutants and wildtype. 
Enrichment was tested for GO biological processes, molecular functions and cellular 
components as well as the KEGG and PANTHER databases. P value was generated 
using the EASE score, a modified Fishers Exact Test. Bonferroni represents the p value 
following multiple test correction for the number of pathways in each database.  
 
 
For Metacore the results are divided so that first the GO ontologies are considered, as 
these correspond to the same ontologies investigated in DAVID, then the results using 
the GeneGO databases (Metacore proprietary databases) are presented.  
 
 
Non proprietary GO ontologies. The GO ontologies of Biological processes, molecular 
functions and localisations (cellular components) were each investigated separately in 
Metacore and KEGG and PANTHER databases were not included. The top 10 most 
significantly enriched pathways for genes differentially expressed between C59X 
mutants and wildtype for the three GO ontologies are displayed in table 7.2. Of the 9 
GO ontologies in the top 10 DAVID results (‘Huntington’s disease’ is a KEGG 
pathway) 8 are replicated in the top 10 from Metacore. All pathways relating to 
translation and the mitochondria replicated. The Metacore algorithm identified the GO 
biological processes of ‘translation’ (p = 1.32 x10-8) and ‘translational initiation’ (p = 
1.67x10
-8
) as enriched for differentially expressed genes. Both were significant at FDR 
threshold of 0.05.  
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Differentially Expressed Genes between C59X mutants and Wildtypes (p≤0.05) 
Metacore GO Biological Processes pValue FDR 
cellular respiration 3.42E-11 Significant  
respiratory electron transport chain 1.02E-10 Significant  
oxidation-reduction process 7.06E-09 Significant  
translation* 1.32E-08 Significant  
small molecule metabolic process 1.45E-08 Significant  
translational initiation* 1.67E-08 Significant  
electron transport chain 2.07E-08 Significant  
negative regulation of protein ubiquitination 1.97E-07 Significant  
energy derivation by oxidation of organic compounds 2.45E-07 Significant  
mitochondrial ATP synthesis coupled electron transport 2.62E-07 Significant  
   
Metacore GO Molecular functions pValue FDR 
structural constituent of ribosome 1.39E-07 Significant  
translation initiation factor activity 3.06E-07 Significant  
oxidoreductase activity 3.27E-07 Significant  
oxidoreductase activity, acting on NADH or NADPH, quinone 
or similar compound as acceptor 
1.23E-05 
Significant  
catalytic activity 3.23E-05 Significant  
gamma-catenin binding 6.99E-05 Significant  
translation factor activity, nucleic acid binding 7.74E-05 Significant  
NADH dehydrogenase activity 7.92E-05 Significant  
NADH dehydrogenase (ubiquinone) activity 7.92E-05 Significant  
NADH dehydrogenase (quinone) activity 7.92E-05 Significant  
   
Metacore GO Localizations pValue FDR 
cytoplasmic part 6.61E-15 Significant  
mitochondrion* 7.15E-14 Significant  
mitochondrial part* 2.15E-13 Significant  
mitochondrial inner membrane* 9.51E-11 Significant  
Cytoplasm 2.30E-10 Significant  
mitochondrial envelope* 3.81E-09 Significant  
organelle inner membrane* 5.29E-09 Significant  
mitochondrial membrane* 2.97E-08 Significant  
respiratory chain 3.22E-08 Significant  
macromolecular complex 4.85E-08 Significant  
Table 7.2 Metacore Analysis of Non proprietary GO ontologies. The results for 
each analysis (Biological processes, molecular function and localisation) are 
generated and presented separately. * Represents pathways that were one of the 10 
most significant pathways in DAVID. These include translation and the mitochondrion. 
 
Proprietry GeneGO database: The Metcore GeneGO process networks of ‘translation 
initiation’ as well as ‘translation in mitochondria’ were significant following multiple 
test correction (FDR 0.05 threshold) (Table 7.3). Although the GeneGo databases use 
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different classification methods the pathways that were the most significant relate to 
translation and the mitochondria which were prominent in the GO ontology results.  
 
Differentially Expressed Genes between C59X mutants and Wildtypes (p≤0.05) 
Metacore GeneGO Pathway Maps pValue FDR  
Oxidative phosphorylation 1.88E-10 Significant  
Ubiquinone metabolism 1.52E-04 Significant  
Immune response_Signaling pathway mediated by IL-6 
and IL-1 
7.40E-04 
Not Significant  
Tricarbonic acid cycle 1.41E-03 Not Significant  
Development_Thyroliberin signalling 1.44E-03 Not Significant  
Immune response_IL-5 signalling 2.81E-03 Not Significant  
Development_Prolactin receptor signalling 3.07E-03 Not Significant  
Aminoacyl-tRNA biosynthesis in cytoplasm 3.17E-03 Not Significant  
Aminoacyl-tRNA biosynthesis in cytoplasm/ Rodent 
version 
3.17E-03 
Not Significant  
GTP-XTP metabolism 3.85E-03 Not Significant  
   
Metacore GeneGO Process Networks pValue FDR  
Translation_Translation initiation 2.05E-07 Significant  
Translation_Translation in mitochondria 2.76E-05 Significant  
Translation_Regulation of initiation 8.68E-05 Significant  
Protein folding_Folding in normal condition 2.50E-04 Significant  
Immune response_IL-5 signalling 2.19E-03 Not Significant  
Translation_Elongation-Termination 4.28E-03 Not Significant  
Translation_Elongation-Termination_test 4.28E-03 Not Significant  
Protein folding_Protein folding nucleus 5.83E-03 Not Significant  
Protein folding_Response to unfolded proteins 6.18E-03 Not Significant  
Proteolysis_Ubiquitin-proteasomal proteolysis 0.01 Not Significant  
Table 7.3. Metacore Analysis of proprietary GeneGO ontologies annotation 
categories significantly enriched for genes which show differential expression in 
the embryonic expression data. The p values displayed are unadjusted but all 4 
pathways remained significant following correction for multiple testing using the FDR 
(q value) with a threshold set at 0.05.  
  
p≤0.01  
When analysing the smaller list (n= 191) based upon the more stringent threshold for 
differential expression (p<0.01) four pathways were significant following Bonferroni 
correction using the DAVID functional annotation chart analysis (Table 7.4). Each of 
the 4 pathways involved translation and included ‘translation’ and ‘translational 
initiation’ both observed when using the less stringent list (Table 7.1). The 
‘mitochondrion’ pathway was also significant when using the more stringent p value 
threshold (p≤0.01). The finding that all 4 Bonferroni significant pathways were related 
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to translation, 2 of which were identified at the less stringent threshold, suggests 
Zfp804a may play a role in regulating genes which control translation.  
 
Differentially Expressed Genes between C59X mutants and Wildtypes (p≤0.01) 
DAVID GO, KEGG, PANTHER  pValue Bonferroni 
GO:0006413~translational initiation † 2.71E-06 0.002 
GO:0006412~translation † 1.35E-05 0.01 
GO:0005852~eukaryotic translation initiation factor 3 complex 1.49E-05 0.003 
GO:0003743~translation initiation factor activity 4.99E-05 0.01 
GO:0008135~translation factor activity, nucleic acid binding 6.70E-04 0.18 
GO:0030027~lamellipodium 1.88E-03 0.31 
GO:0031252~cell leading edge 3.37E-03 0.48 
GO:0006644~phospholipid metabolic process 3.55E-03 0.96 
GO:0019637~organophosphate metabolic process 4.95E-03 0.99 
GO:0005739~mitochondrion † 8.79E-03 0.82 
Table 7.4 Pathways overrepresented for genes with significant differential 
expression at p<0.01 in the analysis of embryonic brains using DAVID (v6.7). In the 
GO ontologies, KEGG and Panther databases, 4 pathways were significantly enriched 
after Bonferroni correction. † Pathway is in the top 10 when using the p value threshold 
p≤0.05 in corresponding DAVID analysis 
 
 
 
 
Metacore Non proprietary GO ontologies Taking the same list of 191 genes which 
show differential expression in the embryonic expression data at p≤0.01 and analysing 
them in Metacore using the GO onotology pathways (Table 7.5). 8 of the top 10 
DAVID pathways were also significantly enriched using the same GO ontologies in 
Metacore. These pathways related to translation and the mitochondria.  
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Differentially Expressed Genes between C59X mutants and Wildtypes (p≤0.01) 
Metacore GO Biological Processes pValue FDR 
translation* † 1.36E-05 Significant 
translational initiation* † 3.29E-05 Significant 
cellular protein metabolic process 4.13E-05 Significant 
protein metabolic process 5.35E-05 Significant 
sulfur amino acid metabolic process 1.30E-04 Not Significant  
cellular metabolic process 5.09E-04 Not Significant  
metabolic process 5.80E-04 Not Significant  
cellular carbohydrate metabolic process 6.92E-04 Not Significant  
phospholipid metabolic process* 1.30E-03 Not Significant  
organophosphate metabolic process* 1.49E-03 Not Significant  
   
Metacore GO Molecular functions pValue FDR 
translation initiation factor activity* † 3.10E-06 Significant 
translation factor activity, nucleic acid binding* † 1.39E-04 Significant 
catalytic activity † 2.60E-04 Significant 
intramolecular oxidoreductase activity, interconverting 
aldoses and ketoses 
5.00E-04 
Not Significant  
isomerase activity 1.00E-03 Not Significant  
alditol:NADP+ 1-oxidoreductase activity 1.31E-03 Not Significant  
S-methyl-5-thioribose-1-phosphate isomerise activity 1.31E-03 Not Significant  
tRNA (guanine) methyltransferase activity 1.31E-03 Not Significant  
monosaccharide binding 1.47E-03 Not Significant  
oxidoreductase activity † 2.24E-03 Not Significant  
   
Metacore GO Localizations pValue FDR 
eukaryotic translation initiation factor 3 complex* 3.46E-07 Signficiant 
cytoplasmic part † 6.51E-06 Significant 
cytoplasm † 2.43E-05 Significant 
mitochondrial matrix 9.68E-04 Not Significant  
eukaryotic translation initiation factor 2B complex 1.38E-03 Not Significant  
mitochondrion* † 1.96E-03 Not Significant  
intracellular part 2.58E-03 Not Significant  
Intracellular 2.76E-03 Not Significant  
mitochondrial part † 3.19E-03 Not Significant  
Arp2/3 protein complex 3.38E-03 Not Significant  
Table 7.5 Pathways overrepresented for genes with significant differential 
expression at p<0.01 in the analysis of embryonic brains using Metacore Non 
proprietary GO databases. * Represents pathways that were one of the top 10 
pathways in the DAVID analysis of the same gene list (191 genes) † Represents 
pathway that is in the top 10 when using p value threshold p≤0.05 in corresponding 
Metacore analysis. FDR p value following Benjamini & Hochberg (1995) False 
Discovery Rate Correction, set at a 0.05 threshold.  
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Metacore Proprietry GeneGO database: The GeneGO databases are curated by 
Metacore and use a different method to assign genes into relevant pathways (7.2.1.2). 
Therefore the lists of genes in each pathway will not be exactly the same. Despite this, 
pathways relating to ‘translation initiation’ and ‘regulation of translation initiation’ were 
the most significantly enriched pathways for genes with differential expression in the 
embryonic data set in both the GeneGO datasets. None of the pathways were significant 
following multiple test correction using a FDR of threshold of 0.05. The pathway 
‘translation in mitochondria’ is significant and the ‘mitochondrion’ pathway was a 
significant GO cellular component when using the GO ontologies.  
Differentially Expressed Genes between C59X mutants and Wildtypes (p≤0.01) 
Metacore GeneGO Pathway Maps pValue FDR  
Translation _Regulation of translation initiation 1.48E-03 Not Significant  
Immune response_MIF-JAB1 signalling 3.35E-03 Not Significant  
Estrone metabolism / Human version 8.68E-03 Not Significant  
Estrone metabolism 8.68E-03 Not Significant  
Androstenedione and testosterone biosynthesis and 
metabolism p.1 
0.01 Not Significant  
Androstenedione and testosterone biosynthesis and 
metabolism p.1/ Rodent version 
0.01 Not Significant  
Sphingolipid metabolism / Human version 0.02 Not Significant  
Sphingolipid metabolism 0.02 Not Significant  
Apoptosis and survival_NGF activation of NF-kB 0.03 Not Significant  
Oxidative phosphorylation † 0.03 Not Significant  
   
Metacore GeneGO Process Networks pValue FDR  
Translation_Translation initiation † 6.12E-04 Not Significant  
Apoptosis_Endoplasmic reticulum stress pathway 1.74E-03 Not Significant  
Translation_Regulation of initiation † 2.55E-03 Not Significant  
Translation_Translation in mitochondria † 9.25E-03 Not Significant  
Inflammation_MIF signalling 0.02 Not Significant  
Inflammation_Kallikrein-kinin system 0.05 Not Significant  
Immune response_IL-5 signalling † 0.07 Not Significant  
Blood coagulation 0.07 Not Significant  
Inflammation_Inflammasome 0.09 Not Significant  
Neurophysiological process_Long-term potentiation 0.12 Not Significant  
Table 7.6 Pathways overrepresented for genes with significant differential 
expression at p<0.01 in the analysis of embryonic brains using Metacore’s 
propriety GeneGO databases. Pathways relating to ‘translation initiation’ were 
significant using this gene list as well as when using a larger gene list with less stringent 
p values (p≤0.05).  † Pathway is in the top 10 when using p value threshold p≤0.05 in 
corresponding Metacore GeneGO analysis. FDR significance following Benjamini & 
Hochberg (1995) False Discovery Rate Correction, set at 0.05 threshold.  
 
 247 
 
Using the same GO ontologies but different pathway analysis tools and algorithms 
produced consistent results. There was also concordance with Metacore’s own curated 
databases. Genes differentially expressed in C59X mutants appeared to be consistently 
overrepresented in pathways relating to translation and the mitochondrion. Translation 
initiation is known to negatively regulate gene expression in response to stress (Harding 
et al., 2000). Differential expression in a number of components of the translation 
initiation pathway in C59X mutants could affect the rate of translation under certain cell 
conditions such as stress.  
7.3.1.2 Pathways Enriched for Genes Differentially Spliced between C59X Mutants 
and wildtypes.   
Selection for genes differentially spliced at p<0.01 and p<0.001 resulted in lists of 530 
and 135 unique Entrez IDs respectively which were compared with the background set 
of genes (12,943 unique Entrez IDs). All 530 Entrez IDs mapped to DAVID IDs and all 
identifiers were recognised in Metacore. The analyses were conducted on the same 
databases as described in 7.3.1.1. 
 
 
p≤0.01 
Entering the list of 530 genes into DAVID resulted in no pathways that were significant 
following Bonferroni correction (Table 7.7). The most significant pathways was ‘axon 
guidance’ from the KEGG database. The GO biological process ‘translation’ was also 
significant for differentially spliced genes as observed for the genes showing differential 
expression in the embryonic data.  
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Pathways enriched for Genes Differentially Spliced between C59X mutants and 
Wildtypes (p≤0.01) 
DAVID GO, KEGG, PANTHER  pValue Bonferroni 
mmu04360:Axon guidance 5.73E-04 0.07 
GO:0031252~cell leading edge 6.10E-04 0.20 
GO:0006412~translation 1.13E-03 0.86 
GO:0006418~tRNA aminoacylation for protein translation 1.82E-03 0.96 
GO:0043038~amino acid activation 1.82E-03 0.96 
GO:0043039~tRNA aminoacylation 1.82E-03 0.96 
GO:0005768~endosome 1.85E-03 0.49 
P00034:Integrin signalling pathway 2.24E-03 0.17 
GO:0016876~ligase activity, forming aminoacyl-tRNA and 
related compounds 2.43E-03 0.72 
GO:0016875~ligase activity, forming carbon-oxygen bonds 2.43E-03 0.72 
Table 7.7 Pathways overrepresented for genes with significant differential splicing 
at p≤0.01 in the analysis of embryonic brains using DAVID (v6.7). The most 
significant pathways was axon guidance from the KEGG database.   
 
 
 
 
Non proprietary GO ontologies. Considering the same GO ontologies in Metacore the 
biological process ‘axon guidance’ was the most significant pathway but did not survive 
the FDR correction for all the pathways in the GO category (Table 7.8). Although the 
‘axon guidance’ pathway that was top of the DAVID list was from the KEGG database 
the fact that the same pathway from two different databases is the most significant in 
DAVID and Metacore suggests that genes differentially spliced between C59X mutants 
and wildtypes are enriched in pathways related to axon guidance.   
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Pathways enriched for Genes Differentially Spliced between C59X mutants and 
Wildtypes (p≤0.01) 
Metacore GO Biological Processes pValue FDR 
axon guidance* 3.26E-05 Not Significant  
cell morphogenesis involved in differentiation 3.46E-05 Not Significant  
cell-substrate adhesion 4.36E-05 Not Significant  
chemotaxis 6.64E-05 Not Significant  
Taxis 6.95E-05 Not Significant  
cellular component organization or biogenesis at cellular 
level 
1.07E-04 
Not Significant  
cell morphogenesis involved in neuron differentiation 1.39E-04 Not Significant  
cellular component organization at cellular level 1.69E-04 Not Significant  
semaphorin-plexin signalling pathway 1.88E-04 Not Significant  
axonogenesis 2.01E-04 Not Significant  
   
Metacore GO Molecular functions pValue FDR 
protein binding 1.66E-06 Significant 
binding 2.26E-05 Significant 
semaphorin receptor activity 3.40E-04 Not Significant  
transferase activity, transferring acyl groups other than 
amino-acyl groups 
4.69E-04 
Not Significant  
choline transmembrane transporter activity 7.11E-04 Not Significant  
transferase activity, transferring acyl groups 9.56E-04 Not Significant  
actin binding 1.36E-03 Not Significant  
semaphorin receptor binding 1.38E-03 Not Significant  
monovalent cation:hydrogen antiporter activity 1.38E-03 Not Significant  
ligase activity, forming aminoacyl-tRNA and related 
compounds* 
1.76E-03 
Not Significant  
   
Metacore GO Localizations pValue FDR 
organelle part 1.62E-06 Significant 
cell leading edge* 1.68E-06 Significant 
lamellipodium 3.81E-06 Significant 
intracellular organelle part 4.05E-06 Significant 
stress fiber 1.88E-04 Significant 
actin filament bundle 3.01E-04 Significant 
cell body 3.93E-04 Significant 
cell projection 4.14E-04 Significant 
endosome* 5.15E-04 Significant 
actomyosin 5.34E-04 Significant 
Table 7.8 Pathways overrepresented for genes with significant differential splicing 
at p≤0.01 in the analysis of embryonic brains using Metacore. The most significant 
biological process was ‘axon guidance’, which was also the most significant pathway in 
the DAVID analysis. * Pathway was one of the top 10 pathways in the corresponding 
DAVID analysis.  
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Metacore Proprietry GeneGO database: Using Metacore’s proprietary GeneGO 
databases 2 pathways were significant following FDR correction using a 0.05 threshold; 
the proprietary pathway map ‘cell adhesion ECM remodelling’ (p = 4.24x10-5) and the 
proprietary process network ‘development neurogenesis axonal guidance (p = 1.33x10-
5
). Both pathways are significantly enriched following an FDR correction at a threshold 
of 0.05 (Table 7.9). 
 
 
Pathways enriched for Genes Differentially Spliced between C59X mutants and 
Wildtypes (p≤0.01) 
Metacore GeneGO Pathway Maps pValue FDR  
Cell adhesion_ECM remodelling 4.243E-05 Significant 
Cell adhesion_Chemokines and adhesion 1.342E-03 Not Significant  
Cell adhesion_Endothelial cell contacts by non-
junctional mechanisms 
5.113E-03 
Not Significant  
Cytoskeleton remodeling_Integrin outside-in signaling 5.859E-03 Not Significant  
Development_Role of HDAC and calcium/calmodulin-
dependent kinase (CaMK) in control of skeletal 
myogenesis 
7.558E-03 
Not Significant  
Cytoskeleton remodeling_Cytoskeleton remodeling 8.810E-03 Not Significant  
Transport_RAB5A regulation pathway 1.623E-02 Not Significant  
Development_Role of CDK5 in neuronal development 1.623E-02 Not Significant  
Nitrogen metabolism 1.743E-02 Not Significant  
Development_VEGF-family signalling 1.911E-02 Not Significant  
   
Metacore GeneGO Process Networks pValue FDR  
Development_Neurogenesis_Axonal guidance 1.328E-05 Significant 
Cytoskeleton_Actin filaments 1.825E-03 Not Significant  
Inflammation_Complement system 3.864E-03 Not Significant  
Cell adhesion_Integrin-mediated cell-matrix adhesion 6.286E-03 Not Significant  
Cell adhesion_Attractive and repulsive receptors 9.440E-03 Not Significant  
Signal transduction_Androgen receptor nuclear 
signalling 
1.412E-02 
Not Significant  
DNA damage_Core 1.898E-02 Not Significant  
Cell adhesion_Synaptic contact 1.988E-02 Not Significant  
DNA damage_Checkpoint 2.413E-02 Not Significant  
Cell cycle_G2-M 2.928E-02 Not Significant  
Table 7.9 Pathways overrepresented for genes with significant differential splicing 
at p≤0.01 in the analysis of embryonic brains using Metacore’s Proprietary 
GeneGO databases. Following a FDR correction for all pathways in the database both 
The ‘Cell adhesion ECM remodelling’ and ‘Development Neurogenesis Axonal 
guidance’ were significant. 
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p≤0.001 
The most significant pathway in DAVID when using the more stringent p≤0.001 
threshold was the KEGG pathway ‘axon guidance’ (p = 8.09x10-5) and it remained 
significant after a Bonferroni correction for all pathways tested (p = 0.006) (Table 7.10). 
This pathway was also the most significant pathway when using the p≤0.01 threshold, 
but did not survive the Bonferroni correction.  8 genes differentially spliced at p<0.001 
are found in this pathway (Epha2, Sema6b, Plxnb2, Sema6a, Rac3, Robo1, Plxna1 and 
Robo3).  The ‘cell adhesion’ pathway was also significant. 
 
Pathways enriched for Genes Differentially Spliced between C59X mutants and 
Wildtypes (p≤0.001) 
DAVID GO, KEGG, PANTHER  pValue Bonferroni 
mmu04360:Axon guidance † 8.09E-05 5.57E-03 
GO:0044420~extracellular matrix part 7.66E-04 0.14 
GO:0005604~basement membrane 2.55E-03 0.40 
GO:0007155~cell adhesion 4.01E-03 0.97 
GO:0022610~biological adhesion 4.06E-03 0.97 
GO:0015629~actin cytoskeleton 5.45E-03 0.66 
GO:0030036~actin cytoskeleton organization 9.06E-03 1.00 
GO:0031252~cell leading edge † 1.16E-02 0.90 
GO:0030029~actin filament-based process 1.17E-02 1.00 
GO:0030030~cell projection organization 1.18E-02 1.00 
Table 7.10 Pathways overrepresented for genes with significant differential 
splicing at p≤0.001 in the analysis of embryonic brains using DAVID (v6.7). The 
most significant pathway was axon guidance as observed at p≤0.01. This pathway was 
the only one to remain significant following a Bonferroni correction.  † Pathway is in 
the top 10 pathways in corresponding DAVID analysis at p value threshold p≤0.01. 
 
Non proprietary GO ontologies: 6 of the top 10 pathways from DAVID overlap in 
Metacore GO analysis of same 3 databases at p≤0.001 threshold (Table 7.11). ‘Cell 
adhesion’ (p = 9.27x10-5) and ‘biological adhesion’ (p = 9.86x10-5) were significantly 
enriched biological processes, but did not remain significant following FDR correction. 
Both these pathways were nominally significant in DAVID (p = 0.01 for both) but 
neither had survived Bonferroni correction for all pathways. Interestingly, these same 2 
pathways (‘cell adhesion’ and ‘biological adhesion’) were also identified as enriched for 
genes showing differential expression following knockdown of ZNF804A in a neural 
cell line (Hill et al., 2012). Of the genes within these pathways one gene, Lama4 was 
found to be differentially spliced between C59X mutants and wildtypes (p=0.00048) 
and also differentially expressed following knockdown of ZNF804A (significant using 
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two ZNF804A siRNA conditions p=0.0139 p=0.0155, Hill et al., 2012).  Mutations in 
this gene cause a mild muscular dystrophy (Patton et al., 2001) and bleeding disorder 
(Thyboll et al., 2002).  
Pathways enriched for Genes Differentially Spliced between C59X mutants and 
Wildtypes (p≤0.001) 
Metacore GO Biological Processes pValue FDR 
cell adhesion* 9.27E-05 Not Significant  
biological adhesion* 9.86E-05 Not Significant  
regulation of neuron migration 1.13E-04 Not Significant  
cellular process 2.47E-04 Not Significant  
positive regulation of histone H3-K9 methylation 3.35E-04 Not Significant  
semaphorin-plexin signalling pathway † 3.94E-04 Not Significant  
cellular component organization or biogenesis at 
cellular level † 
5.02E-04 
Not Significant  
negative regulation of translational initiation in 
response to stress 
6.65E-04 
Not Significant  
regulation of translational initiation in response to 
stress 
6.65E-04 
Not Significant  
cellular component organization or biogenesis 7.28E-04 Not Significant  
Metacore GO Molecular functions PValue FDR 
transferase activity, transferring acyl groups other than 
amino-acyl groups † 
1.30E-05 
Significant 
transferase activity, transferring acyl groups † 1.00E-04 Significant 
binding † 2.92E-04 Significant 
tyrosine-tRNA ligase activity 3.48E-04 Significant 
interleukin-8 receptor binding 3.48E-04 Significant 
sphingosine N-acyltransferase activity 3.48E-04 Significant 
N-acyltransferase activity 5.09E-04 Significant 
protein binding † 5.89E-04 Significant 
aminoacyl-tRNA ligase activity 1.08E-03 Significant 
ligase activity, forming aminoacyl-tRNA and related 
compounds † 
1.08E-03 
Significant 
Metacore GO Localizations pValue FDR 
lamellipodium † 1.40E-04 Significant 
cell leading edge* † 1.98E-04 Significant 
actin cytoskeleton* 6.56E-04 Not Significant  
eukaryotic translation initiation factor 2B complex 7.75E-04 Not Significant  
filamentous actin 8.98E-04 Not Significant  
actin filament 1.73E-03 Not Significant  
stress fibre † 2.37E-03 Not Significant  
basement membrane* 2.50E-03 Not Significant  
extracellular matrix part* 2.55E-03 Not Significant  
organelle part † 2.69E-03 Not Significant  
   
   
Table 7.11. Pathways overrepresented for genes with significant differential splicing at 
p≤0.001 in the analysis of embryonic brains using Metacore. ‘Cell adhesion’ and 
‘biological adhesion’ were the most significant biological processes. * Pathway was one 
of the top 10 pathways in the corresponding DAVID analysis. † Pathway is in the top 10 
pathways in the Metacore analysis when using the less stringent p value threshold 
p≤0.01. 
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Proprietry GeneGO database: When genes meeting the more stringent p value 
threshold (p≤0.001) for differential splicing were examined using the proprietary 
database, the same ‘development neurogenesis axonal guidance’ pathway was 
significantly enriched (p = 1.57x10
-4
) as seen with the less stringent p value threshold 
(p≤0.01) as was the ‘cell adhesion ECM remodelling’ pathway, (p = 0.017) although 
only the former remained significant following multiple test correction (Table 7.12).  
Lama4 is also found in the Metacore proprietary GeneGO database in the ‘cell adhesion 
ECM remodelling’ pathway. 
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Pathways enriched for Genes Differentially Spliced between C59X mutants and 
Wildtypes (p≤0.001) 
Metacore GeneGO Pathway Maps pValue FDR  
Development_Slit-Robo signaling 2.93E-03 Not Significant  
Immune response_Classical complement pathway 3.38E-03 Not Significant  
Immune response_Lectin induced complement pathway 3.88E-03 Not Significant  
DNA damage_DNA-damage-induced responses 5.71E-03 Not Significant  
DNA damage_Role of NFBD1 in DNA damage 
response 
1.09E-02 
Not Significant  
Nitrogen metabolism † 1.30E-02 Not Significant  
Nitrogen metabolism/ Rodent version 1.52E-02 Not Significant  
Cell adhesion_ECM remodelling † 1.68E-02 Not Significant  
Cytoskeleton remodeling_Fibronectin-binding integrins 
in cell motility 
2.00E-02 
Not Significant  
Cell adhesion_Alpha-4 integrins in cell migration and 
adhesion 
2.84E-02 
Not Significant  
   
Metacore GeneGO Process Networks pValue FDR  
Development_Neurogenesis_Axonal guidance † 1.57E-04 Significant 
Cytoskeleton_Actin filaments † 1.94E-03 Not Significant  
Cell adhesion_Attractive and repulsive receptors † 2.98E-03 Not Significant  
Inflammation_Complement system † 1.18E-02 Not Significant  
Cytoskeleton_Regulation of cytoskeleton rearrangement 2.53E-02 Not Significant  
DNA damage_BER-NER repair 3.35E-02 Not Significant  
DNA damage_Checkpoint † 4.06E-02 Not Significant  
DNA damage_Core † 4.13E-02 Not Significant  
Protein folding_Protein folding nucleus 7.83E-02 Not Significant  
Transcription_Transcription by RNA polymerase II 8.14E-02 Not Significant  
Table 7.12. Pathways overrepresented for genes with significant differential 
splicing at p≤0.001 in the analysis of embryonic brains using Metacore’s 
proprietary GeneGO databases. The only pathway that was significant following the 
FDR correction was the process network ‘development neurogenesis axonal guidance’.  
 
The KEGG Pathway of ‘axon guidance’ significantly enriched in the DAVID analysis 
for gene sets showing differential splicing at both thresholds, comprises genes involved 
in axon guidance during brain development and is therefore an attractive candidate 
pathway for schizophrenia. As this is a KEGG pathway it is not tested in Metacore, 
however the Metacore proprietary pathway of ‘development neurogenesis axonal 
guidance’ was FDR significant at both thresholds. There were 6 differentially spliced 
genes that were common to the ‘axon guidance’ pathway (at the p≤0.001 P value 
threshold) in KEGG and the proprietary Metacore GeneGo process ‘Development 
Neurogenesis Axonal Guidance’; Robo1, Robo3, Epha2, Plxna1, Plxnb2 and Sema6a. 
Multiple isoforms of both Robo1 and Robo3 have been demonstrated, the different 
isoforms of Robo3 having been shown to have different functions and roles in 
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embryogenesis (Camurri et al., 2005). Both are also cell adhesion molecules. Different 
splice variants can have a large impact on the function of this general class of molecules 
(Walsh & Doherty, 1991). In addition to roles in axon guidance, the Plexin Plxnb2 is 
known to have important roles during the development of the neocortex including the 
generation, differentiation and migration of cortical cells (Hirschberg et al., 2010).  
 
Using the more stringent threshold (P≤0.001) for selecting differentially spliced genes, 
the GO molecular function pathway ‘interleukin-8 receptor binding’ was one of the 
significant pathways in Metacore (p = 3.48x10
-4
) that survives an FDR correction (0.05 
threshold). Increased levels of IL-8 have been observed in the serum of mothers of 
patients with schizophrenia spectrum disorder (Brown et al., 2004) and have been 
thought to be associated with aberrant brain development (Gilmore & Jarskog, 1997).  
 
 
7.3.1.3. The effect of Probeset Number on Pathway Analysis. 
In Chapter 6.3.4 I showed a significant correlation between the number of probes and 
the differential splice p value. Although the correlation was weak (r = 0.061) the effect 
was significant (P<0.01). Whilst that analysis could not distinguish between the 
possibility that such genes tend to be more significant due to a true biological effect 
(increased occurrence of altered splicing in genes with more exons) or because of the 
effects of multiple testing on genes with more probesets, both phenomena could bias the 
results of pathway analyses. That is if the main driver of significance with respect to 
differential splicing is simply number of probesets, pathways identified as being 
enriched for differentially spliced genes could simply reflect pathways which happen to 
be comprised of genes containing large numbers of probesets regardless of the function 
of those genes. 
 
To determine if the significant pathways were enriched for genes with large numbers of 
probesets, I re-ran the pathway analyses using a gene list selected on the basis of 
probeset number rather than differential splicing p value. Genes were first ranked by 
number of probesets (range from 2-119 for the whole dataset). To make the comparison 
between differentially spliced genes and those selected by probeset number, I ensured 
the number of genes in the latter list was comparable to that selected by splicing p value 
(at a threshold P≤0.01). Thus, I selected the 530 genes with the most probesets which 
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also had Entrez IDs. In these 530 genes the probeset number ranged from 29-119.  As 
before, gene symbols were converted to unique Entrez IDs and, as before, this gene set 
was compared using both Metacore and DAVID against the same background list as 
previously used (n = 12,943). All 530 IDs were recognised in Metacore and all 530 
mapped to DAVID IDs. The same ontologies were investigated as described in 7.3.1.1.  
 
In DAVID, 98 pathways were significant following Bonferroni correction. In both 
DAVID (Table 7.13) and Metacore the GO biological processes of ‘biological adhesion’ 
and ‘cell adhesion’ were significantly enriched for the geneset selected by probeset 
number (Metacore; cell adhesion p = 1.21x10
-16
, biological adhesion p = 1.59x10
-16
, 
both highly significant following multiple test correction (FDR 0.05 in Metacore). 
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Pathways enriched for the 530 genes with the most probesets 
DAVID GO, KEGG, PANTHER  pValue Bonferroni 
GO:0005581~collagen 4.06E-19 1.62E-16 
GO:0044420~extracellular matrix part 3.99E-18 1.59E-15 
GO:0005201~extracellular matrix structural constituent 5.60E-17 5.50E-14 
GO:0005524~ATP binding 6.20E-15 3.08E-12 
GO:0022610~biological adhesion 9.76E-15 1.98E-11 
GO:0007155~cell adhesion 9.76E-15 1.98E-11 
GO:0032559~adenyl ribonucleotide binding 1.31E-14 6.48E-12 
GO:0008092~cytoskeletal protein binding 7.95E-14 3.93E-11 
GO:0001882~nucleoside binding 8.96E-14 4.43E-11 
GO:0003774~motor activity 1.90E-13 9.42E-11 
Table 7.13 Top 10 Significant Pathways enriched for Genes with the Highest 
Number of Probesets in DAVID (v6.7). The 10 most significant pathways enriched for 
530 genes with the largest number of probesets included the biological processes of 
‘cell adhesion’ and ‘biological adhesion’ and the cellular component term ‘extracellular 
matrix part’. 
 
 
 
 
Considering the Metacore proprietary GeneGO databases the process network 
‘Development Neurogenesis Axonal guidance’ was the most significant pathway 
following FDR correction (0.05 threshold) (Table 7.14). This pathway was also the 
most significant pathway in the differential splice data.  
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Pathways enriched for the 530 genes with the most probesets 
Metacore GeneGO Pathway Maps pValue FDR  
cAMP/ Ca(2+)-dependent Insulin secretion 7.49E-05 Significant 
Neurophysiological process_Receptor-mediated axon 
growth repulsion 
1.28E-04 
Significant 
wtCFTR and delta508 traffic / Clathrin coated vesicles 
formation (norm and CF) 
3.88E-04 
Significant 
Immune response_Classical complement pathway 6.19E-04 Significant 
Immune response_Alternative complement pathway 6.19E-04 Significant 
Immune response_Lectin induced complement pathway 8.14E-04 Significant 
Transcription_Ligand-Dependent Transcription of Retinoid-
Target genes 
8.29E-04 
Significant 
Neurophysiological process_ACM regulation of nerve 
impulse 
2.07E-03 
Not Significant 
Neurophysiological process_Netrin-1 in regulation of axon 
guidance 
2.07E-03 
Not Significant 
Development_Osteopontin signaling in osteoclasts 5.33E-03 Not Significant 
   
Metacore GeneGO Process Networks pValue FDR  
Development_Neurogenesis_Axonal guidance 1.38E-08 Significant 
Cell adhesion_Cell-matrix interactions 2.00E-08 Significant 
Cytoskeleton_Actin filaments 3.73E-08 Significant 
Cell adhesion_Attractive and repulsive receptors 4.26E-08 Significant 
Cytoskeleton_Regulation of cytoskeleton rearrangement 1.17E-03 Significant 
Cell adhesion_Cadherins 3.57E-03 Not Significant 
Development_Neuromuscular junction 5.27E-03 Not Significant 
Development_Cartilage development 5.65E-03 Not Significant 
Cell adhesion_Integrin-mediated cell-matrix adhesion 1.81E-02 Not Significant 
Signal transduction_Androgen receptor signaling cross-talk 1.99E-02 Not Significant 
Table 7.14. Top 10 Significant Pathways enriched for Genes with the Highest 
Number of Probesets in Metacore Proprietary GeneGO databases. The most 
significant process network was ‘development neurogenesis axonal guidance’. 
 
 
Evidently, the same pathways that were enriched for differentially spliced genes were 
also enriched for genes with large probeset number. This does not imply that the true 
experimental pathway results were being driven by a statistical or biological artefact 
arising from probeset number, but given the significant (though weak) correlation 
between splicing p value and probeset number, it is consistent with the hypothesis that 
they might be.  It was therefore important to adjust all pathway analyses by probeset 
number.  The issue of gene size has been addressed previously for pathway analysis of 
GWAS data and RNAseq data (Jia et al., 2011; Young et al., 2010), but review of the 
literature revealed no publications which have endeavoured to make such corrections 
for exon array splicing data.  
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To adjust for the effect of probeset number on pathway analysis I carried out a linear 
regression between the number of probesets in a gene and the –log p value. In such an 
analysis, the standardised residual essentially reflects the contribution to the p value that 
is independent of the effect of probeset number. Genes were then ranked on the basis of 
the largest to smallest residuals, in effect identifying ranking the genes based upon their 
splicing p value independent of probeset number. To allow a direct comparison to the 
previous analysis of the experimental groups, the top 530 ranked genes were taken. Of 
these, 500 genes were also present in the unadjusted 530 most significantly 
differentially spliced genelist. This almost complete overlap in the top gene sets for 
adjusted and unadjusted analyses implying most of the variance in splicing p values was 
not related to probeset number, a result not entirely surprising given the correlation 
between p value and probeset number was weak.  
   
Pathway analysis in both Metacore and DAVID was then carried out with these genes 
using all criteria as described previously (7.3.1.1). When correcting for gene size the 
‘axon guidance’ pathway in the KEGG database remained the most significant pathway 
and the GO biological processes ‘axon guidance’ was significant as was the GeneGO 
process network ‘ development neurogenesis axonal guidance. Only the GeneGO 
pathway remains significant following multiple test correction using the FDR (0.05 
threshold). ‘Cell adhesion’ remains significant in DAVID and Metacore GO analysis 
and ‘cell adhesion ECM remodelling’ was still a significant Metacore proprietary 
GeneGO pathway.  
 
The overlap of results from the analyses in Metacore was determined using contingency 
tables (described in Chapter 3.2.11) to compare the outputs based upon the top sets 
derived from the adjusted and unadjusted analyses in GeneGO Pathway Maps and GO 
Molecular Functions. A significant overlap was observed for both (p< 0.01). Genes that 
showed significant differential splicing were still enriched in pathways relating to axon 
guidance in particular during development and cell adhesion.  
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7.3.2 Genetic Analysis  
7.3.2.1 Investigating PGC Schizophrenia Top Hits for Significant Differential 
Expression and Splicing in the Embryonic Dataset.  
The Psychiatric GWAS consortium (PGC) identified genome-wide significant 
association for 10 loci in schizophrenia. The mouse orthologues of the genes or miRNA 
nearest to each of the 10 SNPs were specifically investigated to determine if any of 
them were significantly differentially expressed or spliced in the C59X mutants. Due to 
the LD structure within the MHC (6p21.3-p22.1) this region was excluded. Both 
miR137 and PCGEM1 were also excluded as they did not qualify for the analysis as 
miR137 was targeted by no core probesets and PCGEM1 was on chromosome 2. None 
of the top PGC genes showed differential splicing between those with and without the 
C59X mutation (Table 7.5). Ccdc68 showed nominally significant differential 
expression (p=0.02). The function of CCDC68 is not known. A 1.2 Mb deletion 
including this gene and TCF4 has been identified in a patient with Pitt-Hopkins 
Syndrome, although the resultant phenotype is likely attributable to the deletion of 
TCF4 (Zweier et al., 2007).  
 261 
 
 
Table 7.5 PGC Schizophrenia Top Genome-Wide Association Results. No altered splicing was observed in the top PGC schizophrenia genes in 
C59X mutants. Only Ccdc68 showed nominally significant altered expression in mice with the C59X mutation. Both Mir137 and PCGEM1 were 
excluded as no core probesets target miR137 and PCGEM1 is located on chromosome 2 which had been excluded from the exon array analyses. 
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7.3.2.2 Relevance of Genes Differentially Expressed in C59X Mutants to Disease 
Risk.   
My hypothesis was that genes identified as showing differential expression or splicing 
in mutants compared with wildtype would include genes that are downstream mediators 
of the effects of ZNF804A on disease risk, and that the gene sets might be enriched for 
genes associated with psychosis (schizophrenia and bipolar disorder). In the PGC 
datasets (https://pgc.unc.edu/), the differentially expressed gene sets (Table 7.6) were 
not clearly significantly enriched for genes showing nominally significant evidence for 
association to either disorder, though the geneset selected at a differential expression 
threshold p≤0.05 was nominally significantly enriched for genes showing evidence for 
association to bipolar disorder using Brown’s method.  
Differential 
Expression 
Brown SZ Simes’ SZ 
OR P VALUE OR P VALUE 
p≤0.05 1.20 0.10 1.32 0.06 
P≤0.01 0.77 0.31 0.91 0.42 
P≤0.001 4.01 0.12 2.05 0.30 
P≤0.0001 4.66 0.93 2.74 0.89 
 
Differential 
Expression 
Brown BP Simes’ BP 
OR P VALUE OR P VALUE 
p≤0.05 1.38 0.01 1.20 0.06 
P≤0.01 1.05 0.50 1.37 0.13 
P≤0.001 0.88 0.60 1.31 0.56 
P≤0.0001 No Genes Significant 3.49 0.91 
 
Table 7.6 Genetic Relevance of Genes Differentially Expressed in C59X Mutants. 
OR is the odds ratio that a gene will be nominally significant in the respective PGC 
dataset conditional on it being significantly differential expressed at the indicated P 
value threshold in the embryonic expression data. Brown Brown method used to 
calculate gene wide significance. Simes’ Simes’ method used to calculate gene wide 
significance. SZ schizophrenia BP bipolar disorder. 
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7.3.2.3 Relevance of Genes Differentially Spliced in C59X Mutants to Disease Risk.  
Genes that were significantly differentially spliced (Table 7.7) were also not enriched 
for genes showing evidence (P≤0.05) for association with schizophrenia. Three of the 
tests in the bipolar dataset were significant but there was inconsistency between the 
Simes’ and Brown generated gene-wide p values. Overall, there is some weak evidence 
that genes identified as being differentially expressed and spliced are enriched for genes 
showing evidence for association to bipolar disorder but the findings are far from 
conclusive.  
 
 
Differential 
Splicing 
Brown SZ Simes’ SZ 
OR P VALUE OR P VALUE 
p≤0.05 0.94 0.34 1.12 0.13 
P≤0.01 1.10 0.33 1.10 0.27 
P≤0.001 1.04 0.51 1.11 0.40 
P≤0.0001 0.57 0.33 1.10 0.48 
 
Differential 
Splicing 
Brown BP Simes’ BP 
OR P VALUE OR P VALUE 
p≤0.05 1.22 0.06 1.28 0.01 
P≤0.01 1.50 0.01 1.21 0.13 
P≤0.001 1.59 0.10 1.53 0.09 
P≤0.0001 2.44 0.04 1.95 0.07 
 
Table 7.7 Relevance of Genes Differentially Spliced in C59X Mutant to Disease 
Risk. OR is the odds ratio that a gene will be nominally significant in the respective 
PGC dataset conditional on it being significantly differential spliced at the indicated P 
value threshold in the embryonic expression data. Brown Brown method used to 
calculate gene wide significance. Simes’ Simes’ method used to calculate gene wide 
significance. SZ schizophrenia BP bipolar disorder. 
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7.4 Discussion. 
Pathways enriched for genes showing evidence for differential expression and splicing 
were investigated using DAVID and Metacore which are both widely used pathway 
analysis tools. Despite the different algorithms a consensus between the two sets of 
results was apparent. Genes with altered expression are enriched in pathways related to 
translation, most robustly ‘translation initiation’. Translation rate in a cell is known to 
alter in response to certain conditions where cells need to respond rapidly such as stress 
(Sonenberg & Hinnebusch, 2009).  
Genes with altered splicing were enriched in the pathway ‘axon guidance’ from the 
KEGG database as well as the GeneGO process network ‘Development Neurogenesis 
Axonal Guidance’ and both were significant following Bonferroni and FDR correction 
respectively. These pathways are involved in developing the neuronal network. The 
gene Robo3 found in this pathway was differentially spliced in C59X mutants. The 
alternative isoforms of this gene are known to have distinct roles in embryogenesis 
(Camurri et al., 2005). The disrupted in schizophrenia 1 (DISC1) gene, which as its 
name suggests, has been implicated in schizophrenia and other psychiatric disorders 
(Millar et al., 2000) is thought to have a role in axon guidance (Chen et al., 2011), as is 
semaphorin Sema3a, expression of which has been reported to be increased in 
schizophrenia in the cerebellum (Eastwood et al., 2003). The pathway ‘SLIT/ROBO 
axon guidance’ was significantly enriched in genes differentially expressed between  
neurons derived from human inducible pluripotent stem cells (hiPSC) from 
schizophrenia fibroblast reprogramming compared to control fibroblast reprogramming 
(Brennand et al., 2011). 
One of the prominent functional pathways enriched in genes which show differential 
splicing was ‘cell adhesion’. Initially regarded with extreme caution as it contains genes 
with large numbers of probesets, further investigation revealed that when controlling for 
the number of probesets, cell adhesion categories were still amongst the most 
significantly enriched pathways. This suggests the ‘cell adhesion’ pathway is enriched 
for genes which are directly or indirectly regulated by Zfp804a.  
The KEGG pathway ‘cell adhesion molecule’ has been observed to be enriched for 
genes with significant association signals in schizophrenia and bipolar disorder GWAS 
data (O’Dulshaine et al., 2011). The ‘cell adhesion molecule’ pathway genes NRXN1 
and CNTNAP2 were associated in both association datasets (O’Dulshaine et al., 2011). 
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Genes involved in cell adhesion have also been reported as associated with autism 
spectrum disorder (ASD) in a GWAS study (Wang et al., 2009).  Neither NRXN1 or 
CNTNAP2 showed evidence for differential splicing between C59X mutants and 
wildtypes but both are found in the GO biological process of ‘cell adhesion’ (which 
differs to the KEGG pathway of ‘cell adhesion molecule’), which was significantly 
enriched for differentially spliced genes following correction for the number of 
probesets, though this did not survive the stringent Bonferroni correction (nominal p = 
0.03, Bonferroni p value = 1). This is the same pathway significantly enriched for genes 
differentially expressed between ZNF804A knockdown and wildtype (Hill et al., 2012) 
which also did not survive Bonferroni correction for all pathways in the relevant GO 
database.  
 
An RNA sequencing study looking at expression differences in differentiating and 
mature neurons found increased expression in differentiating neurons in several genes 
(NRXN1, NRXN3, NLGN1, CTNNA2, NCAM1, CHL1, ELAVL4 and PCDH9) with 
functions in cell adhesion (Lin et al., 2011). The neurexins and neuroligins form part of 
this pathway and are necessary for effective neurotransmission and have been 
associated with schizophrenia (Kirov et al., 2009b; Walsh et al., 2008).  None of these 9 
genes were significantly differentially spliced in my study, but the catenins Ctnnb1 (p = 
0.006) and Ctnnd2 (p = 8.57x10
-5
) (also part of the cell adhesion pathway) were. The 
finding that another catenin (CTNND1), also in the cell adhesion pathway, was 
differentially expressed following ZNF804A knockdown in a neural cell line (Hill et al., 
2012) derived from human foetal brain may suggest catenin function is directly or 
indirectly regulated by ZNF804A.  
 
The ‘Cell adhesion extracellular matrix (ECM) remodelling pathway’ was significantly 
enriched for genes with altered splicing. This pathway is involved in embryonic 
development and includes the genes Lama4 and Syndecan-2 which were differentially 
spliced. Lama4 is also part of the ‘cell adhesion’ and ‘biological adhesion’ pathways 
which were significantly enriched for genes differentially expressed following the 
knockdown of ZNF804A (Hill et al., 2012). Lama4 itself was found to be differentially 
expressed in response to ZNF804A knockdown (Hill et al., 2012). The significance of 
cell adhesion pathways in studies of schizophrenia risk genes (O’Dulshaine et al., 
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2011), ZNF804A knockdown (Hill et al., 2012), differentiating neurons (Lin et al., 
2011) and autism (Wang et al., 2009) suggests that aberrant cell adhesion processes in 
the brain during development could underlie neurodevelopmental disorders 
(O’Dulshaine et al., 2011). 
Pathways enriched for genes with the largest number of probesets were similar to those 
obtained with differentially spliced genes. This highlights the potential for artefacts 
influencing pathway analyses. This is a particularly critical issue in differential splice 
data as the way in which differential splicing is calculated may be influenced by the 
number of probesets in the gene, which in the majority of instances is related to gene 
size. Since brain expressed genes are generally larger, and such genes are more likely to 
be significantly differentially spliced, pathways relevant to brain function are more 
likely to be significantly enriched by chance. However, importantly, the main findings 
reported above survived adjustment for probeset number.  
 
As mentioned in the methods (7.2.1) both Metacore and DAVID are described as 
singular enrichment analysis as they follow a linear procedure. The output from both is 
a long list of pathways ordered by enrichment p value. The investigator chooses which 
pathways to investigate further and therefore sometimes the most relevant biological 
pathways for the data can be overlooked (Huang et al., 2008).  
The mouse orthologues of genome wide significant genes from the PGC SZ GWAS 
were specifically investigated for differential expression and splicing; only Ccdc68 had 
nominally significant differential expression. Little is known about the function of this 
gene so it is difficult to postulate how aberrant expression of this gene may mediate the 
effects of ZNF804A on disease risk.  Overall, there was no substantial evidence that the 
human orthologues of genes with altered expression and splicing in the present 
experiments were mediating the effects of ZNF804A on disease risk, although weak 
evidence for a link between differential splicing and bipolar disorder risk was observed.  
As GWAS datasets enlarge, it will be possible to test this more powerfully.  
In conclusion genes showing significant differences between Zfp804a mutant and 
wildtype mouse brain in their expression and splicing were enriched in pathways 
associated with translation, axon guidance and cell adhesion. The latter two are known 
to be important processes during development and fit with a neurodevelopmental 
hypothesis of schizophrenia. However, the human orthologues of genes differentially 
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expressed and spliced were not clearly enriched for associations to either schizophrenia 
or bipolar disorder, thereby providing no evidence that would suggest the human 
orthologues of these genes are responsible for mediating the effects of ZNF804A on 
disease risk.  
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Chapter 8. General Discussion. 
8.1 Research Findings.  
ZNF804A is a strongly supported schizophrenia susceptibility gene, and at the time this 
thesis started, there were few other genes implicated at convincing levels of evidence 
from which insights into schizophrenia pathogenesis could be derived. The function of 
ZNF804A protein is currently unknown, but a hypothesis suggests it regulates gene 
expression and splicing. I have investigated this hypothesis by determining the 
consequences of disrupted ZNF804A in the brains of mice who carry a nonsense 
mutation in the mouse orthologue Zfp804a (a summary of the results is displayed in 
Table 8.1). 
 
Levels of Zfp804a mRNA transcript were essentially unchanged between mutants 
carrying the nonsense and wildtypes indicating the nonsense mutation (C59X) did not 
activate the nonsense mediated decay (NMD) surveillance mechanism. In the absence of 
a suitable antibody to empirically determine if Zfp804a protein was expressed, it was 
postulated that the Zfp804a protein was disrupted.   
Affymetrix exon array analysis of RNA extracted from whole brain of embryonic and of 
adult mice revealed no genes that showed significant expression differences between 
mice with and without the nonsense mutation. My data do not then support the 
hypothesis that Zfp804a is involved in transcription regulation, a finding that contrasts 
with that of others (Hill et al., 2012; Gigenti et al., 2012). This may reflect the absence 
of a significant expression difference between C59X mutants and wildtypes in Zfp804a, 
compared to the knockdown and overexpression of ZNF804A observed in the published 
studies. The discrepancy could also reflect the conflicting results sometimes observed 
between in vitro and in vivo gene expression studies (Tatenhorst et al., 2005; Lund et 
al., 2006; Tsai et al., 2007; Lisle et al., 2008). Expression differences could arise due to 
the complexities of regulation of certain pathways in vivo (Lisle et al., 2008). There are 
however examples where there is agreement between in vivo and in vitro studies (Suryo 
Rahmanto et al., 2007; Ma et al., 2007), but caution should be taken in extrapolating in 
vitro results to complex brain pathways (Tatenhorst et al., 2005).  
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Results Chapter Chapter Outline Differential Expression Candidates Differential Splicing Candidates 
Chapter 3: Expression analysis in 
Adult ENU mutant mice 
Brain mRNA from adult Zfp804a 
mutant and wildtype mice were 
analysed using an Exon array 
(Affymetrix) to determine genes 
differentially expressed and spliced 
between Zfp804a mutants and 
wildtype controls. 
Arc 
Dusp1 
Egr2 
Npas4 
Nr4a1 
Snca 
 
 
 
 
2010106G01Rik 
Centb5/Acap3 
Colec12 
Fam171b/D4300389N05Rik 
Dffa 
Frzb 
Itga6 
Itgav 
Lrp4 
Rapgef4 
Rhobtb2/Prdm4 
Slc39a13 
Ssfa2 
Chapter 4: RNA Sequencing Whole transcriptome RNA Sequencing 
of 4 male mice analysed in the 
previous array experiment (2 Zfp804a 
mutants and 2 wildtypes).  
Arc 
Dusp1 
Npas4 
Nr4a1 
Itga6 
Dffa 
 
 
Chapter 5: Expression Analysis 
in Embryonic Mice 
The analyses carried out in Chapter 3 
were repeated using embryonic tissue 
comparing expression and splicing 
differences between Zfp804a mutants 
and wildtypes. 
Npas4  
Ogn  
Rhobtb2/Prdm4 
 
Chapter 6: Technical Artefacts The results of the exon array analyses 
on embryonic and adult data following 
the exclusion of chromosome 2 
probesets (due to an unusual excess of 
results on this chromosome) and the 
application of more stringent intensity 
filters. 
Npas4 
Ogn 
 
Prdm4 
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Chapter 7: Relevance of altered 
Zfp804a function for 
Schizophrenia  
Pathway analysis in Metacore and 
DAVID. Lists of genes significantly 
differentially expressed or spliced 
between Zfp804a mutants and 
wildtypes were tested for enrichment 
in biological pathways 
Genes enriched in: 
Translation 
Translation initiation 
Genes enriched in: 
Axon Guidance 
Development Neurogenesis Axonal 
Guidance  (Robo3) 
Cell Adhesion (Ctnnb1; Ctnnd2) 
Cell Adhesion Extra Cellular Matrix 
Remodelling (Lama 4; Syndecan-2) 
Table 8.1. Summary of Results. Following each experimental chapter a number of candidate genes were identified as having robust differential 
expression or splicing in mice with a nonsense mutation in Zfp804a relative to wildtype controls.  
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Differential splicing was evident between C59X mutants and wildtypes in both 
embryonic and adult mice with a large number of genes (more than chance) remaining 
significant following multiple test correction. However a caveat to this is that the false 
positive rate in a differential splicing study might be greater than that for differential 
expression analysis because of the additional complexities of the former (Bemmo et al. 
2008 and Chapter 3 of this thesis). 
I employed quantitative RNA sequencing (RNAseq) to provide a guide as to the validity 
of the array results. It was also viewed as a tool with which to discover novel transcript 
variants, which is not possible using the exon array as analysis is restricted to known 
transcripts.  Although statistical evaluations were performed on the sequencing data, the 
studies were based on two animals in each experimental group so I regarded the 
findings as a rough guide to the validity of the array results rather than as a robust 
confirmatory test.  
Through RNAseq I identified (and subsequently confirmed using RT-PCR) a novel 
Zfp804a transcript containing an alternative exon 5’ to the Refseq exon 1. This was 
present in both mutants and wildtypes.  The alternative exon 1 skips the constitutive 
exon 1 and is spliced to exon 2 of Zfp804a. Characterising this transcript was not 
possible within the timeframe of this PhD but doing so will be important to fully 
understand Zfp804a function. 
From the same RNAseq data, I found a deletion that was present in the 
C57BL/6JHsdOla strain that had been used in the breeding programme. This mutation 
has been reported before (Specht & Schoepfer, 2001), but this was unknown to the team 
who had been breeding the mutant mice.  This deletion, which spans Snca, confounded 
the analysis of the adult mice since the majority of wildtype mice were deletion carriers 
whereas only one of the mutant mice were. Effects in gene expression variation due to 
the Snca deletion have not been reported before (Specht & Schoeffer, 2001), but 
nevertheless a caveat of the adult expression results was that the Snca deletion 
correlating with C59X genotype may have confounded the results.  
Although of low quality, the RNAseq data also allowed me to identify a number of 
strain specific cDNA sequence variants at sites corresponding to probesets, many of 
which were providing data indicative of splice differences between C59X mutants and 
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wildtype.  These sequence variants were largely confined to genes on chromosome 2, 
the same chromosome to which Zfp804a maps, and most likely are indicative of genetic 
linkage to the C59X mutation. Since these variants appeared to be largely responsible 
for an excess of significant splicing results on chromosome 2, for subsequent analysis, I 
excluded genes mapping to that chromosome. This was a conservative approach, but 
only removed a modest proportion of the genome and as such was unlikely to impact 
upon the results observed in pathway analyses.  
Embryonic tissue was used to assess splicing and expression differences between C59X 
mutants and wildtypes during development. Impaired development is predicted to 
influence predisposition to schizophrenia (Weinberger, 1986). The genes with 
differential expression and splicing between C59X mutants and wildtype did not 
significantly overlap between embryonic and adult mice datasets, but the Snca deletion 
in the adult mouse data unfortunately prevented me from determining if changes in 
expression and splicing as a result of the Zfp804a mutation differed developmentally 
(between embryonic and adult datasets). 
Prior to carrying out pathway analysis I established that probe number correlated with 
the likelihood of a significant alternative splicing result.  In response to this finding I 
corrected for probe number. One of the prominent functional pathways enriched in 
genes which show differential splicing between C59X mutants and wildtypes was cell 
adhesion. Cell adhesion pathways have been implicated previously in schizophrenia, 
bipolar disorder (O’Dulshaine et al., 2011), autism (Wang et al., 2009) and in genes 
differentially expressed following knockdown of ZNF804A (Hill et al., 2012). 
Significant pathways also included axon guidance and extracellular matrix remodelling 
both important during embryonic development. Processes which are prominent during 
development therefore may be aberrant in C59X mutants following the disruption of 
Zfp804a.  Genes differentially expressed and spliced between mutants and wildtypes 
were not enriched for association with disease in a large case-control genetic dataset.  
 
8.2 Limitations of the data 
The biggest limitation of the study, with regards to accurately determining genes with 
altered expression and splicing as a result of disrupted Zfp804a, was the presence of 
strain specific sequence variants found in the C59X mutants. This included a 
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nonsynonymous SNP found in exon 4 of Zfp804a, in addition to the artefacts relating to 
hybridisation. Nonsynonymous genetically linked mutations may impact upon the 
relevant protein’s function. This in turn could affect expression and splicing results in 
the C59X mutants. Adjusting for the potential effects of these variants was not possible 
in this study and so leaves the caveat that expression and splicing differences observed 
between C59X mutants and wildtypes may not be attributable specifically to Zfp804a 
disruption. 
Sample sizes meant the power of the studies were limited. 5 biological replicates per 
experimental group are recommended (Affymetrix) for determining differential splicing 
on the exon array, but the limited availability of C59X homozygotes meant this couldn’t 
be met in the experiments on adult mice. The RNAseq study consisted of just 2 samples 
per experimental group and therefore the power to determine statistical differences in 
expression and splicing was very low.  
Discrepancies occurring when assessing the overlap of results produced by different 
software may arise due to the annotation methods used. Previous studies have found this 
and note the importance of manually checking the curation (Bemmo et al., 2008). This 
was noted in this study as one of the results from Partek GS is annotated as Prdm4, 
however when the sequence predicted to be differentially spliced was entered into 
BLAT (UCSC) the sequence was found within the Rhobtb2 gene found on a different 
chromosome. The two genes have different Refseq IDs but have the same Affymetrix 
transcript cluster ID annotation.  
The correlation structure of genes is a caveat of pathway analysis but there is no 
standardised way known to deal with it aside from determining the LD between every 
gene. To address this future studies could use gene set enrichment analysis (GSEA). 
GSEA uses permutations and therefore may control for the correlation observed in the 
expression of co-regulated genes.  
Finally, the absence of an antibody is an important limitation since I have no direct data 
regarding the impact of the mutation on protein abundance.  
8.3 Future Work. 
To complement the work carried out in this thesis results could be considered at the 
individual gene level. Genes with the most significant differential expression and 
splicing between C59X mutants and wildtypes would be confirmed using a real time 
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PCR technique in independent tissue derived from C59X mutant and wildtype mice that 
have undergone additional backcrossing to the C57/BL6JHsdOla strain. Further to this 
the confirmed splice and expression differences observed in C59X mutants relative to 
wildtypes could be linked to the psychosis associated risk variant (rs1344706) using 
mRNA from human post-mortem samples.  
An experiment could be carried out in which the C59X mutation is rescued. This could 
be done by promoting read through of the premature termination codon (Kayali et al., 
2012). The absence of expression and splicing differences between rescued C59X 
mutants and wildtypes would imply the differences observed previously were a 
consequence of the C59X mutation specifically.  
The chromatin-immunoprecipitation sequencing technique (ChIPseq) could be utilised 
which would allow the distinction to be made between downstream targets which are 
either directly or indirectly regulated by Zfp804a. Genes found to interact directly with 
Zfp804a are more likely to be aetiologically relevant and would be more beneficial in 
elucidating the mechanisms by which ZNF804A may be linked to schizophrenia and 
psychosis. This approach would ideally rely on the genesis of a sensitive and specific 
antibody.  
A transgenic approach could be taken in which the Zfp804a gene is knocked out in the 
mouse. This would avoid the complications that have arisen in this thesis as a result of 
using ENU random mutagenesis to create a mutation in one strain and then 
backcrossing to another strain for congenicity. By removing the problem of strain 
specific sequence variation any observed expression and splice differences between 
mice with Zfp804a knocked out and wildtype could be more confidently attributed to 
Zfp804a.  
 
8.4 General Conclusion. 
The data generated for this thesis demonstrate that a PTC within exon 2 of Zfp804a 
predominately effects the splicing of genes and suggests a role for ZNF804A in the 
regulation of RNA processing. When addressing the hypothesis that ZNF804A may be a 
transcription factor this cannot be confirmed from the data generated here, but at the 
same time does not rule out the possibility that effects on gene expression only occur in 
a very small number of genes. Downstream targets of Zfp804a were enriched in 
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pathways involved in axon guidance during development and cell adhesion. This 
provides additional support for these pathways in the underlying pathophysiology of 
schizophrenia and the relevance of developmental pathways to the aetiology of the 
disorder.   
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Appendix. 
Chapter 2 Appendices 
 
Appendix 2.1 Zfp804a Exon1-3 Primers  
The primers were used to amplify between exon 1 and exon 3 of Zfp804a under the 
conditions described in Chapter 2.4.2. 
 
Left primer         ctctcagcaagaacgggaac 
Right primer        cgagcaaattctctctgtttca 
Product Size: 208 
 
 
Appendix 2.2 Zfp804a Exon 2 Primers 
Primers used to amplify within exon 2 of Zfp804a spanning the C59X mutation for use 
in the high resolution melt analysis (HRMA) 
 
Left Primer  ccaaagctctggaggatctg 
Right Primer  tgggcgtggtcatatgagtt 
Product Size 109 
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Chapter 3 Appendices 
 
Appendix 3.1 Geneviews of Differentially Expressed Genes between Adult C59X 
Mutants and Wildtypes. 
 
The Geneviews of 9 genes significantly differentially expressed between C59X mutant 
and wildtype following a FDR correction at a threshold of 0.05 in the combined adult 
sample. Of the 9 only 2 looked like differential gene expression (Mettl5 and Nfe212) 
with two others possibly being differential expression of known alternative transcripts. 
The remaining 5 showed differential expression in only a subset of the probesets within 
the transcripts, which could suggest differential expression of novel isoforms. Of the 3 
Bonferroni significant transcripts only Mettl5 displays attributes of a differentially 
expressed gene, with all probesets showing differential expression in the geneview. 
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Ddb2 
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Ncaph 
Slc2a5 
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Psmc3 
Nfe2l2 
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Mettl5 
Nol9 
 282 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Masp2 
 283 
Chapter 4 Appendices 
 
Appendix 4.1 TopHat 
 
Scripts used to align sequence Files in TopHat (v.1.3.2) (Trapnell et al., 2009) 
 
$ tophat –-output-dir s_1_thout -–solexa1.3-quals -–num-threads 10 -–library-type fr-
unstranded –r 40 genome s_1_1_sequence.txt,s_1_3_sequence.txt  
 
Where s_1_1 and s_1_3 represent the paired end reads for sample 1 a C59X mutant. 
The other C59X mutant was annotated as s_2_1; s_2_3 and the two wildtypes were 
s_3_1; s_3_3 and s_5_1; s_5_3.  
 
The use of each option in the script is explained below and derived from the TopHat 
manual (http://tophat.cbcb.umd.edu/manual.html).  
 
--output-dir This option defined the output directory in which the results files were 
placed e.g., s_1_thout 
 
--solexa1.3-quals This option was used because the sequences were in fastq format 
produced using the Illumina GA pipeline version 1.5 and this option is recommended 
for versions 1.3 or later and states that the quality scores are in encoded using the phred 
scale (base 64). 
 
--num-threads 10 10 threads were used to align reads.  
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--library-type fr-unstranded This option is the default and was used as it is suitable 
for sequencing produced using the Illumina Truseq protocol. This means TopHat treated 
the reads as strand specific. Reads at the left end of the transcript were mapped to the 
transcript strand and reads at the right end were mapped to the opposite strand.  
 
-r 40 The –r option represents the mean inner distance between mate pairs. This 
parameter must be set for paired end runs.  As adapters are ligated to the ends of 
sequences this option ensures sequencing begins at the cDNA not the adapter. The 
length of the adapter sequences was subtracted from the length of the library fragment 
size to determine the average distance between the ends of the paired end reads. 
Appendix 4.2 SamTools 
 
Script used to Index Binary Alignment Files (BAM) in order to view them in the 
Integrative Genomics Viewer. This was carried out using Samtools 
(http://samtools.sourceforge.net/) 
 
$ samtools index accepted_hits.bam 
 
Appendix 4.3 Cufflinks 
 
Scripts used for RNAseq Transcript Assembly in Cufflinks (v.1.2.1) (Trapnell et al., 
2010) (http://cufflinks.cbcb.umd.edu/)  
 
$ cufflinks –p 8 –o s_1_clout –b genome.fa –u –N –g genes.gtf 
s_1_thout/accepted_hits.bam 
 
-p reflects the number of threads used and can be either be 4 or 8. 8 was chosen as the 
faster option. 
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-b The NCBI 37.1build genome fasta file was provided to Cufflinks to allow the bias 
detection and correction algorithm to be run. This option was included to improve the 
accuracy of transcript abundance estimates. 
-u This option was included so that cufflinks can accurately weight reads that map to 
multiple sites in the genome by running an estimation procedure.  
-N represents an upper quartile normalisation. Rather than normalising to the total 
number of fragments mapping to an individual loci (default), cufflinks takes the upper 
quartile.  
-g The NCBI build 37.1 reference annotation was supplied to Cufflinks to give 
additional information to increase the accuracy of transcript assembly. Novel 
genes/isoforms are still included in the output as well as reference transcripts.  
 
Appendix 4.4 CuffMerge 
 
Assemblies were merged by first using gedit (a text editor) to create a file called 
‘assemblies.txt’ within which the assembly files for each sample were listed:  
 
./s_1_clout/transcripts.gtf 
./s_2_clout/transcripts.gtf 
./s_3_clout/transcripts.gtf 
./s_5_clout/transcripts.gtf 
 
And then running CuffMerge (http://cufflinks.cbcb.umd.edu/)  
 
$ cuffmerge -g genes.gtf -s genome.fa –p 8 assemblies.txt 
 
The –s option was included to provide Cuffmerge with gDNA reference sequences 
(Mus musculus NCBI build 37.1) to help remove artefacts and define transcript 
fragments.   
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Appendix 4.5 CuffDiff 
 
The following script in Cuffdiff (http://cufflinks.cbcb.umd.edu/) was used to compare 
the relative amounts of assembled transcripts represented in each sample and determine 
if the difference was statistically significant  
 
 
$ cuffdiff –o diff_out -b genome.fa –p 8 –L mut,wt –u merged_asm/merged.gtf 
s_1_thout/accepted_hits.bam,./s_2_thout/accepted_hits.bam 
s_3_thout/accepted_hits.bam,./s_5_thout/accepted_hits.bam   
 
Appendix 4.6 Primers Targeting an Alternative Zfp804a Isoform. 
 
The primers were used to amplify between alternative exon 1 and exon 2 of Zfp804a 
under the conditions described in Chapter 2.4.2. 
 
Left primer         CCACCACCTCAAAGGAGCTA 
Right primer        GTTTGTGGGCGTGGTCATA 
Product Size: 173bp 
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Chapter 5 Appendices 
Appendix 5.1 Embryonic Sample Background. All brain tissue used on the 
embryonic array study was derived from E18.5 mice from a heterozygous intercross 
from parent mice with 98.5% C57BL/6J genome from either the 7
th
 or 8
th
 generation.  
Parent ID Genotype Generation C57BL/6J Genome (%) 
Female E27AD2 Het F7 98.5 
Male E27AJ2 Het F7 98.5 
Parent ID Genotype Generation C57BL/6J Genome (%) 
Female E27AO4 Het F7 98.5 
Male E27P3 Het F7 98.5 
Parent ID Genotype Generation C57BL/6J Genome (%) 
Female B8E1 Het F8 98.5 
Male E27T2 Het F7 98.5 
Parent ID Genotype Generation C57BL/6J Genome (%) 
Female E27AM2 Het F7 98.5 
Male E27X0 Het F7 98.5 
        Parent ID Genotype Generation C57BL/6J Genome (%) 
Female B8A2 Het F8 98.5 
Male E27VO Het F7 98.5 
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Appendix 5.2 Gender PCR Primers  
 
Ssty (forward): CTGGAGCTCTACAGTGATGA 
Ssty (reverse): CAGTTACCAATCAACACATCAC Product: 343bp 
 
Om1a (forward): TTACGTCCATCGTGGACAGCAT 
Om1a (reverse): TGGGCTGGGTGTTAGTCTTAT  Product: 245bp 
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